<?xml version="1.0" encoding="utf-8"?>
<rdf:RDF
  xmlns:owl="http://www.w3.org/2002/07/owl#"
  xmlns:ddiem="http://ddiem.phenomebrowser.net/"
  xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
  xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
  xmlns:obo="http://purl.obolibrary.org/obo/"
  xmlns:foaf="http://xmlns.com/foaf/0.1/"
  xmlns:dc="http://purl.org/dc/elements/1.1/"
  xmlns:void="http://rdfs.org/ns/void#"
  xmlns:dcterms="http://purl.org/dc/terms/"
>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300868">
    <dc:identifier>https://www.omim.org/entry/300868</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a6d42cad-4114-498e-820b-08e1b65c5d70">
        <rdfs:label>PIGA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5277</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2</rdfs:label>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <rdfs:comment>Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216</rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f8ef2bda-7352-4153-8f2b-5f85601e2d3b">
    <rdfs:label>Hydroxymethylbilane synthase.</rdfs:label>
    <ddiem:ecNumber>2.5.1.61</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/174cda5a-dbe3-44b8-82a2-2eeceb881149">
        <rdfs:label>HMBS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3145</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01749</ddiem:keggEntryId>
    <ddiem:uniprotId>P08397</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad8c76be-ffac-46bc-9b43-c88302e83a9f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19285442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cecbc850-2f6c-4c07-97c8-15c0036f62e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bfabb9ae-d21a-49f4-97e9-9cbe9276a240">
        <rdfs:label>Minor visual abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000505</ddiem:url>
        <dc:identifier>HP:0000505</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f342a22-fe08-47d0-8b2c-638430ae3599">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012638</ddiem:url>
        <rdfs:label>Muscular abnormality</rdfs:label>
        <dc:identifier>HP:0012638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0804790f-cee2-41a5-b82b-642d14210a0a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da973bd5-52c3-4fd7-82e5-eec3a1ea1abc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormality</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000352">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000352</ddiem:url>
        <dc:identifier>ECO:0000352</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1083</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1083</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eda7f03a-2a25-4a4b-a1fe-fb4385f86ec4"/>
        <rdfs:label>CHYLOMICRON RETENTION DISEASE; CMRD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/246700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/647b709a-035d-4793-923f-17ca247c11df">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6311fd6e-c53a-45af-a00e-a3dd8f5c369b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7a0ed48-8605-4a1d-9850-529834615fda">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma guanidinoacetate levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24071436</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec394a12-b33c-4cbc-81a5-402cbef1b7e8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f0b3a33-a14a-424a-9056-dea112723ab4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54e35da9-72ac-4194-a9fa-fa47a5a250b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/932ddfa6-6483-43c5-b811-dd4192accb47"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4d1efd3-3531-4167-b248-40e8a2389801"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612736">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d48dc661-01f6-4ae9-9c25-4c04bf0a542f"/>
        <ddiem:iembaseAccessionNumber>104</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/612736</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/104</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000015>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615042">
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/604</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>604</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2aec718-ec47-48d4-b3ce-0677142f84d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8818</dc:identifier>
        <rdfs:label>DPM2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/615042</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ea57461b-8a45-48f2-b8de-6564a3f96be2">
    <ddiem:keggEntryId>K01444</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9e68b4ed-854f-4620-99c4-f2af93470ddc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/175</dc:identifier>
        <rdfs:label>AGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.1.26</ddiem:ecNumber>
    <ddiem:uniprotId>P20933</ddiem:uniprotId>
    <rdfs:label>N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dea78e79-316c-469b-bbff-2b40d6bf97bc">
    <rdfs:label>electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cb135b0e-f168-4a30-bc27-767b10c12e4d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2109</dc:identifier>
        <rdfs:label>ETFB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00311</ddiem:keggEntryId>
    <ddiem:keggEntryId>K03522</ddiem:keggEntryId>
    <ddiem:uniprotId>P38117</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aff771a3-5e21-495c-9c65-b388ee5b7edc">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2110</dc:identifier>
        <rdfs:label>ETFDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.5.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K03521</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3d506fc0-09be-4f18-8122-c89d1f1adede">
        <rdfs:label>ETFA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2108</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P13804</ddiem:uniprotId>
    <ddiem:uniprotId>Q16134</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5b2eb78c-8909-4b40-b1ab-041ae744aa97">
    <rdfs:label>sarcoglycan alpha</rdfs:label>
    <ddiem:uniprotId>Q16586</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d266cf89-a33f-4b2e-ba97-532eea78d278">
        <rdfs:label>SGCA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6442</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12565</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0cc4599d-1b25-4c38-81c4-c60a5edca232">
    <ddiem:keggEntryId>K14710</ddiem:keggEntryId>
    <ddiem:uniprotId>Q6P5W5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89f939d1-ab53-4a58-8a9d-db320e25b473">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55630</dc:identifier>
        <rdfs:label>SLC39A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>zinc/iron-regulated transporter-like protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230200">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/79d7ddad-3008-4d3a-a8e4-1da1ea060af8">
        <rdfs:label>GALK1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2584</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>474</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/474</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/230200</dc:identifier>
    <rdfs:label>GALACTOKINASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f169dd76-b6b3-4e91-a710-38ee73160dc1">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246900">
        <dc:identifier>https://www.omim.org/entry/246900</dc:identifier>
        <rdfs:label>DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c75cbe99-1b89-4bf2-83df-6e478c584e3c"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5bdea9ec-5994-4181-933d-7ba4acae5d35">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7df2af08-0418-4922-8d35-470f62502cd2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d4eca34-70b4-44f5-bc28-beed6123291a">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cognitive imapirment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Oxidative stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d6b2903-8136-4e82-9c1a-92558e77243b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Behavioural abnormalites</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a4fad6e-f875-43f4-a80f-df4a048cbf86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15938133</dc:provenance>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d61262e6-6441-43df-965d-c04705156fef">
        <dc:identifier>HP:0001328</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001328</ddiem:url>
        <rdfs:label>Learning impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/423e021a-8135-4962-bafc-f0cfe4094b78">
        <dc:identifier>HP:0002354</dc:identifier>
        <rdfs:label>Memory impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/85b666c4-af96-4f65-853a-1dde84cf98f8">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/101d9099-ee0c-4259-a97b-36d92c291c88">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3251</dc:identifier>
        <rdfs:label>HPRT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.2.8</ddiem:ecNumber>
    <ddiem:uniprotId>P00492</ddiem:uniprotId>
    <ddiem:keggEntryId>K00760</ddiem:keggEntryId>
    <rdfs:label>hypoxanthine phosphoribosyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03dc39bd-13be-4b5d-8f12-5558158cdc87">
    <ddiem:ecNumber>1.3.8.6</ddiem:ecNumber>
    <ddiem:uniprotId>Q92947</ddiem:uniprotId>
    <ddiem:keggEntryId>K00252</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1c1dceab-6837-4ec6-9881-f4c934b98011">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2639</dc:identifier>
        <rdfs:label>GCDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>glutaryl-CoA dehydrogenase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/186f7712-d624-4af6-83bf-844c96fde70e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/770a217c-46ed-416b-aaf3-ed16e1922c38">
        <rdfs:label>CRAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1384</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Carnitine acetyltransferase</rdfs:label>
    <ddiem:uniprotId>P43155</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:ecNumber>2.3.1.7</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612933">
    <rdfs:label>GLYCOGEN STORAGE DISEASE XI; GSD11</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ac8402fb-b660-43d1-b431-0d7d9726f8f4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3939</dc:identifier>
        <rdfs:label>LDHA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/612933</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/499</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>499</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/20f90d60-0722-4d92-a52a-f7ad7621317a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd157548-1960-4fcb-8e61-eeb4a810cc16">
        <rdfs:label>Reticulocytopenia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001896</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001896</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25a0c679-54b6-4598-9805-61d04566fd1a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>low Hb level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2503027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/105650">
        <rdfs:label>DIAMOND-BLACKFAN ANEMIA 1; DBA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8bbd7650-a89e-4a2d-96f0-0e4ffebba479"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fe18a125-7fb5-4357-af64-6f98a95b1794"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e9526fc7-8770-4cb0-b99f-97029acc4d10"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9f0f607a-9024-4c8d-ae24-5db950170597"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f09992e4-a164-4aa3-9941-cd40c1c302e7"/>
        <dc:identifier>https://www.omim.org/entry/105650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/68607802-a920-400d-9bcd-ca78eea76c11"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11f69317-edde-4f5e-8151-7de600389046"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eddb0342-de54-424d-9991-41e3bc42c31f"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/896377e1-72eb-4932-ae3d-73ff80670af9"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f082b23-8a17-4b4e-9160-2c36a6caa21d"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d3820a80-3878-49de-86ec-df4f82f11b1d"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3eda2d08-8763-431a-bdb8-542c91f1027e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a97c8e50-9442-4393-bf82-f9f9b9d54173"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3389144</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1546717</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/600b3775-2861-4deb-b002-790642663806">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5edd135-e2d0-4e04-b4e7-bc36fd0e91bb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
  </obo:DDIEM_0000015>
  <void:Dataset rdf:about="http://ddiem.phenomebrowser.net/DDIEM">
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/RobertHoehndorf">
        <rdfs:label>Robert Hoehndorf</rdfs:label>
        <foaf:mbox rdf:resource="mailto:robert.hoehndorf@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:description>DDIEM - Drug database for inborn errors of metabolism is a database on therapeutic strategies
     for inborn errors of metabolism. These strategies are classified by mechanism and outcome in DDIEM Ontology. 
     DDIEM uses this ontology to categprise the experimental treatments that have been proposed or applied. It 
     includes descriptions of the phenotypes addressed by the treatment and drugs participating in treatment and procedures.</dcterms:description>
    <dcterms:title>DDIEM - Drug Database for Inborn Error of Metabolism</dcterms:title>
    <dcterms:license rdf:resource="https://creativecommons.org/licenses/by/4.0/"/>
    <dcterms:contributor>
      <foaf:Organization rdf:about="https://www.pdn.cam.ac.uk">
        <rdfs:label>University of Cambridge</rdfs:label>
      </foaf:Organization>
    </dcterms:contributor>
    <void:sparqlEndpoint rdf:resource="http://ddiem.phenomebrowser.net/sparql"/>
    <foaf:page rdf:resource="https://github.com/bio-ontology-research-group/DDIEM"/>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.pdn.cam.ac.uk)/PaulSchofield">
        <rdfs:label>Dr Paul Schofield</rdfs:label>
        <foaf:mbox rdf:resource="mailto:pns12@cam.ac.uk"/>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:contributor>
      <foaf:Organization rdf:about="https://www.kaust.edu.sa">
        <rdfs:label>King Abdullah University of Science and Technology</rdfs:label>
      </foaf:Organization>
    </dcterms:contributor>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/SenayKafkas">
        <foaf:mbox rdf:resource="mailto:senay.kafkas@kaust.edu.sa"/>
        <rdfs:label>Senay Kafkas</rdfs:label>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/AllanKamau">
        <rdfs:label>Allan Kamau</rdfs:label>
        <foaf:mbox rdf:resource="mailto:allan.kamau@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <dcterms:modified>2019-11-19</dcterms:modified>
    <void:feature rdf:resource="http://www.w3.org/ns/formats/RDF_XML"/>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/MarwaAbdelhakim">
        <rdfs:label>Marwa Abdelhakim</rdfs:label>
        <foaf:mbox rdf:resource="mailto:marwa.abdelhakim@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
    <foaf:homepage rdf:resource="http://ddiem.phenomebrowser.net/"/>
    <dcterms:creator>
      <foaf:Person rdf:about="Resource(https://www.kaust.edu.sa)/AliRazaSyed">
        <rdfs:label>Ali Raza Syed</rdfs:label>
        <foaf:mbox rdf:resource="mailto:ali.syed@kaust.edu.sa"/>
      </foaf:Person>
    </dcterms:creator>
  </void:Dataset>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cefc9969-70fd-4bdd-afbd-36d175f0e483">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/855c0cad-b4e5-4d3b-a296-c7fbba08d369">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f8ce08fb-2743-4345-b3eb-c5af16d570e8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20486940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10404446</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28283348</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606824">
        <ddiem:iembaseAccessionNumber>482</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606824</dc:identifier>
        <rdfs:comment>Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187</rdfs:comment>
        <rdfs:label>GLUCOSE/GALACTOSE MALABSORPTION; GGM</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2032fd0a-36a6-4f1b-9d7f-3402ba06dd6a"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/482</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b57e3445-bf2c-4588-a6e5-4fbb750d66d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e876f230-9f5f-499c-b111-25c89921dc35"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/362d78df-ada3-41dd-843b-db3afd4c1369">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:label>Watery Diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/08a6f83b-d86a-4663-8ea6-b502f6945e07">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001944</ddiem:url>
        <dc:identifier>HP:0001944</dc:identifier>
        <rdfs:label>Dehydration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/034618fa-2816-4da3-bc8c-8d82ecfa9fbb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c47895d-e602-4b95-aac4-25fbb314fdc4">
        <rdfs:label>FBP1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2203</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09467</ddiem:uniprotId>
    <rdfs:label>Fructose-1,6-bisphosphatase 1</rdfs:label>
    <ddiem:keggEntryId>K03841</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.11</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e44f816e-84e8-4aad-a078-43555cef6c60">
    <ddiem:uniprotId>P07741</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.2.7</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/38d2dd93-6cf9-4a49-bcd7-11c3d5899ad6">
        <rdfs:label>APRT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/353</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00759</ddiem:keggEntryId>
    <rdfs:label>Adenine phosphoribosyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4ba8393-cbc7-44a8-b7ed-4f21c32f187a">
    <ddiem:ecNumber>2.8.1.8</ddiem:ecNumber>
    <ddiem:uniprotId>O43766</ddiem:uniprotId>
    <ddiem:keggEntryId>K03644</ddiem:keggEntryId>
    <rdfs:label>lipoic acid synthetase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7928fe18-04f4-4500-ab2e-c39002e8b86c">
        <rdfs:label>LIAS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11019</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/216b360f-ec15-47b2-b336-bdc844d392cb">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005542">
        <dc:identifier>ECO:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b841ceb-25c7-4db7-a491-ac3035020444">
        <dc:identifier>HP:0006785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006785</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle dystrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613154">
        <dc:identifier>https://www.omim.org/entry/613154</dc:identifier>
        <ddiem:iembaseAccessionNumber>1125</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1125</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c95084a7-3049-40b4-b249-f6f97cb081b2"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68d9252a-0a48-4c3f-a702-9b5f88e81db7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28df9898-fa24-4312-93f9-6795a4bf0cc8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be24a1d6-ca20-4e1f-8d5d-b024edb4dd6f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261630">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>5</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/261630</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/5</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d96f5243-9798-4df0-baf8-f47d6019f6e1"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbc56082-b832-42fc-9975-0501c0c075dc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51c95db6-fc44-42cf-bc17-ad49d7220117"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0b0a001-d170-4edf-80bf-9034af5108a7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc8507d2-1b62-49e6-8056-10ee4d5594d7">
        <rdfs:label>Abnormality of neurotransmitter metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <dc:identifier>HP:0012535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/274e5766-c070-4a53-9617-0529fa27c710">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>Elevated blood phenylalanine concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5982a861-c60c-4305-b9d0-205736994b21">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7e7be8d-a1f4-410a-a8df-a186151bf89c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e4a9cf5-a2ea-45c8-9e9a-9d9dec91305f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f73ce8e-2a1f-4fd2-a608-3fcfd0fc4d93"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/df423442-03f4-44ef-b5c0-5bbe755c3f1f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f7b8ad9-3eb5-4bb8-bb90-c69322d43625">
        <rdfs:label>High desmosterol,cholesterol ratio</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602398">
        <ddiem:iembaseAccessionNumber>195</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DESMOSTEROLOSIS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7ae0bd6a-e367-40f3-b2e2-5abaa51fbb21"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/195</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602398</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007121">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007121</ddiem:url>
        <dc:identifier>ECO:0007121</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0007764">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0007764</ddiem:url>
        <dc:identifier>ECO:0007764</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97633f78-be14-4738-9620-13eed1576352">
        <rdfs:comment>The change was not statistically significant.</rdfs:comment>
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:label>High desmosterol levels (Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e872a117-c26a-4404-8060-708f5b6d366b">
    <ddiem:uniprotId>P13929</ddiem:uniprotId>
    <ddiem:keggEntryId>K01689</ddiem:keggEntryId>
    <rdfs:label>enolase 3</rdfs:label>
    <ddiem:ecNumber>4.2.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4659b9a-cd11-42b6-8cd9-6342c3b4275a">
        <rdfs:label>ENO3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2027</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e04a739-c20c-4462-8d42-4f5789096e30">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b249fa5-ce76-4942-b098-0b122333821a">
        <rdfs:label>Abnormal bilirubin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8707100</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235555">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/50271af7-97a0-4475-8cdb-fe772dc8d114"/>
        <dc:identifier>https://www.omim.org/entry/235555</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/faf429f2-63da-4267-9c54-d91bb9473e0c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc5b4324-9b55-413e-acdf-8c4131bb0682">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59c68aef-6c46-448b-a3c9-afc3562f46f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b19940c7-a24d-4688-9d8c-e59ac583deef">
        <rdfs:label>Liver biopsy abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f1e691c-d41d-40f1-8b2f-daa27af6515a">
        <rdfs:label>Abnormal liver function tests</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/47ec7ed1-3752-4743-a61b-8046ed4bb92a">
    <ddiem:keggEntryId>K12301</ddiem:keggEntryId>
    <rdfs:label>solute carrier family 17 member 5</rdfs:label>
    <ddiem:uniprotId>Q9NRA2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/11e5e39d-c9ee-4d45-ba9b-c362d3ad790d">
        <rdfs:label>SLC17A5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/26503</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc830d65-16f1-4b56-ae2f-c92189420862">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9f0f607a-9024-4c8d-ae24-5db950170597">
        <rdfs:label>RPL11</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6135</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P62847</ddiem:uniprotId>
    <ddiem:uniprotId>P08708</ddiem:uniprotId>
    <ddiem:uniprotId>P46777</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f09992e4-a164-4aa3-9941-cd40c1c302e7">
        <rdfs:label>RPS19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6223</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f082b23-8a17-4b4e-9160-2c36a6caa21d">
        <rdfs:label>RPL35A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6165</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/896377e1-72eb-4932-ae3d-73ff80670af9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6218</dc:identifier>
        <rdfs:label>RPS17</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eddb0342-de54-424d-9991-41e3bc42c31f">
        <rdfs:label>RPL5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6125</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02917</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02974</ddiem:keggEntryId>
    <ddiem:uniprotId>P62913</ddiem:uniprotId>
    <ddiem:uniprotId>P39019</ddiem:uniprotId>
    <ddiem:uniprotId>P15976</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/11f69317-edde-4f5e-8151-7de600389046">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6201</dc:identifier>
        <rdfs:label>RPS7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02966</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02962</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02947</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/68607802-a920-400d-9bcd-ca78eea76c11">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6231</dc:identifier>
        <rdfs:label>RPS26</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P18077</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e9526fc7-8770-4cb0-b99f-97029acc4d10">
        <rdfs:label>and</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/and</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02932</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8bbd7650-a89e-4a2d-96f0-0e4ffebba479">
        <rdfs:label>GATA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2623</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>40S ribosomal protein S19</rdfs:label>
    <ddiem:uniprotId>P62854</ddiem:uniprotId>
    <ddiem:keggEntryId>K02993</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02868</ddiem:keggEntryId>
    <ddiem:uniprotId>P62081</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fe18a125-7fb5-4357-af64-6f98a95b1794">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6229</dc:identifier>
        <rdfs:label>RPS24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09182</ddiem:keggEntryId>
    <ddiem:keggEntryId>K02976</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d3820a80-3878-49de-86ec-df4f82f11b1d">
        <rdfs:label>RPS10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6204</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46783</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4998cff-9d01-415a-a3c1-0a0c7ca90404">
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <rdfs:label>Glycogen phosphorylase, liver form</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72e2febb-74a7-4a2e-82c2-8203b07b25d8">
        <rdfs:label>PYGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5836</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P06737</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ce4a3def-084f-4fcf-a45e-2c02888fdde7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3a4ca35-2c31-45ee-80fb-941b6b072c04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55f510a0-8e8a-44fd-9e39-c41a5b72adb0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604250">
        <rdfs:label>HEMOCHROMATOSIS, TYPE 3; HFE3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/582</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>582</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604250</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2768cffa-ff3b-4b3f-a12d-90cfb62ea3bc"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f817419b-6370-47c0-b447-040cf6220496">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased plasma iron concentration(Increased serum iron)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
        <dc:identifier>HP:0003452</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c79e6d65-0cae-4f47-add2-c1f6dec41b97">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2a2bd349-e4b9-462c-a6d3-44182df1afbb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/979d2741-0b42-4d41-82df-cb667d4406a8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W464X</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1a5cefa-8cf5-4331-ad9b-1c623a310034">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/623eaaf7-39cc-4524-a654-cca5921e32e4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>Hypertriglyceridemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74d73684-b101-4d05-96fc-b5fbd8faf6f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14be4523-65a8-4abe-88b9-b4b944bd3bf9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f5407e8-65a9-49b1-8a04-a61fe7a31fb4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003074</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperglycemia</rdfs:label>
        <dc:identifier>HP:0003074</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246650">
        <ddiem:iembaseAccessionNumber>1085</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b7701fab-b7a2-4f50-9121-786c0b575b6f"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1085</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/246650</dc:identifier>
        <rdfs:label>LIPASE DEFICIENCY, COMBINED</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e049c06-e199-4f87-aff7-f0f2aad540d9">
    <rdfs:label>cystinosin</rdfs:label>
    <ddiem:keggEntryId>K12386</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/48ce0703-61ae-474b-8335-cf8ceffb339f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1497</dc:identifier>
        <rdfs:label>CTNS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O60931</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66c6f518-94d5-43e5-89b1-6d04396aeaa0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/46233319-5153-45d8-a62f-e8507865fef2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10020</dc:identifier>
        <rdfs:label>GNE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000014">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure to mitigate the immediate or future effects of the presence of a genetically defective protein which involves physical conditioning or anatomical modification.[PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <rdfs:label xml:lang="en">surgical or physical treatment procedure</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:30+00:00</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25f7ef50-ddc3-4f8b-b9c9-2b32a86db93e">
    <rdfs:label>dihydrolipoamide dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c75cbe99-1b89-4bf2-83df-6e478c584e3c">
        <rdfs:label>DLD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1738</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/31804c54-4396-4482-94d0-97d96260c056">
    <ddiem:uniprotId>P54840</ddiem:uniprotId>
    <rdfs:label>glycogen synthase 2</rdfs:label>
    <ddiem:keggEntryId>K00693</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.11</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c3cc4e8-c9e1-49f0-a12f-a592e9974a49">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2998</dc:identifier>
        <rdfs:label>GYS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25b9adb1-e647-416c-90ec-5253be49d351">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>LARGE xylosyl- and glucuronyltransferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c95084a7-3049-40b4-b249-f6f97cb081b2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
        <rdfs:label>LARGE</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/205b96fa-0d00-4423-aef1-2bdabafdbae2">
    <rdfs:label>mevalonate kinase</rdfs:label>
    <ddiem:keggEntryId>K00869</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.1.36</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/143268c8-de60-48ef-804b-536dced45380">
        <rdfs:label>MVK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4598</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q03426</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1812c9b2-8dd3-4805-8fa9-4838f0d5a4d4">
    <ddiem:keggEntryId>K07605</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9a272708-76ab-454a-a2e9-dfcbfdf3e22a">
        <rdfs:label>KRT5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3852</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>keratin 5/protein O-glucosyltransferase</rdfs:label>
    <ddiem:uniprotId>P13647</ddiem:uniprotId>
    <ddiem:keggEntryId>K13667</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-; 2.4.2.26</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/983d363f-2b77-4ae8-aebf-feedd69d8a34">
        <rdfs:label>POGLUT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56983</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8NBL1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/506f39fe-dc7b-4653-8430-4c8fa8ef3dfb">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35c965ce-c5be-4cab-b1fc-a4a94e04c979"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266130">
        <ddiem:iembaseAccessionNumber>512</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/512</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266130</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9dfd67c9-68b7-4bc1-a6f7-b9d52d5ba702"/>
        <rdfs:label>GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0a8b201-2354-4b92-a566-42e46043979c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc18cc19-4ba8-4aa7-8807-a08328aea0d5">
        <rdfs:label>Elevated urine 5-oxoproline</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d38e247c-7920-40a3-8388-0b72ab7aa19c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d0ebebb-70d7-448a-92d1-22bbf2af39ac">
        <rdfs:label>Decreased blood free carnitine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008315</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008315</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a49854a3-5e68-4672-8aaf-39a39d0358da">
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/004aac47-6c56-4dd4-94ad-95f3056e2d36">
        <rdfs:label>MT-ND4L</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND4L</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c4863f1-79bc-462d-8b41-3ea5814ffbdd">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND1</dc:identifier>
        <rdfs:label>MT-ND1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ea21eaa9-345c-47aa-a6af-5e375552ac16">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND6</dc:identifier>
        <rdfs:label>MT-ND6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8125f0ff-4f51-4f09-b338-c40a2fda1656">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20007925-7720-4a40-b65f-25aa21589a5f">
        <rdfs:label>SUMF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/285362</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K13444</ddiem:keggEntryId>
    <ddiem:ecNumber>1.8.3.7</ddiem:ecNumber>
    <rdfs:label>Formylglycine-generating enzyme</rdfs:label>
    <ddiem:uniprotId>Q8NBK3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0cf334c0-4624-4f11-9029-425c82b9a5b5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5449f040-fffe-4cbf-b3b5-ce5d5eecaec4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3add1b30-cbec-4b5b-b18d-daabbb48fa45">
        <dc:identifier>HP:0001285</dc:identifier>
        <rdfs:label>Spastic tetraparesis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001285</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18060820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a4ca557-580b-44c3-9959-33a615356332">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:label>Epilepsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d13c5c1-3158-4aec-bc78-c0b450efc89c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9cd4dc85-22f1-4e37-a933-282938d0cbb0">
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase type II</rdfs:label>
    <ddiem:ecNumber>1.1.1.35; 1.1.1.51; 1.1.1.178</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2db7297e-3281-4b39-8d55-773d4cee1d47">
        <rdfs:label>HSD17B10</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3028</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q99714</ddiem:uniprotId>
    <ddiem:keggEntryId>K08683</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/148f8d9c-a254-4426-868b-3f9414661880">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
        <rdfs:label>Dystonia</rdfs:label>
        <dc:identifier>HP:0001332</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/44c63df5-8ab0-4c09-bc8a-ae37e28be212">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2d5a02e-765d-4f76-b579-e50c8335f86a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300322">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/145</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>145</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/300322</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/101d9099-ee0c-4259-a97b-36d92c291c88"/>
        <rdfs:label>LESCH-NYHAN SYNDROME; LNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1a1a94b-53a9-42a5-9fa4-47a9e245ca88">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chorea</rdfs:label>
        <dc:identifier>HP:0002072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002072</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/47bd0844-9569-48d7-b45f-ea0163240cbf">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/04abc49f-1fdd-4a40-8064-81b92f4f980d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ee08017-8317-423b-82dc-b2063e150432">
        <rdfs:label>Delirium</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031258</ddiem:url>
        <dc:identifier>HP:0031258</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f85b5544-0d88-494f-ac6f-9486e47aa3c4">
        <rdfs:label>Elevated total plasma homocysteine</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fatigue</rdfs:label>
        <dc:identifier>HP:0011025</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277400">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/90</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>90</ddiem:iembaseAccessionNumber>
        <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/277400</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9e0fe81f-5c55-4aea-a1ab-ea4fe356ec39"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41dc8657-2552-4b02-b7ce-c911d189e489"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/90f1452e-02bc-45cd-bd4f-9af0c54d8f56">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
        <dc:identifier>HP:0001878</dc:identifier>
        <rdfs:label>Haemolysis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210590</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76ac3612-4250-4198-8ecc-0ba4d5a561e6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002395</ddiem:url>
        <rdfs:label>Lower limb hyperreflexia</rdfs:label>
        <dc:identifier>HP:0002395</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24210589</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82d382ea-8f89-429b-acdb-65f8cca00509">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Anorexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <dc:identifier>HP:0002039</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/310fc5bc-d29c-4b9a-9858-abe9d7e28cb0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:label>Spasticity</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2428a104-8dda-4a0a-b337-7f6756da3dfe">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>decreased glomerular filtration rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3f5a63a-daae-4f0e-8046-2b904b9e4808">
        <rdfs:label>High urine methylmalonic acid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c631991a-acc0-4cff-927d-cf78a02f8e7d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Impaired renal function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e280d5ff-7a64-47bb-a6a3-fdd70eec525d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8da8db69-d101-48cd-be60-7e71b818e6e3">
    <ddiem:uniprotId>Q9HCJ1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0a554307-7d6d-4fa6-8f4b-ce3deee86b92">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56172</dc:identifier>
        <rdfs:label>ANKH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K22734</ddiem:keggEntryId>
    <rdfs:label>Progressive ankylosis protein homolog</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/60629959-699b-4abd-b4e1-5828f400ac90">
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16857760</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611283">
        <rdfs:comment>It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f459eb33-2bdb-4525-bfd4-9766fa163731"/>
        <dc:identifier>https://www.omim.org/entry/611283</dc:identifier>
        <rdfs:label>ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/135</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>135</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9357be8-9b1c-417e-882e-89ca73d11f70">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth abnormality</rdfs:label>
        <dc:identifier>HP:0001507</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9e529e4c-761c-4de8-b80d-d3061993870e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e63587d-2237-4f75-9c96-e381b8608b61"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b57e3445-bf2c-4588-a6e5-4fbb750d66d3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffc95155-25aa-4571-91a9-7bcc8e13888b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>low visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258870">
        <ddiem:iembaseAccessionNumber>562</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/258870</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a32ec522-4b33-4a95-835e-bf31368136c8"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/562</ddiem:iembaseUrl>
        <rdfs:label>GYRATE ATROPHY OF CHOROID AND RETINA; GACR</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28388263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81959ed2-a627-4208-8ab4-49796ba034ee">
        <dc:identifier>HP:0011505</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011505</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cystoid macular edema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616896">
    <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ed24451-a149-4b62-8a0a-be7b7a541195">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4976</dc:identifier>
        <rdfs:label>OPA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/616896</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/e31450da-447f-4499-b0ec-15237ba5ab40">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec394a12-b33c-4cbc-81a5-402cbef1b7e8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b817ee35-93cd-4ddd-bd7f-a01a072fd78c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61f70be4-8444-465d-8294-2b1629f668d0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7a0ed48-8605-4a1d-9850-529834615fda"/>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3c0a6730-faa7-4586-8b7d-0b78e68ba802">
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/628680ab-ba36-4563-ac88-f7eb81f4eed9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ae570ff-1561-48ad-89c2-9601b81b9a2c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3eda2d08-8763-431a-bdb8-542c91f1027e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25a0c679-54b6-4598-9805-61d04566fd1a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d501e7ec-80be-4287-9f79-20a129bee2d5">
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <rdfs:label>Tyrosine hydroxylase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c285dd25-a070-4509-9c69-50d6c7173e54">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7054</dc:identifier>
        <rdfs:label>TH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/98ba926c-d287-479f-b112-ac2df5f8583c">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>guanosine 5'-diphosphate (GDP)-fucose transporter</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4158b3a-1e29-4449-a91b-115a1916e223">
        <rdfs:label>SLC35C1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55343</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2b82f868-383c-4f29-bc7a-1875fb8a6005">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2767acc1-834a-45da-86cb-e37ac21d2213"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23248042</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca3d56e8-a19a-4117-84d8-593ab6f5d9d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3bde17f7-b195-4961-a42c-c26613de623f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42802682-99f5-4950-ab81-248c949bd70e">
        <dc:identifier>HP:0001250*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial epilepsy(Epilepsy)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610131">
        <ddiem:iembaseAccessionNumber>942</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/610131</dc:identifier>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/942</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b1092921-80f2-46f3-947a-b38d3fca7501"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ba9e5a8-f9de-4050-9264-319d3e3fa95b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c331788-66ef-4d23-8230-d88f8c29ac02"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d0bd5a79-c819-4a2e-a31e-92615585cdb3">
    <rdfs:label>arginine:glycine amidinotransferase</rdfs:label>
    <ddiem:ecNumber>2.1.4.1</ddiem:ecNumber>
    <ddiem:uniprotId>P50440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c0b0de97-4538-4027-8e3d-79495c764abe">
        <rdfs:label>GATM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2628</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00613</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c60de247-6e22-4aed-8646-53fbb479f382">
    <rdfs:label>beta-galactosidase</rdfs:label>
    <ddiem:uniprotId>P16278</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.23</ddiem:ecNumber>
    <ddiem:keggEntryId>K12309</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6476d1c0-0624-47f4-8787-895b071ae02a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2720</dc:identifier>
        <rdfs:label>GLB1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cc0c49f7-dfd9-4a4e-96b6-3e21f7d07079">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2a0c6510-762c-4590-9c89-8583100c8264">
        <rdfs:label>SLC25A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6576</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P53007</ddiem:uniprotId>
    <ddiem:keggEntryId>K15100</ddiem:keggEntryId>
    <rdfs:label>Tricarboxylate transport protein, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3b8da29f-43e2-4404-9077-2ef5dbcc51c4">
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af94adf7-c03d-4043-bf96-00cf970f3013">
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nephropathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c856bb88-6126-473a-ad5d-9b33e7fdf4c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4bc5c3d7-d2ca-4ee6-9cc6-0774a1d09b30"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bae95a97-2e86-4490-a618-a3551f8b317e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e035724-aac4-4529-8236-85c62dbce033"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232200">
        <ddiem:iembaseAccessionNumber>484</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/484</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232200</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/08830f77-38b5-44ad-b62e-29dcba79ad1b"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ia; GSD1A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615041">
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>640</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/640</ddiem:iembaseUrl>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615041</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a56a6d9e-e35e-49cb-be50-ca1c6363fdd1">
        <rdfs:label>RXYLT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8b120396-38d2-43f1-a112-b636268219e9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolic acidosis</rdfs:label>
        <dc:identifier>HP:0001942</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379">
        <rdfs:label>Disease progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231670">
        <dc:identifier>https://www.omim.org/entry/231670</dc:identifier>
        <ddiem:iembaseAccessionNumber>163</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLUTARIC ACIDEMIA I; GA1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1c1dceab-6837-4ec6-9881-f4c934b98011"/>
        <rdfs:comment>It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/163</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c3c1780-fe8b-4a4f-a97b-5e096fa1cc81">
        <rdfs:label>Secondary Carnitine deficiency( Carnitine deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/95a2681e-6b44-4870-865d-b28f01a40657">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9387b43b-67ab-4225-b7b1-3a26eb4e618d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335963</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f72029d2-7d16-47ec-93dd-9e2f06c71646">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/332adf54-c29d-44be-98d9-cc5f19efcb73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b77a5144-aa5f-4012-a2c2-c4bd4b5abe94">
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/192dc6c8-9f2c-44d3-aad9-98454fcac38d">
        <rdfs:label>abnormal coordination of movements</rdfs:label>
        <dc:identifier>HP:0011443</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011443</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16855203</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7a0ed48-8605-4a1d-9850-529834615fda"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9a4ca557-580b-44c3-9959-33a615356332"/>
    <rdfs:comment>This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6a9ff2d-5b64-4929-884a-9306d5c8e288">
        <rdfs:label>low brain creatine phosphate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35ea4714-0afc-45fd-bfb3-367181a1adae">
        <rdfs:label>behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf2520ee-ad24-4f6b-9e21-f4b325a8b216">
        <rdfs:label>low urinary creatine excretion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
        <dc:identifier>HP:0012113</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12557293</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec394a12-b33c-4cbc-81a5-402cbef1b7e8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bca18168-f050-4101-a424-f8b824661744">
        <rdfs:label>low cerebral creatine</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025051</ddiem:url>
        <dc:identifier>HP:0025051</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f119112c-7e81-4ba4-9fdc-b8e035affbbb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3ec5cdf-31e4-4530-a986-78d192e4ed9a">
        <rdfs:label>Postural tremor</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002174</ddiem:url>
        <dc:identifier>HP:0002174</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d2cf367-60be-4384-8323-4319c999e4f1">
        <dc:identifier>HP:0002067</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bradykinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002067</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f1d98d7-f2d7-48ae-b46b-7ded78a8053d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3c682148-2b05-4246-a4cc-31847f40f87c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44c63df5-8ab0-4c09-bc8a-ae37e28be212"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f4f55a2-09ae-4404-b5fa-3b13ecb44820">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030186</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0030186</dc:identifier>
        <rdfs:label>Kinetic tremor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac71ccb8-8cab-4eb4-b4e9-fdbb69b32183">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>parkinsonian symptoms</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <dc:identifier>HP:0001300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f0b2e52-4075-4550-a208-f27a561b97f6">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/97c7ce28-e142-427a-9554-3b199409d802">
        <rdfs:label>SLC6A19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/340024</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <rdfs:label>Sodium-dependent neutral amino acid transporter B(0)AT1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c9cf18de-bcba-4a4c-b45f-7fca6b51f5e4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/86d908c2-77eb-483a-980a-96ff7c18b111">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/767a3efd-1718-4d47-8cc4-601382397eb9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4cbcb85-6a3f-4cc1-a5bf-255b3c5dfafd">
        <dc:identifier>HP:0010818</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010818</ddiem:url>
        <rdfs:label>Generalized tonic convulsions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/238700">
        <rdfs:label>HYPERLYSINEMIA, TYPE I</rdfs:label>
        <rdfs:comment>Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ca7ed10b-a9c3-46b4-a837-f03e1f6045ca"/>
        <dc:identifier>https://www.omim.org/entry/238700</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb">
        <rdfs:label>seizures</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/31e6c248-cadf-4fed-884d-ef25566dd89e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/380fa8e8-a961-4484-89e1-6ff1caade659">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10165</dc:identifier>
        <rdfs:label>SLC25A13</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>citrin ( protein)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/42c9c6d9-9cb0-4be8-b8ea-428d62cbf5c4">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231680">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cb135b0e-f168-4a30-bc27-767b10c12e4d"/>
        <dc:identifier>https://www.omim.org/entry/231680</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD</rdfs:label>
        <ddiem:iembaseAccessionNumber>1257</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1257</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3d506fc0-09be-4f18-8122-c89d1f1adede"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aff771a3-5e21-495c-9c65-b388ee5b7edc"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26236614</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c3c1780-fe8b-4a4f-a97b-5e096fa1cc81"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44de1c34-edcb-40df-b8e2-757a7afa4677"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/beb2f5f7-9dec-4c5f-a9bb-a2eb60fcc751">
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Dysphagia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15df652e-b287-43a6-a6be-8f9381c566e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002355</ddiem:url>
        <dc:identifier>HP:0002355</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Difficulty walking</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/75efe86a-07ac-462b-8998-6b7525ea187f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b817ee35-93cd-4ddd-bd7f-a01a072fd78c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001987</dc:identifier>
        <rdfs:label>Hyperammonemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63f98437-5ac2-4723-a925-725225e80625">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35761893-660e-44c3-89e6-4ef8bfe220aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00345605</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207900">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>15</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/207900</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/15</ddiem:iembaseUrl>
        <rdfs:label>ARGININOSUCCINIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8c2688cc-471b-4b61-a591-8822f18224d2"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/550500">
    <rdfs:label>MYOGLOBINURIA, RECURRENT</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/550500</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b078ee86-0187-40cd-a873-618f363f5ee4">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO3</dc:identifier>
        <rdfs:label>MT-CO3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/12f66f73-7e24-4327-894d-1fe5ebcf5a43">
    <ddiem:ecNumber>6.3.2.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/39e89ee5-f86a-4d89-8f77-7b533522f84c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2937</dc:identifier>
        <rdfs:label>GSS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K21456</ddiem:keggEntryId>
    <rdfs:label>glutathione synthetase</rdfs:label>
    <ddiem:uniprotId>P48637</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0b100e4-eee7-478d-9298-7ae59c65fe25">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2090685-abc2-4135-8b1a-9082f73b12f1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025065</ddiem:url>
        <dc:identifier>HP:0025065</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal MCV level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613839">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f8674a48-8b35-4a07-a0f6-14ccef325874"/>
        <rdfs:label>MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/613839</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2f48cbf-338f-4bf0-91a7-2bde6d9d00bf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025546</ddiem:url>
        <rdfs:label>Abnormal hemoglobin level</rdfs:label>
        <dc:identifier>HP:0025546</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d52fb4f8-c5cd-4a7a-ade4-5d844e7fb862">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b58bc908-732e-4396-92c7-12e04368279d"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614128">
    <rdfs:label>LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/051fae58-29fd-4acf-b807-b489bb7bb795">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3945</dc:identifier>
        <rdfs:label>LDHB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>916</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/916</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/614128</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/65d61fe7-a7bb-48c7-803a-b766750a058f">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47325ca9-38dc-49f2-9374-a10b735104e1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Isoelectric electroencephalogram</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc8a3452-0b9c-4723-828c-e9a1fc85455b">
        <rdfs:label>irritability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
        <dc:identifier>HP:0000737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997880</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da733d5a-5e32-47fb-8413-b4eb9383b767">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f004f834-db36-40f1-aef8-e3ce1e429cf0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256730">
        <ddiem:iembaseAccessionNumber>305</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c6488c73-ab22-4a8a-a2e2-66a67f81bc9a"/>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/305</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/256730</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3ea5d03-8afe-4a7c-96b7-696497a9851c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004372</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004372</ddiem:url>
        <rdfs:label>Defected alertness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bacd63c7-7571-4a0d-801b-691ce61b3a8d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003657</ddiem:url>
        <dc:identifier>HP:0003657</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>granular osmiophilic deposits (GROD)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/763af198-cfdc-4bfd-8d09-6694d07801c5">
    <ddiem:uniprotId>Q13825</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.18; 4.2.1.56</ddiem:ecNumber>
    <ddiem:keggEntryId>K05607</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bfdc6684-cd64-48fd-97f9-1a2077a9893e">
        <rdfs:label>AUH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/549</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylglutaconyl-CoA hydratase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/de4d1b7d-d431-45cc-8463-2805877d20f3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/24e60e6a-b0d3-440a-b81d-98486980fef6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d60cb0b8-17e4-41c2-835e-62e2bb28d95d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e52cee29-119f-43cf-9fe0-34732dece38e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:label>hypertriglycernemia</rdfs:label>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14367b21-9a18-4909-8d49-7dc958e0d679">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a2f7a461-3c8b-44a7-859e-5c122d5cabeb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00214604</dc:provenance>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617347">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/507</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e43df821-fb88-444d-ac16-2d8e4262553e"/>
        <dc:identifier>https://www.omim.org/entry/617347</dc:identifier>
        <ddiem:iembaseAccessionNumber>507</ddiem:iembaseAccessionNumber>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE III</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1bddbe58-8dd4-4c5c-a319-0da3540dfd24">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/570ae277-9f7d-4dcb-a7ed-7ec894977c13">
        <rdfs:label>PIGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/93183</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
    <rdfs:label>beta-alanine-alpha-ketoglutarate transaminase.</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/28d4062f-32fc-449a-9b02-ed843777bc5b">
    <ddiem:uniprotId>Q14739</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/05b0d8e6-3d6b-45da-a686-380ca638b371">
        <rdfs:label>LBR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3930</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lamin B receptor</rdfs:label>
    <ddiem:keggEntryId>K19532</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.1.70</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612932">
    <ddiem:iembaseAccessionNumber>501</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/501</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/612932</dc:identifier>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XIII; GSD13</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4659b9a-cd11-42b6-8cd9-6342c3b4275a"/>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/15c46495-903a-44ad-acf6-6697cf19a93c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d0ebebb-70d7-448a-92d1-22bbf2af39ac"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc18cc19-4ba8-4aa7-8807-a08328aea0d5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/716a1c04-ecca-4583-85bb-0c5dcae453eb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Hypoglycemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b449b856-94c8-417c-92c1-792589ebbb16">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/308050">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/16d31693-9db1-4df2-a4ed-607c4927c722"/>
        <rdfs:label>CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS</rdfs:label>
        <ddiem:iembaseAccessionNumber>194</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/308050</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/194</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29341259</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bdfd1bad-24a0-40e1-8e55-9bfbff69f8f6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f36b91cb-cf64-4275-a357-30ed1fa108e4">
        <rdfs:label>Scaling Skin</rdfs:label>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ba6c32e-a625-4c93-a9d0-0802a1f91bd4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Erythema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
        <dc:identifier>HP:0010783</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9412dea-a33a-422f-91e3-a8f4c98d6672">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007431</ddiem:url>
        <dc:identifier>HP:0007431</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ichthyosiform erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59a4de98-b146-4c42-86f9-fe9e692739e2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Itchy skin</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8a95522-efeb-42ef-bfba-c88ae6b15df9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:label>Verruciform plaques(verruciform xanthomas)*</rdfs:label>
        <dc:identifier>HP:0031517*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c113b697-c07c-423e-8728-7b1669c7a848">
        <rdfs:label>VX‐like lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/07e534a8-978e-460c-aa7e-2644dace1268">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f51d139f-6a2b-4f24-950d-d3018181c90f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4afed489-6cba-4fd7-81e4-1a25f38f37c9">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d6d30b3-0ad7-4209-9a4c-23637cad6ea1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39a99bc2-4b6d-42a2-9434-52913bc4b98e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ac3a693c-83d9-4974-9665-9b15cd37066d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/789ca0f3-40ea-4056-951a-ea6314c34f3f">
        <rdfs:label>PLA2G6</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8398</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phospholipase A(2)</rdfs:label>
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b87ef4a3-c047-46c3-8066-d2bfd2af2037">
    <ddiem:uniprotId>P35575</ddiem:uniprotId>
    <ddiem:keggEntryId>K01084</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.3.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/08830f77-38b5-44ad-b62e-29dcba79ad1b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2538</dc:identifier>
        <rdfs:label>G6PC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose 6-phophatase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f8a4bd49-6017-448a-8712-9e7fb3361b25">
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/09ff3915-3e6f-4561-bc42-5549b5b12b13">
        <rdfs:label>CLCNKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1188</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Chloride channel protein ClC-Kb</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25c7b681-006d-43a9-89e1-f4356b1ac69a">
    <rdfs:label>dysferlin</rdfs:label>
    <ddiem:keggEntryId>K18261</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8bdee6e8-33fa-47c8-8a49-b9c6a44aeffd">
        <rdfs:label>DYSF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8291</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O75923</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/753e4c64-8fe4-4204-804e-0c0435052b08">
    <ddiem:keggEntryId>K13511</ddiem:keggEntryId>
    <rdfs:label>tafazzin ( Protein)</rdfs:label>
    <ddiem:uniprotId>Q16635</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b135081b-1944-4ecb-ad1e-910d0d2ce514">
        <rdfs:label>TAZ</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6901</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/afde594b-4a12-4a8b-89f6-50a945361651">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a56a6d9e-e35e-49cb-be50-ca1c6363fdd1"/>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Ribitol-5-phosphate xylosyltransferase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e02a07e1-7483-45f6-99c4-5863d4dbe336">
    <ddiem:ecNumber>4.3.2.1</ddiem:ecNumber>
    <ddiem:uniprotId>P04424</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8c2688cc-471b-4b61-a591-8822f18224d2">
        <rdfs:label>ASL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/435</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>argininosuccinate lyase</rdfs:label>
    <ddiem:keggEntryId>K01755</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3e14ee32-f417-4222-96ec-244f43762c96">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208900">
        <dc:identifier>https://www.omim.org/entry/208900</dc:identifier>
        <rdfs:label>ATAXIA-TELANGIECTASIA; AT</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8f08a98f-d46c-42bc-ab35-5b7945e356ce"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d9ef854a-4a19-436e-9886-0fef83266e30">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/963090b1-b505-459c-95af-e20683129e12"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7107cad7-7649-4d7b-908c-d835ef5781b1">
        <dc:identifier>HP:0040088</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040088</ddiem:url>
        <rdfs:label>Abnormal lymphocyte counts</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66070ec8-6f2d-4c41-92a6-6cc0d1c31126">
        <rdfs:label>Abnormal serum fast ORAC(oxygen reduced absorbance capacity)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e4a9cf5-a2ea-45c8-9e9a-9d9dec91305f"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/68473b50-4b86-4390-98ea-90ca9d700eb4">
    <ddiem:ecNumber>1.1.99.2</ddiem:ecNumber>
    <rdfs:label>L-2-hydroxyglutarate dehydrogenase.</rdfs:label>
    <ddiem:uniprotId>Q9H9P8</ddiem:uniprotId>
    <ddiem:keggEntryId>K00109</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cb1c956f-fb1b-4b49-b495-15e996d1de7a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79944</dc:identifier>
        <rdfs:label>L2HGDH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614202">
    <ddiem:iembaseAccessionNumber>611</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/611</ddiem:iembaseUrl>
    <rdfs:label>MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/03a417bd-6a76-466b-8c64-614fde94d993">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11253</dc:identifier>
        <rdfs:label>MAN1B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/614202</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/60515e8f-dda2-4c5b-a9f5-f6395afe4ba0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8804338</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
    <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17299485</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/243500">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>56</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/243500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a7d755cf-b31f-47d9-ad33-ad0128810b14"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/56</ddiem:iembaseUrl>
        <rdfs:label>ISOVALERIC ACIDEMIA; IVA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c07abef5-5360-4942-8f38-21a7b35275cb">
        <rdfs:label>Metabolic stress</rdfs:label>
        <dc:identifier>HP:0001942</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
        <rdfs:comment>The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15624372</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74b0998d-888d-40b2-853b-8ee47f63650c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High toxic acyl-CoA level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2bcfa53-5bc7-4d60-b7d0-6cf0506fabcc">
        <rdfs:label>"abnormal Na+,K+-ATPase activity"</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f7d8246-e9a8-4e3c-911f-22768209e65e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/069744d2-e093-4be9-be9a-92bbf43ea273"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069539</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20807522</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10a25872-9231-4dd1-b5bd-e1dd87ecc820">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High 3-hydroxyisovaleric acid level (C5)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16602101</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71aea9fb-5d64-4454-a18f-174158f99aaa">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Developmental delay</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21290185</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611209">
    <dc:identifier>https://www.omim.org/entry/611209</dc:identifier>
    <ddiem:iembaseAccessionNumber>344</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/224651e4-a514-447d-beb9-29e0a2e5c469">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9382</dc:identifier>
        <rdfs:label>COG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/344</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a707954b-3085-4cd2-b2e6-d1e6d68d9059">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72e81347-7d04-4812-aa2b-70c547fb9de5">
        <rdfs:label>SLC6A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19</rdfs:label>
    <ddiem:uniprotId>Q695T7</ddiem:uniprotId>
    <ddiem:keggEntryId>K05334</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffb2c8b0-764e-4386-98dd-755c91cc4ae5">
        <rdfs:label>SLC36A2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/153201</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q495M3</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/97c7ce28-e142-427a-9554-3b199409d802"/>
    <ddiem:keggEntryId>K14209</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9NP91</ddiem:uniprotId>
    <ddiem:keggEntryId>K05048</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ea0f3dc2-c4e7-49f9-9758-9296e63870fb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0dfaedd-db97-4242-aaf3-ac639cb82539">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f69335b-8fbf-4705-b160-2ae95519ec35"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca84bb55-77c7-4eb3-bb93-fb35f582d860">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Study is still recruiting</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/218800">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/218800</dc:identifier>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE I</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b066539-7726-40bf-99cc-ee56bb326b4b"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4fab8c5-2cbf-470d-8031-763a5647deac">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/694231ac-3146-4745-9e54-2b5b08149251">
        <rdfs:label>LRPPRC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10128</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>leucine-rich pentatricopeptide repeat-containing protein</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608799">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/336</ddiem:iembaseUrl>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e7145a9f-c587-4a3d-a61f-7d107ecf6e49">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8813</dc:identifier>
        <rdfs:label>DPM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/608799</dc:identifier>
    <ddiem:iembaseAccessionNumber>336</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9fc5e383-4747-43b6-8aed-ac2210a66273">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14c8bdf7-b2a9-45cf-876f-384392f88126">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4f9495a7-9b51-4ad2-92fe-261e13cd1c32"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15df652e-b287-43a6-a6be-8f9381c566e1"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615156">
        <ddiem:iembaseAccessionNumber>946</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/615156</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/057b72bf-f310-484f-af18-349b54b2b2ba"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/946</ddiem:iembaseUrl>
        <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945"/>
    <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aa93f01c-198d-4d0a-b18c-6b675d0dcb1a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b34e13cb-66f1-4cc0-94a8-749398fadefa">
        <rdfs:label>MT-TS1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/86d9d33e-39f8-46f3-be77-c81c7a39af88">
        <rdfs:label>MT-TE</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TE</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/02d43ae8-8ad4-4f5a-a125-8b9ed3b8c67f">
        <rdfs:label>MT-ND5</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-ND5</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/242250cc-579c-4b86-b9ca-616f549b3da1">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TS2</dc:identifier>
        <rdfs:label>MT-TS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f559171f-1ce5-488b-8e48-61d64181f2de">
        <rdfs:label>MTTC</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MTTC</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ea21eaa9-345c-47aa-a6af-5e375552ac16"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec3bb8b8-2f3d-43ef-8ebf-13474e6e4d59">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TQ</dc:identifier>
        <rdfs:label>MT-TQ</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/362e6f81-6141-4f68-9ca4-ee73102faf8a">
        <rdfs:label>MT-TH</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TH</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3c4863f1-79bc-462d-8b41-3ea5814ffbdd"/>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/489fe16c-30e2-4a77-be10-2aeaeb6a91b6">
        <rdfs:label>MT-TL1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-TL1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060">
        <rdfs:label>MT-TK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/493ded40-ebf3-4592-ae12-f195386008e2">
    <ddiem:keggEntryId>K00857</ddiem:keggEntryId>
    <rdfs:label>Thymidine kinase 2, mitochondrial</rdfs:label>
    <ddiem:uniprotId>O00142</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/193ccddd-29d6-40f8-99bf-0770c6ee1782">
        <rdfs:label>TK2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7084</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.21</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c9bc97ff-8d7e-4354-8d3b-27205efabb17">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e088253-ec29-43f5-bcdd-94130c531deb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5102282e-9dc7-4d0a-9ddb-5a6427deff97"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610768">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/342</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/610768</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>342</ddiem:iembaseAccessionNumber>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d4fd7104-d75d-4465-a2d5-7ed3a489d0cb"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef528711-ef61-4178-8c97-8679e967527a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/482a04bb-974e-4b49-b050-37582ecd4978"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4038779e-b440-4235-a7ce-5be819e687f5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9ed0262d-971f-40cb-a6b9-a5c78e707774">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6be32d14-ba84-44c9-b5a0-352213e73899"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba581f67-45af-4e4a-9680-4a233d1f036a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/423fd858-2700-4ed9-90c6-063cde8137b0">
        <dc:identifier>HP:0000939</dc:identifier>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <rdfs:label>Osteoporosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232400">
        <rdfs:label>GLYCOGEN STORAGE DISEASE III; GSD3</rdfs:label>
        <rdfs:comment>Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b542d036-2949-4809-bec8-bd3cb6952d00"/>
        <dc:identifier>https://www.omim.org/entry/232400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/487</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>487</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/95b2e5ea-c4ba-4458-ba0b-fab3006aaf79">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232220">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0f69d2cc-c67f-4b6a-820e-664bea25c4ed"/>
        <dc:identifier>https://www.omim.org/entry/232220</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/485</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GLYCOGEN STORAGE DISEASE Ib; GSD1B</rdfs:label>
        <ddiem:iembaseAccessionNumber>485</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a98148a-fdb5-4f79-a382-3dc3da7a8e64">
        <rdfs:label>Sleep disturbance,Poor sleep qaulity</rdfs:label>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b202fcb-f19f-45ad-92b7-0b78e188cbf4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aee6c829-ce72-4fc9-afac-d08058afd682"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d32f705-18e7-4385-b2a6-424b59e1977f">
        <rdfs:label>Low quality of life(Constitutional symptoms)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88141393-be5d-4114-9986-90c720b808d9">
        <dc:identifier>HP:0003162</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003162</ddiem:url>
        <rdfs:label>Fasting hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8cb31996-c7b2-4e57-b3a2-efc2d35ed8ea">
    <ddiem:ecNumber>3.1.3.4</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e4cdecaf-3158-4051-bfa6-7bcb8ffddf3d">
        <rdfs:label>LPIN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23175</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphatidate phosphatase</rdfs:label>
    <ddiem:keggEntryId>K15728</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14693</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c36e9a09-86d2-4f01-bcba-399d200851ca">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9fb1c5ba-195c-4acf-84c7-6b5c32c9a0d8">
        <rdfs:label>TTPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7274</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>α-tocopherol transfer protein</rdfs:label>
    <ddiem:uniprotId>P49638</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8905d646-6f54-46e7-abaf-7c9ff8acf157">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ccb1642b-043a-40df-aa5b-8240a4fe6c8c">
        <rdfs:label>GBA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.45; 2.4.1.-; 3.2.1.104</ddiem:ecNumber>
    <ddiem:keggEntryId>K01201</ddiem:keggEntryId>
    <rdfs:label>beta-glucocerebrosidase</rdfs:label>
    <ddiem:uniprotId>P04062</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42093b70-4697-44df-9188-16ff60f50956">
    <ddiem:ecNumber>1.3.1.72</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ae0bd6a-e367-40f3-b2e2-5abaa51fbb21">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1718</dc:identifier>
        <rdfs:label>DHCR24</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09828</ddiem:keggEntryId>
    <rdfs:label>3-beta-hydroxysterol delta-24-reductase</rdfs:label>
    <ddiem:uniprotId>Q15392</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c2f71c75-2411-4c1e-b26d-1571f3dd9f55">
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d18a1a41-b771-4155-b3fd-137c84b67def">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurological abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0804790f-cee2-41a5-b82b-642d14210a0a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47d6a56d-fcb6-40a8-a6d2-f41f419ec89d">
        <rdfs:label>Disease progression (Progressive)</rdfs:label>
        <dc:identifier>HP:0003676</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c5987181-23a0-47e6-b1b9-107a40fc20da">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3ea8285f-859e-441d-aeb2-1598138bad9b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/200100">
        <ddiem:iembaseAccessionNumber>371</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/200100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/371</ddiem:iembaseUrl>
        <rdfs:comment>The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/236420f0-b954-42c0-8fce-df7418752463"/>
        <rdfs:label>ABETALIPOPROTEINEMIA; ABL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43dfa170-99c8-4be0-a11b-6415c3210e62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e7b8c6ac-e798-4fa2-befc-3f1d47a0f40f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcf60db0-3930-4345-9be9-2caacd7a13f5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001877*</dc:identifier>
        <rdfs:label>High erythrocyte turnover(Abnormality of erythrocytes)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9e750dea-6fb6-49d9-bf87-de98e8ed421a">
    <rdfs:label>alpha subunit of muscle phosphorylase kinase</rdfs:label>
    <ddiem:uniprotId>P46020</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6a61423-013f-4868-9ee8-94656ed4f967">
        <rdfs:label>PHKA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5255</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3796bd97-a804-4103-924c-8eff4b3eada5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9017b042-9c89-46e5-83be-4322fc2c74e0">
        <rdfs:label>DPYS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1807</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>dihydropyrimidinase</rdfs:label>
    <ddiem:keggEntryId>K01464</ddiem:keggEntryId>
    <ddiem:ecNumber>3.5.2.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q14117</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9fbeb54e-99cb-41e9-bbf3-d328cc52fa6a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18381602</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26170630</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dcfc99a-6e3c-4372-9221-f17087b34af5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002664</ddiem:url>
        <rdfs:label>neoplastic growth</rdfs:label>
        <dc:identifier>HP:0002664</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/61a30360-9e4b-4df9-9be2-58cbf5962aa0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/006c5a50-65f6-4ab3-88da-a45bd7578e8c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162300">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/04233dcf-bcbd-4d35-aedb-b1ee8bd74743"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/162300</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9e112792-a268-496d-8885-8577e1b0e68d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ff5bd25-907a-4f6c-8da8-056a828f48b9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95b52104-9025-454a-a239-905795db2dc9">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608896">
        <rdfs:label>SARCOGLYCAN, GAMMA; SGCG</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/608896</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3f6b222f-35ac-4789-9495-9a62269c25b4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15252120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd99f5e5-8d5c-4b7e-b78c-2c3872880d75">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b4a6b9a-8d7b-483a-93a0-ac5d86916b3f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/59622a81-72bb-485a-8c04-639b1a51a307">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f33f0ea1-419a-4689-8986-a31da8b83394">
        <dc:identifier>HP:0004923</dc:identifier>
        <rdfs:label>high plasma phenylalanine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d18a1a41-b771-4155-b3fd-137c84b67def"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25d6b5f7-6657-40e8-8c47-de68c77da99d">
        <dc:identifier>HP:0010893</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010893</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal blood Phe levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3d5ba4c-21d3-43d5-aa8d-9cd4631eeaab">
        <rdfs:label>High serum  prolactin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040086</ddiem:url>
        <dc:identifier>HP:0040086</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eebabc76-5b01-4a6b-9047-ef49a71a1abf">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc9a4b4a-9351-4df4-82ef-b76585e0732d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f58e279d-7d8a-480e-9730-aaf9eea38482"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f8790737-5700-4534-b79b-81a6bc7adc5a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <dc:identifier>HP:0002904</dc:identifier>
        <rdfs:label>Study was suspended based on Sponsor Decision.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3f3895a3-d2f3-499c-84cb-18a5d8374455">
    <rdfs:label>atrophin 1</rdfs:label>
    <ddiem:uniprotId>P54259</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/082b2681-5d4d-4da7-a8f5-b9284a313592">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1822</dc:identifier>
        <rdfs:label>ATN1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05626</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3c628303-dbb6-4926-96d8-717b1b140987">
    <ddiem:ecNumber>2.7.1.6</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/79d7ddad-3008-4d3a-a8e4-1da1ea060af8"/>
    <rdfs:label>galactokinase 1</rdfs:label>
    <ddiem:uniprotId>P51570</ddiem:uniprotId>
    <ddiem:keggEntryId>K00849</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/75058b5b-cabf-47eb-9bb1-0c7b26ecbd11">
    <rdfs:comment>Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1a5cefa-8cf5-4331-ad9b-1c623a310034"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a2bd349-e4b9-462c-a6d3-44182df1afbb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/87d681b0-1cbb-4857-ae84-b89cc564c4b4">
    <rdfs:label>dolichol kinase</rdfs:label>
    <ddiem:keggEntryId>K00902</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UPQ8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d4fd7104-d75d-4465-a2d5-7ed3a489d0cb">
        <rdfs:label>DOLK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/22845</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.108</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/76a7fe1f-08a5-4f80-b5f0-0921d3c66827">
    <ddiem:uniprotId>P40939</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fcf081a9-f4df-49c2-bd2e-4fd8c55eeb08">
        <rdfs:label>HADHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3030</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.-; 4.2.1.17; 1.1.1.211</ddiem:ecNumber>
    <rdfs:label>3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase</rdfs:label>
    <ddiem:keggEntryId>K07515</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4175cdf1-25ab-463f-8772-22a185d6aba1">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/017d9159-66c0-4733-b5dd-b30c59a757f4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50484</dc:identifier>
        <rdfs:label>RRM2B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q7LG56</ddiem:uniprotId>
    <ddiem:keggEntryId>K10808</ddiem:keggEntryId>
    <rdfs:label>Ribonucleoside-diphosphate reductase subunit M2 B</rdfs:label>
    <ddiem:ecNumber>1.17.4.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb67af79-8cd9-41da-b38a-4c7d2c40d860">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603174">
        <dc:identifier>https://www.omim.org/entry/603174</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/661e9ec4-5cc6-436a-9906-60648fa3c4dc"/>
        <rdfs:label>HOMOCYSTEINEMIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29246599</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91ac2afd-1bd2-4cf5-85cc-3fccfdbdb245">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>High plasma homocysteine level(Abnormal homocysteine level)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52fb4f8-c5cd-4a7a-ade4-5d844e7fb862"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2bba2115-37b8-4592-a5b8-a2c4ebbf735c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>The combination was accompanied by Low L-lysine diet</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/551d87b6-2ee4-45b1-aff9-bd1e1d3ad888">
        <rdfs:comment>Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003530</ddiem:url>
        <rdfs:label>Glutaric acidemia</rdfs:label>
        <dc:identifier>HP:0003530</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57aef328-ef45-4afb-a83c-700b9074bc47">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b84da21-bca8-4f65-a004-3269172b2522"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20923787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f72029d2-7d16-47ec-93dd-9e2f06c71646"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f98437-5ac2-4723-a925-725225e80625"/>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616538">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/616538</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a2e813f6-ddcf-4d17-b5df-304fa29d45a0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1605</dc:identifier>
        <rdfs:label>DAG1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4e2c099-5d5b-4351-9c1a-4a02c6082ab7">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e43df821-fb88-444d-ac16-2d8e4262553e">
        <rdfs:label>APOE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P02649</ddiem:uniprotId>
    <rdfs:label>apolipoprotein E</rdfs:label>
    <ddiem:keggEntryId>K04524</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/3b14e4cf-f9dd-4e08-94fb-e89b3125a9ac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232700">
        <rdfs:label>GLYCOGEN STORAGE DISEASE VI; GSD6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72e2febb-74a7-4a2e-82c2-8203b07b25d8"/>
        <ddiem:iembaseAccessionNumber>490</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/490</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/232700</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b57e3445-bf2c-4588-a6e5-4fbb750d66d3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86021ead-2790-4022-acc4-de6f6008bb0e">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Hepatic transaminases</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08bde810-5c15-4c7c-adff-df785769ded7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/142b49f7-872a-4874-b785-3cf51b615b7a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18848477</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f85b5544-0d88-494f-ac6f-9486e47aa3c4"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3f5a63a-daae-4f0e-8046-2b904b9e4808"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0720ef36-ffc1-4fb4-8fce-13c125578c0f">
    <ddiem:uniprotId>Q04446</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.18</ddiem:ecNumber>
    <ddiem:keggEntryId>K00700</ddiem:keggEntryId>
    <rdfs:label>Limit dextrin alpha-1,6-maltotetraose-hydrolase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dda8ecd2-daa3-4ef0-ac71-cd36ff3682ea">
        <rdfs:label>GBE1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2632</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f378ca93-6d60-45ad-ad5f-1f950ba9a6e7">
    <rdfs:label>thiamine transporter</rdfs:label>
    <ddiem:uniprotId>Q9BZV2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/929a7de0-efec-4bc4-b7f9-83773738212e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80704</dc:identifier>
        <rdfs:label>SLC19A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14610</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215140">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/05b0d8e6-3d6b-45da-a686-380ca638b371"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/197</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/215140</dc:identifier>
    <ddiem:iembaseAccessionNumber>197</ddiem:iembaseAccessionNumber>
    <rdfs:label>GREENBERG DYSPLASIA; GRBGD</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed24fed3-4c9d-4105-aae2-0a1738705216">
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5071bde7-5c1e-4ddb-947c-93c6260d602d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80270</dc:identifier>
        <rdfs:label>HSD3B7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
    <rdfs:label>3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600627">
    <rdfs:comment>Hypertryptophanemia should be regarded as a benign condition</rdfs:comment>
    <rdfs:label>HYPERTRYPTOPHANEMIA; HYPTRP</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/618</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>618</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d2c7d2d-2292-4b74-aa9e-78261545a00e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6999</dc:identifier>
        <rdfs:label>TDO2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/600627</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/34a4dfbb-d72f-48a2-87c3-9dd6b7228e06">
    <rdfs:label>Ferroxidase</rdfs:label>
    <ddiem:uniprotId>P00450</ddiem:uniprotId>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
    <ddiem:keggEntryId>K13624</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4c7395a-f031-42da-8649-d9a3b240f4ab">
        <rdfs:label>CP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1356</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9168b600-cfe4-47bb-adf7-502f86221751">
    <ddiem:keggEntryId>K12385</ddiem:keggEntryId>
    <rdfs:label>NPC intracellular cholesterol transporter 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/145c8f2b-706c-429f-9740-d4f532266c21">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4864</dc:identifier>
        <rdfs:label>NPC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O15118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3281bd36-e349-4f12-941b-2366fcc16480">
    <ddiem:keggEntryId>K17686</ddiem:keggEntryId>
    <rdfs:label>Copper-transporting ATPase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7baf8ce5-3b10-4980-96ca-188607d9226a">
        <rdfs:label>ATP7A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/538</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q04656</ddiem:uniprotId>
    <ddiem:ecNumber>7.2.2.8</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0fd2f287-8dc8-493b-81ab-7fcb4c3179a4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ec7f2a5c-5fe5-44a6-b378-b8bbe2921cfe">
        <rdfs:label>LCAT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3931</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00650</ddiem:keggEntryId>
    <ddiem:uniprotId>P04180</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.43</ddiem:ecNumber>
    <rdfs:label>lecithin-cholesterol acyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/694e4ad9-2ff2-4b2b-ba00-fda3479ad017">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit beta, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a691596b-c5c6-4cd7-8741-feee0422f97a">
        <rdfs:label>BCKDHB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/594</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00167</ddiem:keggEntryId>
    <ddiem:uniprotId>P21953</ddiem:uniprotId>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/cf34f5cc-fa5a-4283-be4d-369869b2b75c">
    <rdfs:label>battenin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4fe7da94-2aaf-4fb5-92ab-c31e95ca2f47">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1201</dc:identifier>
        <rdfs:label>CLN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12389</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13286</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/134850ff-244d-4aee-b536-06fae5070be2">
    <rdfs:label>Cholestanetriol 26-monooxygenase</rdfs:label>
    <ddiem:keggEntryId>K00488</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c1deed87-3511-422d-8ab3-81f8cd046260">
        <rdfs:label>CYP27A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.15.15</ddiem:ecNumber>
    <ddiem:uniprotId>Q02318</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/baa0a588-abd5-419d-aa36-51c7e17b0606">
    <rdfs:label>Fukutin-related protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/98d61ac2-3497-4d41-b6cf-2f3ac04c348d">
        <rdfs:label>FKRP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79147</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/78f2ad79-ea62-44d4-9fce-ea6a2d4be567">
    <ddiem:keggEntryId>K12359</ddiem:keggEntryId>
    <rdfs:label>CLN6, transmembrane ER protein</rdfs:label>
    <ddiem:uniprotId>Q9NWW5</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7f8a1f50-55f8-4db1-8431-de64b07035b4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54982</dc:identifier>
        <rdfs:label>CLN6</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e080c444-0f01-4e28-aaaf-221e1d6e3c60">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52fb4f8-c5cd-4a7a-ade4-5d844e7fb862"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5301410</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/10921de6-9125-4306-84ae-c8b24173ee3e"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/47</ddiem:iembaseUrl>
        <rdfs:comment>The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/229100</dc:identifier>
        <rdfs:label>GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>47</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ecbc3e5-d9d3-40a4-8134-938cb5542d98">
        <rdfs:label>Megaloblastic anemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001889</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00e5c32e-763d-49fc-baeb-cf601226c055">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/274270">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>159</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/274270</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8b198797-3144-44df-a3e5-d42093f4cdd7"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/159</ddiem:iembaseUrl>
        <rdfs:label>DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86d908c2-77eb-483a-980a-96ff7c18b111"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1c4f30b-fed5-4203-bf5d-9f4f73ec3e57">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fef90df3-884a-4515-926c-078e4a15f187">
        <rdfs:label>POMT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10585</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>protein O-mannosyltransferase 1</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9040c270-f2dd-4452-93f0-f71dcd8019f6">
    <ddiem:uniprotId>P33897</ddiem:uniprotId>
    <rdfs:label>adrenoleukodystrophy protein</rdfs:label>
    <ddiem:keggEntryId>K05675</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1d11548a-63eb-4eed-8e1a-a275a70855ed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/215</dc:identifier>
        <rdfs:label>ABCD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7ba8fbac-20a2-4988-bcea-6a6e49b5d805">
    <ddiem:uniprotId>Q9H3Z4</ddiem:uniprotId>
    <ddiem:keggEntryId>K09525</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ad668847-fdc2-45dd-85a0-89e2f19114e5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/80331</dc:identifier>
        <rdfs:label>DNAJC5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>DnaJ homolog subfamily C member 5(cysteine string PROTEIN)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/162b47d9-f48f-4750-8f26-cc34bc836468">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6da2ec29-acf5-4098-8449-0d492cd8357c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/249</dc:identifier>
        <rdfs:label>ALPL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
    <rdfs:label>tissue-nonspecific alkaline phosphatase (TNSALP)</rdfs:label>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/355521fb-83da-4f07-907d-aace633dd31b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56080811-002d-48b4-b714-739907bcaad6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>anorexia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002039</ddiem:url>
        <dc:identifier>HP:0002039</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de">
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/33918bb1-cf22-46b0-b38a-d1723ad860fe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Poor growth</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d4b0eac-8bdc-4c64-a9bf-83fdb307e947">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011966</dc:identifier>
        <rdfs:label>Elevated plasma citrulline level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64bf5369-14a6-4a16-a650-44fe9d607b42">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated serum pancreatic secretory trypsin inhibitor</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e579e51c-37d6-4d88-8d59-de3f10369cdc">
        <dc:identifier>HP:0004337*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004337</ddiem:url>
        <rdfs:label>Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603471">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/380fa8e8-a961-4484-89e1-6ff1caade659"/>
        <rdfs:comment>Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/603471</dc:identifier>
        <rdfs:label>CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2</rdfs:label>
        <ddiem:iembaseAccessionNumber>18</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/18</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96e271f8-1ebc-48c1-868c-a5ad11c5c752">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001254</dc:identifier>
        <rdfs:label>lethargy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001254</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4778763-5d74-464e-a95c-eec305e38d80">
        <dc:identifier>HP:0012378</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>fatigue</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/072c54bd-247d-4958-9be2-1105e8c76589">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b4cb137-3b00-4fda-8c4b-60934bf934d8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f98437-5ac2-4723-a925-725225e80625"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8549377f-de9d-4d6b-aded-8ab78b982955">
    <rdfs:label>uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/90abb27f-22a6-4e6d-8a70-0e5a26a187c3">
        <rdfs:label>HEF</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/HEF</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/76590087-0290-4d27-a7d3-7820674b85de">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7389</dc:identifier>
        <rdfs:label>UROD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.1.1.37</ddiem:ecNumber>
    <ddiem:uniprotId>P06132</ddiem:uniprotId>
    <ddiem:keggEntryId>K01599</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/646066b0-ae4e-42ae-8a1a-65e0c21d910b">
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b57e3445-bf2c-4588-a6e5-4fbb750d66d3"/>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56e43597-a050-47c2-8daa-29f8a95e228f">
    <ddiem:ecNumber>2.7.11.1</ddiem:ecNumber>
    <rdfs:label>ATM serine/threonine kinase</rdfs:label>
    <ddiem:uniprotId>Q13315</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8f08a98f-d46c-42bc-ab35-5b7945e356ce">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/472</dc:identifier>
        <rdfs:label>ATM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04728</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01686f46-8e36-4e80-9cce-68b51640c6b0">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/990c80cf-5204-4baa-a23b-c3040217bce6">
        <rdfs:label>CUBN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8029</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O60494</ddiem:uniprotId>
    <ddiem:uniprotId>Q9BXJ7</ddiem:uniprotId>
    <ddiem:keggEntryId>K18259</ddiem:keggEntryId>
    <ddiem:keggEntryId>K14616</ddiem:keggEntryId>
    <rdfs:label>cubilin/amnion associated transmembrane protein</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d8520402-b555-41d5-94a3-922f600c4e47">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/81693</dc:identifier>
        <rdfs:label>AMN</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/597af323-28d6-480a-8d92-958eafe8f886">
    <ddiem:uniprotId>P81172</ddiem:uniprotId>
    <rdfs:label>hemojuvelin/hepcidin</rdfs:label>
    <ddiem:uniprotId>Q6ZVN8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1f64ffc8-8823-4057-baae-fb624a3dc06c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/57817</dc:identifier>
        <rdfs:label>HAMP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K23106</ddiem:keggEntryId>
    <ddiem:keggEntryId>K23100</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6a568a0a-1b8c-418d-b918-096def1cdf4a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148738</dc:identifier>
        <rdfs:label>HJV</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4162c91c-a821-49a0-b366-3d508a67b444">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88493032-4aa3-4834-89b6-d80deea738e1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>membranoproliferative glomerulonephritis</rdfs:label>
        <dc:identifier>HP:0000793</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000793</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ac6f019-2738-4d2a-9717-737de462fbbc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d8acc1f-2647-4279-b924-43fe64077193"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f2474751-b88f-4649-b3a8-81f063649d7f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cab8ab31-8471-400c-993c-6a3c71cf4dbc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28087478</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/51</ddiem:iembaseUrl>
        <rdfs:label>LYSINURIC PROTEIN INTOLERANCE; LPI</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/222700</dc:identifier>
        <rdfs:comment>General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffd0b716-871c-421c-8f76-03c3264bf0ed"/>
        <ddiem:iembaseAccessionNumber>51</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b4568b9e-2029-471e-8ced-03385775d546">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/46ead6fb-54f6-4d72-998e-03cb224b9717">
        <rdfs:label>HADH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3033</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q16836</ddiem:uniprotId>
    <ddiem:keggEntryId>K00022</ddiem:keggEntryId>
    <rdfs:label>3-hydroxylacyl-CoA dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.1.1.35</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a64af9b-003f-4a08-a6c9-2f7e312027a9">
    <rdfs:label>3-hydroxy-2-methylbutyryl-CoA dehydrogenase</rdfs:label>
    <ddiem:uniprotId>P45954</ddiem:uniprotId>
    <ddiem:ecNumber>1.3.8.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0cfb1338-fe89-4ac2-88f8-616c15a6fdf5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/36</dc:identifier>
        <rdfs:label>ACADSB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09478</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611722">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/292</ddiem:iembaseUrl>
    <rdfs:label>KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>292</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/611722</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c7e5d5f-e927-47ee-abd6-b0c9dee27018">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5660</dc:identifier>
        <rdfs:label>PSAP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c10aec0-98eb-413e-ad76-d7c6af86c5d2">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d96f5243-9798-4df0-baf8-f47d6019f6e1">
        <rdfs:label>QDPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5860</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>quinoid dihydropteridine reductase</rdfs:label>
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8f9844d8-d210-4e2d-9838-dbd90ecef0cc">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4b829c1f-6a6c-400c-8a91-d623b7724d09">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79158</dc:identifier>
        <rdfs:label>GNPTAB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08239</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.8.17</ddiem:ecNumber>
    <ddiem:uniprotId>Q3T906</ddiem:uniprotId>
    <rdfs:label>(α) &amp;(β)GlcNAc-1-phosphotransferas</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248510">
    <ddiem:iembaseAccessionNumber>261</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/261</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8556cc42-3388-4764-a914-3e4e6c3fba67">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4126</dc:identifier>
        <rdfs:label>MANBA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/248510</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1ed9ccb-bd2d-4450-aa43-21093edb04c1">
    <rdfs:label>iduronidase, alpha-L</rdfs:label>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a7f5a96-2208-476b-affb-88283e09e668">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3425</dc:identifier>
        <rdfs:label>IDUA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/628b30f5-6a7d-4515-a3de-ebe16bed8a7a">
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/535000">
        <rdfs:label>LEBER OPTIC ATROPHY</rdfs:label>
        <ddiem:iembaseAccessionNumber>402</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/535000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/402</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/15f6bfee-cba3-437a-b639-b9993b7e04a4"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5be07c82-a8d4-43fe-8ce6-16586262b3fa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37c14992-7b9e-459a-acc7-bf1fac5bcc6c">
        <dc:identifier>HP:0012823*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012823</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Slow recovery</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b6e4db24-44a2-4636-a252-8d74dfad8590">
    <rdfs:label>Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase</rdfs:label>
    <ddiem:ecNumber>3.4.16.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K13289</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d015184d-9310-47c5-a503-6b1452978a60">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5476</dc:identifier>
        <rdfs:label>CTSA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10619</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e680d05a-1e1f-402d-a68a-39e5940e4df1">
    <ddiem:uniprotId>Q9UBK8</ddiem:uniprotId>
    <ddiem:ecNumber>1.16.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K00597</ddiem:keggEntryId>
    <rdfs:label>Methionine synthase reductase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f3d31e82-7b22-4f80-a4df-1a906362951c">
        <rdfs:label>MTRR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4552</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/252500">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/299</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4b829c1f-6a6c-400c-8a91-d623b7724d09"/>
    <dc:identifier>https://www.omim.org/entry/252500</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUCOLIPIDOSIS II ALPHA/BETA</rdfs:label>
    <ddiem:iembaseAccessionNumber>299</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/53fabc9f-4fba-4913-8fc6-4aa91c55a096">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>Muscle weakness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f7d8246-e9a8-4e3c-911f-22768209e65e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3229565</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c653f7f-69f6-4807-b71a-7099cd9825b3">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2c7e5d5f-e927-47ee-abd6-b0c9dee27018"/>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d3b682cc-1f61-435e-b850-f3f8c12bff4b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0f69d2cc-c67f-4b6a-820e-664bea25c4ed">
        <rdfs:label>SLC37A4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2542</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase)</rdfs:label>
    <ddiem:uniprotId>O43826</ddiem:uniprotId>
    <ddiem:keggEntryId>K08171</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4180ea1f-ff83-480e-a308-5a99d1b9261c">
    <ddiem:uniprotId>P19440</ddiem:uniprotId>
    <ddiem:keggEntryId>K18592</ddiem:keggEntryId>
    <ddiem:ecNumber>3.4.19.13; 2.3.2.2; 3.4.19.14</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c4278b4f-d515-47c2-a0ae-a4b75994da7f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2678</dc:identifier>
        <rdfs:label>GGT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bcd18922-276e-44fd-96e1-8b2754ff8d8a">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>D-ribitol-5-phosphate cytidylyltransferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/96ee0c80-0c9d-406b-af95-9503d212c6d3">
        <rdfs:label>ISPD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9c094199-da0b-4edd-8430-95af2c5170ef">
    <ddiem:uniprotId>Q6PI48</ddiem:uniprotId>
    <rdfs:label>mitochondrial aspartyl-tRNA synthetase</rdfs:label>
    <ddiem:ecNumber>6.1.1.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/668f6568-24a6-4a71-a24a-70f69d40ddba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55157</dc:identifier>
        <rdfs:label>DARS2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01876</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611307">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73531151-6361-428c-a016-5cdee78cef4c">
        <rdfs:label>ANO5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/203859</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/611307</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ed220217-73a0-4a81-8c8f-13590b52ce95">
    <ddiem:keggEntryId>K00948</ddiem:keggEntryId>
    <ddiem:ecNumber>2.7.6.1</ddiem:ecNumber>
    <ddiem:uniprotId>P60891</ddiem:uniprotId>
    <rdfs:label>Ribose-phosphate diphosphokinase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8a8b57ea-0b20-410d-bd87-fa1a73f952ee">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5631</dc:identifier>
        <rdfs:label>PRPS1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/763e78db-d61c-4cfd-92a2-c776472edb9d">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/360f4f51-fd06-42a0-a1ca-26925c8997be">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/427</dc:identifier>
        <rdfs:label>ASAH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13510</ddiem:uniprotId>
    <rdfs:label>acid ceramidase</rdfs:label>
    <ddiem:ecNumber>3.5.1.23; 3.5.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K12348</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c8debfc5-7324-49dc-99bf-a518c06ee400">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c14e05f6-b684-4aa6-9cd3-d67466315313">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:label>Encephalopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e853763f-a77f-4763-9f72-9c8dc97577ba">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3baeee1-ccd6-42e8-9453-a79f7239739c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70f62010-bed7-47ed-bd05-da3fb1623c87">
        <rdfs:label>Lactic acidosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a1dc686-b86c-4ed7-876c-d3cdd8472467">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002572</dc:identifier>
        <rdfs:label>Repeated vomiting</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14765544</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79b1e32f-fe8c-41e2-866e-154e63fcca8c">
    <ddiem:uniprotId>Q9Y276</ddiem:uniprotId>
    <rdfs:label>ubiquinol-cytochrome c reductase complex chaperone</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/83f99ecb-9785-4fa9-86cc-00c40053e17c">
        <rdfs:label>BCS1L</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/617</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K08900</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c32c6b42-36f4-4ac4-b951-bcbfc92cbd78">
    <rdfs:label>methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/661e9ec4-5cc6-436a-9906-60648fa3c4dc">
        <rdfs:label>MTHFR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4524</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000016">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:09:20+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:label xml:lang="en">functional complementation or a defective protein by stimulation</rdfs:label>
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that stimulates a component of the pathway or network in which a genetically defective defective protein is found, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d539b8eb-4d57-4ca3-839e-2eb4e521b0ea">
    <ddiem:ecNumber>2.3.1.9</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/238b8803-1d7e-4550-957d-34fb95b316ac">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/38</dc:identifier>
        <rdfs:label>ACAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Acetyl-CoA C-acetyltransferase.</rdfs:label>
    <ddiem:uniprotId>P24752</ddiem:uniprotId>
    <ddiem:keggEntryId>K00626</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6ff82d8e-664c-4cc9-989c-b8c8a16b67ed">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602473">
        <ddiem:iembaseAccessionNumber>172</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602473</dc:identifier>
        <rdfs:label>ENCEPHALOPATHY, ETHYLMALONIC; EE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c827f6cf-1e13-4d75-a499-c17aa9cb9653"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/172</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26917598</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9fe8e71-6110-4e72-8642-fc847f42f22e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f757f83f-d920-459a-a4d4-cfb8cbd1af74"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606812">
    <ddiem:iembaseAccessionNumber>174</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9c9f932c-f6d7-4ba1-963e-e68f5ae98168">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2271</dc:identifier>
        <rdfs:label>FH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment>The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/606812</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/174</ddiem:iembaseUrl>
    <rdfs:label>FUMARASE DEFICIENCY; FMRD</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/40575777-7951-47cb-a8cf-2d4afbaf75b4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a77622e-6d0a-4c85-920d-e574ed3b2c81">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67ba0189-30f2-4dc2-96d2-2648b7b52b4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10e4dfe8-c325-4413-a022-d4b178fcc25d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05217c53-0b64-45d6-bcd2-9610619e807c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W99L</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602485">
        <ddiem:iembaseAccessionNumber>1289</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1289</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/602485</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3adcf7ca-2d0b-40d7-9785-28a7ec596e3b"/>
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/641d0cc8-331c-48f8-892b-bc69e105d410">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8c8e635-5252-4de6-aaa4-1bdf419e94dc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c265deb9-d858-40d9-8bbb-a4d7c1937e29"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f7a81e0-200b-44d2-8981-f027063e79d8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:label>Short stature</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a540b87-8e63-488b-9a07-e89d17ae4d68">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6a41b890-74df-4c64-9e13-a71443ab1c56"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cfdc3989-1a1c-4852-9751-b5400ca3ea11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7dc7f5e-b6c2-4a93-96a7-76a884496e0b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28288174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607364">
        <dc:identifier>https://www.omim.org/entry/607364</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 3; BARTS3</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/09ff3915-3e6f-4561-bc42-5549b5b12b13"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06e8dad5-f5f8-4483-aa69-c398c24c311b">
    <ddiem:ecNumber>1.1.1.27</ddiem:ecNumber>
    <rdfs:label>lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/ac8402fb-b660-43d1-b431-0d7d9726f8f4"/>
    <ddiem:keggEntryId>K00016</ddiem:keggEntryId>
    <ddiem:uniprotId>P00338</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/051fae58-29fd-4acf-b807-b489bb7bb795"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d4ef5133-a6ef-4a13-bce3-bf260af25ec8">
    <ddiem:keggEntryId>K13699</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1f200d5b-81a5-4d9f-b972-5d23714ef526">
        <rdfs:label>ABHD5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51099</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adipose triglyceride lipase (ATGL)</rdfs:label>
    <ddiem:uniprotId>Q8WTS1</ddiem:uniprotId>
    <ddiem:ecNumber>2.3.1.51</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/dc8b01f2-8547-4aee-8dbe-ce95b548cfd8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f33f0ea1-419a-4689-8986-a31da8b83394"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44c63df5-8ab0-4c09-bc8a-ae37e28be212"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46330122-579b-4b46-978a-7c218a781aeb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99db0eac-8476-42f1-b3f1-e35c703b2e99"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612937">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c8f56d79-8d05-453c-9b03-4360ff11a52c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54344</dc:identifier>
        <rdfs:label>DPM3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/612937</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>387</ddiem:iembaseAccessionNumber>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/387</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a513c0f7-59c6-4ed4-ac3f-3a9d9cca0b29">
    <ddiem:ecNumber>3.2.1.76</ddiem:ecNumber>
    <rdfs:label>alpha-L-iduronidase</rdfs:label>
    <ddiem:keggEntryId>K01217</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8a7f5a96-2208-476b-affb-88283e09e668"/>
    <ddiem:uniprotId>P35475</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7be89046-d9f8-4d4d-97bb-c6eaa0d6d96b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce044aa2-47ae-4114-9a16-6eeee1ac65c6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Petechiae</rdfs:label>
        <dc:identifier>HP:0000967</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000967</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/883f2884-e259-4eae-8d88-5b6cd073ced2">
        <rdfs:label>Cognitive impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d591384f-c4df-4818-8ac7-4df9a98b7078">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
        <rdfs:label>Functional motor deficit</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004302</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13c25221-3030-4a01-b389-12dee37bc805">
        <dc:identifier>HP:0025356</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025356</ddiem:url>
        <rdfs:label>Psychomotor retardation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d36b4f52-049a-4df2-8f20-5b0fa304e110">
        <rdfs:label>Chronic mucoid diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <dc:identifier>HP:0002028</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916321</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d00eea5-5d0a-4c1b-8e15-93314bf350fa">
        <rdfs:label>Elevated plasma acylcarnitine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045045</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b217b983-9a4b-47c1-82db-3b071123691c">
    <ddiem:ecNumber>5.4.2.2</ddiem:ecNumber>
    <ddiem:uniprotId>P36871</ddiem:uniprotId>
    <ddiem:keggEntryId>K01835</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2119e47b-1a9e-4f1c-b977-1f57648c3215">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5236</dc:identifier>
        <rdfs:label>PGM1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Phosphoglucomutase-1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc9c4b40-8553-4705-8d0a-967d75bf8df5">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236792">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cb1c956f-fb1b-4b49-b495-15e996d1de7a"/>
        <dc:identifier>https://www.omim.org/entry/236792</dc:identifier>
        <ddiem:iembaseAccessionNumber>165</ddiem:iembaseAccessionNumber>
        <rdfs:label>L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/165</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26208971</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c748c9d8-1cc2-41bf-8ae1-914e7272063f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b09a89c3-bf56-422f-bbaa-344b13ea18c7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70b78671-c034-43d2-b146-cb649c1b3770">
        <rdfs:label>Neurological impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2c6640d1-e57e-4bb8-abe6-48e0573a4226">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/0022510X89901123</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/540000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/489fe16c-30e2-4a77-be10-2aeaeb6a91b6"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec3bb8b8-2f3d-43ef-8ebf-13474e6e4d59"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/242250cc-579c-4b86-b9ca-616f549b3da1"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b34e13cb-66f1-4cc0-94a8-749398fadefa"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060"/>
        <rdfs:label>MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/399</ddiem:iembaseUrl>
        <rdfs:comment>MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/362e6f81-6141-4f68-9ca4-ee73102faf8a"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f559171f-1ce5-488b-8e48-61d64181f2de"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c4863f1-79bc-462d-8b41-3ea5814ffbdd"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ea21eaa9-345c-47aa-a6af-5e375552ac16"/>
        <ddiem:iembaseAccessionNumber>399</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/540000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/02d43ae8-8ad4-4f5a-a125-8b9ed3b8c67f"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0378306f-dd90-4903-8e88-3450698f79b0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:label>Abnormal EEG</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/42a2f8e7-c770-4a68-adae-5ae9d6a6cda9">
    <ddiem:uniprotId>P80404</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f466ed60-4604-4085-a1ae-5ac0418cae45">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/18</dc:identifier>
        <rdfs:label>ABAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.6.1.19; 2.6.1.22</ddiem:ecNumber>
    <rdfs:label>GABA-transaminase</rdfs:label>
    <ddiem:keggEntryId>K13524</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/20ae44e5-18eb-4cba-a2a9-884742b07dbe">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2c7e5d5f-e927-47ee-abd6-b0c9dee27018"/>
    <ddiem:uniprotId>P07602</ddiem:uniprotId>
    <ddiem:keggEntryId>K12382</ddiem:keggEntryId>
    <rdfs:label>Prosaposin</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ab3ac10f-0a24-47cc-b8b8-55547fc1e6a8">
    <ddiem:ecNumber>2.8.3.13</ddiem:ecNumber>
    <ddiem:uniprotId>Q9HAC7</ddiem:uniprotId>
    <rdfs:label>succinate-hydroxymethylglutarate coA-transferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc5c4ad2-fb97-4a37-b7d9-c6fe2113759d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79783</dc:identifier>
        <rdfs:label>SUGCT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K18703</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d7f04ec3-75fa-4a33-988b-3b8432044887">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/14c5b40f-dc28-4ab3-b45d-46ee1eac581c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3295</dc:identifier>
        <rdfs:label>HSD17B4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12405</ddiem:keggEntryId>
    <ddiem:uniprotId>P51659</ddiem:uniprotId>
    <rdfs:label>17β-hydroxysteroid dehydrogenase type 4</rdfs:label>
    <ddiem:ecNumber>1.1.1.n12; 4.2.1.107; 4.2.1.119</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7f4a3ce3-a364-46ab-9f4f-b08f6802f349">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae367cdf-369d-4fb3-8ecd-6a4488e5b9ae">
        <rdfs:label>Ankle weakness progression(Disease progression)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f1b0aef-2a90-49aa-ad98-a4b211b02a56">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003288</ddiem:url>
        <rdfs:label>High resting plasma lactate concentration</rdfs:label>
        <dc:identifier>HP:0003288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9ef854a-4a19-436e-9886-0fef83266e30"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17080429</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/545000">
        <rdfs:comment>Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/400</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/545000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060"/>
        <rdfs:label>MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF</rdfs:label>
        <ddiem:iembaseAccessionNumber>400</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0dce02c4-03a9-4b64-8242-7cf26a3fa196">
    <ddiem:uniprotId>P02787</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/36e50ad3-5cdf-471a-84f6-a3756a80fd32">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7018</dc:identifier>
        <rdfs:label>TF</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>transferrin</rdfs:label>
    <ddiem:keggEntryId>K14736</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/352f24aa-be6d-4f7b-801a-b6d1145af1fa">
    <ddiem:ecNumber>1.3.8.4</ddiem:ecNumber>
    <rdfs:label>isovaleryl-CoA dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00253</ddiem:keggEntryId>
    <ddiem:uniprotId>P26440</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a7d755cf-b31f-47d9-ad33-ad0128810b14">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3712</dc:identifier>
        <rdfs:label>IVD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/aad9592d-5ee5-4078-a773-c91ed5f4e303">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cf4cf392-ba60-4367-ab2a-aeef251fa407">
        <rdfs:label>GALT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>beta-1,4-galactosyl transferase.</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/08918974-e681-43c0-83a2-8a3ced72d301">
    <ddiem:keggEntryId>K00451</ddiem:keggEntryId>
    <rdfs:label>Homogentisate 1,2-dioxygenase.</rdfs:label>
    <ddiem:uniprotId>Q93099</ddiem:uniprotId>
    <ddiem:ecNumber>1.13.11.5</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d860afed-c913-4606-ae9b-f20358673630">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3081</dc:identifier>
        <rdfs:label>HGD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/35606d73-3caf-4b28-8dde-89885d2a8518">
    <rdfs:label>sodium chloride co-transporter/ chloride channel called ClC-Kb</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eda252ab-b9c3-4c3a-a837-f3b35bc5b2ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6559</dc:identifier>
        <rdfs:label>SLC12A3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51801</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/09ff3915-3e6f-4561-bc42-5549b5b12b13"/>
    <ddiem:uniprotId>P55017</ddiem:uniprotId>
    <ddiem:keggEntryId>K05018</ddiem:keggEntryId>
    <ddiem:keggEntryId>K14426</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/85385645-9786-4b2c-98d5-9ea7e2e7e8cb">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612073">
        <dc:identifier>https://www.omim.org/entry/612073</dc:identifier>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7a7b4c20-5572-4165-a482-a8497a987237"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/503</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>503</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e391ab6c-036e-4c0b-a0a7-451a95a25439">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca23dd10-de08-4ade-8f69-0ee1d28c0661">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:label>Hyperphenylalaninemia</rdfs:label>
        <dc:identifier>HP:0004923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71aea9fb-5d64-4454-a18f-174158f99aaa"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70b78671-c034-43d2-b146-cb649c1b3770"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59fd0a5f-44c4-4144-930c-607085995f6c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c6033562-a089-43a0-8c99-331ce08c8de3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e9c64e8-f419-4abb-a40b-d9033640afac">
        <dc:identifier>HP:0010863</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
        <rdfs:label>Delayed receptive language</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5e657824-5a0f-45b2-a6cf-6bcb0ee48236">
    <ddiem:ecNumber>2.1.1.20</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cb205b0d-be14-4133-bcdf-5eff47431e41">
        <rdfs:label>GNMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27232</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00552</ddiem:keggEntryId>
    <ddiem:uniprotId>Q14749</ddiem:uniprotId>
    <rdfs:label>glycine N-methyltransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0f07b808-6040-4913-93f7-9fa21a29ec7c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f459eb33-2bdb-4525-bfd4-9766fa163731">
        <rdfs:label>ACAD8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27034</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UKU7</ddiem:uniprotId>
    <ddiem:keggEntryId>K11538</ddiem:keggEntryId>
    <ddiem:ecNumber>1.3.8.-</ddiem:ecNumber>
    <rdfs:label>isobutyryl-CoA dehydrogenase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56a20f67-abc4-48c3-bc74-604eb3bbf146">
    <rdfs:label>Ribonuclease H1</rdfs:label>
    <ddiem:keggEntryId>K03469</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6abb6839-844b-4374-8b26-ad3b75b02775">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/246243</dc:identifier>
        <rdfs:label>RNASEH1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>O60930</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.26.4</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/863b90c1-a2e4-4a13-9d98-38e6c9fe42e2">
    <rdfs:label>Hormone ( Arginine vasopressin)</rdfs:label>
    <ddiem:keggEntryId>K05242</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/35641d54-8774-4d20-ac3f-48affda0a8c1">
        <rdfs:label>AVP</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/551</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P01185</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/59b2ab94-ae8d-4fe3-a488-c8b60a7acfee">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fe166200-6574-4adc-9c9c-e8b2267b2114">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20557e1e-538b-4bb8-9102-eeb0a6f2e7d2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162000">
        <ddiem:iembaseAccessionNumber>1405</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/162000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4b943b0-097e-45d7-b19e-271269f4c5e4"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1405</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cba8f78-1907-4950-b32d-00301c85b057">
        <dc:identifier>done</dc:identifier>
        <rdfs:label>Hyperurecemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6fbf1401-0663-47de-8b6b-ef5b06bdc136">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8cc02b1-9c50-4ffb-9c06-ebf5cc35ba45"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/544d0b62-16b9-42ab-b0e9-e5afdfaaf43c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/224651e4-a514-447d-beb9-29e0a2e5c469"/>
    <ddiem:keggEntryId>K20288</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8WTW3</ddiem:uniprotId>
    <rdfs:label>component of oligomeric golgi complex 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/be9129f2-3011-45a7-a766-279b60be3c76">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/50271af7-97a0-4475-8cdb-fe772dc8d114">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6718</dc:identifier>
        <rdfs:label>AKR1D1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE</rdfs:label>
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_epigenetic_manipulation">
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:IAO_0000115 xml:lang="en">Modulation of the level or specificity of expression of a genetically defective gene through modification of an epigenetic mark or process using chemical, biological or genetic means.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by epigenetic manipulation</rdfs:label>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1fd8f7cb-5527-44d5-ba37-b25b2430f654">
    <rdfs:label>Mitochondrially encoded tRNA lysine</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7d3c77d4-f22d-4eeb-a58e-96dd94b07976">
    <ddiem:ecNumber>1.3.1.3</ddiem:ecNumber>
    <ddiem:uniprotId>P51857</ddiem:uniprotId>
    <ddiem:keggEntryId>K00251</ddiem:keggEntryId>
    <rdfs:label>Aldo-keto reductase family 1 member D1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/50271af7-97a0-4475-8cdb-fe772dc8d114"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f567bacb-9877-45e0-8db7-7102a3ab6c4e">
    <ddiem:uniprotId>P07949</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.10.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/04233dcf-bcbd-4d35-aedb-b1ee8bd74743">
        <rdfs:label>RET</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5979</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05126</ddiem:keggEntryId>
    <rdfs:label>Proto-oncogene tyrosine-protein kinase receptor Ret</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a5b36c72-0be0-4a7e-8253-db1fef2a4280">
    <rdfs:label>malonyl-CoA decarboxylase</rdfs:label>
    <ddiem:keggEntryId>K01578</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.1.9</ddiem:ecNumber>
    <ddiem:uniprotId>O95822</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d9ddbb3-96b5-456a-9c74-c7217c2dfd57">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23417</dc:identifier>
        <rdfs:label>MLYCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b7d6c14-1eee-4557-a2cd-a62884217fbe">
    <rdfs:label>apolipoprotein A5</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/773169c4-5012-4901-a15c-5e73b8adf910">
        <rdfs:label>APOA5</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/116519</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19675e91-fbbc-4ea8-b52f-0d5ca3d717a5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f50f123d-9cb2-440c-8533-438cd7e839d7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51604</dc:identifier>
        <rdfs:label>PIGT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05292</ddiem:keggEntryId>
    <ddiem:uniprotId>Q969N2</ddiem:uniprotId>
    <rdfs:label>GPI transamidase component PIG-T</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_genome_editing">
    <obo:IAO_0000115 xml:lang="en">Modulation of the activity or stability of a genetically defective gene through direct modification of one or both endogenous alleles of the gene, using genome editing techniques such as CRISPR/Cas</obo:IAO_0000115>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein by genome editing</rdfs:label>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </owl:Class>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ccdc21aa-10aa-4b30-9529-1e44f71585b4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/271245">
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/271245</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c1a7bd1-5476-4b06-9f6a-2598fb378875"/>
        <rdfs:comment>Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/944</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>944</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798">
        <rdfs:label>Seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec240001-0e05-4680-91c8-48bfad890484">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6761cbb-2845-4d8f-b03e-f574e5736b23"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/399b2879-cba5-412d-b93f-105a2ef65963">
    <ddiem:keggEntryId>K01099</ddiem:keggEntryId>
    <rdfs:label>inositol polyphosphate 5-phosphatase OCRL-1</rdfs:label>
    <ddiem:ecNumber>3.1.3.36; 3.1.3.56; 3.1.3.86</ddiem:ecNumber>
    <ddiem:uniprotId>Q01968</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f165dc7b-fc92-4bc5-8b21-2be7f3c7e266">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4952</dc:identifier>
        <rdfs:label>OCRL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c0d43e1b-d77a-4cd7-9037-946fe579c4ce">
    <ddiem:keggEntryId>K12408</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5071bde7-5c1e-4ddb-947c-93c6260d602d"/>
    <rdfs:label>3-beta-hydroxy-delta-5-C27 steroid oxidoreductase</rdfs:label>
    <ddiem:ecNumber>1.1.1.-; 1.1.1.181</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H2F3</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/98886052-a98d-4331-af6a-27548d2ac779">
    <rdfs:label>uroporphyrinogen III synthase</rdfs:label>
    <ddiem:keggEntryId>K01719</ddiem:keggEntryId>
    <ddiem:ecNumber>4.2.1.75</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4dee27e-da3c-4212-b86c-c0d04fa69a7f">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7390</dc:identifier>
        <rdfs:label>UROS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P10746</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f74f83b7-f8c7-4d2a-b93d-46f595509a2c">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/25d10eda-f59d-4432-b96b-02558a75f895">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/338</dc:identifier>
        <rdfs:label>APOB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>apolipoprotein B-48 + apolipoprotein B-100</rdfs:label>
    <ddiem:uniprotId>P04114</ddiem:uniprotId>
    <ddiem:keggEntryId>K14462</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614830">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c476efc9-7a67-49d6-aa44-6e62b964ffab">
        <rdfs:label>POMGNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84892</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1120</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/614830</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8</rdfs:label>
    <ddiem:iembaseAccessionNumber>1120</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/eb6186b5-3aa2-4fa3-a3ae-6a3cf3d7a988">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3b957ba5-d557-43ad-91ce-249418e9eddd">
        <rdfs:label>POMGNT1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55624</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09666</ddiem:keggEntryId>
    <rdfs:label>Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q8WZA1</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222730">
    <rdfs:label>DICARBOXYLIC AMINOACIDURIA; DCBXA</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/49</ddiem:iembaseUrl>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2aab6a1a-c4b6-40e2-8f9d-63e280cfa390">
        <rdfs:label>SLC1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6505</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseAccessionNumber>49</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/222730</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/44af9870-ca2c-4eaa-acd7-95b7e2c09d5b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffa7346d-1705-43f4-b3b5-79ecb8914d20">
        <dc:identifier>HP:0012444</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012444</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>brain atrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0475b22-d156-4613-8d59-9572a0b206c1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a09d91f4-cb59-416b-933c-ea777c92f50b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204500">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/306</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/204500</dc:identifier>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>306</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8702dddd-4931-4740-b46e-ee739075de93"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0001565">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0001565</ddiem:url>
        <dc:identifier>ECO:0001565</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/230051d4-dbec-4d96-8664-179975ababe5">
    <rdfs:label>6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0d7b067c-ef00-4a7d-a71d-9f16837fcc71">
        <rdfs:label>PTPS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c151d0f0-9dab-44c9-b35c-d494d164e57f">
    <rdfs:label>Multidrug resistance protein-2</rdfs:label>
    <ddiem:uniprotId>Q92887</ddiem:uniprotId>
    <ddiem:keggEntryId>K05666</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/609115ab-b96c-4291-ab27-becf78fcd1ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1244</dc:identifier>
        <rdfs:label>ABCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>7.6.2.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/18bd6cd4-3b96-473d-abc8-af70280fd44b">
    <ddiem:uniprotId>P15735</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.11.19</ddiem:ecNumber>
    <ddiem:keggEntryId>K00871</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase gamma catalytic chain, liver/testis isoform</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba20419f-7a66-41fb-898a-6735763e128a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5261</dc:identifier>
        <rdfs:label>PHKG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92a7868d-3478-472a-8a58-825430864240">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261515">
        <rdfs:comment>No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>274</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/274</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261515</dc:identifier>
        <rdfs:label>D-BIFUNCTIONAL PROTEIN DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/14c5b40f-dc28-4ab3-b45d-46ee1eac581c"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc5b4324-9b55-413e-acdf-8c4131bb0682"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63913e0c-9fe5-4fde-866c-68beaee78863">
        <rdfs:label>The study was terminated</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f7559e9-f985-4acd-b711-2efaed2e706b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19249206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10723193</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8893502-6741-439c-b70d-02967cdbedb9">
        <rdfs:label>High serum creatine kinase</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <dc:identifier>HP:0003236</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c3c1780-fe8b-4a4f-a97b-5e096fa1cc81"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/27f8b1dc-2d36-4167-bb0d-b4f8c93aea32">
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0adc44b6-77d5-4260-98c1-9d2ce24f025b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/65080</dc:identifier>
        <rdfs:label>MRPL44</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrial ribosomal protein L44</rdfs:label>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3323a3e0-da26-483a-b0a9-e08085114dd7">
    <ddiem:ecNumber>3.1.-.-; 3.6.4.12</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/057b72bf-f310-484f-af18-349b54b2b2ba">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1763</dc:identifier>
        <rdfs:label>DNA2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P51530</ddiem:uniprotId>
    <rdfs:label>DNA replication ATP-dependent helicase/nuclease DNA2</rdfs:label>
    <ddiem:keggEntryId>K10742</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/454016dc-d59f-4d14-9593-201b7a490058">
    <ddiem:ecNumber>1.14.16.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/549db1db-482a-4371-acff-b00d97d0e7f7">
        <rdfs:label>SPR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6697</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00501</ddiem:keggEntryId>
    <ddiem:uniprotId>P35270</ddiem:uniprotId>
    <ddiem:keggEntryId>K00072</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c285dd25-a070-4509-9c69-50d6c7173e54"/>
    <ddiem:uniprotId>P07101</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8edda9be-9596-4cca-93cd-8b2fc2bb8df0">
        <rdfs:label>GCH1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2643</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <rdfs:label>GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase</rdfs:label>
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.1.153</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f9944801-bd92-4d86-b6e9-6005ff955ff2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17275787</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3aff983-f662-4644-a014-a9b48cad3d3f">
        <dc:identifier>HP:0002180</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Myoclonus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2255f880-3881-40fa-9c8f-aae1ac1d1430">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low quality of life (Constitutional symptoms)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28686997</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e4108eb6-8d03-4b7b-a20c-8149a548601b">
    <ddiem:uniprotId>P23109</ddiem:uniprotId>
    <rdfs:label>AMP deaminase</rdfs:label>
    <ddiem:ecNumber>3.5.4.6</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6e1ee623-fe3a-4542-b0d7-8378cf0c1301">
        <rdfs:label>AMPD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/270</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01490</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f9c3cda2-3d3d-4935-84c4-a2606a0513be">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b84b2031-ea56-4a3e-8586-a70c3a9d6fb2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11041</dc:identifier>
        <rdfs:label>B4GAT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K21032</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060"/>
    <ddiem:uniprotId>O43505</ddiem:uniprotId>
    <rdfs:label>Beta-1,4-glucuronyltransferase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/272200">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/301</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MULTIPLE SULFATASE DEFICIENCY; MSD</rdfs:label>
    <ddiem:iembaseAccessionNumber>301</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/272200</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20007925-7720-4a40-b65f-25aa21589a5f"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/14722310-6141-4260-9769-f2ec4e0f9dca">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c6488c73-ab22-4a8a-a2e2-66a67f81bc9a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5538</dc:identifier>
        <rdfs:label>PPT1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.1.2.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01074</ddiem:keggEntryId>
    <ddiem:uniprotId>P50897</ddiem:uniprotId>
    <rdfs:label>PALMITOYL-PROTEIN THIOESTERASE</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f3e6ed9c-c966-4a45-8d4b-058b89dfca49">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91eabce4-b060-45d6-bca1-3e4f940db468">
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:label>Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80276a63-3f63-4f6c-9288-6a748795bd9d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939 </ddiem:url>
        <dc:identifier>HP:0001939 *</dc:identifier>
        <rdfs:label>Acute metabolic crisis ( Metabolism abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/BF00710419</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f7d8246-e9a8-4e3c-911f-22768209e65e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/210200">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b48ff2ce-318b-4493-af38-a12f8c90feff"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/745c3b60-bc54-458b-867c-48d1c96a8050"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/210200</dc:identifier>
        <ddiem:iembaseAccessionNumber>1284</ddiem:iembaseAccessionNumber>
        <rdfs:label>3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/45840bc8-a113-4f99-bd42-66121d82d14d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0748ab9f-a105-4806-b896-557443f3be53">
        <rdfs:label>Abnormal brain stem auditory evoked potentials</rdfs:label>
        <dc:identifier>HP:0006958</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006958</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3f5a63a-daae-4f0e-8046-2b904b9e4808"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15df652e-b287-43a6-a6be-8f9381c566e1"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05b9cfac-21d7-4e30-be0b-cc9d1490bd8a">
        <rdfs:label>Psychiatric disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b6c3de7-bf41-4d91-9561-532867cf657a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <dc:identifier>HP:0000726</dc:identifier>
        <rdfs:label>Dementia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/711a199f-bd61-4a00-94aa-5453bae0e4f5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000649</ddiem:url>
        <dc:identifier>HP:0000649</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal visual evoked potentials</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530304</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c87754f2-6457-4df2-9206-4e20a3673737">
        <dc:identifier>HP:0100543</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:label>Mental impairment</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f85b5544-0d88-494f-ac6f-9486e47aa3c4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2873525</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f17723b7-ca5d-4d6c-a122-6891d246a38d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:label>Emotional lability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/737161cc-b24d-4977-941e-3e4c7967008c">
    <rdfs:label>dihydropyrimidine dehydrogenase</rdfs:label>
    <ddiem:ecNumber>1.3.1.2</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8b198797-3144-44df-a3e5-d42093f4cdd7">
        <rdfs:label>DPYD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1806</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00207</ddiem:keggEntryId>
    <ddiem:uniprotId>Q12882</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d6082cd9-c5c0-4e64-bed1-ba81ac602158">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0adc44b6-77d5-4260-98c1-9d2ce24f025b"/>
    <ddiem:ecNumber>3.1.26.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9J2</ddiem:uniprotId>
    <ddiem:keggEntryId>K17425</ddiem:keggEntryId>
    <rdfs:label>MITOCHONDRIAL RIBOSOMAL PROTEIN L44</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/545ff75e-62da-4ada-95c3-672b48d03dfa">
    <ddiem:keggEntryId>K01772</ddiem:keggEntryId>
    <rdfs:label>ferrochelatase</rdfs:label>
    <ddiem:uniprotId>P22830</ddiem:uniprotId>
    <ddiem:ecNumber>4.99.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/54bb8601-b487-4f93-b40a-84cc1a6e9aaa">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2235</dc:identifier>
        <rdfs:label>FECH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0470bf7e-8e72-4e52-9368-266732c782c6">
    <ddiem:keggEntryId>K12311</ddiem:keggEntryId>
    <ddiem:uniprotId>O00754</ddiem:uniprotId>
    <ddiem:ecNumber>3.2.1.24</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/00fec955-d750-40fd-ba98-bafa2fc386ec">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4125</dc:identifier>
        <rdfs:label>MAN2B1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Alpha-mannosidase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0e7b93fa-dfd9-4f17-9a5d-dbdea6a98859">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e24d309-c152-4324-bfc8-d6f71b61afd7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Stroke-like attacks</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11382201</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0a50b67-0d77-445e-bb1e-1eb357a31ca0">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG (focal epileptiform activity)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/322f8354-5cc6-4dd1-92ba-80adfe52fe37">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperintensity of cerebral white matter on MRI</rdfs:label>
        <dc:identifier>HP:0030890</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030890</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/edc6477b-5a29-441a-8d88-f5ba5df45cdd">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5c1a7bd1-5476-4b06-9f6a-2598fb378875">
        <rdfs:label>TWNK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56652</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>Twinkle protein, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2eb63e90-a0bf-41e5-850c-3b584e8c741e">
    <rdfs:label>Melanoma-associated antigen D2</rdfs:label>
    <ddiem:uniprotId>Q9UNF1</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2ee1f90-ceca-4ed9-93e0-72323846082d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10916</dc:identifier>
        <rdfs:label>MAGED2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/58a48acc-bcb2-4570-8a04-717cc6dd1571">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07e534a8-978e-460c-aa7e-2644dace1268"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30097991</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607330">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/196</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>196</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/607330</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d4e4d03-0e14-4ae6-9829-212d2f511037"/>
        <rdfs:label>LATHOSTEROLOSIS</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/745917b5-f7af-40ca-ae54-d5a92b03241e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood lathosterol level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/93a23ec7-3245-4d66-b7fa-69e60cab7f61">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/50021bef-bd48-4c84-b6d7-4d1397a8f2a4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/530a2993-9539-4f2a-bcdb-1ebc96242705"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b9887cc-c1dd-4e7b-8a64-205e0ff6e1f2">
        <rdfs:label>Abnormality of lipid metabolism</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003119</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c40f1a0-99ff-4f02-9a8f-dd1c7c85a5a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5be0a32c-cb64-4da9-a1ee-357ff50fbab5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e596e2b-6620-4647-9697-24df9c6a4a70">
        <dc:identifier>HP:0002180*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:label>Cerebeller neurodegeneration( neurodegeneration)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd807aef-568c-4e89-9d3a-db8ee1b51ff9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased number of splenic myeloid cells</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c30d238-9a28-4695-98dc-324dc03e21fc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb6b1f90-ad1f-426e-8638-b425d2cb8f10"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23948640</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/257220">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/145c8f2b-706c-429f-9740-d4f532266c21"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/303</ddiem:iembaseUrl>
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C1; NPC1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>303</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/257220</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f05c6e6e-4ae2-454c-87d4-3c99e759c8cf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Splenomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
        <dc:identifier>HP:0001744</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31248418</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25400034</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a03105a4-457b-45c5-8573-db115accc5a9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Motor function impairment</rdfs:label>
        <dc:identifier>HP:0002275</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/f34a8af5-35fe-42c0-91c2-93da957d2128">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65b8ad2e-e97d-44b3-8f4e-ec69ee596e89">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f974e2f3-bb3b-4215-9dc9-ae2e0e440919"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/183f7dac-56d1-42d4-866f-8152f109c293">
        <dc:identifier>HP:0001681</dc:identifier>
        <rdfs:label>angina pectoris</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001681</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3aca313c-ef5f-4768-ac09-b61ba7d60675">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d07c692-ee69-47cb-931e-7066577f8356"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9a245bc-5773-4075-9d8d-bc1de9e7bca7">
        <rdfs:label>stenotic coronary atherosclerosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001677</ddiem:url>
        <dc:identifier>HP:0001677</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba97c535-6aa2-40f3-bb78-1b70a60c2408">
        <rdfs:label>xanthomas</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000991</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000991</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
  </obo:DDIEM_0000012>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/95b68621-5f6f-4a50-a70a-084023efd5b4">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/73f4f118-b2f6-4639-820a-17affad85562">
        <rdfs:label>CTH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1491</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01758</ddiem:keggEntryId>
    <ddiem:ecNumber>4.4.1.1</ddiem:ecNumber>
    <rdfs:label>cystathionine gamma-lyase</rdfs:label>
    <ddiem:uniprotId>P32929</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8076a59f-9929-4496-8d31-cab82f7c8150">
    <ddiem:uniprotId>Q8NAT1</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.312</ddiem:ecNumber>
    <rdfs:label>Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c476efc9-7a67-49d6-aa44-6e62b964ffab"/>
    <ddiem:keggEntryId>K18207</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/30dc38c2-58ca-432c-9426-18cf02ec0c1b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa7a3f5e-e466-42f0-87c6-1e62a0215d3a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>episodic behavioral abnormalities</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da8b63a7-0b15-4db5-a762-e286c195cba2">
        <dc:identifier>HP:0000817</dc:identifier>
        <rdfs:label>lack eye-eye contact</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7e25611-5b15-47cd-b59f-8020f82da1bb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/62d6391b-9072-4486-a4de-272361d524cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2012bde9-133d-40d2-a7e1-20f099cc61c1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>social interaction defect</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000735</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54e35da9-72ac-4194-a9fa-fa47a5a250b2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddc6b4ef-bd37-4e20-af88-662e60b01cfc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001433</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:label>Hepatosplenomegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/996deb93-a706-4d35-b56e-7ac01796ee12">
    <ddiem:ecNumber>2.-.-.-</ddiem:ecNumber>
    <rdfs:label>GPI ethanolamine phosphate transferase 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4844658c-9a38-4b7e-9139-926744f0baa7">
        <rdfs:label>PIGN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23556</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05285</ddiem:keggEntryId>
    <ddiem:uniprotId>O95427</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ce346a92-24cf-4018-8953-e0b24b6ea4fb">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/15f6bfee-cba3-437a-b639-b9993b7e04a4">
        <rdfs:label>MT-ND4</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>mitochondrially encoded NADH dehydrogenase 4</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4ea1909e-805e-4dfa-a0af-08a39f10d445">
    <ddiem:uniprotId>P29992</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7736fdea-04f0-44f8-98da-d05540b8131b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2767</dc:identifier>
        <rdfs:label>GNA11</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>guanine nucleotide-binding protein (Gα11)</rdfs:label>
    <ddiem:keggEntryId>K04635</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3e34dce7-c0f2-45a7-b391-33b2c83e2193">
    <ddiem:ecNumber>1.2.1.18; 1.2.1.27</ddiem:ecNumber>
    <rdfs:label>3-hydroxyisobutyrate dehydrogenase</rdfs:label>
    <ddiem:keggEntryId>K00140</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b9383202-f2bb-47fc-98c4-0a189b6c6f5a">
        <rdfs:label>ALDH6A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4329</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q02252</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239510">
    <rdfs:label>HYPERPROLINEMIA, TYPE II; HYRPRO2</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/38</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/239510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>38</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81401428-1fc9-4819-9c62-020240fbdff4">
        <rdfs:label>ALDH4A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8659</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d9a67c73-86e6-4f36-babf-da527beac0f5">
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68d9252a-0a48-4c3f-a702-9b5f88e81db7"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b841ceb-25c7-4db7-a491-ac3035020444"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236670">
        <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fef90df3-884a-4515-926c-078e4a15f187"/>
        <dc:identifier>https://www.omim.org/entry/236670</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6eee5ea8-eb76-4d1a-9c23-8e2810b509f5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/002a6172-a716-44b7-9388-bfc70bbacfe4">
        <rdfs:label>SLC25A20</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine-acylcarnitine translocase</rdfs:label>
    <ddiem:keggEntryId>K15109</ddiem:keggEntryId>
    <ddiem:uniprotId>O43772</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609308">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/352</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1</rdfs:label>
    <ddiem:iembaseAccessionNumber>352</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/609308</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fef90df3-884a-4515-926c-078e4a15f187"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1a2d7fd9-8cd3-48fb-a15b-108952c44f87">
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <rdfs:label>uridine diphosphate–glucuronyl transferase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1b066539-7726-40bf-99cc-ee56bb326b4b">
        <rdfs:label>UGT1A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54658</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/95fc85f0-3751-4fc7-97e2-f7e437cf4f4a">
    <rdfs:label>DnaJ heat shock protein family (Hsp40) member C19</rdfs:label>
    <ddiem:uniprotId>Q96DA6</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1907f093-9d0b-4e01-baa4-291343ed7221">
        <rdfs:label>DNAJC19</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/131118</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K09539</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/51c0de69-3678-46e0-bf33-1a05d5add635">
    <rdfs:label>extracellular matrix protein 1</rdfs:label>
    <ddiem:uniprotId>Q16610</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/747e18c2-3fe0-4e81-af62-d9e9705f2288">
        <rdfs:label>ECM1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1893</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/63c38721-7976-484b-9fb1-bd668fe95af1">
    <ddiem:uniprotId>Q15738</ddiem:uniprotId>
    <rdfs:label>NAD(P) dependent steroid dehydrogenase-like</rdfs:label>
    <ddiem:keggEntryId>K07748</ddiem:keggEntryId>
    <ddiem:ecNumber>1.1.1.170</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/16d31693-9db1-4df2-a4ed-607c4927c722">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/50814</dc:identifier>
        <rdfs:label>NSDHL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/25a86006-cba2-4bc8-9845-5f3853ed30bc">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <rdfs:label>DNA polymerase subunit gamma-2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/281a64eb-af70-464b-ac4b-607d2f081765">
        <rdfs:label>POLG</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5428</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c33a53d6-04f5-45b7-b68b-56eadbda8385">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a29acf58-28f7-464a-8195-259817d48fcc">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>hypercholesterolemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57aef328-ef45-4afb-a83c-700b9074bc47"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43b54b4e-5327-4c8f-ba09-290d1e300509">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ea0333b6-f59d-43b9-9763-2bbdd8d6789e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/51125e0b-f782-4349-a18d-cbb23c9bbf71">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f7a81e0-200b-44d2-8981-f027063e79d8"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608747">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/608747</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bab9d202-21f1-4c4c-b313-861702e428e0"/>
        <rdfs:label>INSULIN-LIKE GROWTH FACTOR I DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9cd05b41-0031-46e9-8866-3d17eabe391d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06303de8-072e-4011-bd8e-e2ff2e1c2eb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c5243eb-0c17-4734-8eb9-bc79cd0761b3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/82a2b5a5-99ab-4a42-b681-58a322275608">
    <rdfs:label>Methylenetetrahydrofolate reductase</rdfs:label>
    <ddiem:keggEntryId>K00297</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.20</ddiem:ecNumber>
    <ddiem:uniprotId>P42898</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/661e9ec4-5cc6-436a-9906-60648fa3c4dc"/>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a3ddf16b-9151-43bc-930b-b4655550fd32">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/398aa76d-70cb-42be-b13b-50c4e7db10bd">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>low muscle tone</rdfs:label>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e7ffcfa-be19-4ab4-863b-81c5f8e9bfcd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <dc:identifier>HP:0010919</dc:identifier>
        <rdfs:label>Abnormality of homocysteine metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/530f4c80-aaef-4862-95b2-10deb2c7cb04">
    <ddiem:uniprotId>O75845</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d4e4d03-0e14-4ae6-9829-212d2f511037">
        <rdfs:label>SC5D</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6309</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.19.20</ddiem:ecNumber>
    <ddiem:keggEntryId>K00227</ddiem:keggEntryId>
    <rdfs:label>3-beta-hydroxysteroid-delta-5-desaturase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c02030e-cbe8-4322-83e6-9f7ed761137a">
    <rdfs:label>GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase</rdfs:label>
    <ddiem:keggEntryId>K03370</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/67ccf7cb-6bbb-431e-a39e-5dcffb82dc62">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8869</dc:identifier>
        <rdfs:label>ST3GAL5</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UNP4</ddiem:uniprotId>
    <ddiem:ecNumber>2.4.99.9</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/2962ee81-7e8d-44d5-8b35-fa3bce904f08">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fce12d58-7f68-4b7c-91f4-acd6be197b03">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance,Poor sleep quality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment>The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88141393-be5d-4114-9986-90c720b808d9"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d32f705-18e7-4385-b2a6-424b59e1977f"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b202fcb-f19f-45ad-92b7-0b78e188cbf4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4c7277ce-dc7c-4830-a8ee-092c4b399448">
    <ddiem:ecNumber>1.13.11.11</ddiem:ecNumber>
    <ddiem:keggEntryId>K00453</ddiem:keggEntryId>
    <rdfs:label>tryptophan 2,3-dioxygenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0d2c7d2d-2292-4b74-aa9e-78261545a00e"/>
    <ddiem:uniprotId>P48775</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4699de5b-1e05-45b8-baef-7bfbaf33e055">
    <ddiem:ecNumber>2.7.1.1</ddiem:ecNumber>
    <ddiem:uniprotId>P35557</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3adcf7ca-2d0b-40d7-9785-28a7ec596e3b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2645</dc:identifier>
        <rdfs:label>GCK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12407</ddiem:keggEntryId>
    <rdfs:label>glucokinase-4</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7c1521a-ac4a-4e00-8801-aa4891acbae3">
    <ddiem:keggEntryId>K17680</ddiem:keggEntryId>
    <ddiem:ecNumber>3.6.4.12</ddiem:ecNumber>
    <ddiem:uniprotId>Q96RR1</ddiem:uniprotId>
    <rdfs:label>twinkle mtDNA helicase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/5c1a7bd1-5476-4b06-9f6a-2598fb378875"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605637">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA</rdfs:label>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/183cc80b-2957-4499-bf84-c979ef406bbb">
        <rdfs:label>MYH2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4620</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/605637</dc:identifier>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c3e48a7-6e74-4763-a9da-734ae8ea47da">
    <ddiem:uniprotId>Q9HCC0</ddiem:uniprotId>
    <rdfs:label>3 Methylcrotonyl-CoA carboxylase</rdfs:label>
    <ddiem:keggEntryId>K01969</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/745c3b60-bc54-458b-867c-48d1c96a8050">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/56922</dc:identifier>
        <rdfs:label>MCCC1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96RQ3</ddiem:uniprotId>
    <ddiem:ecNumber>6.4.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K01968</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b48ff2ce-318b-4493-af38-a12f8c90feff">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64087</dc:identifier>
        <rdfs:label>MCCC2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d16a1f88-5e89-46cd-980f-9d0593b84ac7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b57e3445-bf2c-4588-a6e5-4fbb750d66d3"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/306000">
        <ddiem:iembaseAccessionNumber>492</ddiem:iembaseAccessionNumber>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXa1; GSD9A1</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/492</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/306000</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7c23ce16-8b45-4571-9c2c-c4c639aee536"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated hepatic transaminases</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/162350">
    <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/162350</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/309</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ad668847-fdc2-45dd-85a0-89e2f19114e5"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>309</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0e121a4e-a9c3-4172-954c-849702ac9815">
    <ddiem:ecNumber>1.16.1.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9Y4U1</ddiem:uniprotId>
    <ddiem:keggEntryId>K14618</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9e0fe81f-5c55-4aea-a1ab-ea4fe356ec39">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/25974</dc:identifier>
        <rdfs:label>MMACHC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type C protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/fa8769d7-7534-496d-acdf-42e1eb301b97">
    <ddiem:keggEntryId>K19054</ddiem:keggEntryId>
    <ddiem:uniprotId>Q16595</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2982ba66-ea5a-4723-9ef0-4a31a6ae059a">
        <rdfs:label>FXN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2395</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Frataxin, mitochondrial</rdfs:label>
    <ddiem:ecNumber>1.16.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f72b7f5-2679-4004-b936-f53492a8dae5">
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ca7ed10b-a9c3-46b4-a837-f03e1f6045ca">
        <rdfs:label>AASS</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10157</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0f3c9556-7e5e-47a9-8300-5cad64df6159">
    <ddiem:uniprotId>O95571</ddiem:uniprotId>
    <rdfs:label>persulfide dioxygenase</rdfs:label>
    <ddiem:keggEntryId>K17725</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c827f6cf-1e13-4d75-a499-c17aa9cb9653">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/23474</dc:identifier>
        <rdfs:label>ETHE1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.18</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b528b9f7-acaf-4635-bd4b-eac80a587a69">
    <ddiem:uniprotId>Q9UP52</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>transferrin receptor 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2768cffa-ff3b-4b3f-a12d-90cfb62ea3bc">
        <rdfs:label>TFR2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7036</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50a8ba14-18d1-4ab6-bac5-f3a1f973167f">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f6a6ccde-995a-4b9e-b39b-f38c0f0179d4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3242</dc:identifier>
        <rdfs:label>HPD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.13.11.27</ddiem:ecNumber>
    <rdfs:label>4-hydroxyphenylpyruvate dioxygenase</rdfs:label>
    <ddiem:uniprotId>P32754</ddiem:uniprotId>
    <ddiem:keggEntryId>K00457</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/d178eb7b-ba6e-46f4-987d-85bb9c988a6c">
    <rdfs:label>alpha-galactosidase A</rdfs:label>
    <ddiem:keggEntryId>K01189</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/88657e23-7981-43e1-9d4c-c2574efdfeb0">
        <rdfs:label>GLA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2717</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.2.1.22</ddiem:ecNumber>
    <ddiem:uniprotId>P06280</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611881">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fcb4a650-8961-43a2-8220-57d9f2b1facd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/226</dc:identifier>
        <rdfs:label>ALDOA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <dc:identifier>https://www.omim.org/entry/611881</dc:identifier>
    <ddiem:iembaseAccessionNumber>500</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/500</ddiem:iembaseUrl>
    <rdfs:label>GLYCOGEN STORAGE DISEASE XII; GSD12</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0db2fbfe-e643-42ec-9eb5-75a3425e44c5">
    <ddiem:uniprotId>P35914</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7ad82b40-861a-4d28-951f-0cd4456eefcb">
        <rdfs:label>HMGCL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3155</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01640</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.3.4</ddiem:ecNumber>
    <rdfs:label>HMG-CoA lyase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/95f9f125-54e3-485d-a0a0-5a863dd00d3e">
    <rdfs:label>UDP glucuronosyltransferase family 1 member A1</rdfs:label>
    <ddiem:keggEntryId>K00699</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.17</ddiem:ecNumber>
    <ddiem:uniprotId>P22309</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/1b066539-7726-40bf-99cc-ee56bb326b4b"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9097cf9f-8109-47ec-852a-5a5df9489cda">
    <ddiem:ecNumber>1.2.1.88</ddiem:ecNumber>
    <ddiem:keggEntryId>K00294</ddiem:keggEntryId>
    <rdfs:label>Δ1-pyrroline 5-carboxylate dehydrogenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/81401428-1fc9-4819-9c62-020240fbdff4"/>
    <ddiem:uniprotId>P30038</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2b5b49f8-3440-4897-91d0-7bc057170d92">
    <ddiem:keggEntryId>K00503</ddiem:keggEntryId>
    <rdfs:label>dopamine beta (β)-hydroxylase</rdfs:label>
    <ddiem:uniprotId>P09172</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6133cc0e-076f-470e-9763-3ae94be4970b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1621</dc:identifier>
        <rdfs:label>DBH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.14.17.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7bd0906b-d3cd-4461-a885-b22c0ca38a58">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac6a44f3-48e5-4151-8957-0e4aba31a8e7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a183f5fe-8df5-442f-8ae4-2a3e9bec1536"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125700">
        <dc:identifier>https://www.omim.org/entry/125700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>DIABETES INSIPIDUS, NEUROHYPOPHYSEAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/35641d54-8774-4d20-ac3f-48affda0a8c1"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c171987a-44d9-455b-b6e4-7598c088cf01">
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Polyuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86d908c2-77eb-483a-980a-96ff7c18b111"/>
    <rdfs:comment>This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3f09e089-eca8-42eb-adcd-649ea45fe89f">
        <dc:identifier>HP:0001943*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:label>chlorpropamide-induced hypoglycaemia (Hypoglycemia)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9b3c8a97-9202-4c7f-a749-f065b11ef636">
    <rdfs:label>Dihydrofolate reductase</rdfs:label>
    <ddiem:ecNumber>1.5.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/f8674a48-8b35-4a07-a0f6-14ccef325874">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1719</dc:identifier>
        <rdfs:label>DHFR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P00374</ddiem:uniprotId>
    <ddiem:keggEntryId>K00287</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/222748">
    <rdfs:label>DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/222748</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/268</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>268</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9017b042-9c89-46e5-83be-4322fc2c74e0"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4828e786-799c-4788-8945-61d69acad67c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/212138">
        <dc:identifier>https://www.omim.org/entry/212138</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/229</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>229</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/002a6172-a716-44b7-9388-bfc70bbacfe4"/>
        <rdfs:label>CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17508264</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cb066d4-d587-4fec-bd89-aa23900bafdb">
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>developmental delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b01fdd76-a7a9-49ca-86ab-852e4a65a9c9">
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypocarnitinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b59b9531-7873-4a5b-8249-a4793aa6666a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045045</ddiem:url>
        <dc:identifier>HP:0045045</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma long-chain acylcarnitines</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a7c98f6e-fe7f-4ee4-9f57-adc11cbdf855">
    <ddiem:ecNumber>3.1.1.13</ddiem:ecNumber>
    <ddiem:uniprotId>P38571</ddiem:uniprotId>
    <ddiem:keggEntryId>K01052</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cdb32024-056e-4022-82d2-c262cd585f92">
        <rdfs:label>LIPA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3988</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>lysosomal acid lipase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/00d9a683-0f0b-4a4f-b247-67eb1f8b16a2">
    <ddiem:uniprotId>P15328</ddiem:uniprotId>
    <rdfs:label>Folate receptor alpha</rdfs:label>
    <ddiem:keggEntryId>K13649</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/74730ced-af57-4962-888f-383420e6560b">
        <rdfs:label>FOLR1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2348</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e597baeb-299e-4402-808f-d0095b68e181">
    <ddiem:keggEntryId>K00500</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3adac8d7-db8b-4569-b777-9b837a9497f5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5053</dc:identifier>
        <rdfs:label>PAH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>PHENYLALANINE HYDROXYLASE</rdfs:label>
    <ddiem:ecNumber>1.14.16.1</ddiem:ecNumber>
    <ddiem:uniprotId>P00439</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a4cfde7f-f00f-42ca-a9c4-3314cbbdce7f">
    <rdfs:label>Alkaline phosphatase</rdfs:label>
    <ddiem:keggEntryId>K01077</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6da2ec29-acf5-4098-8449-0d492cd8357c"/>
    <ddiem:uniprotId>P05186</ddiem:uniprotId>
    <ddiem:ecNumber>3.1.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f44a68ae-d6de-430a-bffa-227a02f44e98">
    <rdfs:label>lipase maturation factor 1</rdfs:label>
    <ddiem:keggEntryId>K23555</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b7701fab-b7a2-4f50-9121-786c0b575b6f">
        <rdfs:label>LMF1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/64788</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q96S06</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/179850">
    <dc:identifier>https://www.omim.org/entry/179850</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/983d363f-2b77-4ae8-aebf-feedd69d8a34"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DOWLING-DEGOS DISEASE 1; DDD1</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66f65c2b-ec37-4d94-9162-c511dd0892af">
    <ddiem:ecNumber>3.2.1.113</ddiem:ecNumber>
    <rdfs:label>mannosidase alpha class 1B member 1</rdfs:label>
    <ddiem:keggEntryId>K01230</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/03a417bd-6a76-466b-8c64-614fde94d993"/>
    <ddiem:uniprotId>Q9UKM7</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5f1e1934-890f-4f8d-a82b-09cc0668dec8">
    <ddiem:uniprotId>P05019</ddiem:uniprotId>
    <ddiem:keggEntryId>K05459</ddiem:keggEntryId>
    <rdfs:label>insulin like growth factor 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bab9d202-21f1-4c4c-b313-861702e428e0">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3479</dc:identifier>
        <rdfs:label>IGF1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/4647b7c3-e8ae-4a8f-9974-e600542c81d2">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b202fcb-f19f-45ad-92b7-0b78e188cbf4"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/88141393-be5d-4114-9986-90c720b808d9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6b65fe8-119b-47cc-b75b-9b9c81f80745">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:label>Sleep disturbance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000010>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7d4fb8a-01d9-4c99-8e69-6bfb8cbf0df2">
    <rdfs:label>Mannose-6-phosphate isomerase</rdfs:label>
    <ddiem:uniprotId>P34949</ddiem:uniprotId>
    <ddiem:ecNumber>5.3.1.8</ddiem:ecNumber>
    <ddiem:keggEntryId>K01809</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8d7a40d3-d23d-4919-8888-4c2dc9e6bcad">
        <rdfs:label>MPI</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4351</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/7f71bbad-3996-4464-857c-cccb2f0404a2">
    <ddiem:uniprotId>P12235</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/77a50843-80aa-4df6-8c7a-702f33bbb119">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/291</dc:identifier>
        <rdfs:label>SLC25A4</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05863</ddiem:keggEntryId>
    <rdfs:label>ADP/ATP translocase 1</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5699638-a8a4-4f29-86db-1c074e07e8ff">
    <dc:provenance>https://www.nature.com/articles/nm1059</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68d9252a-0a48-4c3f-a702-9b5f88e81db7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613153">
        <dc:identifier>https://www.omim.org/entry/613153</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5</rdfs:label>
        <ddiem:iembaseAccessionNumber>645</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98d61ac2-3497-4d41-b6cf-2f3ac04c348d"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/645</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b841ceb-25c7-4db7-a491-ac3035020444"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f75db3ab-404b-45fc-90d2-d5b48f9f49fc">
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6dec3649-3d6d-4888-b50f-ad185b5b6146">
        <rdfs:label>FKTN</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2218</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Fukutin</rdfs:label>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd1fb90b-811f-485f-81d4-b8acc1465d09">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a0b045b-3ff0-4a3a-ba10-cac3513d8529">
        <rdfs:label>seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8a28cf99-f61e-4c86-8736-bf0fbc834f97">
    <rdfs:label>2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P12694</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/bdfefad7-ee7c-405c-a5a7-de669e6d7fa6">
        <rdfs:label>BCKDHA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.2.4.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K00166</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/03122f10-1701-456d-9ef5-99f6f537c5df">
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
    <rdfs:label>cytochrome c oxidase assembly factor</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/6d156ae5-1061-49cf-a838-510ee60e725b">
        <rdfs:label>D2HGDH</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/728294</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/616479">
    <dc:identifier>https://www.omim.org/entry/616479</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6abb6839-844b-4374-8b26-ad3b75b02775"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/407702be-c38b-4326-ba95-9ec91b69d201">
    <ddiem:ecNumber>2.4.1.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K05284</ddiem:keggEntryId>
    <rdfs:label>GPI mannosyltransferase 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/570ae277-9f7d-4dcb-a7ed-7ec894977c13"/>
    <ddiem:uniprotId>Q9H3S5</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/79e0df5e-df34-48e2-b390-86771d38a9ec">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e6ab7039-7a58-4029-af4c-00f0c6fee922">
        <rdfs:label>CTSC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1075</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Dipeptidyl peptidase 1</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6626e81e-7221-4609-bd98-d1a3045dc09e">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7c23ce16-8b45-4571-9c2c-c4c639aee536">
        <rdfs:label>PHKA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5256</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P46019</ddiem:uniprotId>
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit alpha, liver isoform</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/db6f22c4-f613-41ad-b565-6498fa3945e9">
    <ddiem:ecNumber>4.2.1.2</ddiem:ecNumber>
    <ddiem:keggEntryId>K01679</ddiem:keggEntryId>
    <ddiem:uniprotId>P07954</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/9c9f932c-f6d7-4ba1-963e-e68f5ae98168"/>
    <rdfs:label>Fumarate hydratase, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:label>activity_modification_of_a_genetically_defective_protein_by_transcriptional_or_translational_modification</rdfs:label>
    <obo:IAO_0000115>modification of the amount or stability of a transcript or the efficiency of translation of a transcript in order to reduce or increase the expression of a  genetically abnormal protein.</obo:IAO_0000115>
    <dc:date>3.10.19</dc:date>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115>any procedure designed to suppress or mitigate the effects of a recessive genetic change in an abnormal protein by modification of its transcription or translation, excluding those strategies which involve epigenetic modification or modification of the germline or somatic genome sequence. For example an abnormal Vmax of reaction, alteration of KM, failure to respond to positive  feedback, acquisition of neofunction.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0863dc4a-0396-4bae-9646-4fd71fb2efd3">
    <rdfs:label>Glycerol kinase</rdfs:label>
    <ddiem:keggEntryId>K00864</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dc753442-00bc-436f-bf45-a3e14a654d7e">
        <rdfs:label>GK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2710</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.30</ddiem:ecNumber>
    <ddiem:uniprotId>P32189</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c6fb1f4-3781-47b8-bea6-0fff4d99347c">
    <ddiem:keggEntryId>K09659</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9P2X0</ddiem:uniprotId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 3</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c8f56d79-8d05-453c-9b03-4360ff11a52c"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a0d408c9-d770-4218-bad2-224316d3925d">
    <ddiem:uniprotId>P09417</ddiem:uniprotId>
    <rdfs:label>Dihydropteridine reductase</rdfs:label>
    <ddiem:keggEntryId>K00357</ddiem:keggEntryId>
    <ddiem:ecNumber>1.5.1.34</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/d96f5243-9798-4df0-baf8-f47d6019f6e1"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615249">
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/04934ace-add1-4c29-a4e7-d25c860cb03d">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/84197</dc:identifier>
        <rdfs:label>POMK</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/615249</dc:identifier>
    <ddiem:iembaseAccessionNumber>1122</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1122</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615287">
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>1124</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b84b2031-ea56-4a3e-8586-a70c3a9d6fb2"/>
    <dc:identifier>https://www.omim.org/entry/615287</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1124</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6c7ecd09-2e9b-4643-9e16-0c60b51faf50">
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H9S5</ddiem:uniprotId>
    <ddiem:keggEntryId>K19873</ddiem:keggEntryId>
    <rdfs:label>fukutin-related protein (FKRP)</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/98d61ac2-3497-4d41-b6cf-2f3ac04c348d"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/40f9dd40-77ba-482c-9aa9-cf91ef7fa835">
    <rdfs:label>Protein O-mannose kinase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/04934ace-add1-4c29-a4e7-d25c860cb03d"/>
    <ddiem:ecNumber>2.7.1.183</ddiem:ecNumber>
    <ddiem:uniprotId>Q9H5K3</ddiem:uniprotId>
    <ddiem:keggEntryId>K17547</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/dbd61b15-5a7e-412b-9313-b1b58ad670d8">
    <ddiem:uniprotId>Q00266</ddiem:uniprotId>
    <ddiem:ecNumber>2.5.1.6</ddiem:ecNumber>
    <ddiem:keggEntryId>K00789</ddiem:keggEntryId>
    <rdfs:label>S-adenosylmethionine synthase isoform type-1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/557f6a5f-e75a-4f2f-acf9-fbdf3212758c">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4143</dc:identifier>
        <rdfs:label>MAT1A</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9a54e536-686c-49f8-ba99-bf9c419135fb">
    <ddiem:uniprotId>Q99707</ddiem:uniprotId>
    <rdfs:label>Methionine synthase</rdfs:label>
    <ddiem:ecNumber>2.1.1.13</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94d18fbb-3836-4e39-9857-6e05e6fa4800">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4548</dc:identifier>
        <rdfs:label>MTR</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K00548</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c6e58908-8198-4643-9218-369d47b1a6f2">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59f04063-4da6-4482-aba7-8be8eba7bc96">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6f6f427b-85c2-43ee-8835-7ae13aaa6254"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606762">
        <rdfs:label>HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72470a6e-3692-478c-a602-0ef261882487"/>
        <rdfs:comment>Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/</rdfs:comment>
        <ddiem:iembaseAccessionNumber>567</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/606762</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/567</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2">
        <dc:identifier>HP:0001943</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoglycemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/13abf97c-8da2-4f43-ab21-67e3eac23a5d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/412d0bd8-390c-4669-93ef-344820ba2204"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10e4dfe8-c325-4413-a022-d4b178fcc25d"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/06cda6fc-27ca-4410-a9ab-954c2c3a02d4">
    <rdfs:label>Apolipoprotein A-V</rdfs:label>
    <ddiem:uniprotId>Q6Q788</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/773169c4-5012-4901-a15c-5e73b8adf910"/>
    <ddiem:keggEntryId>K09025</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/57526946-822e-475c-9c2d-8e7c90861360">
    <ddiem:keggEntryId>K01279</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8702dddd-4931-4740-b46e-ee739075de93">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1200</dc:identifier>
        <rdfs:label>TPP1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>TRIPEPTIDYL PEPTIDASE I</rdfs:label>
    <ddiem:ecNumber>3.4.14.9</ddiem:ecNumber>
    <ddiem:uniprotId>O14773</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f79efa3a-2837-4ae8-b315-552449d1d7f0">
    <rdfs:label>Pyridoxamine 5'-phosphate oxidase</rdfs:label>
    <ddiem:uniprotId>Q9NVS9</ddiem:uniprotId>
    <ddiem:ecNumber>1.4.3.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K00275</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/1f505eb6-344a-43b8-8f56-3ae42b48046e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/55163</dc:identifier>
        <rdfs:label>PNPO</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/05c354a9-2ea4-448f-b945-07c171c1b5ea">
    <rdfs:label>pterin-4 alpha-carbinolamine dehydratase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/aca85188-6102-4947-a0aa-d13fcea038e2">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5092</dc:identifier>
        <rdfs:label>PCBD1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K01724</ddiem:keggEntryId>
    <ddiem:uniprotId>P61457</ddiem:uniprotId>
    <ddiem:ecNumber>4.2.1.96</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ca517800-461f-4a7c-a8f3-62a29cab6717">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eda88e4c-a826-4055-a10f-a2df95b85522">
        <rdfs:label>ADCK3</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Atypical kinase COQ8A, mitochondrial</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8ae8e1c7-a6dc-4114-a8e2-ac35c27a717c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/183cc80b-2957-4499-bf84-c979ef406bbb"/>
    <ddiem:keggEntryId>K10352</ddiem:keggEntryId>
    <ddiem:uniprotId>Q9UKX2</ddiem:uniprotId>
    <rdfs:label>myosin heavy chain 2</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/242600">
    <dc:identifier>https://www.omim.org/entry/242600</dc:identifier>
    <ddiem:iembaseAccessionNumber>798</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/798</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97c7ce28-e142-427a-9554-3b199409d802"/>
    <rdfs:label>IMINOGLYCINURIA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/72e81347-7d04-4812-aa2b-70c547fb9de5"/>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e7e330d8-0294-42f8-928d-ea92812a63fc">
    <ddiem:keggEntryId>K12564</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13326</ddiem:uniprotId>
    <rdfs:label>sarcoglycan gamma</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3f6b222f-35ac-4789-9495-9a62269c25b4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6445</dc:identifier>
        <rdfs:label>SGCG</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8b8c996d-011b-42d0-b466-640c8316d5a9">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ddddd1f4-77b9-42b1-9d0c-cc0e9ffa9dc0">
        <rdfs:label>GIF</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/""</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>gastric intrinsic factor</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/76034d8f-6867-4080-aa6b-53f41a663978">
    <rdfs:label>hepatic lipase</rdfs:label>
    <ddiem:ecNumber>3.1.1.3</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/30cc24f2-ddc0-43a6-a6d9-7828d6b5b794">
        <rdfs:label>LIPC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3990</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K22283</ddiem:keggEntryId>
    <ddiem:uniprotId>P11150</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ec7f2c52-c74e-4143-be25-51446da775d0">
    <ddiem:keggEntryId>K16343</ddiem:keggEntryId>
    <ddiem:ecNumber>3.1.1.4</ddiem:ecNumber>
    <rdfs:label>85/88 kDa calcium-independent phospholipase A2</rdfs:label>
    <ddiem:uniprotId>O60733</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/789ca0f3-40ea-4056-951a-ea6314c34f3f"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/413a6055-a9ae-4789-bec8-3339fd8478a7">
    <ddiem:uniprotId>Q9UKY4</ddiem:uniprotId>
    <ddiem:keggEntryId>K00728</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/20a0cd13-1fd2-490c-a3b1-f2aad13cfeaa">
        <rdfs:label>POMT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/29954</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Protein O-mannosyl-transferase 2</rdfs:label>
    <ddiem:ecNumber>2.4.1.109</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f1c55a74-55d4-42d1-849e-3d839f904575">
    <ddiem:keggEntryId>K03165</ddiem:keggEntryId>
    <ddiem:ecNumber>5.6.2.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c73d6539-c0bd-4efb-84f9-aabdd306348f">
        <rdfs:label>TOP3A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7156</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q13472</ddiem:uniprotId>
    <rdfs:label>DNA topoisomerase 3-alpha</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/97394aa3-2a9f-4577-b6ac-9611962a3f0b">
    <ddiem:uniprotId>P07911</ddiem:uniprotId>
    <ddiem:keggEntryId>K18274</ddiem:keggEntryId>
    <rdfs:label>uromodulin</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a4b943b0-097e-45d7-b19e-271269f4c5e4">
        <rdfs:label>UMOD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7369</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b78cbcf1-7e3b-43a4-bb9d-d5ca75652f51">
    <ddiem:uniprotId>O95954</ddiem:uniprotId>
    <rdfs:label>formiminotransferase cyclodeaminase</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/10921de6-9125-4306-84ae-c8b24173ee3e">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10841</dc:identifier>
        <rdfs:label>FTCD</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.1.2.5; 4.3.1.4</ddiem:ecNumber>
    <ddiem:keggEntryId>K13990</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/66e10181-70b8-440a-a72e-4c3e481fc164">
    <ddiem:ecNumber>2.7.1.31</ddiem:ecNumber>
    <ddiem:keggEntryId>K11529</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2c29acd0-c9ae-4e8e-bd72-ea132330e12b">
        <rdfs:label>GLYCTK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/132158</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>d-glycerate kinase</rdfs:label>
    <ddiem:uniprotId>Q8IVS8</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a912b1b-fb05-4538-92a9-e304c94fcf98">
    <rdfs:label>Y+L amino acid transporter 1</rdfs:label>
    <ddiem:keggEntryId>K13867</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffd0b716-871c-421c-8f76-03c3264bf0ed">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/9056</dc:identifier>
        <rdfs:label>SLC7A7</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q9UM01</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/procedure_to_mitigate_dominant_effects_of_a_genetically_abnormal_protein">
    <obo:IAO_0000115>a procedure to suppress or mitigate the effects of a dominant alteration in a genetically abnormal protein by reducing or suppressing  transcription or translation of the abnormal protein gene or rna, or destabilising or otherwise inhibiting an abnormally increased activity or neoactivity of the abnormal protein.</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <dc:creator>ORCID: 0000-0002-5111-7263</dc:creator>
    <dc:date>4.10.19</dc:date>
  </owl:Class>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/373ea834-f856-4da6-8c06-04e3785e17b4">
    <ddiem:uniprotId>P11166</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8e413a23-049b-4ee7-93a4-c9a55eac954c">
        <rdfs:label>SLC2A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6513</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07299</ddiem:keggEntryId>
    <rdfs:label>glucose transporter protein type 1 (GLUT1)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/49ed1826-1da6-44d6-9e41-8e7f1b4d80ad">
    <ddiem:uniprotId>Q75V66</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/73531151-6361-428c-a016-5cdee78cef4c"/>
    <ddiem:keggEntryId>K19480</ddiem:keggEntryId>
    <rdfs:label>anoctamin 5</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bcaff2e7-1527-4fb9-9469-2cfa8506f198">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/acb4c1bd-685b-4bbf-a48c-43b79439e077">
        <rdfs:label>DBT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1629</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.3.1.168</ddiem:ecNumber>
    <ddiem:keggEntryId>K09699</ddiem:keggEntryId>
    <ddiem:uniprotId>P11182</ddiem:uniprotId>
    <rdfs:label>Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8c445687-1d84-4e79-a2ad-a9f4af484ee2">
    <ddiem:uniprotId>Q9UHN1</ddiem:uniprotId>
    <ddiem:keggEntryId>K02333</ddiem:keggEntryId>
    <rdfs:label>DNA polymerase subunit gamma-2, mitochondrial</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b1092921-80f2-46f3-947a-b38d3fca7501">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/11232</dc:identifier>
        <rdfs:label>POLG2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2c351d8a-16b9-4b69-ae1d-aff965c02c28">
    <rdfs:label>Solute carrier family 12 member 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/61b19bfc-90a8-4af0-bdad-bce3574b8905">
        <rdfs:label>SLC12A1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6557</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K14425</ddiem:keggEntryId>
    <ddiem:uniprotId>Q13621</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/518331d3-ef35-4b18-b930-e547bc1d38f0">
    <ddiem:keggEntryId>K01204</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4c592a34-cfe2-4fa3-8861-69d491b10d80">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4668</dc:identifier>
        <rdfs:label>NAGA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-N-acetylgalactosaminidase</rdfs:label>
    <ddiem:ecNumber>3.2.1.49</ddiem:ecNumber>
    <ddiem:uniprotId>P17050</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/88bca0c0-115a-49f9-a2cc-b04844aeffb1">
    <rdfs:label>barttin</rdfs:label>
    <ddiem:keggEntryId>K19331</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/34d7fac6-6674-4f91-99a0-2f562f6f27b5">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/7809</dc:identifier>
        <rdfs:label>BSND</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q8WZ55</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83c22191-7fd8-4425-b5d3-a04a13b5502c">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/e7145a9f-c587-4a3d-a61f-7d107ecf6e49"/>
    <ddiem:keggEntryId>K00721</ddiem:keggEntryId>
    <ddiem:uniprotId>O60762</ddiem:uniprotId>
    <rdfs:label>dolichol-P-mannose synthase 1</rdfs:label>
    <ddiem:ecNumber>2.4.1.83</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6199e2d4-2eb1-46ad-9886-96211bc6e418">
    <ddiem:ecNumber>3.2.1.25</ddiem:ecNumber>
    <rdfs:label>Beta-mannosidase</rdfs:label>
    <ddiem:uniprotId>O00462</ddiem:uniprotId>
    <ddiem:keggEntryId>K01192</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8556cc42-3388-4764-a914-3e4e6c3fba67"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/50fab08e-7914-4c10-8de1-0500fc348285">
    <ddiem:ecNumber>1.4.1.3</ddiem:ecNumber>
    <rdfs:label>Glutamate dehydrogenase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>P00367</ddiem:uniprotId>
    <ddiem:keggEntryId>K00261</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/72470a6e-3692-478c-a602-0ef261882487">
        <rdfs:label>GLUD1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2746</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0cac1320-c43c-45bb-ba07-a00ad0d325d3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7029596a-95f8-4ee9-90c3-cad5c037c8df">
        <rdfs:label>CASR</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/846</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P41180</ddiem:uniprotId>
    <rdfs:label>calcium-sensing receptor</rdfs:label>
    <ddiem:keggEntryId>K04612</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ab84fc74-3c34-45b0-b30b-d35b10b568a3">
    <ddiem:keggEntryId>K01623</ddiem:keggEntryId>
    <ddiem:uniprotId>P04075</ddiem:uniprotId>
    <ddiem:ecNumber>4.1.2.13</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/fcb4a650-8961-43a2-8220-57d9f2b1facd"/>
    <rdfs:label>aldolase, fructose-bisphosphate A</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/26e955cc-8f77-42b7-a0eb-300f846bd827">
    <ddiem:keggEntryId>K11827</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/50d64aa0-19d8-4f8a-9051-a65c74b81770">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1175</dc:identifier>
        <rdfs:label>AP2S1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>adaptor protein-2 σ-subunit</rdfs:label>
    <ddiem:uniprotId>P53680</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2507e449-efb0-470c-8793-44f7edfa8f18">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a6d42cad-4114-498e-820b-08e1b65c5d70"/>
    <ddiem:ecNumber>2.4.1.198</ddiem:ecNumber>
    <rdfs:label>Phosphatidylinositol N-acetylglucosaminyltransferase subunit A</rdfs:label>
    <ddiem:uniprotId>P37287</ddiem:uniprotId>
    <ddiem:keggEntryId>K03857</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614643">
    <ddiem:iembaseAccessionNumber>641</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/96ee0c80-0c9d-406b-af95-9503d212c6d3"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/614643</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/641</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/afcf0acd-fb60-4904-9674-b353c7b13e41">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4dedcbb0-db0d-490c-91b3-4350b362f6ae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/875</dc:identifier>
        <rdfs:label>CBS</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>4.2.1.22</ddiem:ecNumber>
    <ddiem:keggEntryId>K01697</ddiem:keggEntryId>
    <rdfs:label>cystathionine beta-synthase</rdfs:label>
    <ddiem:uniprotId>P35520</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/677f84af-0df5-45f1-b805-d6f78dbba5bb">
    <ddiem:keggEntryId>K15279</ddiem:keggEntryId>
    <rdfs:label>GDP-fucose transporter 1</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c4158b3a-1e29-4449-a91b-115a1916e223"/>
    <ddiem:uniprotId>Q96A29</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a9ddf679-5ccd-4f96-ad63-1e81d4e50cc1">
    <rdfs:label>proline dehydrogenase 1</rdfs:label>
    <ddiem:uniprotId>O43272</ddiem:uniprotId>
    <ddiem:keggEntryId>K00318</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/3a65cf92-933c-4dfd-827f-379a76aa5c53">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5625</dc:identifier>
        <rdfs:label>PRODH</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>1.5.5.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/8482994f-20b1-48ae-9487-be5df5fdd8a8">
    <ddiem:keggEntryId>K08573</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e4f79f94-3977-4262-b523-0b59b53cc9c9">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/825</dc:identifier>
        <rdfs:label>CAPN3</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>calpain 3</rdfs:label>
    <ddiem:uniprotId>P20807</ddiem:uniprotId>
    <ddiem:ecNumber>3.4.22.54</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c7239805-8d9a-4b57-b4bc-6920cf4913be">
    <ddiem:ecNumber>3.1.11.7; 3.1.12.2</ddiem:ecNumber>
    <ddiem:uniprotId>Q7Z2E3</ddiem:uniprotId>
    <rdfs:label>Aprataxin</rdfs:label>
    <ddiem:keggEntryId>K10863</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/95016809-9cba-4bc4-859d-6e5c860689ba">
        <rdfs:label>APTX</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/54840</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/0097f67d-933e-45b0-b8db-24243aab37c3">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c525900b-cfb8-4763-b057-5f79f279b426">
        <rdfs:label>NPC2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/10577</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>NPC intracellular cholesterol transporter 2</rdfs:label>
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ccd394ff-2ee1-4662-b7af-759cebdef592">
    <ddiem:ecNumber>2.7.7.7</ddiem:ecNumber>
    <ddiem:uniprotId>P54098</ddiem:uniprotId>
    <rdfs:label>DNA polymerase subunit gamma-1</rdfs:label>
    <ddiem:keggEntryId>K02332</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/281a64eb-af70-464b-ac4b-607d2f081765"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/29854067-7c9a-49d2-b847-269d8f90f153">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/eda7f03a-2a25-4a4b-a1fe-fb4385f86ec4">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/51128</dc:identifier>
        <rdfs:label>SAR1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Sar1b protein</rdfs:label>
    <ddiem:uniprotId>Q9Y6B6</ddiem:uniprotId>
    <ddiem:keggEntryId>K07953</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e1ccd749-b6de-44b5-8d0f-190158993aed">
    <rdfs:label>Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)</rdfs:label>
    <ddiem:uniprotId>P35573</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/b542d036-2949-4809-bec8-bd3cb6952d00">
        <rdfs:label>AGL</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/178</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.4.1.25; 3.2.1.33</ddiem:ecNumber>
    <ddiem:keggEntryId>K01196</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/53c84a80-aac5-45dd-b481-a2305481e39f">
    <rdfs:label>fukutin</rdfs:label>
    <ddiem:keggEntryId>K19872</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.2.-</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6dec3649-3d6d-4888-b50f-ad185b5b6146"/>
    <ddiem:uniprotId>O75072</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613724">
    <ddiem:iembaseAccessionNumber>1114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/613724</dc:identifier>
    <obo:RO_0004020>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/0864c4a9-c4d3-4deb-8ce4-cebb3ce7245a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6342</dc:identifier>
        <rdfs:label>SCP2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0004020>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1114</ddiem:iembaseUrl>
    <rdfs:label>LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9610acc8-d7ac-4271-abcd-a2dc40c425f7">
    <ddiem:keggEntryId>K09658</ddiem:keggEntryId>
    <rdfs:label>dolichyl-phosphate mannosyltransferase subunit 2</rdfs:label>
    <ddiem:uniprotId>O94777</ddiem:uniprotId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a2aec718-ec47-48d4-b3ce-0677142f84d4"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5a73f92c-0a45-42c4-afeb-0c2ae7f61a65">
    <rdfs:label>sodium/glucose cotransporter protein called SGLT1</rdfs:label>
    <ddiem:keggEntryId>K14158</ddiem:keggEntryId>
    <ddiem:uniprotId>P13866</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2032fd0a-36a6-4f1b-9d7f-3402ba06dd6a">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6523</dc:identifier>
        <rdfs:label>SLC5A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24e3d0ac-ba11-4103-abcb-c8528b6012da">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/97b56f8a-b6b4-4658-ad0e-354ed9cceab8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/19</dc:identifier>
        <rdfs:label>ABCA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05641</ddiem:keggEntryId>
    <rdfs:label>Phospholipid-transporting ATPase ABCA1</rdfs:label>
    <ddiem:uniprotId>O95477</ddiem:uniprotId>
    <ddiem:ecNumber>7.6.2.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b3fe224b-4b13-48b5-b4bc-3a92d9f27873">
    <ddiem:keggEntryId>K01593</ddiem:keggEntryId>
    <ddiem:ecNumber>4.1.1.28</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/8ad38cd5-46b6-443f-b9ac-751d0637359b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1644</dc:identifier>
        <rdfs:label>DDC</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Aromatic-L-amino-acid decarboxylase</rdfs:label>
    <ddiem:uniprotId>P20711</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/a83bae4f-f4c1-4c64-b2c0-f5e5fd36961b">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/89d78dcd-1df9-43d0-ba70-11723dfb3517">
        <rdfs:label>LMNA</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4000</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K12641</ddiem:keggEntryId>
    <rdfs:label>lamins ( Lamins A and C)</rdfs:label>
    <ddiem:uniprotId>P02545</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/6fc8ae9f-4180-4b2e-89d6-a0a8bcba9d66">
    <ddiem:ecNumber>2.4.1.313</ddiem:ecNumber>
    <ddiem:keggEntryId>K09654</ddiem:keggEntryId>
    <ddiem:uniprotId>Q8NCR0</ddiem:uniprotId>
    <rdfs:label>UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/2d6107f4-1706-4794-9587-db7fde42df05">
        <rdfs:label>B3GALNT2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/148789</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/11a5d3d2-435b-408b-9f5b-eed1fd026054">
    <ddiem:uniprotId>P09622</ddiem:uniprotId>
    <ddiem:ecNumber>1.8.1.4</ddiem:ecNumber>
    <rdfs:label>Dihydrolipoyl dehydrogenase, mitochondrial</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/c75cbe99-1b89-4bf2-83df-6e478c584e3c"/>
    <ddiem:keggEntryId>K00382</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3355e956-27bb-4c0f-9149-f21ab7123bb4">
    <rdfs:label>Choline/ethanolamine kinase</rdfs:label>
    <ddiem:uniprotId>Q9Y259</ddiem:uniprotId>
    <ddiem:ecNumber>2.7.1.32; 2.7.1.82</ddiem:ecNumber>
    <ddiem:keggEntryId>K14156</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e2d81cb9-c4d1-4dfc-b4de-9f0952cb5a9f">
        <rdfs:label>CHKB</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1120</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/918ae68d-9d3a-4b3d-b353-3fa6354d0fe1">
    <ddiem:uniprotId>Q9H3L0</ddiem:uniprotId>
    <rdfs:label>Methylmalonic aciduria and homocystinuria type D protein, mitochondrial</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ffc1c0a4-d407-4adc-b545-e726bb65bf9e">
        <rdfs:label>MMADHC</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/27249</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/24e843e4-cedc-4e03-aac4-17563b643b67">
    <ddiem:keggEntryId>K08765</ddiem:keggEntryId>
    <rdfs:label>carnitine palmitoyltransferase 1A</rdfs:label>
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5e67b4cf-cfbc-48e4-b841-5d38eed9aac9">
        <rdfs:label>CPT1A</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1374</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P50416</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e95dfc4c-60e2-46f6-9241-3935841c04ed">
    <ddiem:keggEntryId>K00512</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.14.19; 1.14.14.32</ddiem:ecNumber>
    <rdfs:label>Steroid 17-alpha-hydroxylase</rdfs:label>
    <ddiem:uniprotId>P05093</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/94624af1-0d56-4d95-86fa-686e040a99f7">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1586</dc:identifier>
        <rdfs:label>CYP17A1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/215720">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eda7f03a-2a25-4a4b-a1fe-fb4385f86ec4"/>
    <dc:identifier>https://www.omim.org/entry/215720</dc:identifier>
    <rdfs:label>CITRULLINE TRANSPORT DEFECT</rdfs:label>
  </ddiem:Disease>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/756520be-a37c-4ac8-963a-74dab0b0d694">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/dd49f2f4-1cfc-486a-a1e3-afa2a2f86c2f">
        <rdfs:label>CDAN1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/146059</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>codanin 1</rdfs:label>
    <ddiem:uniprotId>Q8IWY9</ddiem:uniprotId>
    <ddiem:keggEntryId>K19531</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/4a79b8b9-c17c-4d20-9096-60485a108ba6">
    <ddiem:uniprotId>P31327</ddiem:uniprotId>
    <ddiem:keggEntryId>K01948</ddiem:keggEntryId>
    <rdfs:label>Carbamoyl-phosphate synthase (ammonia</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c40fdbfb-aaaf-4896-b3d7-3a93bbd5bceb">
        <rdfs:label>CPS1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1373</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>6.3.4.16</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/240fd684-9847-4233-b31c-d72ab9859043">
    <ddiem:uniprotId>""</ddiem:uniprotId>
    <rdfs:label>Adenosine deaminase</rdfs:label>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/58bc2f4e-7b10-4199-9234-8a616a2ec6cb">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/100</dc:identifier>
        <rdfs:label>ADA</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/67159f03-d032-4b05-9982-17963496cdb4">
    <ddiem:ecNumber>6.3.1.2; 2.3.1.225</ddiem:ecNumber>
    <ddiem:keggEntryId>K01915</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/9dfd67c9-68b7-4bc1-a6f7-b9d52d5ba702">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2752</dc:identifier>
        <rdfs:label>GLUL</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glutamine synthetase</rdfs:label>
    <ddiem:uniprotId>P15104</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bc5c42fe-0da1-4487-815b-4cf9ae7b2e8d">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/b078ee86-0187-40cd-a873-618f363f5ee4"/>
    <rdfs:label>Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/99950311-4854-4962-bc89-45e16943db7b">
        <rdfs:label>MT-CO1</rdfs:label>
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CO1</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/162ae8ae-1a56-41f8-85b1-a8958251a266">
        <dc:identifier>https://ghr.nlm.nih.gov/gene/MT-CYB</dc:identifier>
        <rdfs:label>MT-CYB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/2a1cd74a-7425-411a-96c1-5bcd14bb0b0a">
    <rdfs:label>mitochondrial dynamin like GTPase</rdfs:label>
    <ddiem:uniprotId>O60313</ddiem:uniprotId>
    <ddiem:ecNumber>3.6.5.5</ddiem:ecNumber>
    <ddiem:keggEntryId>K17079</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/7ed24451-a149-4b62-8a0a-be7b7a541195"/>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/bd1ba528-06bd-40e8-bf0c-bed9127bf10c">
    <ddiem:ecNumber>3.2.1.51</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/71450365-8c67-4e06-8346-4d6bbc07f0f9">
        <rdfs:label>FUCA1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2517</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04066</ddiem:uniprotId>
    <rdfs:label>a-L-fucosidase</rdfs:label>
    <ddiem:keggEntryId>K01206</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ee2bfeb5-0280-45fb-bb12-ec24996b4b88">
    <ddiem:uniprotId>P05089</ddiem:uniprotId>
    <ddiem:keggEntryId>K01476</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/e4831891-8893-4906-9801-eda35c5807f4">
        <rdfs:label>ARG1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/383</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Arginase</rdfs:label>
    <ddiem:ecNumber>3.5.3.1</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/ff44726d-e988-43b0-9965-b9386ef0a03c">
    <rdfs:label>D-2-hydroxyglutarate dehydrogenase</rdfs:label>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/6d156ae5-1061-49cf-a838-510ee60e725b"/>
    <ddiem:uniprotId>Q8N465</ddiem:uniprotId>
    <ddiem:ecNumber>1.1.99.-</ddiem:ecNumber>
    <ddiem:keggEntryId>K18204</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/01999ccb-d54b-412b-8d90-5673af65f135">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/0864c4a9-c4d3-4deb-8ce4-cebb3ce7245a"/>
    <rdfs:label>sterol carrier protein 2</rdfs:label>
    <ddiem:ecNumber>2.3.1.176</ddiem:ecNumber>
    <ddiem:keggEntryId>K08764</ddiem:keggEntryId>
    <ddiem:uniprotId>P22307</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/968e2e74-8229-4497-ace3-e29c41afcb63">
    <ddiem:uniprotId>P01009</ddiem:uniprotId>
    <ddiem:keggEntryId>K03984</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/ba29f016-e021-4a3b-b573-792f16cffb27">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5265</dc:identifier>
        <rdfs:label>SERPINA1</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>alpha-1-antitrypsin (major plasma serine protease inhibitor)</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/5c3915b3-df74-4e8a-b0bb-8ba5510629ed">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/23aefb6b-6615-4c82-ace7-b7bebeb51952">
        <rdfs:label>DGUOK</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1716</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>2.7.1.113</ddiem:ecNumber>
    <ddiem:keggEntryId>K00904</ddiem:keggEntryId>
    <rdfs:label>Deoxyguanosine kinase, mitochondrial</rdfs:label>
    <ddiem:uniprotId>Q16854</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/56f4de12-fd18-4136-8666-129aa729469c">
    <rdfs:label>ATP-sensitive inward rectifier potassium channel 1</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/fd0d3ec4-d641-47f4-8cc8-b1d187e5a78d">
        <rdfs:label>KCNJ1</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3758</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K04995</ddiem:keggEntryId>
    <ddiem:uniprotId>P48048</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/19ee19df-dd1f-4d67-92c5-d4cdf7e498da">
    <ddiem:ecNumber>2.3.1.21</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/904b407f-6f21-4c0a-adaa-3cce78351cdd">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/1375</dc:identifier>
        <rdfs:label>CPT1B</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>carnitine O-palmitoyltransferase 1, muscle isoform</rdfs:label>
    <ddiem:uniprotId>Q92523</ddiem:uniprotId>
    <ddiem:keggEntryId>K19523</ddiem:keggEntryId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/13e0dce5-f597-406d-9d58-86b3306b3c9e">
    <ddiem:uniprotId>Q30201</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/c9cb58c7-fef3-4b22-a651-0469cf570339">
        <rdfs:label>HFE</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/3077</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>""</ddiem:keggEntryId>
    <rdfs:label>Hereditary hemochromatosis protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9b590a27-8081-4e36-a80d-9d3e7257647a">
    <rdfs:label>ATP binding cassette subfamily C member 8</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a014643c-be79-4bb8-a61e-f0452367ff97">
        <rdfs:label>ABCC8</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6833</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K05032</ddiem:keggEntryId>
    <ddiem:uniprotId>Q09428</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3932e457-8ab8-442f-9147-b40e4d219aa1">
    <rdfs:label>Solute carrier family 2, facilitated glucose transporter member 2</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/cbcfa84b-cec1-48a0-a207-9544a9f3bd76">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/6514</dc:identifier>
        <rdfs:label>SLC2A2</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:keggEntryId>K07593</ddiem:keggEntryId>
    <ddiem:uniprotId>P11168</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/97fd722c-9558-48f0-aa69-e014b6458acc">
    <ddiem:keggEntryId>K14463</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/236420f0-b954-42c0-8fce-df7418752463">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4547</dc:identifier>
        <rdfs:label>MTTP</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P55157</ddiem:uniprotId>
    <rdfs:label>microsomal triglyceride transfer protein</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c449ea17-ab34-44c6-a876-73d15d5b6fcb">
    <ddiem:ecNumber>2.6.1.13</ddiem:ecNumber>
    <ddiem:keggEntryId>K00819</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/a32ec522-4b33-4a95-835e-bf31368136c8">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/4942</dc:identifier>
        <rdfs:label>OAT</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>P04181</ddiem:uniprotId>
    <rdfs:label>ornithine aminotransferase</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/83eb0626-ee1f-43b4-9e2a-23a5ac0741f7">
    <ddiem:keggEntryId>K00688</ddiem:keggEntryId>
    <ddiem:ecNumber>2.4.1.1</ddiem:ecNumber>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/81a9da44-2a98-4acf-a4f1-61b29d7ebe94">
        <rdfs:label>PYGM</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5837</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Glycogen phosphorylase, Muscle form</rdfs:label>
    <ddiem:uniprotId>P11217</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/3c3275f9-3e0c-4fe7-809a-0a5ffb4e07e5">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/d48dc661-01f6-4ae9-9c25-4c04bf0a542f">
        <rdfs:label>GAMT</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/2593</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q14353</ddiem:uniprotId>
    <ddiem:keggEntryId>K00542</ddiem:keggEntryId>
    <rdfs:label>guanidinoacetate methyltransferase</rdfs:label>
    <ddiem:ecNumber>2.1.1.2</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/b9b1907b-3cb9-454f-9673-75906068e34c">
    <ddiem:keggEntryId>K08105</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/786a2ff6-8240-4b54-8cab-70e6e056f188">
        <rdfs:label>CHST14</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/113189</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>Dermatan-4-sulfotransferase-1</rdfs:label>
    <ddiem:ecNumber>2.8.2.35</ddiem:ecNumber>
    <ddiem:uniprotId>Q8NCH0</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/f45824ca-332e-438c-be68-caa1f458d838">
    <ddiem:ecNumber>3.5.4.16</ddiem:ecNumber>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/8edda9be-9596-4cca-93cd-8b2fc2bb8df0"/>
    <ddiem:keggEntryId>K01495</ddiem:keggEntryId>
    <rdfs:label>GTP cyclohydrolase 1</rdfs:label>
    <ddiem:uniprotId>P30793</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9cf7ce50-4dfe-4c62-b9d6-2f65d22e9ced">
    <ddiem:keggEntryId>K19703</ddiem:keggEntryId>
    <ddiem:ecNumber>1.14.18.-</ddiem:ecNumber>
    <rdfs:label>fatty acid 2-hydroxylase</rdfs:label>
    <ddiem:uniprotId>Q7L5A8</ddiem:uniprotId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/4e5c50f2-0c32-402b-9de6-2f8f6cfed5e6">
        <rdfs:label>FA2H</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/79152</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/e40cf3ba-968d-4069-b84f-52ebea4a7b4b">
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/2aab6a1a-c4b6-40e2-8f9d-63e280cfa390"/>
    <ddiem:keggEntryId>K05612</ddiem:keggEntryId>
    <ddiem:uniprotId>P43005</ddiem:uniprotId>
    <rdfs:label>Excitatory amino acid transporter 3</rdfs:label>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/1fe3cb0e-6d3d-43c7-9be8-33c225987b39">
    <rdfs:label>Dystroglycan</rdfs:label>
    <ddiem:keggEntryId>K06265</ddiem:keggEntryId>
    <obo:RO_0002204 rdf:resource="http://ddiem.phenomebrowser.net/a2e813f6-ddcf-4d17-b5df-304fa29d45a0"/>
    <ddiem:uniprotId>Q14118</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/9381f559-6a77-47f2-879b-b39ca44034e5">
    <ddiem:uniprotId>Q16719</ddiem:uniprotId>
    <ddiem:keggEntryId>K01556</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/180d67e7-4a4d-47ce-9749-e2ed9ac1d43b">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8942</dc:identifier>
        <rdfs:label>KYNU</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <rdfs:label>kynureninase</rdfs:label>
    <ddiem:ecNumber>3.7.1.3</ddiem:ecNumber>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/04b89d13-dbd5-4c00-bf40-a0911e9497fa">
    <ddiem:keggEntryId>K01900</ddiem:keggEntryId>
    <ddiem:ecNumber>6.2.1.5</ddiem:ecNumber>
    <ddiem:uniprotId>Q9P2R7</ddiem:uniprotId>
    <rdfs:label>Succinyl-CoA synthetase ( beta subunit)</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/7a7b4c20-5572-4165-a482-a8497a987237">
        <rdfs:label>SUCLA2</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/8803</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <foaf:Person rdf:about="Resource(https://www.pdn.cam.ac.uk)/EuniceMcMurray">
    <rdfs:label>Eunice McMurray</rdfs:label>
    <foaf:mbox rdf:resource="mailto:emm1@cam.ac.uk"/>
  </foaf:Person>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/c14c5ad0-6d8c-4ccf-8ffd-c0ff922e1658">
    <ddiem:ecNumber>2.7.1.11</ddiem:ecNumber>
    <ddiem:uniprotId>P08237</ddiem:uniprotId>
    <rdfs:label>ATP-dependent 6-phosphofructokinase, muscle type</rdfs:label>
    <ddiem:keggEntryId>K00850</ddiem:keggEntryId>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/5e8f82dc-eea0-4959-9a07-0fbd11cbacae">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5213</dc:identifier>
        <rdfs:label>PFKM</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
  </ddiem:ProtienOrEnzyme>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/date"/>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/463bae7d-d31a-4baf-b3e6-da7f356c7d54">
    <ddiem:keggEntryId>K07190</ddiem:keggEntryId>
    <rdfs:label>Phosphorylase b kinase regulatory subunit beta</rdfs:label>
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/356e723f-b5a9-4705-9ee7-df0f053c3607">
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/5257</dc:identifier>
        <rdfs:label>PHKB</rdfs:label>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:uniprotId>Q93100</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <ddiem:ProtienOrEnzyme rdf:about="http://ddiem.phenomebrowser.net/057dcd7c-edb1-47d1-b4ce-d66cdc21bb4a">
    <obo:RO_0002204>
      <ddiem:Gene rdf:about="http://ddiem.phenomebrowser.net/650714e2-57af-4e5c-bc32-679d4960ff62">
        <rdfs:label>BTD</rdfs:label>
        <dc:identifier>https://www.ncbi.nlm.nih.gov/gene/686</dc:identifier>
      </ddiem:Gene>
    </obo:RO_0002204>
    <ddiem:ecNumber>3.5.1.12</ddiem:ecNumber>
    <ddiem:keggEntryId>K01435</ddiem:keggEntryId>
    <rdfs:label>biotinidase</rdfs:label>
    <ddiem:uniprotId>P43251</ddiem:uniprotId>
  </ddiem:ProtienOrEnzyme>
  <owl:Ontology rdf:about="http://purl.obolibrary.org/obo/">
    <owl:imports rdf:resource="http://purl.obolibrary.org/obo/ogms.owl"/>
  </owl:Ontology>
  <owl:AnnotationProperty rdf:about="http://purl.org/dc/elements/1.1/creator"/>
  <owl:AnnotationProperty rdf:about="http://purl.obolibrary.org/obo/IAO_0000115"/>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/820224c6-2ce5-457d-9e43-62b3a9234f85">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ed170404-b292-46fe-b472-76b16a0f01b7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ced2fbb7-de08-469c-b224-0d1e5bdb91ba"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6955aa7f-e11c-49c6-b06f-0b31c6a8a30b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal kidney function</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01769001</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01678898</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01981720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301500">
        <dc:identifier>https://www.omim.org/entry/301500</dc:identifier>
        <ddiem:iembaseAccessionNumber>296</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/88657e23-7981-43e1-9d4c-c2574efdfeb0"/>
        <rdfs:label>FABRY DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/296</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03180840</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78ff97bc-6709-44b8-82eb-30936047770b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ochronosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030764</ddiem:url>
    <dc:identifier>HP:0030764</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0dbe5966-8363-4d99-a893-0db636adf376">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ea25bbc-e948-4ce9-b0c7-535f1b9dbe4a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased 3-methylcrotonylglycine excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef528711-ef61-4178-8c97-8679e967527a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a182c85-ea4e-4220-93ab-3ca8cc3c559d">
        <rdfs:label>Increased 3-hydroxyisovaleric acid excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02aaecd0-735c-4bd6-9f1b-c454965060f1">
        <rdfs:label>abnormal Biotinidase activity in plasma</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e609a182-f092-4ef0-b8ca-b33b7d7a8eed">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>EEG abnormality</rdfs:label>
        <dc:identifier>HP:0002353</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a63a748b-59a3-45e5-a814-accafae2c297">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e07e2b44-1817-4d38-8b31-25afb4003176">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
        <rdfs:label>fiber necrosis</rdfs:label>
        <dc:identifier>HP:0003713</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/edd3c338-b0bc-42da-a6cb-b48525d6e3e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab84f039-9981-4409-abae-ea8c6c859d98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b41e9f7-1c69-418b-8062-7bdb363aae18">
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:label>muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74a9c043-5128-4b32-bf35-a210bb66d66a">
        <rdfs:label>ER (endoplasmic reticulum) stress</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/268200">
        <dc:identifier>https://www.omim.org/entry/268200</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/750</ddiem:iembaseUrl>
        <rdfs:label>MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e4cdecaf-3158-4051-bfa6-7bcb8ffddf3d"/>
        <ddiem:iembaseAccessionNumber>750</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c18fb74c-ce95-4b81-a91f-e896d3dd4194">
        <dc:identifier>HP:0012240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012240</ddiem:url>
        <rdfs:label>Increased muscle lipid droplets</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83e63537-1f01-439b-9695-1a1610807136">
        <rdfs:label>Myopathy</rdfs:label>
        <dc:identifier>HP:0003198</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cd391c6e-ad73-4a0a-92c6-069d3cc4eca3">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309400">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MENKES DISEASE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7baf8ce5-3b10-4980-96ca-188607d9226a"/>
        <ddiem:iembaseAccessionNumber>199</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/309400</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/199</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c7486fd-cf18-4665-9fc7-460b6a261bec">
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Low survival rate (Mortality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbefa83a-2fec-4af2-8ead-0051d211f5b5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ed8d2a0-edf7-4587-b824-9c0b511eb0a1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ef84f7f-0d42-43f0-9d23-1517b7060aab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb332d6d-7b8a-458c-ac1e-b224a03cf7b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d5e8cb58-54cf-4f89-9cb6-b6df4151b530">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42f308f3-55e7-429d-b55d-f312cae85720">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100753</ddiem:url>
        <dc:identifier>HP:0100753</dc:identifier>
        <rdfs:label>schizophrenia</rdfs:label>
        <rdfs:comment>The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24787057</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/239500">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3a65cf92-933c-4dfd-827f-379a76aa5c53"/>
        <ddiem:iembaseAccessionNumber>40</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/40</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPROLINEMIA, TYPE I; HYRPRO1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/239500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca13d019-5d26-492f-a066-c5d39dc86ab0">
    <rdfs:label>Movement Disability</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0530521b-2217-405f-b028-215a0731ccc8">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8a54172-c972-4139-90e9-5f4893ff3539">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d000371-20ff-49f6-8e5a-48da6a4e337a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001749</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/600b3775-2861-4deb-b002-790642663806"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89c77a0a-bb3e-40fd-ad34-af6ac05d7787">
        <dc:identifier>HP:0012410</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012410</ddiem:url>
        <rdfs:label>Pure red bllod cell aplasia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4ae18680-44cf-4e91-b3ba-7a04f48d06cb">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f66e11a-1059-4961-b9d0-27a080a38202">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f273ba9d-610f-4c9e-935d-791fbfeb225a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656398</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b757bc7-8e17-4e07-ac54-fb5bd1ee2232">
        <dc:identifier>HP:0000559</dc:identifier>
        <rdfs:label>Corneal scar</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000559</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/260920">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/143268c8-de60-48ef-804b-536dced45380"/>
        <dc:identifier>https://www.omim.org/entry/260920</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/191</ddiem:iembaseUrl>
        <rdfs:label>HYPER-IgD SYNDROME; HIDS</rdfs:label>
        <ddiem:iembaseAccessionNumber>191</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fde6ed41-501b-4847-b114-7c1b87048824">
        <dc:identifier>HP:0000491</dc:identifier>
        <rdfs:label>Nummular keratitis(keratitis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000491</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d9c8f2d-e146-4a6c-9201-98becc0991c9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>Decreased visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1e253828-d716-413c-9e8e-7755c2315515">
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/987a48ab-09a1-447d-82db-2c6329e8c1df">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>abnormal hepatic function tests</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60b6f4d7-de07-42f7-a2aa-3156526f3a25">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <rdfs:label>Acute hyperammonemia</rdfs:label>
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f98437-5ac2-4723-a925-725225e80625"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23040521</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc5688e2-899b-4bc9-a1f6-7c4b73f8300d">
        <rdfs:label>Low plasma arginine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005961</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d19ddbd-5626-4fa9-8f59-11db8ad3bd38">
    <rdfs:label>"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)"</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002872</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002872*</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fa62878f-cd76-49ee-a68d-62568c273bc0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54e35da9-72ac-4194-a9fa-fa47a5a250b2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24ae58a8-ee94-43ec-9bbe-9338d2d7b385">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203750">
        <ddiem:iembaseAccessionNumber>65</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/238b8803-1d7e-4550-957d-34fb95b316ac"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/65</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/203750</dc:identifier>
        <rdfs:label>ALPHA-METHYLACETOACETIC ACIDURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>Abstract</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1110863016300763</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30b49202-1676-4ed6-89f0-84fdfcd0baec">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:label>Organic aciduria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/816a9192-1a27-4784-a4a5-78117999f688">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93fbc0d2-170a-4f2e-885c-ceec8261791f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003566</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003566</dc:identifier>
        <rdfs:label>Elevated prostaglandin E2</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a4ae849-cc1e-4f5f-af63-df2420edea3e">
        <rdfs:label>Hypokalemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002900</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c97c58-40f1-473a-beba-4082b10c197d">
        <dc:identifier>HP:0002150</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
        <rdfs:label>High calcium excretion in urine</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49325469-1198-4b9b-9116-ed5beb3eb793">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39e48d23-ef08-4064-9b8a-7d1f58504c6c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c1d207a1-15bb-4e9d-a8a0-fd80a771e668">
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51c84d41-04d3-4876-a575-31aed83c81c7">
        <rdfs:label>High lactate ,pyruvate ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/996118c8-5d77-4fac-aefb-bcdb84321ff1">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002151</dc:identifier>
        <rdfs:label>Elevated serum lactate level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002151</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15c2b692-a845-48cb-a1d9-5b2fe4109b0e">
        <rdfs:label>High serum GDF15 level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/072c54bd-247d-4958-9be2-1105e8c76589"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ff94eb21-58c3-4a82-b598-1c5af9b55887">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased lateral ventricular lactate level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcfa4de0-1197-4ad8-a6f6-1e08701f1463">
    <dc:identifier>HP:0012130*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012130</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>premature differentiation of erythroid cells</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b">
    <rdfs:label>Abnormal liver function</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b36c48c8-79cd-430b-89fa-bd09cf726aef">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f785512c-bb8d-4177-a0d5-aace69bf1361">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypolysinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a48a1ce2-6f7f-4a19-b6ff-a1fd9f153cb1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48f732b5-f9ed-41a8-b19f-a3b70e24e075"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e474d2e-66da-4c9c-b20e-50a41d44fabe">
    <rdfs:label>High plasma citrulline levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011966</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011966</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6322e27d-52cb-4d0f-ba3f-0774528ff8bb">
    <rdfs:label>Gemcabene</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a855525a-34e9-4ad1-b189-8af253ce69fd">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03508687</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/295babd2-7803-459d-8fa8-5049881d99d3"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/567bd347-d4e5-4853-9f36-7c1d0b62dc94"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB05123</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05123</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7ab84f93-188c-4d40-8548-417d57aa368d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e7276fb-927b-4be1-b6e9-148ab7b8d347">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased ROS formation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/177000">
        <rdfs:label>PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/54bb8601-b487-4f93-b40a-84cc1a6e9aaa"/>
        <ddiem:iembaseAccessionNumber>107</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/177000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/107</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f21fabb-6955-4763-a238-2556dc016f60">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd8779a5-a0b9-4e05-b7a2-17f33c5f2d68"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/54141c2c-03ba-47aa-9566-5e9659b0d09e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/996118c8-5d77-4fac-aefb-bcdb84321ff1"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a76d907d-7cca-41e2-ac03-2e1e2a3a1642">
        <rdfs:label>High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*</rdfs:label>
        <dc:identifier>HP:0200125</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/072c54bd-247d-4958-9be2-1105e8c76589"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ff94eb21-58c3-4a82-b598-1c5af9b55887"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a378288-7c97-4a5f-99fb-97c9e98a3dfe">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:label>Generalized tonic-clonic seizures</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30738201</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/530000">
        <dc:identifier>https://www.omim.org/entry/530000</dc:identifier>
        <rdfs:label>KEARNS-SAYRE SYNDROME; KSS</rdfs:label>
        <ddiem:iembaseAccessionNumber>398</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/398</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c7e5d5f-e927-47ee-abd6-b0c9dee27018"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15c2b692-a845-48cb-a1d9-5b2fe4109b0e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7a2e03aa-2c1b-4a75-8ebc-48bc9ca3a33a">
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d07912ab-ccba-41a4-99a3-71201658bee6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cutaneous abnormalities</rdfs:label>
        <dc:identifier>MP:00011911</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_00011911</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f40efe4e-87e5-4d50-9616-1ad22489c079">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7d696863-a955-4685-92ff-21b6e145659a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/036705c2-7896-4817-81b1-689596205ef9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236200">
        <rdfs:label>HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/27</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4dedcbb0-db0d-490c-91b3-4350b362f6ae"/>
        <dc:identifier>https://www.omim.org/entry/236200</dc:identifier>
        <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
        <ddiem:iembaseAccessionNumber>27</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cecfe342-5403-4f04-b965-7d6deb342fe9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f63b3b3b-bf85-42e1-aba3-d8e37569d783"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a74553fa-5bcb-408b-9cf6-5c93f2ad2759">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/234500">
        <ddiem:iembaseAccessionNumber>50</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HARTNUP DISORDER; HND</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97c7ce28-e142-427a-9554-3b199409d802"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/50</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/234500</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9494790-1cb2-4e6a-bf33-f54ba0aea29f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/13054d20-cdfd-48b9-beaa-18778f3e242a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34b5f3af-ed74-4263-8c11-3ddfee568114">
        <dc:identifier>HP:0002028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002028</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Chronic diarrhea</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25526748</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/556ade49-ff3f-4e98-89b2-3a5b5179c7cf">
        <rdfs:label>Hypoalbuminemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003073</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003073</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afea2d24-7292-4c4b-b4b1-91464cbd5ae7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Exfoliative erythema</rdfs:label>
        <dc:identifier>HP:0001019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245010">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/245010</dc:identifier>
    <ddiem:iembaseAccessionNumber>1110</ddiem:iembaseAccessionNumber>
    <rdfs:label>HAIM-MUNK SYNDROME; HMS</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1110</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6ab7039-7a58-4029-af4c-00f0c6fee922"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d903ba5e-33d0-4229-8082-7dc1a86d587d">
    <rdfs:label>Abnormal retinal ganglion cell function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001112</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001112</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11046879-3624-472d-930e-7b3a409febc5">
    <dc:identifier>HP:0002917</dc:identifier>
    <rdfs:label>Hypomagnesemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/550400e4-ca60-463b-a51e-aee3afe1c59a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a032b19-7c9f-42cd-9507-8cdbf047110b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf62c67b-6751-4378-9e25-b295e37694ae"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5422236d-70b6-4ebd-acd8-59501bd2bcda">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000709</ddiem:url>
        <rdfs:label>Psychosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000709</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/125370">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/082b2681-5d4d-4da7-a8f5-b9284a313592"/>
        <dc:identifier>https://www.omim.org/entry/125370</dc:identifier>
        <rdfs:label>DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cbd79600-76af-4cdd-b5d8-5fca921bce2a">
        <dc:identifier>HP:0008765</dc:identifier>
        <rdfs:label>Auditory hallucinations</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008765</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccc071db-3de1-42f1-b927-0c5246ee69f9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011999</ddiem:url>
        <dc:identifier>HP:0011999*</dc:identifier>
        <rdfs:label>Hallucinatory-paranoid state</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <rdfs:comment>"A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA." https://www.ncbi.nlm.nih.gov/pubmed/29739138</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e963576-6ca8-4cd0-bb16-8441575a1506">
    <dc:identifier>HP:0001324</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
    <rdfs:label>abnormal muscle strenght</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0be27dcf-f4bb-4b59-8e3b-013088d30f74">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118600">
        <rdfs:label>CHONDROCALCINOSIS 2; CCAL2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0a554307-7d6d-4fa6-8f4b-ce3deee86b92"/>
        <dc:identifier>https://www.omim.org/entry/118600</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27790033</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3eda2d08-8763-431a-bdb8-542c91f1027e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7121aa2-b69f-4d64-aa4e-04e4c071c6bb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <dc:identifier>HP:0001369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5df7b718-3146-4610-b90a-5c18b48c8ede">
    <dc:identifier>HP:0040126</dc:identifier>
    <rdfs:label>Low level of serum B12</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040126</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1c7ffb0a-9357-404c-ab6f-7ec824c1dde2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57aef328-ef45-4afb-a83c-700b9074bc47"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8810b34-bb08-4372-b055-3b0060b69af6">
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum  bilirubin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606785">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/661</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>661</ddiem:iembaseAccessionNumber>
        <rdfs:label>CRIGLER-NAJJAR SYNDROME, TYPE II</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/606785</dc:identifier>
        <rdfs:comment>Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b066539-7726-40bf-99cc-ee56bb326b4b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7483726</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f5bbb73a-66b4-4725-83f2-c432bab91d90">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a037830-ad7f-4cbc-8595-ad89f2f93d93">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4cbe756d-4af8-4843-86d6-7d0d7e215b5f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/227810">
        <dc:identifier>https://www.omim.org/entry/227810</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/481</ddiem:iembaseUrl>
        <rdfs:label>FANCONI-BICKEL SYNDROME; FBS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cbcfa84b-cec1-48a0-a207-9544a9f3bd76"/>
        <ddiem:iembaseAccessionNumber>481</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9abf3dc2-5956-4df3-8b50-cc29f3b66e6c">
        <dc:identifier>HP:0002748</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
        <rdfs:label>Rickets</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/802ed18d-f060-44ad-b0f6-01dfd2409d09">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3af4d1f5-fe02-43a1-8b15-27f1bdead4d6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>disability(Functional motor problems)*</rdfs:label>
        <dc:identifier>HP:0004302*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232600">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/81a9da44-2a98-4acf-a4f1-61b29d7ebe94"/>
        <rdfs:label>GLYCOGEN STORAGE DISEASE V; GSD5</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/489</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>489</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/232600</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4387914b-ba3c-4fd9-920d-25669c6f9521">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2c9863a4-d7df-4389-b334-72b0c2693a6b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cc83191-3ed7-465a-8af5-da172f76c82d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <dc:identifier>HP:0009020</dc:identifier>
        <rdfs:label>Abnormal exercise physiology</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18098237</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fcd54381-975a-4409-90a4-f85225c8805a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612319">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1054</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/612319</dc:identifier>
        <ddiem:iembaseAccessionNumber>1054</ddiem:iembaseAccessionNumber>
        <rdfs:label>SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4e5c50f2-0c32-402b-9de6-2f8f6cfed5e6"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2578f55c-f587-4017-8ad8-bc78bec49183">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14f15a76-ccf7-439d-ae7a-f59e36336e88"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7092a4-7ce3-477b-bba7-635a499339a3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal muscular co-contraction</rdfs:label>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/34842cfb-c0cd-4b39-9711-2174bd2b882d">
    <dc:identifier>HP:0000117</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000117</ddiem:url>
    <rdfs:label>low phosphate reabsorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bcc68f6-d97e-443d-beb6-8fcd234f9fdc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>high non-HDL-C (Abnormality of lipid metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003119*</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60648970-4ae8-424c-a5d0-f8df29b423c3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa9b79b3-4798-426b-a596-e0e276aa7caa">
        <rdfs:label>antisense oligonucleotide (VMO AED cocktail)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86009a68-9535-4f68-b911-32f15b9bcd2d"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253260">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/650714e2-57af-4e5c-bc32-679d4960ff62"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/93</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/253260</dc:identifier>
    <rdfs:label>BIOTINIDASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>93</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3de78ff7-e72b-41e2-9058-517ac2cd5905">
    <dc:identifier>HP:0012363</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012363</ddiem:url>
    <rdfs:label>Low circulating levels of free sialic acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609283">
    <ddiem:iembaseAccessionNumber>1372</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1372</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/609283</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/77a50843-80aa-4df6-8c7a-702f33bbb119"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/114a9d47-b05a-4b91-b65c-8e338e209fb3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Acidosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
    <dc:identifier>HP:0001941</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77cd63a5-a291-42b8-8ebd-c5832783e3d4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
    <dc:identifier>HP:0012379</dc:identifier>
    <rdfs:label>Low IDUA activity(Abnormal enzyme activity)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/664e23dd-6b20-4850-8c89-61cd48685ee3">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d822735-cd39-4531-9805-aa839f761c62">
        <dc:identifier>HP:0030213</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030213</ddiem:url>
        <rdfs:label>Lack of emotional expressions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/140a2fa7-2cc3-4de9-a8c8-75af0063c4fd">
        <rdfs:label>Low CSF glutamine level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
        <dc:identifier>HP:0030980*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f72029d2-7d16-47ec-93dd-9e2f06c71646"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e89b584e-5c0d-47ac-94de-792836fb38b6">
        <dc:identifier>HP:0010903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
        <rdfs:label>Abnormal plasma glutamine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dbae027e-520f-4695-9a21-400d05579f03">
        <rdfs:label>Low brain glutamine concentration</rdfs:label>
        <dc:identifier>HP:0030980</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030980</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d5c6a73-121a-4d3d-a652-12b37a42c7bc">
        <rdfs:label>Secondary NAD+ deficiency in leucocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c47c6a3-d306-4442-8471-d2110877c54b">
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal EEG results</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43f5dbba-d195-47cc-8107-63b2a7f5c78b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
        <rdfs:label>unalertness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002329</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e51de5dd-2162-44a2-bc85-350b0b6cb374">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23b03dba-32d6-49eb-a4a4-545ea1d2458d">
        <ddiem:url>https://www.drugbank.ca/drugs/DB08909</ddiem:url>
        <dc:identifier>DB08909</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5837c000-6876-4e80-8e08-43fcb502f3a2"/>
        <rdfs:label>Glycerol phenylbutyrate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64980eb9-5ac1-4da3-803c-dc73c0d40544">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec240001-0e05-4680-91c8-48bfad890484"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25024447</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/36f8e7fa-ff8b-4247-8a61-a2fdda3983b7">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f0744bbd-bb89-416f-b80e-032dbc9b105f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5e892d9-4a69-4dd1-ada9-f9139fa397d5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24848070</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/768bed80-0d9b-4524-94e0-b84721c50b4d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PCBD1-diabetes (Noninsulin-dependent diabetes)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005978</ddiem:url>
        <dc:identifier>HP:0005978*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/264070">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/aca85188-6102-4947-a0aa-d13fcea038e2"/>
        <dc:identifier>https://www.omim.org/entry/264070</dc:identifier>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D</rdfs:label>
        <rdfs:comment>Protein and phenylalanine restriction should be maintained in order to avoid disease progression.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/6</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>6</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/64c12ba2-e995-4ea9-8acc-5725f1ef6cc6">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220110">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6d156ae5-1061-49cf-a838-510ee60e725b"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/937</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL COMPLEX IV DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>937</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/220110</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec240001-0e05-4680-91c8-48bfad890484"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/520000">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/489fe16c-30e2-4a77-be10-2aeaeb6a91b6"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/86d9d33e-39f8-46f3-be77-c81c7a39af88"/>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/409</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>409</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/520000</dc:identifier>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bac2de75-9d74-4be2-afb5-2e52966b5168">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4decad14-b98e-4596-96fa-e4e391695e2a">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/603f8e8c-d173-4799-b893-280abfd1f831"/>
        <rdfs:label>Gene therapy *</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22b72fe2-2ab0-472f-9cd4-d8f1a275e03f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01045</ddiem:url>
    <dc:identifier>DB01045</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2b7f6e90-047d-4fea-a42c-26fdacd5a16d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc2998d6-b08b-4d23-8796-58ce2e0f91c5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/414ef5df-075a-4beb-8fd9-8c8b6a65dd53"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16952291</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16083704</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85b52695-8d0f-4de9-a408-d7b92271ee50"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e3492c91-7d2b-4f79-a43f-367049878be1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12012642</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9d51e99-ea6c-4c38-a181-7816471323f4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26264947</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4031f921-d64a-40b3-81f5-9f3d0c9a2e1f"/>
        <rdfs:comment>Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974C→G nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5542fd97-f26c-455f-ac30-f4a52520d63d"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Rifampicin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f79775dc-ec00-4d52-9792-77b90c543dd7">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <dc:identifier>HP:0001939*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602579">
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8d7a40d3-d23d-4919-8888-4c2dc9e6bcad"/>
    <dc:identifier>https://www.omim.org/entry/602579</dc:identifier>
    <ddiem:iembaseAccessionNumber>322</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/322</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/836106ad-3c70-49c1-9feb-0e03fc582145">
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5165585-ae2e-446e-8093-bf6f6f50091b">
        <dc:identifier>HP:0001941</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <rdfs:label>acidosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4cfd98cc-cdc0-405b-b07c-e00af20e09ad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9eb86c31-2218-4baf-ba50-32cb6f78a05c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219800">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48ce0703-61ae-474b-8335-cf8ceffb339f"/>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
        <rdfs:label>CYSTINOSIS, NEPHROPATHIC; CTNS</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/219800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53bf820a-1368-49bd-a45b-4c45f329c729">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
    <dc:identifier>HP:0001877*</dc:identifier>
    <rdfs:label>Short erythrocyte survival (Abnormality of erythrocytes)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b643d498-8b65-42d0-9eff-f86a804f11a8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02346461</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/964fcb05-e100-4e08-abcb-eefc1b1ce934">
        <rdfs:label>Decreased sialylation of muscle glycans</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012350</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012350</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c634a346-cda2-4612-8333-91165d81f7fe">
        <rdfs:label>Rimmed vacuoles</rdfs:label>
        <dc:identifier>HP:0003805</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003805</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3263e856-f528-4a44-b753-a064321f5323">
        <dc:identifier>HP:0003216*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Amyloid deposition</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003216</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de745986-0215-44ac-91e3-6709d557db45">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b02ac1a-c1c7-4eb3-b3fd-875ead9beaea"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605820">
        <ddiem:iembaseAccessionNumber>1299</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/605820</dc:identifier>
        <rdfs:label>NONAKA MYOPATHY; NM</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1299</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/46233319-5153-45d8-a62f-e8507865fef2"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3de78ff7-e72b-41e2-9058-517ac2cd5905"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9749b986-99e8-4835-a075-8c33f274f282">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/042ab30f-05ed-4e43-9913-42a8837b8af6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/110bf34a-7a92-41ae-a8a1-a6d2038b8eef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/152b11ac-32c6-49c1-b521-b9b02108f57a">
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230650">
        <dc:identifier>https://www.omim.org/entry/230650</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6476d1c0-0624-47f4-8787-895b071ae02a"/>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE III</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17164772</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e18307c4-5c67-401f-8eb8-d8d89f8e3236">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d43a726-a9c5-46ca-a68f-556754b33340"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/79728be5-0c45-4af2-9e86-5bf8606bd4c0">
        <rdfs:label>Abnormally decreased rate of beta-galactosidase activity</rdfs:label>
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/384f5ac9-8619-4220-8264-2794558027e7">
    <dc:identifier>HP:0002160</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
    <rdfs:label>Elevated plasma homocysteine concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69af3283-85f4-4520-ac75-4f7cde0677bd">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>Low HDL-C  level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/485a39b7-f3cf-430e-a85f-c4daab8973cc">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/429cb568-02a0-40ea-84c9-1efb0f909bd7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ba683889-8fa1-4712-8dd8-ac1c40f3e97e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91aa61f6-091a-435b-8c1b-7c91dc3b52ba">
        <rdfs:label>No result was accessible</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3728152</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa5ab7ce-da21-4827-8f56-d4e296692607">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/67961c98-5082-43cc-afe0-5245868fe58d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffc95155-25aa-4571-91a9-7bcc8e13888b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a61ff704-7605-43c3-b8a3-9f69b11f85db"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81863dee-874e-4452-8a7a-3116ea097654"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/247ff6e0-4bc6-42ca-9867-42c1428c47ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Arginine-restricted diet</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c4cfff86-b3c7-42aa-8eaf-613a038d33fa">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <obo:RO_0003304>TT-1131</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb4c5806-deb4-4182-82ec-d7dcdbe3e926">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>hypertriglyceridemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19530961</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfad4b89-ccd2-408e-864f-9415da317fc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/561c40f2-fd36-4f9e-aa8a-a4ab5e497e18"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d60cb0b8-17e4-41c2-835e-62e2bb28d95d"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d07c692-ee69-47cb-931e-7066577f8356"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <ddiem:failedToContributeToCondition>C-1131</ddiem:failedToContributeToCondition>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/144650">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERLIPOPROTEINEMIA, TYPE V</rdfs:label>
        <ddiem:iembaseAccessionNumber>1086</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/773169c4-5012-4901-a15c-5e73b8adf910"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1086</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/144650</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/544ab5fc-ddca-447b-8e0c-5df538195027">
    <dc:identifier>DB0084</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2597aaac-4ba1-4462-b123-91c79a151122">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43bd3401-f2c9-4bb9-9ea5-9582501375ca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d6556204-8898-4cc4-a35a-fbd61ebe92c7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8680e551-8fc8-4686-9077-d9c14da8d2cd"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e9e993cf-862c-4e57-baa7-441e308f34da"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7cb3c409-648e-4747-a097-c5df7cabdd3c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB0084</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bccbd83e-a4da-46ab-a78d-e0ad5c78905e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <rdfs:comment>According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8b32c1aa-2693-4043-9d0f-3aeecea30903">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94c8575f-2edc-4ff0-b37d-ca8b6692d5cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a025cd2-565f-4a65-bca5-01e70b813b25">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002181</ddiem:url>
        <rdfs:label>Brain oedema</rdfs:label>
        <dc:identifier>HP:0002181</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16449956</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/278000">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cdb32024-056e-4022-82d2-c262cd585f92"/>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/302</ddiem:iembaseUrl>
    <rdfs:label>LYSOSOMAL ACID LIPASE DEFICIENCY</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/278000</dc:identifier>
    <ddiem:iembaseAccessionNumber>302</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/93bfe607-b1eb-4deb-8456-6f5dc6be9ab6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10e4dfe8-c325-4413-a022-d4b178fcc25d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8adb6529-2206-4b6d-8d75-a76c62278b17">
        <rdfs:label>Hyperinsulinism</rdfs:label>
        <dc:identifier>HP:0000842</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000842</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20936362</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/630356cc-334c-475c-a080-6d27ae16af14">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>epileptic seizures</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28621098</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23295286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7e5344c-3284-41f7-9a8a-f6c035778392">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
    <rdfs:label>Methylmalonic aciduria</rdfs:label>
    <dc:identifier>HP:0012120</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/809e2f72-9cc5-4f39-afa5-eb6bbebf063f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604369">
        <rdfs:label>SALLA DISEASE; SD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11e5e39d-c9ee-4d45-ba9b-c362d3ad790d"/>
        <ddiem:iembaseAccessionNumber>1369</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604369</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1369</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794688</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e38b369f-a60c-46c8-8f72-872fa0f0c9b2">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ac67a85-fa16-4e0d-a9b5-5856fff7ebd3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031517</ddiem:url>
        <rdfs:label>verruciform xanthomas</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031517</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07e534a8-978e-460c-aa7e-2644dace1268"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fda1991a-3135-4b19-99a7-38b61b68f23b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6872991a-bca5-4314-acf8-9b75d35fc692"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43b54b4e-5327-4c8f-ba09-290d1e300509"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d4674c66-053f-4959-a0d1-33a27ae6399c">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c649282-6039-45c5-a1d1-6677d0942e9c">
        <rdfs:label>Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*</rdfs:label>
        <dc:identifier>HP:0011031*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14a45bf2-37c7-4c10-ae7e-b535462703d8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/498e87a6-13f6-43ab-9e71-0927e27dc2a5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/594977ad-15e9-468a-82ce-467bd9f7ce97">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:label>low hemoglobin concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001931</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/224120">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dd49f2f4-1cfc-486a-a1e3-afa2a2f86c2f"/>
        <dc:identifier>https://www.omim.org/entry/224120</dc:identifier>
        <rdfs:label>ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/323a692f-144c-412c-a7fb-ea5ceedad0f2">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003040</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003040</ddiem:url>
    <rdfs:label>Arthropathy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39892a09-4a8f-4aff-a3d6-b84d2fe069d0">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/63793817-0364-456e-a142-977bc9c6d4ab">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e1e70256-965c-4751-a2c2-d875f58b584f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e7f0fd52-9166-45c5-adea-a5511de70234"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/daf77a87-f8ea-494c-a974-4654dafab894"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/84e0d234-b169-450b-93b0-47e20e67bdf7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24935455</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00005</ddiem:url>
    <rdfs:label>Etanercept</rdfs:label>
    <dc:identifier>DB00005</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/a8464ee8-6d24-4b88-bf4a-dc495c730b17">
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0b6f26b-19af-407e-bc98-6aaf26f9ed44">
        <rdfs:label>Bacterial glutric acid production</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231690">
        <dc:identifier>https://www.omim.org/entry/231690</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/537</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dc5c4ad2-fb97-4a37-b7d9-c6fe2113759d"/>
        <rdfs:label>GLUTARIC ACIDURIA III; GA3</rdfs:label>
        <ddiem:iembaseAccessionNumber>537</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2676d27d-c3b5-45be-bf79-1d699c324224">
        <dc:identifier>HP:0002013</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cyclic vomiting (Vomiting)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002013</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00007121">
        <dc:identifier>ECO:00007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766179</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/e13e6bd6-1c9f-4389-9ad3-b6a11d12f8f1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10485305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155631</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d7a6742b-d866-4115-b93b-47d98ce82b8d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>elevated serum toxic intermediates (</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddcef8aa-f26c-4201-b1f4-5a1cc4b82a06">
        <rdfs:label>Abnormality of muscle physiology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17968484</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45d818f9-787f-434f-9571-882ec7fc3b00">
        <dc:identifier>HP:0003234*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>secondary carnitine deficiency</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3e34aad-49ba-45a2-ab66-0707a19eb160">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12930917</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613027">
        <ddiem:iembaseAccessionNumber>1259</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613027</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1259</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE IXc; GSD9C</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba20419f-7a66-41fb-898a-6735763e128a"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a0f81e5-06fe-4030-9fbc-717c9ae75b47">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/68480119-ad53-4189-b972-000482e3b474"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3321c90-8b9e-4df7-b7bf-af8ab8bc1930">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012279</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012279</ddiem:url>
    <rdfs:label>Low plasma serine levels</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/75a19f98-4bdf-414e-bc80-e1c25326b8be">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241500">
        <dc:identifier>https://www.omim.org/entry/241500</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/561</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6da2ec29-acf5-4098-8449-0d492cd8357c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPOPHOSPHATASIA, INFANTILE</rdfs:label>
        <ddiem:iembaseAccessionNumber>561</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9bfc2def-694c-499c-a2c6-f2e243a76a1e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb529eff-9f4e-4a03-bb9a-7dfe8a35c5ad"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3482025e-6ebb-4049-b834-2345ab66d033">
        <dc:identifier>HP:0002757</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002757</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>bone fructure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1b2d917-00b5-4276-889e-8dda1395fdc5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004349</ddiem:url>
        <rdfs:label>low bone mineral density</rdfs:label>
        <dc:identifier>HP:0004349</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/532b22f8-6600-44c3-b984-714a25eee270">
        <rdfs:label>bone weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002749</ddiem:url>
        <dc:identifier>HP:0002749</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01406977</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81e5248e-6071-4bcc-ac1d-71560777de6e">
        <rdfs:label>low bone formation biomarkers</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031429</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031429</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/1b692860-9ece-420f-886d-288f95a4bdc8">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30765910</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30875019</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/42470b25-5d05-41b1-b48d-25397fca0ba5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d66338a5-e1da-4267-8d08-48d86d92b73f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e711f92f-7b7b-44e9-9131-51c0626d7412">
        <rdfs:label>High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27509102</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d5d7524-06b7-4e15-b5b0-865b167769ec">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma lyso-globotriaosylsphingosine level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>"p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W"</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <ddiem:failedToContributeToCondition>"E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S"</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/461bf747-c152-49cf-b5f0-26e6e9038b75">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001712</dc:identifier>
        <rdfs:label>Left ventricular hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/91323a08-2832-4999-bf91-c1be981db98e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6656f936-0b55-45a4-9cbb-a8ddd224b75b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed Growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <dc:identifier>HP:0001510</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7833193</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5e641eb0-fc62-4af1-8bbb-f39247ef563e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15bf5764-dd32-4399-a8d9-4baea628e835"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/765e2c80-bd43-4b5b-8942-cf2411a86c80">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypocholesterolaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003146</ddiem:url>
        <dc:identifier>HP:0003146</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d8fac7e-e664-452f-ae51-da4ee0354d6d">
        <dc:identifier>HP:0002149</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hyperuricaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/302060">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/59</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/302060</dc:identifier>
        <rdfs:label>BARTH SYNDROME; BTHS</rdfs:label>
        <ddiem:iembaseAccessionNumber>59</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b135081b-1944-4ecb-ad1e-910d0d2ce514"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6001b20c-40cd-489b-8ce2-01da495914f8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
        <rdfs:label>Low myocardial function</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a546c4f6-d18d-40a2-bef6-5ec1a1ed8fe0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>Neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9199ced-2b82-4d72-8161-f3ac98f91116">
        <dc:identifier>HP:0005135</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005135</ddiem:url>
        <rdfs:label>T wave abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76817761-9acf-4109-aaea-aeabc1428482">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230800">
        <rdfs:label>GAUCHER DISEASE, TYPE I</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccb1642b-043a-40df-aa5b-8240a4fe6c8c"/>
        <ddiem:iembaseAccessionNumber>288</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/288</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/230800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/120a1dac-65b2-49f3-8fac-6a643a503fb7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>primary low heamoglobin level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <dc:identifier>HP:0001903*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f514908e-8b6f-41a4-b3ed-3a616052dc9e">
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT02770625</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dca81e5-835f-4f62-b660-a590d2a35ae4">
        <rdfs:label>thrombocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/726e5580-0dfc-45a2-9ed2-36b0c51904fd">
        <rdfs:label>splenomegaly</rdfs:label>
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/04172f94-e611-4b95-9cd6-e9e810c31fee">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/50736745-81ff-48ad-a9af-34a7867d35c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87">
        <rdfs:label>Hepatomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e81931a-d115-4ab0-8063-c044d61b0c59">
        <rdfs:label>high angiotensin- converting enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000841</ddiem:url>
        <dc:identifier>HP:0000841</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baf8ddd8-3589-42b8-9fcf-19dcdadc298a">
        <rdfs:label>elevated Chemokine Ligand (CCL-18) Level [ng,mL]</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c66e4809-a296-448f-8ecb-9d33bfffdf97">
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavior al abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a1cdac22-50b3-4005-be6c-24965491cfb7">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25a2c0cc-cc84-42b7-a291-ee9b8e90f587">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28dd4a59-32b8-4611-9ffc-95bef514d65f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14800995-92c6-4411-9e37-8ca0f76bac2b">
        <rdfs:label>Neuropathic pain(Abnormality of pain sensation)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010832*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010832</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d8d3c95-85c1-4e0d-84cb-1b20cb2b199b">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2fbed80b-439c-49b2-9ea3-b380e68db55f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94da83a7-92a1-47a2-8776-69391416a7f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b5eb250-2ed0-40ed-967a-7358f24a5554">
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal mental status</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1450cff-d355-4779-be57-9526f3d1a702">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9d70598-6484-404d-8bae-0c54c19e1715">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb13c699-e766-44b7-8668-f2eb65380055"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/de745986-0215-44ac-91e3-6709d557db45"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/964fcb05-e100-4e08-abcb-eefc1b1ce934"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28641925</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/925d7d7c-67e5-4e18-9024-00c00d851fec">
    <rdfs:label>iron overload(Abnormality of iron homeostasis)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011031*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011031</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1637b817-2e0d-45bd-82a1-9300ece0b7f0">
    <dc:identifier>HP:0000565</dc:identifier>
    <rdfs:label>esotropia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000565</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/373c11d0-ccc4-4aff-bd46-8191a5d44c2e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b817ee35-93cd-4ddd-bd7f-a01a072fd78c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26865117</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
    <rdfs:comment>Drug has no difference in terms of prognosis.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a55dc935-5476-47a0-adeb-9e1fba55c7c3">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1cf014d-2f2d-4f36-8226-bc97d2425974">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>oxidative stress</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24578415</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dcc4c654-f88b-42a5-b9a8-64df7bd50d5f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7161e076-94d8-4c5a-ba19-88eca249295b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca3be94a-0fe1-40a8-958c-54d4d53cca27">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>elevated CSF GHB levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613163">
        <ddiem:iembaseAccessionNumber>36</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/36</ddiem:iembaseUrl>
        <rdfs:label>GABA-TRANSAMINASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/613163</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f466ed60-4604-4085-a1ae-5ac0418cae45"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb6dedaf-d8c9-4ccc-aa75-f842cfab889c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hemolytic anemia</rdfs:label>
    <dc:identifier>HP:0001878</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8695369a-432b-4179-9fc8-09a071f215bf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>conjunctival irritation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030953</ddiem:url>
    <dc:identifier>HP:0030953</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/28754e45-cf2e-459e-a6f0-44a08cb39c92">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40043a43-bf78-4ad1-a3ed-ad1cee51b439">
        <dc:identifier>HP:0002011</dc:identifier>
        <rdfs:label>nervous system abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002011</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e39daf9-b605-483a-bce6-34110d5c8557">
        <dc:identifier>HP:0000488</dc:identifier>
        <rdfs:label>Retinopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30358967</dc:provenance>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a07bed5-2bc5-4e60-9022-64893061cc0e">
        <rdfs:label>neurologic dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4195ad1f-46ca-4736-968c-602b7606827c">
    <rdfs:label>abnormal energy production in damaged mitochondria</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy">
    <rdfs:label xml:lang="en">direct complementation of a genetically defective protein by gene therapy</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000004"/>
    <dc:creator>https://orcid.org/0000-0002-5111-7263</dc:creator>
    <obo:IAO_0000115 xml:lang="en">Insertion of one or more normal copies of a genetically defective gene into the genome of affected cells.</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615181">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2d6107f4-1706-4794-9587-db7fde42df05"/>
    <dc:identifier>https://www.omim.org/entry/615181</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11</rdfs:label>
    <ddiem:iembaseAccessionNumber>1121</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1121</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1b2ea7da-fa38-4f5a-933e-a8f63748bbb9">
    <rdfs:label>Reduced ejection fraction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
    <dc:identifier>HP:0012664</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c0769626-0ff6-4f88-a4d1-b208bbda744b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/257ab35f-b06b-406d-a0b8-71376c82ff5d">
        <dc:identifier>HP:0012187</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>high erythrocyte protoporphyrin levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5cbb29c2-f6c6-4a77-b907-29c525528a06">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7228d411-f929-40d1-ac33-416bb9c129df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02979249</dc:provenance>
    <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2602d864-e5c1-4a70-9b47-2282ca3b4e07">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <rdfs:label>Increased muscle fatiguability</rdfs:label>
    <dc:identifier>HP:0003750</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1c534d8-d2c5-4074-ae36-c6d22e9aecaa">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604290">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/872</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>872</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACERULOPLASMINEMIA</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/604290</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4c7395a-f031-42da-8649-d9a3b240f4ab"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/621b05d5-2fd8-440e-9fcf-d6b7a90fc5c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3cca4a8-fc3a-4c56-95a2-4009aa66fee0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6a4e379-0ac6-4d2c-ac54-e0797221ef08">
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>high serum ferritin concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b94168a-1c73-4217-ac18-a3081efcefbd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high brain and liver iron stores</rdfs:label>
        <dc:identifier>HP:0003281*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be6e452a-dff9-41e3-8207-e5ab68f1007e">
    <dc:identifier>HP:0005340</dc:identifier>
    <rdfs:label>spastic bladder</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005340</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601678">
    <dc:identifier>https://www.omim.org/entry/601678</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/61b19bfc-90a8-4af0-bdad-bce3574b8905"/>
    <rdfs:label>BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5494990-a4ad-4b64-a09a-7ceb7d4be846">
    <dc:identifier>HP:0010783</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010783</ddiem:url>
    <rdfs:label>erythema</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5243f7b6-c757-4280-9343-f581db4dbcd5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/128230">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/549db1db-482a-4371-acff-b00d97d0e7f7"/>
        <dc:identifier>https://www.omim.org/entry/128230</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8edda9be-9596-4cca-93cd-8b2fc2bb8df0"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c285dd25-a070-4509-9c69-50d6c7173e54"/>
        <rdfs:label>DYSTONIA, DOPA-RESPONSIVE; DRD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7119d279-4544-4625-a995-9d0e44186849">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/58e3148d-33e5-42b4-bcd8-0bcf45eea879"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60b60f26-0ace-41ae-81ed-01335260dd8e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000722</ddiem:url>
        <rdfs:label>Obsessive-compulsive behavior</rdfs:label>
        <dc:identifier>HP:0000722</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ba78866-59fc-4d10-9f17-88bb50177fdd">
        <rdfs:label>Depression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000716</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000716</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/87039fd7-3f1c-4790-8894-e94930b90ee8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00712738</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5eba15b-f611-4dc5-99d1-5f03a8e9930a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b22e530-b6df-4b45-89ab-5fc52a89cebf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/925d7d7c-67e5-4e18-9024-00c00d851fec"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c22c77d9-28cc-4af2-8ae0-e7028353dd01">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4d8a1d9-01d4-4a42-8ff4-66ca9c490c4d">
        <rdfs:label>GSD-associated enterocolitis(enterocolitis)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004387</ddiem:url>
        <dc:identifier>HP:0004387</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/84e0d234-b169-450b-93b0-47e20e67bdf7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fc606fb0-3d98-4230-b43b-7347570193a4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18172743</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/11987230-4dad-4360-892e-3036c9110da1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>photosensitivity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <dc:identifier>HP:0000992</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d4062ef0-5460-43be-b83b-5f6c98c83ce8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c6273dc-04f9-4f1c-9435-b459b30e4d8e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
        <rdfs:label>Gait abnormality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23279108-6b80-4459-bb29-8c3c9179fd98">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <dc:identifier>HP:0002167</dc:identifier>
        <rdfs:label>Speech problem</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18319074</dc:provenance>
    <obo:RO_0003304>Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs)</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f15fcde2-bd96-4660-9772-29b5580b501c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>exercise intolerance</rdfs:label>
        <dc:identifier>HP:0012211</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/052b19ee-077e-4560-8736-172d2a5247df">
        <dc:identifier>HP:0001337</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <rdfs:label>tremor</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29159460</dc:provenance>
    <obo:RO_0003304>homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f85adf66-e68f-43e2-84a3-7ea3957a27bc">
        <rdfs:label>Neurological abormalities</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f450a37b-b007-48c1-8c9d-b46150c79285">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>hyperlactatemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612016">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eda88e4c-a826-4055-a10f-a2df95b85522"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612016</dc:identifier>
        <rdfs:label>COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24b667f9-d935-4155-88d8-ad1aa0a600fe">
        <rdfs:label>dysarthric speech</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001260</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3aff983-f662-4644-a014-a9b48cad3d3f"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9704d36a-e18e-4fbb-8f0f-a056c80d53f4">
        <rdfs:label>Drawing inabiliity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0004144</ddiem:url>
        <dc:identifier>MP:0004144</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
    <obo:RO_0003304>comp. htz c.1523 T &gt; C exon13 + del exons 3 to 15 p.Phe508Ser</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aafdce60-c3b3-4b65-830c-13bed0110eac">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <rdfs:label>High ataxia score ( Ataxia)*</rdfs:label>
        <dc:identifier>HP:0001251*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26818466</dc:provenance>
    <obo:RO_0003304>Homozygous deletion (c.504del_CT)</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193</dc:provenance>
    <obo:RO_0003304>comp. htz c.[895C &gt; T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24]</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42605488-7c2f-4a3d-a199-9ea17d1bce0d">
        <dc:identifier>HP:0002066</dc:identifier>
        <rdfs:label>ataxic gait</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74c737d4-b390-4e68-b90d-27d4e8828caf">
        <dc:identifier>HP:0001336*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Myoclonic abnormalities(Myoclouns)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Hetero c.[1541A→G] + [1750_1752 delACC]</obo:RO_0003304>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9ed12e0-5528-4085-ac25-c43c0e31841e">
    <dc:identifier>HP:0100512*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100512</ddiem:url>
    <rdfs:label>concommitant low vit D level</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/e13b6e43-1e79-411c-9008-d7c4ae152871">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/57aa77ab-31a9-46a5-ac11-bd69991abc41">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1200b0e9-be5c-4809-bd1c-2168457d3f75"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee0c9f0a-b317-4a89-96eb-5ffcaff843a4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth Failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f3f6cd9-5832-41b9-9d2e-18268054e316">
        <rdfs:label>Hyperlipidemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003077</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16672983</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/13f6d838-e255-4dca-b40d-cb551c03db30">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b8d4df8-050b-4f1c-88d6-8f23fcac907d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased apolipoprotein AI level</rdfs:label>
        <dc:identifier>HP:0031799</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031799</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/604091">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/97b56f8a-b6b4-4658-ad0e-354ed9cceab8"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/379</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>379</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/604091</dc:identifier>
        <rdfs:label>HYPOALPHALIPOPROTEINEMIA, PRIMARY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02827941-f646-4fae-bdd9-d0b05431a0cd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002633</ddiem:url>
        <rdfs:label>Vasculitis</rdfs:label>
        <dc:identifier>HP:0002633</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8bceb56-a45d-4caa-a8f0-b7d91627f68e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4978602-229c-4175-821e-7648c3fe1c38"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a85a9b6-9dc2-4469-a5c4-a4da96bcd8b0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Decreased plasma HDL-c levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:00055442">
        <dc:identifier>ECO:00055442</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_00055442</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28213743</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8616b121-9f36-4bb8-84e1-3795a0acc511">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002621</dc:identifier>
        <rdfs:label>Arterial pluque</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3f6dac04-3691-4f86-a17f-e8f5799c7541">
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c20db8cc-b346-486a-b581-ba5b5a58eb32">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
        <dc:identifier>HP:0003128</dc:identifier>
        <rdfs:label>lactic acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9ef854a-4a19-436e-9886-0fef83266e30"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6418873</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef82dd32-0c68-49ed-9163-2390b7c327e6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:label>pyruvic acidemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/246aa9c3-ff61-4367-a0c3-cc92c01abf24">
    <rdfs:label>Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7402da98-9488-47df-af18-29de0e1ce023">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261515"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/63913e0c-9fe5-4fde-866c-68beaee78863"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004442</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d37307f4-3fb9-4674-ad07-7aa9574bae30">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d3bf32ac-beda-43cf-9c35-41da24ff1b74"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc5b4324-9b55-413e-acdf-8c4131bb0682"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d027371-cb1e-421c-a61d-4cdb0bd10ea5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aca4371e-ec70-4e4b-9e91-f42ba375bcb5">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000713</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000713</ddiem:url>
        <rdfs:label>Agitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38f0972d-505c-4742-b70e-a26fab76d71a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000718</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive behavior</rdfs:label>
        <dc:identifier>HP:0000718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f837f4a-d423-46d6-bfae-a7867b5403b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42de30ab-b663-4e4c-9262-abeb63852725"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b71cfa4-749a-44e0-bc8d-6e5b12452859">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Complex partial seizure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7119d279-4544-4625-a995-9d0e44186849"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e0f1d02-6d1f-437f-9f44-1486c34854bb">
        <rdfs:label>Generalized convulsion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3393a16-72f6-4331-a1d5-f0ffcc6f548e">
    <dc:identifier>HP:0001249</dc:identifier>
    <rdfs:label>Low IQ</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d039b330-2213-41ac-81b2-806ea6b44c14">
    <rdfs:label>Low plasma membrane expression of R8Lin kidney</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253600">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/253600</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e4f79f94-3977-4262-b523-0b59b53cc9c9"/>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1</rdfs:label>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/640c2660-0185-4676-b506-1d6618e1a7e3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal prostaglandin level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011023</ddiem:url>
    <dc:identifier>HP:0011023</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2d5a02e-765d-4f76-b579-e50c8335f86a">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/12d9276e-17af-456d-b801-0866db378c2a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2861ff2b-9e44-4887-bc36-61c140fd9307"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee418253-16a9-4b2e-be46-d00976d558f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30349988</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44c63df5-8ab0-4c09-bc8a-ae37e28be212"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430801</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb066d4-d587-4fec-bd89-aa23900bafdb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94f253fa-4ddf-48c1-84b9-9e05bc6f5e2e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB00190</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/fece013a-aaff-4066-9337-65212bc78b55">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16908750</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a"/>
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d13ce77f-f7bc-4071-a3dc-a280ecbb8a1f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9886460</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc76b781-80cc-40f4-b9c1-58956de2647f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/47259d9e-4562-4965-8ff7-c1610aaa3446"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00190</ddiem:url>
    <rdfs:label>Carbidopa</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/42872d3f-dd4e-4a53-933c-80bf1ff91c60">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44c63df5-8ab0-4c09-bc8a-ae37e28be212"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc8507d2-1b62-49e6-8056-10ee4d5594d7"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3063e3b6-bdb0-4b93-a71d-4161bd062466">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/44c63df5-8ab0-4c09-bc8a-ae37e28be212"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/052b19ee-077e-4560-8736-172d2a5247df"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment></rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263570">
    <dc:identifier>https://www.omim.org/entry/263570</dc:identifier>
    <rdfs:label>POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/dda8ecd2-daa3-4ef0-ac71-cd36ff3682ea"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ab900e0b-7191-4d8c-acf3-52d6fb40c848">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0fe7f5b-f247-49e5-9359-032318ab930a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012664</ddiem:url>
        <dc:identifier>HP:0012664</dc:identifier>
        <rdfs:label>Low ejection fraction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd6783e8-269d-4e76-886a-b7662eb14e7e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94f4d26a-8918-45f0-aac2-1cbc8cf78eab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4226e131-019d-42a6-9ae1-48c25ab4d97a">
        <rdfs:label>Mitral incomptence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001653</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001653</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3fc926b-cc04-4f4f-9c3b-b4b4d4a8d6d5">
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:label>Tricusped incompetence</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01612e51-dc50-4ba1-b3f9-139fd1d5b992">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbd38496-e510-4073-b0cb-c8dce21a4ee3">
        <rdfs:label>Myoclonus jerk</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
        <dc:identifier>HP:0001336</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53466607-f189-4c54-9604-7ebcb026acbe">
        <rdfs:label>lack of gross motor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815559</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10753262</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee9272c6-2940-459e-a51e-56ccefe1c6e3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor head control</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002421</ddiem:url>
        <dc:identifier>HP:0002421</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/46330122-579b-4b46-978a-7c218a781aeb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10585338</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10407773</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cb3ae7f-5048-477d-a498-357ecc45bd3b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal epinephrine,norepinephrin ratio</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4cddb6c0-7669-4d42-9325-10831ce7ca81">
        <dc:identifier>HP:0003785</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003785</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased CSF homovanillic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8817341</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/118df99a-9667-4d98-9204-208a7a8504af">
        <rdfs:label>Delayed motor skills</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002194</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002194</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5865e1cb-ba6f-46dd-a381-6f822976d070">
        <rdfs:label>lack of eye contact</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d581267-a918-4322-b345-389ca64ab452">
        <rdfs:label>Hypokinesia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38b70768-4907-4e15-ac1d-41971eff21e6">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:label>Delayed mental development</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/605407">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c285dd25-a070-4509-9c69-50d6c7173e54"/>
        <rdfs:label>SEGAWA SYNDROME, AUTOSOMAL RECESSIVE</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/605407</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <ddiem:failedToContributeToCondition>(926T&gt;C</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11241071</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20399390</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/675de7c6-eefe-4edb-9ef4-bf9c3740ff23">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8802f2b3-2e62-4f40-bf02-e75e778abf22">
        <dc:identifier>HP:0002900*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
        <rdfs:label>Refractory hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/235db8ab-4d4a-4eca-99fb-68d4f163e151">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7909f59d-0cef-4301-9758-dac0c5ac505b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263800">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/889</ddiem:iembaseUrl>
        <rdfs:label>GITELMAN SYNDROME; GTLMNS</rdfs:label>
        <ddiem:iembaseAccessionNumber>889</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/eda252ab-b9c3-4c3a-a837-f3b35bc5b2ae"/>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/09ff3915-3e6f-4561-bc42-5549b5b12b13"/>
        <dc:identifier>https://www.omim.org/entry/263800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0085253816306020</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93556a85-6d53-45a0-9078-bbe17cf01ac0">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:label>Abnormal serum renin level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12141411</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9de7fae2-d961-4d97-afd8-49ce753c5b04">
        <dc:identifier>HP:0004319</dc:identifier>
        <rdfs:label>Abnormally reduced levels of aldosterone</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004319</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4de61461-934e-4397-a020-e14b11a0b657">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031884</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal CSF glucose levels</rdfs:label>
    <dc:identifier>HP:0031884</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/08b93502-018f-4246-ba9f-cfcbb9317726">
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0fe3b349-e3f5-4c2f-8375-4d7b992c2dd2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/78d9f841-2228-4030-951f-5f6f16db52e6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/341298ab-b3fb-46d2-a007-fe2b89f04cab">
        <rdfs:label>Metabolic acidosis (Hyperchloremic metabolic acidosis)</rdfs:label>
        <dc:identifier>HP:0004918</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004918</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a4ae849-cc1e-4f5f-af63-df2420edea3e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/309000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f165dc7b-fc92-4bc5-8b21-2be7f3c7e266"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1061</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>1061</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/309000</dc:identifier>
        <rdfs:label>LOWE OCULOCEREBRORENAL SYNDROME; OCRL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fba1654-e531-45df-8fe8-ee98c72de6e4">
    <rdfs:label>Congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b6a64ad-fe4e-41a0-b682-bd27fe96e040">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000934</ddiem:url>
    <rdfs:label>chondrocalcinosis</rdfs:label>
    <dc:identifier>HP:0000934</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/24e829c5-b8e0-4aaf-a63c-4fee30669579">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd6c2310-9e8b-4745-9e6c-b47445307901">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3e347ab2-7bea-40b2-b6aa-af09c25eb35e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230500">
        <ddiem:iembaseAccessionNumber>284</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE I</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/284</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/230500</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6476d1c0-0624-47f4-8787-895b071ae02a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f091402-c088-4711-ab98-d9b9fd831ab1">
        <rdfs:label>Decreased beta-galactosidase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008166</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008166</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb2e18c6-5bed-418d-bcd9-2d0fb0560fbb">
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high serum phenylalanine</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2610fee-abb6-4dc9-804e-8913beba831c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008347</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0008347</dc:identifier>
    <rdfs:label>Decreased activity of mitochondrial complex IV</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8ecdc891-9ddc-4153-8b39-8a4752a25133">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01203897-562c-4e90-997a-fd048514f79b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012759*</dc:identifier>
        <rdfs:label>Low developmental score</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602360">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c0b0de97-4538-4027-8e3d-79495c764abe"/>
        <rdfs:label>L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602360</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b41e9f7-1c69-418b-8062-7bdb363aae18"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a72c1b12-aa0d-4e17-9a0a-0f18206f2543">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>language impairment</rdfs:label>
        <dc:identifier>HP:0002463</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002463</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20625172</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/707eadfd-5994-48ef-ad87-aca7801bf1f7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012758</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012758</dc:identifier>
        <rdfs:label>neurodevelopmental delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22386973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cfd6240-c787-42b6-8a0e-ef39b049800f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:label>Low IQ score</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c66e4809-a296-448f-8ecb-9d33bfffdf97"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23770102</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3d2fc03-5e47-4939-8af4-b64d2ba6cff6">
        <dc:identifier>HP:0002474*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002474</ddiem:url>
        <rdfs:label>communicative skills abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24295474-5e78-4f36-ac45-e7263add9293">
        <rdfs:label>METABOLIC ENCEPHALOMYOPATHY</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55a570bb-c696-4746-878c-89e345ad8afd">
        <rdfs:label>psychomotor retardation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001263</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29c7232e-8a42-4577-9f3f-896a71d78884">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07f9164c-3573-45b0-a08f-17ec0c661aad"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4d1efd3-3531-4167-b248-40e8a2389801"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42880c37-41ab-4a6c-9668-f784c69ec3b5">
        <rdfs:label>Low cerebral creatine content</rdfs:label>
        <dc:identifier>HP:0012113*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012113</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20682460</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a031bb8-ec01-4e04-a561-7131dde39d35">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <dc:identifier>HP:0100543</dc:identifier>
        <rdfs:label>cognitive dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6315721e-390e-482c-8eff-25b3e9030278">
    <rdfs:label>Abnormal methylmalonic acid level.</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012120</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e0e171e1-b337-4ad7-8750-f45de6193384">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca91bc47-131d-4f74-9dcd-61471113d191">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Xanthoma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001114</ddiem:url>
        <dc:identifier>HP:0001114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/213700">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CEREBROTENDINOUS XANTHOMATOSIS; CTX</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c1deed87-3511-422d-8ab3-81f8cd046260"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/183</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/213700</dc:identifier>
        <ddiem:iembaseAccessionNumber>183</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7964884</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78863421-2873-4007-b6f0-4f0164afecfc">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003124</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <rdfs:label>Elevated serum cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14367b21-9a18-4909-8d49-7dc958e0d679"/>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95a3831b-1947-4556-a5ee-b6920099a897">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5e0b68-8229-4f8e-9bad-d37204d13258">
        <rdfs:label>Lip-smacking automatisms(Epilepsy)*</rdfs:label>
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0003304>R229W</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0d2f49e-6481-42fb-9680-379b03717306">
        <rdfs:label>Clonic contractions</rdfs:label>
        <rdfs:comment>There was partial improvement then patients died</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610090">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1f505eb6-344a-43b8-8f56-3ae42b48046e"/>
        <rdfs:label>PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/610090</dc:identifier>
        <ddiem:iembaseAccessionNumber>76</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/76</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf69db97-2867-422f-9388-c7c54aafaa79">
    <dc:identifier>B01A</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/43b10b89-0785-4db5-8f04-96b4518c273c">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/59bf53d5-b9c3-4bb7-955e-db79868c8853"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/02e286d8-3761-468a-9954-d523f0c56ebb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5b6dcc2e-94c6-4351-a619-f26531983629"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01A</ddiem:url>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/136a5399-751d-4845-8299-ff773caf5c91">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25660576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/612953">
        <rdfs:label>PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/789ca0f3-40ea-4056-951a-ea6314c34f3f"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/612953</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5ee4a2c-778d-42b7-9457-24f694d598bb">
        <dc:identifier>HP:0001300</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001300</ddiem:url>
        <rdfs:label>parkinsonism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02ef9132-ba61-4796-bfe7-1def8bd6b871">
    <rdfs:label>Atypical bile acid synthesis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256600">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/760</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/789ca0f3-40ea-4056-951a-ea6314c34f3f"/>
    <rdfs:label>NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/256600</dc:identifier>
    <ddiem:iembaseAccessionNumber>760</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73851382-ce75-49f6-b9f0-0e9f2843503f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>Abnormal AST level (Abnormal liver enzymes)*</rdfs:label>
    <dc:identifier>HP:0002910</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/64cf81d2-661f-4b54-982d-e8165eea294b">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525984</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f26449e2-38c2-4f29-a761-1c329095872f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001928</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001928</dc:identifier>
        <rdfs:label>blood coagulation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83547cc7-9eb9-450d-a463-b0d20973e2ca">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>hypoglycaemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/01cc0c24-177e-4a04-8ce2-8cc3943c828e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Metabolism abnormality</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602579"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/54011cb4-4bf7-49e3-b81c-acc78375f30e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1b33817b-cdf7-49ae-bca5-c55d7e790fa7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10484808</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da96fcc2-2350-43b5-847f-521531b99eca">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0005567</ddiem:url>
        <dc:identifier>MP:0005567</dc:identifier>
        <rdfs:label>hypoproteinemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/325edac1-f857-4524-a51b-8373227a9a16">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypoglycosylation of serum glycoproteins</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35449f7d-97c1-4b90-8250-745a4056405d">
        <rdfs:label>protein-losing enteropathy</rdfs:label>
        <dc:identifier>HP:0002243</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002243</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99ef058b-38a7-4a50-b18f-3d848d2f7203">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:label>urinary tract infection</rdfs:label>
        <dc:identifier>HP:0000010</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/263112b9-6839-4fa7-8aff-8419ff9c5093">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b801dfd-4213-44dc-8c4e-65f38d1f1839">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Impaired fine motor skillls</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/304af44e-d0a9-471f-a2d8-9fe37def3a8d">
        <dc:identifier>HP:0010919</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
        <rdfs:label>High total homocysteine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/417288</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609a182-f092-4ef0-b8ca-b33b7d7a8eed"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/20584029</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fdee3a2-e4db-4981-b17f-bb01ca55244e">
        <rdfs:label>Cystathioninuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003153</ddiem:url>
        <dc:identifier>HP:0003153</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219500">
        <dc:identifier>https://www.omim.org/entry/219500</dc:identifier>
        <ddiem:iembaseAccessionNumber>28</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/73f4f118-b2f6-4639-820a-17affad85562"/>
        <rdfs:comment>Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/28</ddiem:iembaseUrl>
        <rdfs:label>CYSTATHIONINURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b9930e6-7c64-4d8c-9585-ffd43eeea1ba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001337</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tremor</rdfs:label>
        <dc:identifier>HP:0001337</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b4a6b9a-8d7b-483a-93a0-ac5d86916b3f">
    <rdfs:label>AAV2/1-MCK-Sgca</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/3fcc44e4-d63a-4658-8085-22318b08870d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd99f5e5-8d5c-4b7e-b78c-2c3872880d75"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a803c5f-2d0f-475b-a543-6f34dda25162"/>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608099"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf20cc38-bdb6-47da-ab5f-c419e5c8e70e">
    <rdfs:label>Vitamin D insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0b7b0d3a-41ce-44fe-9939-9927db31d7ef">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec88b708-c253-452f-b7dd-5b0054d18753">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8365ee00-20d0-40d5-9389-a8d3838671c4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c763332-72ab-423c-9f7f-3e68f7d56969">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008373</ddiem:url>
        <dc:identifier>HP:0008373</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Puberty and gonadal disorders</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/202110">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/94624af1-0d56-4d95-86fa-686e040a99f7"/>
        <ddiem:iembaseAccessionNumber>125</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/202110</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/125</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/295babd2-7803-459d-8fa8-5049881d99d3">
    <dc:identifier>HP:0001397</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
    <rdfs:label>Hepatic steatosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3895de8f-e979-4b23-8700-a9398e8f204b">
    <rdfs:label>working spatial memory impairment*</rdfs:label>
    <dc:identifier>HP:0002354</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002354</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b8d32f40-ff03-4a90-94a7-d1aee07807ea">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3aff983-f662-4644-a014-a9b48cad3d3f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609a182-f092-4ef0-b8ca-b33b7d7a8eed"/>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa6de61f-98c1-447e-b7c8-c7f8213f2cb3">
        <dc:identifier>HP:0001250</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <rdfs:label>Epileptic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7ac2dde-1130-4a88-b7c5-07e7bbbe3b72">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
        <rdfs:label>Poor appetite</rdfs:label>
        <dc:identifier>HP:0004396</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9060258f-593c-4358-b5d3-430cc69914cd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low quality of life</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d546ac81-9252-4b55-81fa-544acff626e5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Tonic-clonic seizures</rdfs:label>
        <dc:identifier>HP:0002069</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25558587</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/7ae0ded6-c24f-4b5f-a348-362c9b95b77c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ac99f9e-bf7e-4202-b2ef-8ba8c0a35b75">
        <dc:identifier>HP:0000790</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000790</ddiem:url>
        <rdfs:label>Hematuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614723">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/38d2dd93-6cf9-4a49-bcd7-11c3d5899ad6"/>
        <rdfs:label>ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614723</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ac959b2-9566-4044-9796-6ccdc698db73">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000010</ddiem:url>
        <rdfs:label>Recurrent urinary tract infections</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f675eb22-0e0f-4b52-b402-7cbe1ad54b0e">
        <dc:identifier>HP:0000787</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000787</ddiem:url>
        <rdfs:label>urolithiasis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a98c085e-ddbc-4016-83d0-3e08787b39d6">
        <rdfs:label>Dysuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2da30293-87c2-481d-b887-0f6ed3b527ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/134b831e-38f0-4f02-a7bf-087d188f565e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af4d2944-a2bb-4a82-80d2-d21e1d98581b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000112</ddiem:url>
        <rdfs:label>crystalline nephropathy</rdfs:label>
        <dc:identifier>HP:0000112</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c9f4bc5-f999-4aa6-bf77-0443e59aa21a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Urinary DHA excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/57cd992e-2e0d-4df5-b7aa-337ff635ec1b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:label>Chronic kidney disease</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/92ed5697-59a4-4a41-b52f-7601b20fed11">
    <dc:identifier>DB00869</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00869</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad1b7eec-05e1-484d-a00d-f4896fd1bd7c">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45cf0b26-55b0-4ca0-9096-95b276235f09"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81959ed2-a627-4208-8ab4-49796ba034ee"/>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/504db0d5-d6b0-411b-ae2f-09182f0d6560"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29395598</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Dorzolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d97614b-8667-4554-a5d7-0871e1a10892">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003949</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0003949</dc:identifier>
    <rdfs:label>dyslipidemia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/594e369f-2d39-4f3d-b815-b7622b91ff2b">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ac6f019-2738-4d2a-9717-737de462fbbc"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261000">
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>80</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ddddd1f4-77b9-42b1-9d0c-cc0e9ffa9dc0"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/80</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/261000</dc:identifier>
        <rdfs:label>INTRINSIC FACTOR DEFICIENCY; IFD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20b4b970-60cf-4a28-a534-980a31027f60">
        <rdfs:label>Gastric mucosal atrophy(Abnormality of gastric mucosa)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004295</ddiem:url>
        <dc:identifier>HP:0004295</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/921733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3362d06c-116d-4a88-93f5-2da3d50b8897">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01681940</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609458">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/00fec955-d750-40fd-ba98-bafa2fc386ec"/>
        <rdfs:label>MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/609458</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5472fc21-f1c0-4d0a-936c-5d9762d52d3e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated GFAP(Glial fibrillary acidic protein) level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ecadbe3b-107f-49dd-a405-e095d65fd8df">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c3c1149c-1f72-4835-82ee-02e4957dbc5a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1bc6fa08-5982-4e2a-80d5-a5ef83d89c3d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High CSF MAN2-oligosaccharides</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e34d7b82-1bee-440b-a3fa-32275851692e">
        <rdfs:label>cognitive deficits</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0100543</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2b99e87-08cd-4f48-9c88-6b13ea9a79f5">
        <dc:identifier>HP:0030878*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030878</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low FVC%</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/965ceea6-e0a5-40ce-ae45-3b17843b1909">
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:label>Reduced pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/707acb89-7a5c-4a01-b44c-6efbac970a58">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated Tau-p level in CSF</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e793f989-f303-46e6-a0fc-d9c2893d8704">
        <rdfs:label>High NFL (neurofilament light signature ) in CSF</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d7729b80-fab3-4d56-87de-d99c84969134">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/008981f6-077d-4590-b850-a18ac5d5eeb4">
        <dc:identifier>HP:0012217</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <rdfs:label>Accumulated  urine porphobilinogen</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1b487354-970a-4bd2-94fe-b935c5c6ca31">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79df5a6b-11bc-4df6-8249-d295fbee306e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b032f049-0ae0-4938-8e97-542e205c4146">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Accumulated  plasma porphobilinogen</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176000">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/174cda5a-dbe3-44b8-82a2-2eeceb881149"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/112</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/176000</dc:identifier>
        <rdfs:label>PORPHYRIA, ACUTE INTERMITTENT; AIP</rdfs:label>
        <ddiem:iembaseAccessionNumber>112</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17375984</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5618b2d-19ae-4e75-b2ce-33f0b833cd34">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012075</ddiem:url>
    <rdfs:label>Personality disorder</rdfs:label>
    <dc:identifier>HP:0012075</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2d5e3c87-811d-47f4-988e-f980c5608af2">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0040189</dc:identifier>
    <rdfs:label>Scaling</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8de1704-f658-43f0-b910-ca62ba45053f">
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f89c2cb2-a2bd-494b-b9cc-ac19cab526c3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/14e712f7-c352-4cdf-8fd0-55937fa31eaf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7946a681-6d18-45cb-baa8-260cbc1d1ab8">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiomegaly</rdfs:label>
        <dc:identifier>HP:0001640</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddbc2e62-e181-46f3-93ba-d80d7104d576">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012213</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012213</dc:identifier>
        <rdfs:label>low renal glomerular filtration rate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb327687-a3e0-41be-acbe-d2a0d28ba065">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pain</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
        <dc:identifier>HP:0012531</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03018730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/afce3ff9-43fd-48fb-90ee-a733b8c0c190">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73196abf-e2f1-4db7-acd1-390ae0881535">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
        <rdfs:label>Recurrent bacterial infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002718</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1709246</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd3a44a4-3711-43eb-84a1-efa6be3a6ae1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"Frequent, severe infections"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/307e45d6-73dc-44ce-9da0-a309497a81b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c705bbf1-08a0-40bc-9fdc-7198991e9728"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1719175</dc:provenance>
    <rdfs:comment>Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8447561</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a546c4f6-d18d-40a2-bef6-5ec1a1ed8fe0"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/04581989-489c-49a8-95fd-7e0947ca3033">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8775fc0b-3ee0-4264-814d-ea66b76cd66e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/85946b43-3414-460c-8d5e-218785524618"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b8cd17f-3068-44bd-afde-d68aaecfb55e">
        <dc:identifier>HP:0000972</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000972</ddiem:url>
        <rdfs:label>Palmoplantar hyperkeratosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/22668dd2-8999-49d5-b15d-9062891856d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/979eab39-b975-4130-b1a8-cfcadde0b8df"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7c3cfcf-4b17-425d-bfc5-5068ebdfd737">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Adipose tissue tocopherol level.</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9100c012-aa89-4b75-8582-a3e0531371e0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07186a79-4dbe-4380-8aae-1580091e0f1d">
        <dc:identifier>HP:0100769</dc:identifier>
        <rdfs:label>Synovitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100769</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22341584</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7121aa2-b69f-4d64-aa4e-04e4c071c6bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19289295</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03cc7c1e-f276-4f62-b236-3e98ada7b0ff">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031375</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Refractory Arthritis</rdfs:label>
        <dc:identifier>HP:0031375</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22658375</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1742948d-e751-4939-9107-28d5171ba312">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025303</ddiem:url>
        <rdfs:label>Recurrent repisode of flares (Recurrent)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025303</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60694f50-3179-4b77-a765-9616686cf175">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/acccba5e-7034-4b0e-9a23-f6d1f8421187"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e25b051b-0466-438b-8de1-eb986d6b9dd9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2eac204c-00e7-4269-8e05-b2f772f8e8b6">
    <dc:identifier>A11</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cc452cc9-369d-406f-b0e5-4eb49f8b5e68">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d2bb9ab-8522-4199-a576-7f761725ada8"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f29ca0b1-b53b-46ed-b0d5-62e2397d9f34"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>VITAMINS</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/976b406f-3a7d-48c3-ba8d-3a655f26ee6a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72068b5f-4d05-473b-a11c-aad999064543">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012120</dc:identifier>
        <rdfs:label>High urinary malonic acid</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012120</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248360">
        <rdfs:label>MALONYL-CoA DECARBOXYLASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/248360</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/177</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0d9ddbb3-96b5-456a-9c74-c7217c2dfd57"/>
        <ddiem:iembaseAccessionNumber>177</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0884b9a4-ee91-4835-bb17-f81ca3dd1b6e">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f30417e6-ea05-428c-b13d-1587f17f86a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6d98ae23-a1c0-4b7e-a861-8391972d4a76"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e250047a-6eca-40e4-8dc5-f1a97dee9753">
        <dc:identifier>HP:0001596</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001596</ddiem:url>
        <rdfs:label>Alopecia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/201100">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/202</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/201100</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>202</ddiem:iembaseAccessionNumber>
        <rdfs:label>ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89f939d1-ab53-4a58-8a9d-db320e25b473"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14354277</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66963a46-d641-46fd-9315-6a37b6a85d80">
        <dc:identifier>HP:0040181</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040181</ddiem:url>
        <rdfs:label>Perioral dermatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b93cc8e-ef27-4555-bd63-23246b92d6df">
        <dc:identifier>HP:0002014</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Diarrhea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95a301c7-ae4c-407a-a952-5d2d85be5ed3">
        <rdfs:label>Acrodermatitis (Dermatitis)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011123</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/933ce3be-e61d-4a10-8051-8ce9123a5490">
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57aef328-ef45-4afb-a83c-700b9074bc47"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1a5cefa-8cf5-4331-ad9b-1c623a310034"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151660">
        <rdfs:label>LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2</rdfs:label>
        <rdfs:comment>Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/</rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/151660</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/89d78dcd-1df9-43d0-ba70-11723dfb3517"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27710244</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d7b5927-b54a-4230-905d-212394a4fdba">
    <dc:identifier>HP:0004356</dc:identifier>
    <rdfs:label>Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c3460a83-cd1c-4465-a4b1-a71aa8d20c3a">
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a2bd349-e4b9-462c-a6d3-44182df1afbb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2137a684-5177-43b8-aa4d-fd83d9d12d4f">
        <rdfs:label>High VLDL triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bcc68f6-d97e-443d-beb6-8fcd234f9fdc"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8f144be0-8c21-4a77-b4a9-1d419391f7f5">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00528151</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/898f9317-0edf-462a-b559-591806bf3f0c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fcaeab5c-2394-4bb9-8bf2-71fe7d470b83"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf90e243-7fd8-4434-a678-1079aa338892">
    <rdfs:label>Abnormal reflexes</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001347</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/37120c55-ca06-46c4-94cb-edca1eb09531">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28973635</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c20db8cc-b346-486a-b581-ba5b5a58eb32"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c94a1e43-4220-4d40-8f95-20fd016198ae">
        <dc:identifier>HP:0002149</dc:identifier>
        <rdfs:label>hyperuricemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3dda7601-ece7-415d-b437-9d59bcdef8ab">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52711171-ee01-4d08-bb1e-5f2636c04ee5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40b77614-3199-4595-abc6-9f7b8feb713d">
        <rdfs:label>obesity</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001513</ddiem:url>
        <dc:identifier>HP:0001513</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c57dc9b8-516b-4d41-99a0-23638febbc52">
        <rdfs:label>hyperlipidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
        <dc:identifier>HP:0003077</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/065a6337-8c38-4ecd-94bb-4f4d0d80aafa">
        <dc:identifier>HP:0000855*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:label>age-related insulin resistance(Insulin resistance)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4308b98c-3577-4fe5-a264-1497b440e66d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012594</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012594</dc:identifier>
    <rdfs:label>Microalbuminura</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0861bba1-5644-44e5-9f1d-7a5ebc62e54c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>psychotic  disorder</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000725</ddiem:url>
    <dc:identifier>HP:0000725</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66c5dd62-6f05-45bd-aeac-5113bbc709b6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001897</dc:identifier>
    <rdfs:label>Normocytic anemia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001897</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce8715f9-e0c4-4c9f-9c3c-fd3cff4fd5ad">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>neurological abnormalities</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78ce5c3f-14f4-467e-be30-de326f1290df">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Histological abnormalities (Abnormal test result)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <dc:identifier>HP:0500014</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/853cbe42-6d30-48f2-bbed-ca7cd86077e7">
    <rdfs:label>Rigidity</rdfs:label>
    <dc:identifier>HP:0002063</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002063</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6f22bee7-9c00-4d15-a063-d9d856e094a7">
    <rdfs:label>Vitamin K insufficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/118610">
    <rdfs:label>CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0a554307-7d6d-4fa6-8f4b-ce3deee86b92"/>
    <dc:identifier>https://www.omim.org/entry/118610</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/227c586f-857a-40af-ab57-4fd953bd748a">
    <obo:RO_0003304>C2129-2A &gt; C</obo:RO_0003304>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0003304>c.982G &gt; A and c.1072C &gt; A</obo:RO_0003304>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600890">
        <rdfs:label>HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/178</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/600890</dc:identifier>
        <ddiem:iembaseAccessionNumber>178</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fcf081a9-f4df-49c2-bd2e-4fd8c55eeb08"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edd3c338-b0bc-42da-a6cb-b48525d6e3e0"/>
    <obo:RO_0003304>c.1528G &gt; C</obo:RO_0003304>
    <obo:RO_0003304>c.180 + 3A &gt; G</obo:RO_0003304>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0003304>c.914 T &gt; A</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b2c7340-3637-46ab-825e-3941558220c9">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:label>Abnormal Fatty acid oxidation</rdfs:label>
        <dc:identifier>HP:0004359*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>c.1528G &gt; C</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>c. 1393_1479del-Del exon</obo:RO_0003304>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71c770d8-043a-4277-97a2-9f4bc842f3d0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cab8ab31-8471-400c-993c-6a3c71cf4dbc">
    <rdfs:label>Mycophenolate mofetil</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00688</ddiem:url>
    <dc:identifier>DB00688</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7864fc00-48ac-4bd9-b27b-4386a13c6c6d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f2474751-b88f-4649-b3a8-81f063649d7f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01399047</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0341e517-a386-4978-9d19-da3c63bc554b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204200"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b53239bb-8bc9-4357-88b1-bb2991d163cf">
    <dc:identifier>DB06210</dc:identifier>
    <rdfs:label>Eltrombopag</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2d147dc-aebb-468b-a6cd-5826dea9a567">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9fc07f-1f33-4ed3-ba94-b1b5252f0f90"/>
        <obo:RO_0003304>(c.356+3&gt;C)</obo:RO_0003304>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fb52c1bc-7a84-4b52-91d5-0e176a1bf510"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/128/22/2682</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01328587</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29684566</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25a0c679-54b6-4598-9805-61d04566fd1a"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06210</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94c61246-7790-47de-bd60-ae1b179e28f8">
    <rdfs:label>Skin papules</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0200034</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0200034</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb0e1afe-314e-4b38-b510-64dd8493add2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607765">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5071bde7-5c1e-4ddb-947c-93c6260d602d"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607765</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1eb3bf14-ede7-4337-8ca8-2a4259b403e2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6dd48dc1-7266-4ee2-8520-0087af4b8f04"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e70f7efd-f8f4-445b-a1e5-705f250d2f3e">
        <dc:identifier>HP:0002630*</dc:identifier>
        <rdfs:label>fat soluble vitamin malabsorption(Fat malabsorption)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0">
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:label>Failure to thrive</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5cb6c8b3-8a43-46e6-b3be-f737ac47057d">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cab58010-8246-448b-a3ce-e68559c4b55d">
        <dc:identifier>HP:0002917</dc:identifier>
        <rdfs:label>hypomagnesemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002917</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3904230-201f-4f68-8692-620055bed4e4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/228e626a-6b08-4448-886a-3d24c8e74967"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b6a64ad-fe4e-41a0-b682-bd27fe96e040"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56d050e8-a35a-4f4f-9ff9-f0605c15537b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
    <rdfs:label>Functional motoe deficit</rdfs:label>
    <dc:identifier>HP:0004302</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a5873e17-570f-4feb-90c8-b53b21aa6b27">
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22f089cd-4dd4-4f7e-859e-97ac643550c3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100725</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>skin thickening</rdfs:label>
        <dc:identifier>HP:0100725</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef52cd98-3243-4df5-ba3b-71063557580a">
        <rdfs:label>inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0001845</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001845</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/457d9cef-f865-484b-972a-5fc049b08ff6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189*</dc:identifier>
        <rdfs:label>waxy scaling plaques</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35bb3ed3-72b1-4e7a-8f83-504e688cab14">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Accumulation of toxic metabolites in cholesterol biosynthetic pathway</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0689027d-1cbc-4672-ab43-61795f6d993a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008064</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:label>ichthyosiform erythematous plaques</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9841c54-f937-455d-abf6-aef1f900037b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e50aa75-94d1-4f48-977a-b6d810b4557f">
        <rdfs:label>Abnormal circulating IGFBP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0031034</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031034</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20624436-7996-44c2-b730-0c3284248cba">
        <dc:identifier>HP:0025521</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025521</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Body fat composition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4866a60c-bc81-45dc-bd5c-d41a0fd98e29">
        <rdfs:label>Low height velocity</rdfs:label>
        <dc:identifier>HP:0004322</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da55789a-46b0-429e-a303-af01efb2b98d">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0032367</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0032367</ddiem:url>
        <rdfs:label>Abnormal circulating GH level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5647fb8a-46b4-4c69-8b07-5e261449b30d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <rdfs:label>Low lean body mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0045082</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10323388</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10770174</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c858b49f-20f7-4d42-8fe8-4d13ea017413">
        <rdfs:label>Abnormal linear growth (Decreased linear growth ,Abnormal body height)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of "increlex " supply.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b677a8bd-1109-4b0a-8dab-cb5b06844849">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008189</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008189</ddiem:url>
        <rdfs:label>low insulin senstivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c12cb433-742b-41d1-af36-e1aa6d87a236">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000855</ddiem:url>
        <rdfs:label>Insulin resistance</rdfs:label>
        <dc:identifier>HP:0000855</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c81074b2-bbf9-4e40-8c78-4452b5c14e34">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045082</ddiem:url>
        <rdfs:label>Decreased body mass index</rdfs:label>
        <dc:identifier>HP:0045082</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/06303de8-072e-4011-bd8e-e2ff2e1c2eb3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e84dbda5-e4fa-49c4-973e-40b5225125a0">
        <rdfs:label>Abnormal circulating insulin level</rdfs:label>
        <dc:identifier>HP:0040215</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040215</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/fe122bb1-361c-4d3d-9355-0ee869a44ae0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc9a4b4a-9351-4df4-82ef-b76585e0732d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8810b34-bb08-4372-b055-3b0060b69af6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03223194</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0f79a85-3a3b-4b27-946c-103d01b0e4b3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>growth impairment</rdfs:label>
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e331004-166e-4efd-a9b8-d971a0b2d15e">
    <rdfs:label>Triheptanoin</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/29dedb0d-b231-428e-a883-c0be5eb8a2c4">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f01a48d6-6134-44e1-ac0b-24723c7345e2"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232800"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03642860</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
        <rdfs:comment>A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&amp;rank=1</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6850e98b-3ba7-4c16-a13d-bee121dbced7">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d00ede78-ff45-4715-96bf-cd473848f33b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca21a54f-b0b9-487c-b0bc-ee7147440773"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/089068a6-2122-499a-8ebe-e0b7753466c3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>PMC2676979</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18645163</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/255120"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/07999ba8-213c-4e0c-9378-478f347b980f">
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2154b6dc-9275-4fab-a4da-12a35de7f38b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74e695ab-52b9-43b4-806a-2fb44b9cb594"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02432768</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11940-017-0473-2</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/743f067d-52a6-4544-a092-cc49a5494f33">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT01379625</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83530693-72e4-4059-bcfb-3dc37814f7f2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55809cf5-204e-4e2d-b0fd-49717c3766b3"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb626c3b-0786-4699-a822-2da7fa2d10bc">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01993186</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/62bbfc8d-342e-4c65-bf4c-3cba3680badb"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
        <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02036853</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02960217</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/722eb1b1-b9d5-41df-b998-c32584e3db07"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26982753</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56466793-e9ec-463e-936c-5f3241369125"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f02e55d-f90e-4064-a4e1-91312dfc69df"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0156c486-f550-4d41-a8a3-5a7ee2310345">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2e3d129-1e4d-44a5-8299-271f7fa1dfa5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/68df942a-c606-4eef-bd86-16b244a336bc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca21a54f-b0b9-487c-b0bc-ee7147440773"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00947960</dc:provenance>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263570"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/a048f896-6535-4579-bb3d-21ee415bd81a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50b9b6b4-3646-4205-a9ee-032560cd1cfb"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16763896</dc:provenance>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12122118</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9060258f-593c-4358-b5d3-430cc69914cd"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8e9c736-1d6f-43b5-8a2d-7b89a44d4fcd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11677</ddiem:url>
    <dc:identifier>DB11677</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f1c6bb7f-bca0-4245-b0e0-b8c84fc1c66b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd115f63-b644-4400-84cb-0a8c6e623a29">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/32f2b6cf-4251-493b-a2f8-6d8f3fddc593"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5574e1a1-81f8-46d2-b8a6-84fd5c20ec27">
        <dc:identifier>HP:0001877</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001877</ddiem:url>
        <rdfs:label>low RBC count</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00229619</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99c7c71d-8cbd-4d02-be5c-356d997d3924">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02285</ddiem:url>
    <rdfs:label>Protoporphyrin</rdfs:label>
    <dc:identifier>DB02285</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/49959038-92af-447f-989d-876c77996a79">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>http://pediatrics.aappublications.org/content/86/1/152</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/93f55e89-07a9-47b3-b355-7952d5571e5b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.nature.com/articles/pr1989488</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a698388c-e2e9-412c-a286-b287cd950660"/>
        <rdfs:comment>The drug is effective in conjuction with phototherapy</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9dbe630-9270-4358-b6d8-3a46f36a989e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
    <rdfs:label>poor skeletal mineralization</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006462</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3e7b8e26-0ddc-4db0-a423-695ce0a415ec">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a2171d49-a48d-41e4-8402-dd15e48c3547">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/81b4c384-5e18-4b94-8fb2-0144e2fc1b8c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94e4a44f-7ead-40ed-a6b6-706d51b4ecd6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <rdfs:label>Decreased cellular ATP level</rdfs:label>
        <dc:identifier>HP:0011925*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be13f4db-a1e3-4d3f-9eb1-19d50d2d1127">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Mitochondrial dysfunction</rdfs:label>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65aab3f6-9c90-4103-80c6-481d08f9f8c4">
    <dc:identifier>HP:0002014</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
    <rdfs:label>diarrhoea</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e0e52be-0601-4785-819e-ca2d61e234de">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03727555</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9b47d171-1c9b-489c-b7ab-c133e13fb311">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/944b46c5-82fc-4d1d-9286-e7029199e334"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.myelin.org/tag/lenti-d</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16009761</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7666063</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9378e56-f13c-49c1-bab1-84b5cb28c05c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <rdfs:label>Abnormal elevated level of VLCFA in plasma</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003455</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300100">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1d11548a-63eb-4eed-8e1a-a275a70855ed"/>
        <dc:identifier>https://www.omim.org/entry/300100</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/280</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ADRENOLEUKODYSTROPHY; ALD</rdfs:label>
        <ddiem:iembaseAccessionNumber>280</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00545597</dc:provenance>
    <rdfs:comment>It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76e3b739-c547-41d2-b177-c5da5e23d45b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Functional disability(Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b01aeb10-c083-426e-991d-bb09e20a4f6c">
    <rdfs:label>D-alpha-Tocopherol acetate</rdfs:label>
    <dc:identifier>DB14002</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/760b0e37-7367-43ed-8255-4efd79b7c865">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d18397bf-2d37-4d59-ac44-721ef72494ae"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4cc69c3b-74e2-4b9a-9a84-b404733c8d97"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699704245</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277460"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52d63561-c6a7-43c4-ab1a-86c748880642"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14002</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/678dd3b0-302a-4bfb-8df7-07b060939f86">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29908244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d2fd3fe-8c62-4297-8cf3-f18a940c4a71">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <dc:identifier>HP:0040006</dc:identifier>
        <rdfs:label>mortality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0000305">
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0000305</ddiem:url>
        <dc:identifier>ECO:0000305</dc:identifier>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07832ee3-e2b7-4761-b2e8-39880b6f8bb5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001824</ddiem:url>
        <rdfs:label>Weight loss</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001824</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7052e6b-7364-4cea-a94d-2907c6bd1d11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8945aee6-b07f-4344-97ac-0071a25e4ef5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fba7177-4dc6-4fb5-8152-df60a3d44d48">
    <rdfs:label>high plasma MCP-1</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/158797ba-2930-41f6-8de0-d6d8f770b428">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c169b68-c628-4732-8740-9b0d6fe295d5">
        <rdfs:label>abnormal parathyroid hormone level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
        <dc:identifier>HP:0003165</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6d72f20-772b-454b-8aba-62086a19aee9">
        <dc:identifier>HP:0003072*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <rdfs:label>high serum ionized calcium concentrations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c6eacad-3e2f-4510-a2f2-4f2f894c923a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dd2522d3-7c80-4ec6-8dc4-3e6710578efa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3800323-6a00-4a2a-b3dd-42a10ae02bcf">
        <rdfs:label>low calcium urine excretion</rdfs:label>
        <dc:identifier>HP:0003127</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003127</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27050234</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600740">
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/600740</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/50d64aa0-19d8-4f8a-9051-a65c74b81770"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/236d23a7-0e36-4d9f-8f67-4efecdd2c0ed">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b45220fa-de8d-4449-a4bd-b5e30acc0240">
        <dc:identifier>HP:0001635</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>congestive cardiac failure</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980384</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27f4d3a6-9156-450a-9695-5ff0a59b30f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca9161e8-3a85-434c-b7d2-0db837b58c2c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/43591d2f-ccee-4191-b489-22e15e4f9ce6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tachypnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002789</ddiem:url>
        <dc:identifier>HP:0002789</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613150">
        <dc:identifier>https://www.omim.org/entry/613150</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/353</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/20a0cd13-1fd2-490c-a3b1-f2aad13cfeaa"/>
        <ddiem:iembaseAccessionNumber>353</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff72eb5b-a932-48e9-a899-7c9493cda578">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/27326934-68e5-4d47-81d3-58a1d5b9ce46">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>low physical activity</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d70078b7-c3e0-49b6-9c95-042a4732b05a">
        <rdfs:label>decreased male libido</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040306</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040306</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28160246</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cefe03a5-268c-4c6e-8813-3b38fb42fe0f">
        <dc:identifier>HP:0001324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>decrease muscle strenght</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec88b708-c253-452f-b7dd-5b0054d18753"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abfe36fd-4021-452f-9888-5737a439c7bf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Mild attack</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012825</ddiem:url>
    <dc:identifier>HP:0012825</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2bd800a7-46dc-4cba-951e-b81ccbbec92c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09917e19-6c8f-44d0-a134-a5e5684ff340">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:label>neutropenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd3a44a4-3711-43eb-84a1-efa6be3a6ae1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/847f35e9-0d9d-4a54-8ff8-abc082e0d2c2">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16ba20cd-bcc6-4aac-ae14-edabf3ab31cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4637e0f6-c50c-4ba6-a48c-af9c7e48c839"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1577dd23-7f9d-4f31-b3bb-0211d6ead7a9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/029ae30e-baf4-4b72-a1c1-6e98c2e83e1e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92e681cf-3fc7-4cad-8d61-aafe49d84b3a">
        <rdfs:label>Macular cystoid changes</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008028</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008028</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95210585-9a07-4310-839f-7c26e3834b56">
    <dc:identifier>HP:0000144</dc:identifier>
    <rdfs:label>low reproductive capacity (infertility)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000144</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a9847569-1b39-4328-9bbb-0d0add316d62">
    <rdfs:label>High macrophage infiltration into tissues(Abnormal inflammatory response)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012647*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0fe106d5-da50-45da-90bb-d85bd7e44a63">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88f26d72-f133-41b6-b164-2160fb75097b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/979976e0-edfa-43c9-b0b4-61a09aaee29c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9457971</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/786010dd-719a-41e5-b77d-01102eb81eb7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperbilirubinemia</rdfs:label>
        <dc:identifier>HP:0002904</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1dcf0c2-0bff-43ae-9ae2-b8447119033c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
    <rdfs:label>Abnormal neurololgical function</rdfs:label>
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35c965ce-c5be-4cab-b1fc-a4a94e04c979">
    <dc:identifier>DB00115</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00115</ddiem:url>
    <rdfs:label>Cyanocobalamin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c3d1427d-40b3-4eee-9e2d-4ecd81bc6af0">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cbb29c2-f6c6-4a77-b907-29c525528a06"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e43d1abc-8d23-482e-8c77-a9c67974a287"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fc546f51-10fa-4651-944d-17ba8a08325b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0b38024d-1339-489b-9eef-8f9fb39f70b3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6823973</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9694707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24424200</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f3557920-66b0-4e34-9cfb-54ccbe95c2f7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d0464d6-bc71-4dac-89db-35f377bdf6a5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25308559</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3bfc914e-3583-4e56-956b-37b6bed5804e"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <rdfs:comment>The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c5f2b5a1-e300-4eed-be2a-55b3c657435c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c1e34981-291c-4f69-aa09-fecbeea23ad8">
        <rdfs:label>Low enzyme activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a68a6ab6-1342-4b5a-b239-10b8272d888a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96a38e85-bb4c-411a-b9f8-5bd487addb66"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5586569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236800">
        <dc:identifier>https://www.omim.org/entry/236800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/180d67e7-4a4d-47ce-9749-e2ed9ac1d43b"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYDROXYKYNURENINURIA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d53bd1e-f302-4a3f-b014-301b94a26dfc">
    <rdfs:label>Pancreatic beta-cell dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006279</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006279</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/15bb4c9c-bc86-45e6-b91b-6ea10b6649f0">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/306ddda4-9b0a-4bd0-8e6c-9c71c7ad1358">
        <rdfs:label>"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM."</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20506325</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/99cd2b8a-fc39-4afd-9422-59a406d9e310">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3f73f306-23dd-4070-a361-d71cb81b2ac8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fa6a5fb-f153-405d-bd9e-4b99317b5411">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002459</ddiem:url>
    <rdfs:label>Autonomic dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002459</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aeab8d77-53a0-4be6-b88d-5049aefdd9ec">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29c9cd59-a4b0-429f-8c39-7353d8ce972d">
        <rdfs:label>retarded growth</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/34842cfb-c0cd-4b39-9711-2174bd2b882d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/46dc73b9-4d45-4987-9797-9a574c620fff">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aa690677-09ab-4d07-9705-059b4efaa53e">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f21fabb-6955-4763-a238-2556dc016f60"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64dbf323-2fbe-4474-bba0-5ab077276d42"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14104</ddiem:url>
    <rdfs:label>Linoleic acid</rdfs:label>
    <dc:identifier>DB14104</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/be49032f-46f0-4c68-8bd1-122174a334c9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec59e3e2-3bea-4100-8a70-aa963072663e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:label>Neurodevelopmental abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c0c6825-79fb-4871-972e-aa90faf605e1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurodevelopmental abnormality</rdfs:label>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4f016cb9-590f-4074-9857-69bab097e3e7">
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671893</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/246aa9c3-ff61-4367-a0c3-cc92c01abf24"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f179605b-876f-42ee-bb5c-307c5c0e81f7">
        <dc:identifier>HP:0000737</dc:identifier>
        <rdfs:label>Irritability</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000737</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e1c09d9-c6a8-4a51-a631-bb3a812d935a">
        <dc:identifier>HP:0007266</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain demylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007266</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78b50572-980a-4861-a611-b499adac4192">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Awake EEG</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <dc:identifier>HP:0002353</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9740c93-ffb7-47e7-ae21-7e83c3ca6bee">
        <rdfs:label>Delayed mylination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012449</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012449</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c8e6968-5389-4082-a53a-053a8a29ad16">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Behavioural abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a3393a16-72f6-4331-a1d5-f0ffcc6f548e"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f615d916-5c21-43fc-ad13-651764b4a770">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671891</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30389272</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250850">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/557f6a5f-e75a-4f2f-acf9-fbdf3212758c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1283</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/250850</dc:identifier>
        <rdfs:label>METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY</rdfs:label>
        <rdfs:comment>Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891</rdfs:comment>
        <ddiem:iembaseAccessionNumber>1283</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99cd2b8a-fc39-4afd-9422-59a406d9e310"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00cfc9c9-19c9-4651-80fd-1f523dfeaa30">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>Poor weight gain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001508</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59a65871-e925-44a4-b968-20d12fea3a0e">
        <rdfs:label>Delayed motor milestone</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671896</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7ac2dde-1130-4a88-b7c5-07e7bbbe3b72"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/80c3359c-3f33-4f10-b1c1-581200c1cb66">
        <dc:identifier>HP:0011448</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011448</ddiem:url>
        <rdfs:label>Foot clouns</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4771ece-5938-404b-952c-f6323d6a5684">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:label>Poor traction response (Poor muscle tone)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14c18937-ef74-4ee9-87fa-35afd162dd00">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Poor traction response</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74477ef0-69a0-450b-aecc-c9beb3288a7b">
        <dc:identifier>HP:0001347</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001347</ddiem:url>
        <rdfs:label>Hyperreflexia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671894</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27671892</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9d8b462f-4bd9-46f9-96db-ea7725ca32e1">
    <rdfs:comment>Study was terminated due to safety issues.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07539bc5-4a22-4e1d-a53c-045f5b0e6e4e">
        <rdfs:label>Study was terminated due to lack of safety</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3aca313c-ef5f-4768-ac09-b61ba7d60675"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d441714-f088-4119-922d-bc4d6489bb4c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f09df761-60b4-4f75-a57c-d7c4d0656002"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00145431</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55636bfa-eca3-485f-9cb3-4ef6e53097df">
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/5991445a-9af6-40c9-bc7a-0930e7ed94ac">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17505475</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17430128</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6988af76-7ddf-4a06-acbc-e2a5150be625"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
    <rdfs:label>HDAd-G6Pase</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3176f43d-f85a-4cee-a5c1-f58e7c7885f2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24142275</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607330"/>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/745917b5-f7af-40ca-ae54-d5a92b03241e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d152f2e1-29f9-489d-bcfd-67e5ff08acae">
        <rdfs:label>Abnormal neurodevelopmental profile</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <dc:identifier>HP:0012759</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71aea9fb-5d64-4454-a18f-174158f99aaa"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0003304>p.K148E and p.D210E</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <ddiem:failedToContributeToCondition>c.479C&gt;G p.(Pro160Arg) and c.630C&gt;A p.(Asp210Glu)</ddiem:failedToContributeToCondition>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d40b6f66-a291-462b-a64f-46013bf91666">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High chitotriosidase level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f4eaf68-7f84-4f31-88eb-0616377e6469">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002375</ddiem:url>
    <rdfs:label>hypokinesia</rdfs:label>
    <dc:identifier>HP:0002375</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3648469a-7854-410c-beb3-8238e545dc4b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001744</dc:identifier>
    <rdfs:label>High spleen volume</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/15c60d20-bac5-4fc7-a6d1-f7b8e9632ed8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65b8ad2e-e97d-44b3-8f4e-ec69ee596e89"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
  </obo:DDIEM_0000012>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17a4ca7e-a763-465c-b9db-0267e850244f">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/90a8647e-3cab-40f0-b955-acb4195c2f8c">
        <dc:identifier>DB15146</dc:identifier>
        <rdfs:label>Adrabetadex</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcadaebb-4e8f-4b0f-b9f9-7a364f3d4f86"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB15146</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac427c49-24e5-457c-a7a5-1459de59c3a4"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c482c83e-08ef-4df0-8d5a-ceff9b3b44e2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613839"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c08b243-010b-43c9-ac56-f91554fce697">
        <rdfs:label>Abnormal CSF folate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dbf9a77-6419-4108-bd21-4f554abf72f0">
        <rdfs:label>Abscent 5-MTHF(Abnormal CSF metabolite level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025454*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025454</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b56a480-18db-47c8-8dc9-52dbb06b7184">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040087</dc:identifier>
        <rdfs:label>Low total RBC folate level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/188eca77-05ad-41c8-ae7d-c208caea987d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bone marrow megaloblastic changes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001980</ddiem:url>
        <dc:identifier>HP:0001980</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ecbc3e5-d9d3-40a4-8134-938cb5542d98"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310276</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/234a690c-def0-403f-ae74-6476304ffc3f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low 5-MTHF level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <dc:identifier>HP:0012446</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/57a392d5-a450-4960-80a2-265e4f026d7e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a767426-cac5-4c38-9fab-66fc7b676110">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003737</ddiem:url>
        <rdfs:label>Mitochondrial myopathy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003737</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4b38928-294e-4b29-a40d-a2e2b0f41a37">
        <rdfs:label>Low energy level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003473</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d551cc6f-823e-4316-812f-d4e0bd73960a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a8e2bd8-5b83-422c-9812-2fbc5da2e532">
        <rdfs:label>Homocystinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002156</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002156</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0003304>R266K</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20490928</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c6742721-78e7-4410-91e6-3e2c8e728fd2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a777fa3-48b3-44bb-beb5-f87441f6c537"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <ddiem:failedToContributeToCondition>H65R</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>R125Q</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c0aa3af-4127-4ea5-8d57-f63ea6d27966">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012379*</dc:identifier>
        <rdfs:label>Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aa479e36-2b77-4106-a61c-2f36f3dd56ec">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/450d7c9f-5ac3-4d71-90b2-67b0039fc94c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/29f79d4a-e0c0-4d9a-953a-59ac6a7de2ff"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0259468-8b07-4912-81c9-49408a4913a0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fdc440fe-8cdb-41a3-971e-84d1f5d150f7"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB09043</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09043</ddiem:url>
    <rdfs:label>Albiglutide</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4b86afd2-4729-4ab9-9c7d-f69403ffa591">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9ef854a-4a19-436e-9886-0fef83266e30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:comment>Due to its strong copper chelation capability, a copper salt should be added simultaneously</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07a3e8e1-6513-4173-ad49-7a6083625ca5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:label>Copper storage abnormalities (Copper storage abnormalities)*</rdfs:label>
        <dc:identifier>HP:0010836*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9d1b14f7-9efc-4a17-bba0-69cc36b7cd14">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20803213</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3904230-201f-4f68-8692-620055bed4e4"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39382c68-acec-49f2-9405-e92487476459">
        <rdfs:label>Status epilepticus</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/411</ddiem:iembaseUrl>
        <rdfs:label>MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/281a64eb-af70-464b-ac4b-607d2f081765"/>
        <dc:identifier>https://www.omim.org/entry/203700</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>411</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe2a29dc-ba62-47fb-933b-027955d4ae1d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/82ffdc1a-4a82-46b9-995a-d5c969b768ae">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29260356</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/883f2884-e259-4eae-8d88-5b6cd073ced2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/769bfa37-e1f4-42b3-aa8e-26a0d5df32f2">
        <rdfs:label>Incoordination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002311</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28980151</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ddc215a0-3aeb-4f2a-bbab-6be547615506">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>EEG abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9bbb349-4c10-41f9-a6bb-7815a99b8b6c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:label>neurological dysfunctions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6216e934-761a-4eb8-a42f-ff54a2576888">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal nerve conduction velocity</rdfs:label>
        <dc:identifier>HP:0040129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56a074bf-ec0a-44e2-85c1-026cb2136058">
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0001665</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>chronic diarrhoea</rdfs:label>
        <dc:identifier>MP:0001665</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31115677</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78863421-2873-4007-b6f0-4f0164afecfc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca91bc47-131d-4f74-9dcd-61471113d191"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3ee798bd-3e96-4764-bfb6-c114c6c33413">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cataracts</rdfs:label>
        <dc:identifier>HP:0000518</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a0b045b-3ff0-4a3a-ba10-cac3513d8529"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e68a8c3d-c504-4b26-a459-84056cdeddba">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <rdfs:label>abnormal gait</rdfs:label>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca0db591-56a5-4f12-ae77-a34b27cfad9c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Movement disorder</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25424010</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1533b579-192c-40c4-bb5a-30bec0edbea2">
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d8f8dbd-bdee-4cae-90b6-994075590e4e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Hypotonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ca473f8-2ba6-4344-a885-d683fb4a48b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7776b2c-2087-480f-b815-88862299a965"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608643">
        <ddiem:iembaseAccessionNumber>100</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/608643</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8ad38cd5-46b6-443f-b9ac-751d0637359b"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/100</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/142ae25f-d9c6-4b0a-9300-b91516d63f05">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21788663</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0003304>"m.3460G&gt;A, m.11778G&gt;A, and m.14484T&gt;C"</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00747487</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d903ba5e-33d0-4229-8082-7dc1a86d587d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01495715</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17573650</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02771379</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/434607c1-5465-4a64-9db3-1ef83cb823b5">
        <rdfs:label>Functional loss of vision</rdfs:label>
        <dc:identifier>HP:0000572</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5b0c4c36-8f34-4c48-9b83-8dfd0b7f5526">
        <dc:identifier>HP:0030532</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030532</ddiem:url>
        <rdfs:label>Abnormal visual acuity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001192</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c47d9602-8722-435e-a8e6-8d6f7ed1c2fb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000630</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000630</dc:identifier>
        <rdfs:label>Retinal thickness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/18fd8e00-5115-4513-b441-edba81889c08">
        <dc:identifier>HP:0002171</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002171</ddiem:url>
        <rdfs:label>Gliosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21810891</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6fbb3341-1500-403a-88e8-5141502184a7">
    <rdfs:label>limb hypertonia</rdfs:label>
    <dc:identifier>HP:0002509</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002509</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d98196c3-6421-45d5-bc71-b8d97bba0999">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734130</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a0b045b-3ff0-4a3a-ba10-cac3513d8529"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2def6539-d47b-4a7d-9c77-9ef9ec831a3b">
        <dc:identifier>HP:0000735</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000735</ddiem:url>
        <rdfs:label>Impaired social interaction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ccb6066-3c02-4183-a358-43b0f3931190">
        <dc:identifier>HP:0010819</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010819</ddiem:url>
        <rdfs:label>astatic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613068">
        <rdfs:label>NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/661e9ec4-5cc6-436a-9906-60648fa3c4dc"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/71</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>71</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/613068</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca0db591-56a5-4f12-ae77-a34b27cfad9c"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2cf1a32-e9a0-4f68-aca0-c8f008070a31">
        <rdfs:label>Myoclonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bca2ab94-f5af-40dd-8eb4-d64f748da2df">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc8507d2-1b62-49e6-8056-10ee4d5594d7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/400e07a6-72c6-43af-93aa-5e988c4ead36">
        <rdfs:label>Intellectual disability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001249</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca23dd10-de08-4ade-8f69-0ee1d28c0661"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6dfa2ade-1e07-4f1f-bd8d-490aa79ace77">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002188</ddiem:url>
        <dc:identifier>HP:0002188</dc:identifier>
        <rdfs:label>Delayed CNS mylinaton</rdfs:label>
        <rdfs:comment>The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8c0c6825-79fb-4871-972e-aa90faf605e1"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261640">
        <dc:identifier>https://www.omim.org/entry/261640</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/4</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A</rdfs:label>
        <ddiem:iembaseAccessionNumber>4</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0d7b067c-ef00-4a7d-a71d-9f16837fcc71"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1e9a3afc-1b79-4ec2-86f2-e9ae4735bff2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5c4219f8-7a91-447a-9534-84da40051c57">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eff3198d-974c-472d-ae03-de3ff086856c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b377b4e2-ca1d-4900-93ef-c86a76c4314d">
        <dc:identifier>HP:0002829</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002829</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Arthralgia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1742948d-e751-4939-9107-28d5171ba312"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b84d4a5f-4a2b-470f-9302-c93127780f71">
    <dc:identifier>HP:0012040</dc:identifier>
    <rdfs:label>Corneal Oedema</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012040</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f43decca-da5f-46ae-ad4f-799105c046ce">
    <rdfs:label>Voluntary movement abnormalities(Abnormality of movement)*</rdfs:label>
    <dc:identifier>HP:0100022*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/15011668-6ff0-47db-a625-9b1f3ed3bc3d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3eda2d08-8763-431a-bdb8-542c91f1027e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2b62abd-d784-4c3a-bd83-cb81b05ca784">
        <rdfs:label>Pathological apoptosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27329125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa547026-087d-4840-94dc-490fa9aad2ec">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of ife</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26305041</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcfa4de0-1197-4ad8-a6f6-1e08701f1463"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4506bfb9-93c0-4772-a2eb-02cffc2fc9b9">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025034*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025034</ddiem:url>
        <rdfs:label>erythroid progenitor depletion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e201255c-e9b7-4022-9dd9-97fb94e1714d">
        <rdfs:label>low hb level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26758319</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/94c1c31a-af7a-4eb1-ab64-53f61d4a3fe5">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5102282e-9dc7-4d0a-9ddb-5a6427deff97">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0f4315f-a1d3-4818-9d9c-098f01d53634"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01068</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/162e5d97-a0ad-4b21-b1ea-abe2138ff385"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/283bb79a-cacc-4d22-8656-736712d62c99"/>
        <rdfs:label>Clonazepam</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eaafee4d-1bb5-4279-a75c-73769cba81e6"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5dcac541-9991-4282-9d6e-f8da28d55ca9"/>
        <dc:identifier>DB01068</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/113a7e64-2273-46c4-b90b-141752ea669b"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d13c5c1-3158-4aec-bc78-c0b450efc89c">
        <rdfs:label>Valproic Acid</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ad885d78-507f-45b8-b5cf-a48bd697c9d6"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/40d426f0-5c11-455b-bf8b-046891754c8e"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f878a34-0c22-4c78-81a5-195a02d71902"/>
        <dc:identifier>DB00313</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00313</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e6bae8e-62b8-4647-bdc7-005e2ffe7d87"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/283bb79a-cacc-4d22-8656-736712d62c99"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bfbe905d-40cb-4edf-b8c3-3c9eacb09583"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/94b8625a-56ac-4a21-b636-db141eaabab4"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/871613b4-5f3b-49ab-9130-30cf49b30a1a"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5449f040-fffe-4cbf-b3b5-ce5d5eecaec4">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0a6fe00-83a4-40d1-bd54-cd6da4988c5a"/>
        <dc:identifier>DB01174</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/809e2f72-9cc5-4f39-afa5-eb6bbebf063f"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/283bb79a-cacc-4d22-8656-736712d62c99"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b3fcb10-0689-4a57-8350-a47d3fae3116"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c42cce93-b81c-4c6e-8fee-408466364ded"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3bdcf55b-d521-4935-86c8-3c0fe32d750c"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/082f7657-ae04-4755-9be0-1e8f7b638ffb"/>
        <rdfs:label>Phenobarbital</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01174</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26b92198-829c-4132-964f-2250cd660de3">
        <rdfs:label>Midazolam</rdfs:label>
        <dc:identifier>DB00683</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00683</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/283bb79a-cacc-4d22-8656-736712d62c99"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/51c95db6-fc44-42cf-bc17-ad49d7220117">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/464d03ee-3e83-405e-9fc0-512eb67ff755">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609286"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc76b781-80cc-40f4-b9c1-58956de2647f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Levodopa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fece013a-aaff-4066-9337-65212bc78b55"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e58af4d1-13be-4d16-b4bf-81e7161d774d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30013934</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment></rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d49a0683-803a-4375-bb05-c6b3deef16f5">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12391354</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2c5e4293-33b9-4c37-8cc0-4b632dc79001">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613077"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/39123752-0a87-436c-a5e1-eff5085464bf">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d2cf367-60be-4384-8323-4319c999e4f1"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/157640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b9930e6-7c64-4d8c-9585-ffd43eeea1ba"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0cb2994d-9160-4d4f-9ed0-b7095c7a3ab5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30838265</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f576693b-98be-4820-b431-f073a146f486"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24943079</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/853cbe42-6d30-48f2-bbed-ca7cd86077e7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30941926</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc76b781-80cc-40f4-b9c1-58956de2647f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c6273dc-04f9-4f1c-9435-b459b30e4d8e"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5c057a9-0847-4bd8-82e6-2ccc587a1e6a">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617070"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/47da5cec-9adf-4387-bf75-a10485994d64">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/618098"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c5a311ef-c5fb-4b8a-974d-fb875c46e5bb">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8ed2cc7e-c0b7-4f3c-89ba-d48bb01396d8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca0db591-56a5-4f12-ae77-a34b27cfad9c"/>
        <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia " LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc8507d2-1b62-49e6-8056-10ee4d5594d7"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/819e21f9-8db5-467e-9f5b-2174a1e59a42">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258450"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fc76b781-80cc-40f4-b9c1-58956de2647f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB01235</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3f1763cd-0ed1-4378-8617-8566c9b179ad">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>Abstract</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607483"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/136a5399-751d-4845-8299-ff773caf5c91"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8a0d6df9-9849-4cb7-86ed-16f1bba58114">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/042fca02-077c-4dd8-8163-c82871d5888c"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
        <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d591384f-c4df-4818-8ac7-4df9a98b7078"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19666145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bd07bfa6-0b09-4330-ad3f-37de7c1a06c2">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617069"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24076137</dc:provenance>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d8ae829-961e-4d09-be63-8fce340a6a2a">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609283"/>
        <rdfs:comment>Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12872260</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01235</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f80b7a77-2856-4e3f-91ac-bcbd930b0d6b">
    <obo:RO_0003304>m.8344A &gt; G</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28717435</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0d144282-1466-4386-9fd8-9527db71f696">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16be01ff-3fd6-4e48-9c9e-7bd436658248"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2cf1a32-e9a0-4f68-aca0-c8f008070a31"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/377b244b-64bd-4adf-91f7-84d12ee38880">
    <dc:identifier>DB00213</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0e08eb57-7e79-456e-b17b-7adbea86f605">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a8b87e8b-ec49-4ce6-9790-980e989dee10"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235200"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01524757</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60af17fc-b7df-465b-96b4-08338273bc0c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pantoprazole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00213</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/ac427c49-24e5-457c-a7a5-1459de59c3a4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607625">
        <rdfs:label>NIEMANN-PICK DISEASE, TYPE C2; NPC2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c525900b-cfb8-4763-b057-5f79f279b426"/>
        <dc:identifier>https://www.omim.org/entry/607625</dc:identifier>
        <ddiem:iembaseAccessionNumber>304</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/304</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78757786-f657-433a-80c0-f0c8d5113e7d">
        <dc:identifier>HP:0003107*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/456d2f5c-9fa3-4923-b056-af2b9a607c60">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intraneuronal GSL storage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2aacac2-c760-4ace-907e-42b2927dab13">
        <rdfs:label>Increased free sphingosine accumulation(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17a4ca7e-a763-465c-b9db-0267e850244f"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000015>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220120">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c29acd0-c9ae-4e8e-bd72-ea132330e12b"/>
    <rdfs:label>D-GLYCERIC ACIDURIA</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/220120</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b2c5bca5-635c-4c83-b578-7523c7272b3f">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236795">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-HYDROXYISOBUTYRIC ACIDURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/b9383202-f2bb-47fc-98c4-0a189b6c6f5a"/>
        <dc:identifier>https://www.omim.org/entry/236795</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1f74c2a-4904-4716-a055-48608bf715bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941</dc:identifier>
        <rdfs:label>acidemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>http://eknygos.lsmuni.lt/springer/365/81-92.pdf</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d69bea8f-3c3c-4f64-9f12-856b40d0cba5">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/26f55ff2-7fd3-48e1-8f53-8346e04e9ddb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d23c778d-d2fb-40dc-b987-eb5831180f95"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/114a9d47-b05a-4b91-b65c-8e338e209fb3"/>
    <dc:provenance>http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>Abstract</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e72c250-f772-4f5d-ae52-41c418e138e3">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030872</ddiem:url>
    <dc:identifier>HP:0030872</dc:identifier>
    <rdfs:label>Left ventricle dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e24e0fb6-d494-4363-9b19-9e7b5f1dde43">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5321e651-2811-4c2b-91e3-79b8becdb479">
        <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5422236d-70b6-4ebd-acd8-59501bd2bcda"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7b166c28-e358-40cc-a46b-f70a0079887c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/722bb76e-4fee-49c2-9c84-ebc5d43a3ae0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11449034</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Haloperidol</rdfs:label>
    <dc:identifier>DB00502</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00502</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f007d250-961c-40e3-9a36-46a96156fd43">
    <dc:identifier>DB01257</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/47779477-f68e-4046-8618-4c34b04237e3">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300818"/>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae1cae6d-8381-4769-a130-460397d6b1bf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28516949</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234b8a3f-d128-4ced-943d-87bff41c2ef5"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/63aca977-7e51-4aea-acff-aff1b0534721">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/234b8a3f-d128-4ced-943d-87bff41c2ef5"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4308b98c-3577-4fe5-a264-1497b440e66d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e43d1abc-8d23-482e-8c77-a9c67974a287"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9fc07f-1f33-4ed3-ba94-b1b5252f0f90"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250940"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a651277e-49a1-4432-8103-f2991d0773db"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b18bb34-0a07-4967-8796-15a488fa4ee3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01257</ddiem:url>
    <rdfs:label>Eculizumab</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dcadaebb-4e8f-4b0f-b9f9-7a364f3d4f86">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26027824</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c68793e1-b8c9-418d-b446-6978e77fe994">
        <rdfs:label>Reduced life span (Mortality)*</rdfs:label>
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1fadc37-8b5e-4994-988a-65734d49897a">
        <rdfs:label>Neurodegeneration</rdfs:label>
        <dc:identifier>HP:0002180</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46e9a579-9f7d-4333-9f3a-b5c5a52a8d8c">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007010</dc:identifier>
        <rdfs:label>Fine motor impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4976393f-0dcf-46a8-b880-75214a2ca57c">
        <rdfs:label>Rapid progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52073ba5-d35e-457c-b0d8-a0dcdcb61a7d">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
        <rdfs:label>Cholesterol sequestration (Abnormality of cholesterol metabolism)*</rdfs:label>
        <dc:identifier>HP:0003107*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29429782</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/17a4ca7e-a763-465c-b9db-0267e850244f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c2aacac2-c760-4ace-907e-42b2927dab13"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/432f3b22-81f8-4880-9aba-1678561c5f2d">
        <rdfs:label>Liver injury</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001392</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001392</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/883f2884-e259-4eae-8d88-5b6cd073ced2"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/456d2f5c-9fa3-4923-b056-af2b9a607c60"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bee295e7-202a-4802-837e-0dfe5c7e48e3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002015</dc:identifier>
        <rdfs:label>Poor swallowing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c4cfb54d-f829-41e0-8d92-2b4746cbb74e">
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc32989f-49db-469b-bfc5-e51a3f2f789a">
        <rdfs:label>Granulocytopenia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001913</ddiem:url>
        <dc:identifier>HP:0001913</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71aea9fb-5d64-4454-a18f-174158f99aaa"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a651277e-49a1-4432-8103-f2991d0773db">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002907</dc:identifier>
        <rdfs:label>Microhematuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002907</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ecbc3e5-d9d3-40a4-8134-938cb5542d98"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/384f5ac9-8619-4220-8264-2794558027e7"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae9fc07f-1f33-4ed3-ba94-b1b5252f0f90">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001873</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>Thrombocytopenia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250940">
        <ddiem:iembaseAccessionNumber>30</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/250940</dc:identifier>
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/94d18fbb-3836-4e39-9857-6e05e6fa4800"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/30</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606777">
    <rdfs:label>GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1</rdfs:label>
    <ddiem:iembaseAccessionNumber>480</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/606777</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/480</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8e413a23-049b-4ee7-93a4-c9a55eac954c"/>
    <rdfs:comment>The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract</rdfs:comment>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d2bb9ab-8522-4199-a576-7f761725ada8">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2eac204c-00e7-4269-8e05-b2f772f8e8b6"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e83104c1-d8ec-470e-994f-c94fbb0f0dc8">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7aedfc28-edc6-4623-9f8e-ab846ba99782">
        <rdfs:label>cerebral folate depletion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012446</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a063df6e-e58f-4ed1-922e-3b06763d6611">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04931</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cdf50ff4-7f39-4182-b400-a1675865c887">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/573613b5-a103-4b96-98d5-0034a6fd336e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ba6c32e-a625-4c93-a9d0-0802a1f91bd4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95694d82-ee2d-48b7-b8a4-3883bfa93404"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28003770</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB04931</dc:identifier>
    <rdfs:label>Afamelanotide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41304f63-6c0b-4cc8-bf08-2b058540bd55">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0009830</dc:identifier>
    <rdfs:label>neuropathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df2c5576-0263-4c9c-afcc-cdc08a108bad">
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/848e82ca-5707-40b9-8650-8a89d22cfb54">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:label>Pruritus</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f1e691c-d41d-40f1-8b2f-daa27af6515a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdb0ff84-3ead-45ec-9d0c-984365ce8d03">
        <rdfs:label>Ill-being (Constitutional symptoms)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf284bb9-3a68-4d1d-87b3-53d57bfc29b6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012029</dc:identifier>
        <rdfs:label>Abnormal urinary steroids levels(Abnormality of urine hormone level)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012029</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67be7fe8-9d64-4dbc-9dc9-0747b69dc8a2">
        <dc:identifier>HP:0012030</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012030</ddiem:url>
        <rdfs:label>Abnormal urinary steroid level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/011fead1-d643-4f8b-b19e-5cad72196a93">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffa7346d-1705-43f4-b3b5-79ecb8914d20"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0475b22-d156-4613-8d59-9572a0b206c1"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a46c556-7026-4220-857f-a5bb821ae55e">
    <dc:identifier>DB00147</dc:identifier>
    <rdfs:label>Pyridoxal</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00147</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/80efdaef-a476-4f01-8530-09dc689181e1">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64fb59ea-cfba-4daa-b7e1-b7b138e904aa"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b121e446-9a8e-4288-9d06-46987eeb968f"/>
        <dc:provenance>"ENB-0040</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9ca606f-c5c0-41b0-86b3-76cf67f43cb4">
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1cf014d-2f2d-4f36-8226-bc97d2425974"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8301428</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ede574bb-fcfa-4f63-adf0-409fedfa8931">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f74ae55-649c-41f6-9f5d-f82b6760e608">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c204e8ca-a9f5-4c13-a81a-ef08ac03362b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3dfc7967-fbb4-4c57-a1e6-ef8821cb1349">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012048</ddiem:url>
        <dc:identifier>HP:0012048</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>oromandibular dystonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/233910">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/3</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/233910</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8edda9be-9596-4cca-93cd-8b2fc2bb8df0"/>
        <ddiem:iembaseAccessionNumber>3</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1aea4fce-61e8-4a14-aff2-7ad087d958c8">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c8aa410-869b-4d1d-ad27-e367302f5810">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a3b96a4-39b7-455b-af28-dd8438e2a9f3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f29ca0b1-b53b-46ed-b0d5-62e2397d9f34">
    <rdfs:label>Malnutrition</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004395</ddiem:url>
    <dc:identifier>HP:0004395</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4e420c13-322a-45d2-839f-3fad17bc5abe">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7cc8e4b-ab5f-4727-b607-9ddd2b1c46ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ecf01806-b5b0-478c-a709-67f2621697e3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0fe3b349-e3f5-4c2f-8375-4d7b992c2dd2"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f55ff2-7fd3-48e1-8f53-8346e04e9ddb"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5337dfcb-ac7e-4504-86ab-7c656ca5fac2">
    <rdfs:label>Tocofersolan</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11635</ddiem:url>
    <dc:identifier>DB11635</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2eb17554-6d9d-4618-9471-ef8ebe1c1e66">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6b339151-b16e-485d-9df1-a6b46ee17ce3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/77701cd3-55f9-4834-9c69-6f5351a980fa"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27520363</dc:provenance>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5f74f1d-524c-4e1d-b59a-f97c6b68a6ac">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a60b350c-8125-45db-9b16-3f65a1ac4bbf">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/906f2e50-25a6-418f-be43-3592b917ffbb"/>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_84293</ddiem:url>
        <dc:identifier>CHEBI_84293</dc:identifier>
        <rdfs:label>dimethyldithiocarbamic acid anion</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/48c643e1-7436-4def-b27d-f5ca559c0a7b">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f9b110f-da2b-48ed-91e1-5a16c27d9670">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0003678*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>development of extra-renal pathologies ( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8991875-181c-4346-9465-001733519ba0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <rdfs:label>Photophobia</rdfs:label>
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/972a3cbe-d5f1-47d2-9a13-3b82000cf7cd">
        <rdfs:label>Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism)</rdfs:label>
        <dc:identifier>HP:0010918*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6ec9603a-d882-4875-b96e-123b9d193e51">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000531</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000531</dc:identifier>
        <rdfs:label>corneal crystals</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bac5ce7b-453c-4381-8cd9-9c08f12a64aa">
        <dc:identifier>HP:0001510</dc:identifier>
        <rdfs:label>Delayed growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7d7af7ce-0c76-4479-8ee4-46a27d3d5442">
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0000821</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
        <rdfs:label>hypothyroidism</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2db080cc-f14f-4b9e-9fa4-3c93dda7df5a">
        <rdfs:label>glomerular damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000095</ddiem:url>
        <dc:identifier>HP:0000095*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/afd6de93-9a9d-4473-bd39-488f3a6ce294">
        <rdfs:label>cystine accumulation in muscle parenchyma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003358</ddiem:url>
        <rdfs:comment>lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications</rdfs:comment>
        <dc:identifier>HP:0003358</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9758713</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/72cb5eb8-e5e6-4040-a76a-3d9140a1947c">
        <rdfs:label>renal function declines</rdfs:label>
        <dc:identifier>HP:0012622</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012622</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6238d06c-59c6-4920-998d-a85eb77ce8c7">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>shorter life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da733d5a-5e32-47fb-8413-b4eb9383b767"/>
    <rdfs:comment>Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2719a70-5b4b-49f3-a73f-60b4ba25d95d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Kidney disease progression ( Progressive disorder)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/221212ee-ee7a-4d2b-a636-bd4c35dda288">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Reduction of WBC cystine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11001803</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23416144</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609056">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/67ccf7cb-6bbb-431e-a39e-5dcffb82dc62"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/360</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>360</ddiem:iembaseAccessionNumber>
    <rdfs:label>SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/609056</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9baff459-00e6-40c0-995e-f3b846533a75">
    <rdfs:label>generalized tonic-clonic seizure</rdfs:label>
    <dc:identifier>HP:0002069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f6424dc-6f68-462a-bf33-a7ff3927da91">
    <rdfs:label>Elevated liver enzyme levels</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <dc:identifier>HP:0002910</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f2dc773a-6fe6-4864-b6ae-effb64b53a36">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8">
        <rdfs:label>Disease progression (Rapidly progressive)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc460426-452f-4388-8b9e-6eba6440a223">
        <rdfs:label>Elevated blood arginine levels( Abnorality in arginie metabolism)*</rdfs:label>
        <dc:identifier>HP:0010909*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010909</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7f6af22e-946f-4804-b1d1-b6ee396e7118">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2896e753-4ce9-4e08-b110-07d78a668351"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03378531</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac854eb0-8429-4f04-a7c7-eb3318029fdc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Unstable neurological function (Abnormality of the nervous system)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26358771</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/207800">
        <ddiem:iembaseAccessionNumber>16</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e4831891-8893-4906-9801-eda35c5807f4"/>
        <rdfs:label>ARGININEMIA</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/16</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/207800</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb6b1f90-ad1f-426e-8638-b425d2cb8f10">
    <rdfs:label>Brexanolone</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/383d89fc-861e-47cd-a3d4-350b30eda070">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c40f1a0-99ff-4f02-9a8f-dd1c7c85a5a9"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c30d238-9a28-4695-98dc-324dc03e21fc"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af98e9cd-520a-46f3-88ff-741484fb07f0"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <dc:provenance>https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11859</ddiem:url>
    <dc:identifier>DB11859</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/c4f74921-ad14-49b0-869f-e7f2fabcecde">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7b5007e-0cc7-4966-80b6-f875517ea852"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/257220"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7861588b-9bce-4c84-b7b1-c2ce8564ebd8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/87b9261a-2c9b-4239-9d77-c4927b240d52"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c30d238-9a28-4695-98dc-324dc03e21fc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208706</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/48483bb9-ad37-4659-9715-9a39e3cf0b08">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/163409dd-b89b-4e27-8dbe-0a87bba904d0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2348be2f-3d7d-40a7-9898-9ec0429d06f0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d782dbb8-a320-4b7e-b0fe-5d5db6e69079">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004356*</dc:identifier>
        <rdfs:label>Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/739324f5-6f5a-4d7d-ada8-7641bcd188a0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/09231138-bcb0-4b2d-b52f-6bba0e71b523">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cb6faedf-7a16-4d43-88fd-d2d8d378603c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1ec0da-8258-4d36-8351-cd7cee607aea">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>UDP-glucuronosyltransferase gene defect</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10468611</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8011d37f-af0b-43d6-9dba-11645d0effc0">
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:label>Growth retardation</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/04b137c4-11b9-41de-a658-6afc945a0cb2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47d30ba2-7f14-4a54-982c-325cd0dac7e5">
        <dc:identifier>HP:0000982</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Keratoderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10738634</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/860e76e1-5308-4183-a9b3-13a01b92eb1e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/255224b3-3747-4bb0-9207-d260bf5cfc60"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7badab6f-62a8-47ae-bd89-c52e1142cee2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000166</ddiem:url>
        <dc:identifier>HP:0000166</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Aggressive periodontitis(Sever periodontitis)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a2479b43-8244-4634-bd22-212b6ed7d902">
    <dc:identifier>HP:0011123</dc:identifier>
    <rdfs:label>skin inflammation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d38e247c-7920-40a3-8388-0b72ab7aa19c">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/341eca2c-a69a-4dea-a1e6-62636c0bd1f0">
        <rdfs:comment>Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9718357</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d4408d6-6b4f-459f-87cc-c267fb8da88c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2cb28a4f-2c7f-4fd2-b8a6-16a72f680727"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d588ea7e-31ea-48ce-a262-4b826c36eaa8">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74e1a091-80d0-4075-bca0-bd12fb7d9ef0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
        <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00126</ddiem:url>
    <rdfs:label>Ascorbic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3a3f7197-4426-4b6a-9d17-0f6cf1cdb2c4">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41cc2333-0aec-4b95-acba-21644bc70aaa"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26226126</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14206878</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9ca606f-c5c0-41b0-86b3-76cf67f43cb4"/>
    <dc:identifier>DB00126</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f8dd85d0-c877-4cec-8a21-fbc9e99c4760">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1cf014d-2f2d-4f36-8226-bc97d2425974"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d6d30b3-0ad7-4209-9a4c-23637cad6ea1"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26984560</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6417016e-f13d-489d-a70b-c5831f829a80">
    <rdfs:label>Flumazenil</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/5510dd97-3428-4b7e-995b-a75bed2e4c1d">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6de2b764-00b7-4854-a3ce-17f8a6da3e53"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609a182-f092-4ef0-b8ca-b33b7d7a8eed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9dec5755-7da4-4b76-89e0-5f96df87bfa8"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71aea9fb-5d64-4454-a18f-174158f99aaa"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6c533026-4dc0-4d16-8370-aa866b0f4c9f"/>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d591384f-c4df-4818-8ac7-4df9a98b7078"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/43f5dbba-d195-47cc-8107-63b2a7f5c78b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28411234</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/312f4ed0-814d-4ab8-9636-b1d64c9831fa"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <dc:identifier>DB01205</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01205</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/921eb4a0-0c08-4596-ac58-6269759fe498">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d747cc32-4b85-4818-b27d-9e237ae62bbd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cardiomyopathy</rdfs:label>
        <dc:identifier>HP:0001638</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/636acdbe-be6a-4d2f-b74f-cb8c52543ba9">
        <rdfs:label>low energetic state of heart(Abnormality of cardiovascular system physiology)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011025*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0f02d5c4-9f46-4d85-a773-b093957106f6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ae1d41a0-3f3e-4623-b17e-d56e3d4e3b5f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1234bdd-43e3-4293-8041-8f095bf33390">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
        <rdfs:label>Abnormal blood levels of  fatty acids</rdfs:label>
        <dc:identifier>HP:0004359</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa44fa8e-65b3-49b9-9ec7-d1a31e818c4a">
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:label>Increased creatine kinase activity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfca4ad3-8ac7-4856-8112-f1373535740c">
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>abnormal blood levels of ketone bodies</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cda87ff2-2d1f-4914-83eb-1c7c6f81cdfb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003236</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>high creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66147585-4714-48c9-8656-2135549d6a0a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>low energetic state of skeletal muscle</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011804</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b54a51a2-09a0-41e4-93bb-620ef24682e5">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300971">
        <dc:identifier>https://www.omim.org/entry/300971</dc:identifier>
        <rdfs:label>BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2ee1f90-ceca-4ed9-93e0-72323846082d"/>
        <rdfs:comment>Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cfdc3989-1a1c-4852-9751-b5400ca3ea11"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0d185a9e-2dd5-45d6-bd9a-068792e3fb83">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666c257f-cd01-43e5-b26e-a716fde2e56a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Recurrent infection</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15098233</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/05292c5f-bf6f-4623-8cf3-1015cf1cd217">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/015fff50-30c1-471b-98ae-a082f1a5f295"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a546c4f6-d18d-40a2-bef6-5ec1a1ed8fe0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f02e55d-f90e-4064-a4e1-91312dfc69df">
    <rdfs:label>Nonepileptic paroxysmal abnormalities</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e0bf5e5a-19c2-4b1a-b9aa-afbd24e09a58">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613490">
        <dc:identifier>https://www.omim.org/entry/613490</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ba29f016-e021-4a3b-b573-792f16cffb27"/>
        <rdfs:label>ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e6b00a3d-5592-409d-bcba-1d1749be2fd3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5f6cf3fc-7ad9-453d-bc4a-338ce27b8ad9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/666c257f-cd01-43e5-b26e-a716fde2e56a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39baf4a4-b67e-4d5f-9ef5-60b60787b9cb">
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:label>Decreased lung function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c983ed73-5d37-4a14-9d5d-c1a80d3c0171">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Progressive emphysema</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002097</ddiem:url>
        <dc:identifier>HP:0002097</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/11a86e20-bed2-4fed-a181-ab543fdd1831">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ba9e5a8-f9de-4050-9264-319d3e3fa95b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614080">
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/614080</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1145</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1145</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4844658c-9a38-4b7e-9139-926744f0baa7"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/69f4dfc0-50b6-4cc0-84da-14e57bec1077">
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0005542">
        <dc:identifier>EC0:0005542</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0005542</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/42470b25-5d05-41b1-b48d-25397fca0ba5"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609242">
        <ddiem:iembaseAccessionNumber>263</ddiem:iembaseAccessionNumber>
        <rdfs:label>KANZAKI DISEASE</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/609242</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4c592a34-cfe2-4fa3-8861-69d491b10d80"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/263</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7c92036c-566b-4939-a711-49d570eac29c">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f921eb0d-eeb2-4ab7-9e05-73e7c404f192">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6ca722fe-5021-4dbe-847d-643432808790"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acfb2bfb-8747-423d-94f7-ff86d50381d0">
        <rdfs:label>Muscle abnormality related to mitochondrial dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003800</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003800</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03432871</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606175">
    <dc:identifier>https://www.omim.org/entry/606175</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/770a217c-46ed-416b-aaf3-ed16e1922c38"/>
    <ddiem:iembaseAccessionNumber>671</ddiem:iembaseAccessionNumber>
    <rdfs:label>CARNITINE ACETYLTRANSFERASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/671</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/158a81a1-721c-4416-81a6-118f75f5ce58">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25173351</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d1803d6-d582-4df3-8f0c-f4fd84dc6d6b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/64671cbc-8647-4b9a-aeb6-dd1e02e4fbbf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/323e12c8-b52e-4e1f-802d-70e417ca7be1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000155</ddiem:url>
        <rdfs:label>Oral ulceration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9683d038-53a6-4547-b072-8efb19bdf42d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pain</rdfs:label>
        <dc:identifier>HP:0012531</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012531</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aafd563-03aa-4b9b-8f24-5b52d4403ba2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
        <dc:identifier>HP:0001945</dc:identifier>
        <rdfs:label>Fever</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30225156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7783847c-7672-45f9-8db8-bce3c71138cd">
        <dc:identifier>HP:0012647</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012647</ddiem:url>
        <rdfs:label>Abnormal inflammatory response</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6c96e808-8611-4987-84cf-0c5661731256">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1378a8ca-865f-46b6-b682-4743072704bf">
    <dc:identifier>HP:0008344</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
    <rdfs:comment>Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.</rdfs:comment>
    <rdfs:label>Branched-chain amino acid accumulation</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ee507423-9956-41d3-8658-fa59cbe3edfc">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9fe8e71-6110-4e72-8642-fc847f42f22e"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d8f8dbd-bdee-4cae-90b6-994075590e4e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2334bbe7-23ef-4c95-ad2a-8a607c67d9d8">
        <rdfs:label>diarrhea</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002014</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002014</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47568902-abfe-4e78-a842-7d528f856f8a">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003219</ddiem:url>
        <rdfs:label>high EMA levels</rdfs:label>
        <dc:identifier>HP:0003219</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20657580</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96b8c5b5-9b5d-4a19-99a3-9fbbac9fcaf9">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/f1bb7720-028e-42a0-a701-629b8bc00e81">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac7f8c1f-8862-4d6e-a751-5f5fa6ca6499"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03570931</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d859a264-d440-4026-9725-35734cdeb214"/>
        <dc:provenance>http://n.neurology.org/content/90/15_Supplement/P3.327</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee9272c6-2940-459e-a51e-56ccefe1c6e3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8fae3ac-aa44-4367-a3c1-2694c94411c9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <rdfs:comment>The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/03b10ead-9b5b-497b-b997-9afdb94dd06e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56d050e8-a35a-4f4f-9ff9-f0605c15537b"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>RT001 (11,11-di-deutero-linoleic acid ethyl ester)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261100">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/990c80cf-5204-4baa-a23b-c3040217bce6"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d8520402-b555-41d5-94a3-922f600c4e47"/>
    <ddiem:iembaseAccessionNumber>83</ddiem:iembaseAccessionNumber>
    <rdfs:label>MEGALOBLASTIC ANEMIA 1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/261100</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/83</ddiem:iembaseUrl>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3b26ceaa-76fc-4a13-b3fe-1e06f727d94f">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/81d8be46-bd18-4be9-b0d5-32eb9e251f80">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b199fed3-9d37-460a-bb69-0777e4c3926d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d8a61c4-f31b-4e0f-9548-572d4a7e0d17">
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>Low mean hemoglobin level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d9f9d7c0-0471-4ac4-89d8-047daa282df6">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ac6f019-2738-4d2a-9717-737de462fbbc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/daf77a87-f8ea-494c-a974-4654dafab894">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
        <rdfs:label>periodic fever</rdfs:label>
        <dc:identifier>HP:0001954</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>compound V377I and I126T mutations</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3725c103-a9eb-4cc7-911c-abef6ca07e1d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c97f7be8-8d63-4c3e-b076-0a900f8d6928"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18839211</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3373bc80-3e51-49b6-99b2-10ba6a4b29ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b300ce9f-471f-4c5d-93e8-57d7f878a4c9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1f9550e0-f262-4d4a-bbb8-f5f184089707">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01751802</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/239db986-2216-46fb-9418-a45b29c75d50">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
        <dc:identifier>HP:0100716</dc:identifier>
        <rdfs:label>Self-injurious Behavior</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2e4a86b9-1054-49d3-9851-845c8c5b8240">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28745b0f-be91-470e-b876-986fdc1a0b98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/269920">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/267</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/269920</dc:identifier>
    <rdfs:label>INFANTILE SIALIC ACID STORAGE DISEASE; ISSD</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/11e5e39d-c9ee-4d45-ba9b-c362d3ad790d"/>
    <ddiem:iembaseAccessionNumber>267</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9852323-e37a-46b2-b640-7cc7968f06e3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0a4101c-c26f-45ac-b7ed-d1db36e95e21">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/faaa6c9f-edac-4ff4-99ee-8ab5ed57b33a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/269920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92ea3aac-6817-409b-8569-821ee6a65e75">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e588a298-b777-4ed8-b72d-2d0b5efb3841">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006*</dc:identifier>
        <rdfs:label>Low life span (Mortality)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f378c12-62c4-40c8-998e-a4b3e0a4cb18">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44f02a50-267a-4956-af36-5939c7031a14"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30127521</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/44e645ca-bcc9-49e8-bc39-aeec26121869">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13044560</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/375935</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7b7d029-c4d6-4a26-9f94-75a23199a1ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55c68595-123e-4da3-89ee-46cc6c0c0742"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30669644</dc:provenance>
    <rdfs:comment>Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4929571</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bab9c258-d6d9-49a3-aadf-9e8db40e6f7e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
        <rdfs:label>Dermatitis</rdfs:label>
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/eebcdf2d-38a3-4919-b71d-e9037668f169">
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af07731e-d8ae-4fee-9605-7e4d0da10cf9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma branched chain amino acids</rdfs:label>
        <dc:identifier>HP:0008344</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008344</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0166432812001830</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/248600">
        <ddiem:iembaseAccessionNumber>1252</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/acb4c1bd-685b-4bbf-a48c-43b79439e077"/>
        <dc:identifier>https://www.omim.org/entry/248600</dc:identifier>
        <rdfs:comment>In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.</rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1252</ddiem:iembaseUrl>
        <rdfs:label>MAPLE SYRUP URINE DISEASE; MSUD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/057ade4d-f98a-4ffc-b14e-82e95762a8ff">
        <rdfs:label>High plasma branched chain keto acids</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b817ee35-93cd-4ddd-bd7f-a01a072fd78c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/502c68e5-5ed7-4b0b-992d-5960528527f6">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003434</ddiem:url>
    <dc:identifier>HP:0003434</dc:identifier>
    <rdfs:label>Progressive ataxic neuropathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/42dff221-d191-4ad4-b55d-6c8cca1c3ef1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfc0d038-cef2-4312-a689-24d814d71dd5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2d07c692-ee69-47cb-931e-7066577f8356"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ab84f039-9981-4409-abae-ea8c6c859d98"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21354122</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73187ef9-a18b-471b-a451-59231e767b3e">
        <rdfs:label>Atherogenic dyslipidemia(Dyslipidemia)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/d7cf58ca-8527-4fae-b5bb-f79a248e8e72">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a170d33-82ae-4578-be5a-94491050baea">
        <rdfs:label>High VLDL-triglycerides</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003362</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb4c5806-deb4-4182-82ec-d7dcdbe3e926"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9494790-1cb2-4e6a-bf33-f54ba0aea29f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1894760</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5679950</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30367039-6958-42fb-b0ab-765d72c8bbec">
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-C</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18001312</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e04c8ebd-ae6f-4677-aed8-23f904f7d53a">
        <dc:identifier>HP:0003141</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated LDL-C level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/389217ed-dbc9-4ed9-b45d-2db789fe7d01">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High total plasma cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7ecb4f36-123d-4e10-84ac-913f728b559b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25734254</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29044799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00025883</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd308c67-7663-4d2e-82e4-436c6d7a8853">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040300</ddiem:url>
        <rdfs:label>abnormal free fatty acid levels</rdfs:label>
        <dc:identifier>HP:0040300</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/339f99a9-a1f1-44c5-87cb-b39f6e5e2bc3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000287</ddiem:url>
        <dc:identifier>HP:0000287</dc:identifier>
        <rdfs:label>high facial soft tissue volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26584826</dc:provenance>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/870007ab-0075-49fc-917b-263f7ea0f2b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/547c211f-9044-43fe-b825-9b100a5dec78"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fdc440fe-8cdb-41a3-971e-84d1f5d150f7">
        <dc:identifier>HP:0040217</dc:identifier>
        <rdfs:label>high  HbA1c levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040217</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0259468-8b07-4912-81c9-49408a4913a0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0013277</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013277</ddiem:url>
        <rdfs:label>abnormal fasting glucose</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28993984</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efe48826-7fc4-4e52-a435-0fc78f3e91d6">
    <dc:identifier>HP:0001889</dc:identifier>
    <rdfs:label>Megalobalstic anaemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001889</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0b0a001-d170-4edf-80bf-9034af5108a7">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e399e929-713b-4ca5-b536-3d878646bd04">
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca23dd10-de08-4ade-8f69-0ee1d28c0661"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5618b2d-19ae-4e75-b2ce-33f0b833cd34"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a18d40fe-0986-4ef0-bcf8-c74198c17811"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB00360</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/d80e7bec-e212-40e5-b77b-bf7d3dec1b9b">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7110811</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8433887</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b"/>
        <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a5044f5-0832-46ab-8a1b-e95c275e8671"/>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/8d34a749-cfa2-48f5-b8b9-4c9142901d12">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9667588</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205003057</dc:provenance>
        <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eb2e18c6-5bed-418d-bcd9-2d0fb0560fbb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/1b4e3202-9381-4dbc-b82a-891bc2284c82">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9585615</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca23dd10-de08-4ade-8f69-0ee1d28c0661"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9760199</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9ad1934-8b8c-49a1-9bd6-0ae9dbbeb830"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0d298a5-d565-400a-a47f-58ba42db41bb"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/187bbb2e-6080-43a4-b131-2fabcbe8f858"/>
        <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/264070"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/81613ebf-1eaa-4e32-ab7c-6052ece3d39a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20971365</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022347699701381</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca23dd10-de08-4ade-8f69-0ee1d28c0661"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0003304>P407S,A373T,R241C</obo:RO_0003304>
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <ddiem:failedToContributeToCondition>Homozygotes of R252W ,Homozygotes of IVS4-1G→A ,Homozygotes of R413P</ddiem:failedToContributeToCondition>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01977820</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/98101df1-9126-4914-9f28-a71cae8fc2be">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
        <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a73368a9-f9ba-4bc1-97ba-83efa36a51fd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00935753</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Sapropterin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00360</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c10d36cf-c1c5-42a7-84eb-6b6225869944">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/245900">
        <ddiem:iembaseAccessionNumber>380</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/245900</dc:identifier>
        <rdfs:label>LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/380</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec7f2a5c-5fe5-44a6-b378-b8bbe2921cfe"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bbb04ad0-e1a6-451b-b623-1580209a36cc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b38d3186-530c-4999-8656-39e94ca1d001"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a62b1355-f983-4de9-8be2-afe2dfef5741">
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>Oedema</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/72534857-6c28-44f1-ad9f-df814d2cb78b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/66eda23f-d169-422a-8ae5-b5aef85e3816">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67f2cfd0-7556-4e27-963a-f3657f73496c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d52fb4f8-c5cd-4a7a-ade4-5d844e7fb862"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5cbb29c2-f6c6-4a77-b907-29c525528a06"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b83be83d-f995-4fe8-9473-feda8cd760c8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>anaemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/312f4ed0-814d-4ab8-9636-b1d64c9831fa">
    <dc:identifier>HP:0100786</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hypersomnolence</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a2f7a461-3c8b-44a7-859e-5c122d5cabeb">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55fb101d-1a35-4d78-a3b5-82b174660ec1">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b69427ed-84dd-4702-b4cb-25ec56e4bbd7"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14367b21-9a18-4909-8d49-7dc958e0d679"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24636183</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00175</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00175</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0da59287-ccab-4c9d-abd7-ba9037427a63">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9826fd07-d2d3-4408-b039-569331b67f83"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14367b21-9a18-4909-8d49-7dc958e0d679"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/840e1ef6-8299-42b5-85a5-794bcecc6775"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41da0e94-7db2-41a2-b4ba-166b79b25dd9"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
        <obo:RO_0003304>R219K</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
        <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24854628</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT00458055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0e171e1-b337-4ad7-8750-f45de6193384"/>
    <rdfs:label>Pravastatin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615511">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6e1ee623-fe3a-4542-b0d7-8378cf0c1301"/>
    <rdfs:label>MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/615511</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a698388c-e2e9-412c-a286-b287cd950660">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum bilirubin level</rdfs:label>
    <dc:identifier>HP:0002904</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/441b1e41-d576-4db2-baed-23bfee14441c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3954973</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f634ca6-ce4f-48bb-8eed-8f96f1543440">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008897</ddiem:url>
        <dc:identifier>HP:0008897</dc:identifier>
        <rdfs:label>Growth impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/1fad1424-9bdc-43c6-88e4-7ce41662981d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb0ab9fd-8e66-4f2b-84a0-cfc84a53b81b">
        <dc:identifier>HP:0012535*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8e0aa44e-8d03-4605-90dd-c8514998f76c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalties</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c29288c7-4dfe-400e-88b8-4abd76107ad6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low brain copper levels (Abnormal copper levels)*</rdfs:label>
        <dc:identifier>HP:0010836*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2e386b6-0a77-4720-b6df-0edc6699f5f8">
        <rdfs:label>Abnormal growth</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001507</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a18d40fe-0986-4ef0-bcf8-c74198c17811">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <rdfs:label>Behavioral abnormality</rdfs:label>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36ec7556-0586-4afd-a47f-13278ff7f961">
        <dc:identifier>HP:0003287*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <rdfs:label>Brain mitochondrial abnormalities (Mitochondrial dysfunction)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d2123fe9-eed5-45dc-9740-542e0279ae69">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e5351f1d-6abd-448c-8817-6089fc56fa80"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e6bae8e-62b8-4647-bdc7-005e2ffe7d87">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25455802</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25762569</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03112889</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15df652e-b287-43a6-a6be-8f9381c566e1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2437e3c-4048-4e33-95f6-21f46ef73020">
    <rdfs:label>High liver triglyceride level(hyperlipidemia)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003077</ddiem:url>
    <dc:identifier>HP:0003077*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1b9a7f34-ba55-4ff5-8fb5-9e66b9c60f1d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/656ecd0e-09c4-4f2e-8f17-ae0d2fa52bf2">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Self-injurious behaviour</rdfs:label>
        <dc:identifier>HP:0100716</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100716</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24055166</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38f0972d-505c-4742-b70e-a26fab76d71a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16906475</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24001191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99cd2b8a-fc39-4afd-9422-59a406d9e310"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a7aef978-2f92-4759-99f0-1f9424b40e27">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa6a5fb-f153-405d-bd9e-4b99317b5411"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee9272c6-2940-459e-a51e-56ccefe1c6e3"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d8f8dbd-bdee-4cae-90b6-994075590e4e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a7c49e4-6222-476e-9c9c-378a42e16a93">
        <dc:identifier>HP:0010553</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Oculogyric crisis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f43decca-da5f-46ae-ad4f-799105c046ce"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca882d0e-534c-485c-b26f-b6977fedd67f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0d322b4d-d115-47d5-b792-02140cac1735"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/add205c8-ade9-4d94-bdcd-946b7192fa13">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9415ba47-e341-4712-857f-af4607967df6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7e188f77-322e-4dd7-b6d7-01dfc1b7a4c5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d5e3c87-811d-47f4-988e-f980c5608af2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21981352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4ba6c32e-a625-4c93-a9d0-0802a1f91bd4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a65ccb64-8493-4fe1-997e-785808083843">
        <dc:identifier>HP:0007479*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007479</ddiem:url>
        <rdfs:label>Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d2e4bed-5f71-461b-9c84-5a1d87aeffd0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05c7c052-a969-4be2-8668-714f62d2a6d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd909f96-3aa2-4890-a64d-75a5922e13a1">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001019</ddiem:url>
        <dc:identifier>HP:0001019</dc:identifier>
        <rdfs:label>Erythroderma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28979034</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4f0ec0c-234f-4842-80fb-40598871870b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189*</dc:identifier>
        <rdfs:label>Diffuse scaling(Skin Scaling)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/275630">
        <ddiem:iembaseAccessionNumber>753</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/753</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/275630</dc:identifier>
        <rdfs:label>CHANARIN-DORFMAN SYNDROME; CDS</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1f200d5b-81a5-4d9f-b972-5d23714ef526"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/202175bf-0906-4069-a706-fdba70615da6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008064</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0008064</dc:identifier>
        <rdfs:label>Ichthyosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/56d9a815-62c5-4fa6-9389-462b60af4526">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd6f6cb5-b8ab-4441-b511-f3b457b22545">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:label>Fat malabsorption</rdfs:label>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6947cd37-eeab-4886-9218-331f0c77dd0e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/38064bff-99de-4a01-9c73-66ebfae593c3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2596948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7b07908b-6355-4f81-8e94-995d7576da80">
    <rdfs:comment>Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
    <rdfs:label>Diabetes</rdfs:label>
    <dc:identifier>HP:0000819</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f222476c-a072-4a62-bb2b-2bb00159f35d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f72029d2-7d16-47ec-93dd-9e2f06c71646"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/76326269-56dd-4120-af3c-64f206beaf65">
        <rdfs:comment>Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:label>Brain damage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3470f5b0-43c0-49f9-b058-cfe691475902">
        <dc:identifier>HP:0100021</dc:identifier>
        <rdfs:comment>Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100021</ddiem:url>
        <rdfs:label>Cerebral palsy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23326493</dc:provenance>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10630918</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16435214</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c3c1780-fe8b-4a4f-a97b-5e096fa1cc81"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0c8ac0a4-b78e-4217-a2ed-693eae9646d7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4778d7c-a777-4575-859d-4b6e450f1280"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1e283375-e77b-44ed-9b3d-c738fdf1b640">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28662915</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604369"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301643</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9baff459-00e6-40c0-995e-f3b846533a75"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9dbf4ed8-8d86-46b9-9ad4-1813568cb25f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3940717</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d78b1c3c-eb78-4456-bef3-52fe4a3383ec">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f6cec2cb-aaed-44fa-b152-1c64cebb123f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c85601f-209d-4587-a5fd-3d8caf4d150d">
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:label>Ployuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b5fc4cd2-be8e-4c4d-9fd7-f570df0f6f7a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10e4dfe8-c325-4413-a022-d4b178fcc25d"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <obo:RO_0003304>E1506K</obo:RO_0003304>
    <obo:RO_0003304>delSer1387</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0003304>R1353H</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240800">
        <dc:identifier>https://www.omim.org/entry/240800</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a014643c-be79-4bb8-a61e-f0452367ff97"/>
        <rdfs:label>HYPOGLYCEMIA, LEUCINE-INDUCED; LIH</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15356046</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fea19929-ce0c-41bf-af15-a2bb793a46ad">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Antithrombin-III levels</rdfs:label>
    <dc:identifier>HP:0001976</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/414ef5df-075a-4beb-8fd9-8c8b6a65dd53">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
    <dc:identifier>HP:0002904</dc:identifier>
    <rdfs:label>hyperbilirunbinemia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c827ae0-34fe-4a00-a655-768de728d776">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12319</ddiem:url>
    <dc:identifier>DB12319</dc:identifier>
    <rdfs:label>Benzbromarone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b60ad005-0236-4505-916d-f6ddf1a0c247">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac51ec91-7b47-4255-828c-9fe39474644b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9678437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cba8f78-1907-4950-b32d-00301c85b057"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe166200-6574-4adc-9c9c-e8b2267b2114"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ab84f039-9981-4409-abae-ea8c6c859d98">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/227c586f-857a-40af-ab57-4fd953bd748a"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d412801a-73e0-4ebd-b1ac-6123004aa37a">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/edd3c338-b0bc-42da-a6cb-b48525d6e3e0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef41d703-b6a0-4300-ba97-cff2fdd75fdf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28279226</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dfdd596b-3d45-4d91-aade-9a7ddc3655f6"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01393</dc:identifier>
    <rdfs:label>Bezafibrate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a63a748b-59a3-45e5-a814-accafae2c297"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01393</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/42dff221-d191-4ad4-b55d-6c8cca1c3ef1"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4413c208-e78a-431e-a176-8190bcf770d7">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00572156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>The study is terminated (The study was prematurely terminated due to strategic reasons.)</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f7a81e0-200b-44d2-8981-f027063e79d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2dd313b5-cc2e-4708-a617-748835096f76">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11486915</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c726e6cc-f90d-44dd-9194-65660de16a35">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>high ornithine level		HP:0012026</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10896280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a48a1ce2-6f7f-4a19-b6ff-a1fd9f153cb1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/55bebabb-d326-4e2c-af27-153e2b196299">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2d962d0-ebc3-4a3a-98a9-97f9c845e38c">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f21cbe78-2e4a-4d8f-a985-7fc5b05db4b7"/>
        <dc:identifier>DB00477</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00477</ddiem:url>
        <rdfs:label>Chlorpromazine</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/907ac2a9-5e8f-4dc8-a3e7-979f1a503d19">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/247100">
        <rdfs:label>LIPOID PROTEINOSIS OF URBACH AND WIETHE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/747e18c2-3fe0-4e81-af62-d9e9705f2288"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/247100</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18808438</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a549fbca-30a2-4564-a3a8-560a289c48ae">
        <rdfs:label>Elbow skin thickening</rdfs:label>
        <dc:identifier>HP:0001072</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001072</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f9ab44f-c8d8-4e14-af49-81e83e269d66">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000962</ddiem:url>
        <dc:identifier>HP:0000962</dc:identifier>
        <rdfs:label>hyperkeratosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea606565-452b-4f8b-b86e-c0e01a2e2ce5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001609</ddiem:url>
        <dc:identifier>HP:0001609</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hoarseness</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/94c61246-7790-47de-bd60-ae1b179e28f8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a68f2e5-27f3-4586-a9be-3514d6097411">
        <dc:identifier>HP:0011122</dc:identifier>
        <rdfs:label>Skin lesion</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011122</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28681064</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28720532</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23259080</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9415ba47-e341-4712-857f-af4607967df6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24748909</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ecd46841-5f57-429c-b981-6aba156419af">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012500</ddiem:url>
        <dc:identifier>HP:0012500</dc:identifier>
        <rdfs:label>verrucous lesions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/317d62f1-3af1-41c9-a89d-528ecf2d5f66">
        <rdfs:label>Mucosal lesions</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/636793ff-bf83-43f5-9317-0659c6cebf62">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78a7564c-870b-4696-a0c1-b85a8542cdfe">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ba37bb5-4970-463a-b8dd-e34fb08ad9e3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24ad6442-da10-46b7-91cb-779a9d267651">
        <dc:identifier>HP:0003111</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003111</ddiem:url>
        <rdfs:label>electrolyte disturbances</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a540b87-8e63-488b-9a07-e89d17ae4d68"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f8c8e635-5252-4de6-aaa4-1bdf419e94dc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95f83d4d-ba1c-4132-9ede-9d4671237315">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602390">
        <ddiem:iembaseAccessionNumber>581</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/602390</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1f64ffc8-8823-4057-baae-fb624a3dc06c"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HEMOCHROMATOSIS, TYPE 2A; HFE2A</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/581</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6a568a0a-1b8c-418d-b918-096def1cdf4a"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/107/7/2952.abstract</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3a4ca35-2c31-45ee-80fb-941b6b072c04"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f817419b-6370-47c0-b447-040cf6220496"/>
    <dc:provenance>https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a8197d1-f300-4bf1-bc9f-1bb45e8ba656">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Noctornal difficulty breathing</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
    <dc:identifier>HP:0002098</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b987539b-9421-4572-b101-3aa39b83a274">
    <dc:identifier>HP:0004302</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal motor function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004302</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8680e551-8fc8-4686-9077-d9c14da8d2cd">
    <rdfs:label>acute congestive heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1ea280d-cf7c-4b15-aa9e-0ca32b28e428">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002160</dc:identifier>
    <rdfs:label>Elevated blood homocystine</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/176100">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/114</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/76590087-0290-4d27-a7d3-7820674b85de"/>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/90abb27f-22a6-4e6d-8a70-0e5a26a187c3"/>
    <ddiem:iembaseAccessionNumber>114</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/176100</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PORPHYRIA CUTANEA TARDA</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b98194e6-5784-4f76-a259-74e1c1f527df">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/307030">
        <ddiem:iembaseAccessionNumber>542</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/570ae277-9f7d-4dcb-a7ed-7ec894977c13"/>
        <dc:identifier>https://www.omim.org/entry/307030</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/542</ddiem:iembaseUrl>
        <rdfs:label>GLYCEROL KINASE DEFICIENCY; GKD</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b817ee35-93cd-4ddd-bd7f-a01a072fd78c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17442906</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2c9863a4-d7df-4389-b334-72b0c2693a6b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/802ed18d-f060-44ad-b0f6-01dfd2409d09"/>
    <rdfs:label>Ramipril</rdfs:label>
    <dc:identifier>DB00178</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00178</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/133d27d4-0daf-4157-b6ad-52f43ab9fe06">
    <rdfs:label>Low Apo B protein level</rdfs:label>
    <dc:identifier>HP:0025201*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/9b0db20a-1be9-401a-a770-7d353a821f8c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/89d2bdac-489c-45af-b294-905b30daa6a5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011042</ddiem:url>
        <dc:identifier>HP:0011042</dc:identifier>
        <rdfs:label>Abnormality of potassium homeostasis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c10e961-3cd8-471c-bbf1-7ad572a910df">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040084</ddiem:url>
        <rdfs:label>Abnormal circulating renin</rdfs:label>
        <dc:identifier>HP:0040084</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa1c40ae-893e-4d2a-bd83-680900efda08">
        <dc:identifier>HP:0000822</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypertension</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4b43a492-b01d-4c2c-a1e4-2c56d52c3828">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07c05d66-88c7-49a2-805c-0c8a2df15436"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/360bd36a-5ec6-400f-9d54-f926e728a970">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040085</ddiem:url>
        <rdfs:label>Abnormal plasma aldosterone</rdfs:label>
        <dc:identifier>HP:0040085</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc690b16-c77e-4bc6-ab1c-a66763900634">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02693119</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cd0c0ea-b54c-46d9-b0ea-68c2e487eaee">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:label>Low ATP synthesis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15672d06-2721-453e-b668-07de21216ebc">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased reactive oxygen species production</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21008e61-3a1f-450d-85b6-e88fc66aa29b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60d34ac9-3f99-4f28-8e4f-82b5e9889599"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/da1642be-579a-4a83-a957-db26c71f2798">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e220bbc8-b670-495d-8e37-eef7b9bdc9f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200125</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mitochondrial respiratory chain defects</rdfs:label>
        <dc:identifier>HP:0200125</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19891905</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e63537-1f01-439b-9695-1a1610807136"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4aea0f39-2c36-4ca2-81ca-b6c5d96a7a0d">
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd501ff5-1f5c-42de-ae90-f048bc5346d5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040189</ddiem:url>
        <dc:identifier>HP:0040189</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>scaling</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3f8dc86-d4c1-424d-bac4-08643c8fb4dd">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pruritis</rdfs:label>
        <dc:identifier>HP:0000989</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5494990-a4ad-4b64-a09a-7ceb7d4be846"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d2e4bed-5f71-461b-9c84-5a1d87aeffd0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/202175bf-0906-4069-a706-fdba70615da6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28636073</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b99a4271-c3fd-467a-8aee-2bc0e51d9092">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
    <rdfs:label>Serotonin deficiency</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003117*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c3c75ed-4fbc-486c-a454-89b56c87874b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>"No remarkable clinical improvement was observed and therefore, treatment was discontinued"</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10254206-85b0-4854-9316-8e4831b57448">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:label>Tiredness</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e00342f-2711-4f30-b0b6-fa4337e85d03">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003713</ddiem:url>
    <rdfs:label>Muscle necrosis</rdfs:label>
    <dc:identifier>HP:0003713</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99db0eac-8476-42f1-b3f1-e35c703b2e99">
    <rdfs:label>Selegiline</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01037</ddiem:url>
    <dc:identifier>DB01037</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01612e51-dc50-4ba1-b3f9-139fd1d5b992"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4678935d-b8fa-4430-b935-bd0f3eba4b5f">
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>impaired Visual acuity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/61ca1b74-ca40-46d3-868a-b2691acb4197">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1c55a7d3-f8d0-4d31-8e96-9a9b622dfa7e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/207d2bb2-3868-4dc4-be47-c1a8037c6d2c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02234024</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e15d7153-316f-4080-8eed-b3f18a3a5d0d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed Develoment</rdfs:label>
        <dc:identifier>HP:0001263</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC0:0007121">
        <dc:identifier>EC0:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC0_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c348aeae-cdf6-4199-ab7f-1f5b50b5ee34">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22830360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e4a9cf5-a2ea-45c8-9e9a-9d9dec91305f"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25896882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d5c6a73-121a-4d3d-a652-12b37a42c7bc"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27775558</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cf1095c2-66b9-444d-b0ed-b8264a0e0840">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac6a44f3-48e5-4151-8957-0e4aba31a8e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0266e11-13e9-4e7d-9dcc-7aa9f8a473a1">
        <rdfs:label>Polyurea</rdfs:label>
        <dc:identifier>HP:0000103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1d28d787-84d1-44bc-b61d-cf01171a13fc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6d1803d6-d582-4df3-8f0c-f4fd84dc6d6b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7121aa2-b69f-4d64-aa4e-04e4c071c6bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230000">
        <ddiem:iembaseAccessionNumber>259</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/71450365-8c67-4e06-8346-4d6bbc07f0f9"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FUCOSIDOSIS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/230000</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/259</ddiem:iembaseUrl>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bf8c8c7-29cb-4f16-9dd4-491fc2cdfa36">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011506</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011506</ddiem:url>
    <rdfs:label>choroidal neovascularization</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1ba30851-08a4-41b7-9214-a8a84773da4a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/757fda1b-0d23-45ef-8db5-1b31365dfd51">
        <rdfs:label>High plasma level of very-long-chain fatty acids</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16949688</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43b54b4e-5327-4c8f-ba09-290d1e300509"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/494c52de-90d9-4695-b730-563b6420f177">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High plasma levels of hexacosanoic acid</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089986</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/54d9c939-6951-4508-a6fc-9eb0083c771f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/219750">
        <dc:identifier>https://www.omim.org/entry/219750</dc:identifier>
        <rdfs:label>CYSTINOSIS, ADULT NONNEPHROPATHIC</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/525</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/48ce0703-61ae-474b-8335-cf8ceffb339f"/>
        <ddiem:iembaseAccessionNumber>525</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1929112</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da733d5a-5e32-47fb-8413-b4eb9383b767"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12370309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6ec9603a-d882-4875-b96e-123b9d193e51"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/21897743</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12488257</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/266ca317-978e-495e-9648-b50143a7fc18">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002173</dc:identifier>
    <rdfs:label>hypoglycemic seizures</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002173</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f99b74cd-d231-4c58-bd9f-cda82d0370cc">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d804a51b-7cba-4940-8d23-2840644ce7a3">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00994</ddiem:url>
        <dc:identifier>DB00994</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/34f0423e-7d53-4a0b-8af1-9621802df23e"/>
        <rdfs:label>Neomycin</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/85f032ed-7517-4650-8510-bd5168a4709b">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b5ed585-77c2-442c-942c-9f4a2afaaedb">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002020</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002020</ddiem:url>
        <rdfs:label>Acid regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe875e3f-8554-4b9c-86c8-506742cf35ec">
        <rdfs:label>Epigastric pain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0410019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0410019</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/afdd7d71-a6e2-4918-a7b4-86478e70ff39">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c0d1ab6d-3f77-463e-8a32-a60281ca9714"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/95018197-9fb3-43f0-a56f-cdb2b89c90e7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e268cd04-3b44-4e7b-897d-2f9987e247ff">
        <rdfs:label>Inflammation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <dc:identifier>HP:0012649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6efe8d71-d16d-42aa-85b1-21e04b61de5e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025460</ddiem:url>
        <rdfs:label>concentration of myo-inositol in brain</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025460</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02583672</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fd7432a-f21b-4c34-9306-26579fc585d4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011118</ddiem:url>
        <dc:identifier>HP:0011118*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>concentration of TNF-alpha in plasma</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01427517</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a7359b7-5832-42bb-b857-ccc5aa9d1814">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0012604*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0012604</ddiem:url>
        <rdfs:label>Low blood glutathione redox ratios</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/46a21544-8b44-49ca-84b3-0cca9e140bf5">
    <dc:identifier>HP:0004348</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defect of bone mineralisation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fc55dd2-43a1-4bb5-a9f8-1543e6e129e4">
    <rdfs:label>pathology in many somatic tissues</rdfs:label>
    <dc:identifier>HP:0000924*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000924</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2ebcac5-2571-449a-bb5d-55b7b160c96a">
    <rdfs:label>Short Progression-free survival</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f247bc9a-0853-4131-bea3-847e5fb19407">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004732</ddiem:url>
    <rdfs:label>Impaired renal uric acid clearance</rdfs:label>
    <dc:identifier>HP:0004732</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3c9362aa-390a-4a76-a528-4a2d2af55c8c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/072c54bd-247d-4958-9be2-1105e8c76589"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bd5724dc-6774-4420-8df9-797376effc74">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a4af655-0058-445d-8485-a25a6ea1f64b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>PL-induced cytotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/220111">
        <dc:identifier>https://www.omim.org/entry/220111</dc:identifier>
        <ddiem:iembaseAccessionNumber>425</ddiem:iembaseAccessionNumber>
        <rdfs:comment>Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/694231ac-3146-4745-9e54-2b5b08149251"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/425</ddiem:iembaseUrl>
        <rdfs:label>LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dd5f2709-6797-4b46-9cab-4e4f1bb69ef7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b0c4c36-8f34-4c48-9b83-8dfd0b7f5526"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cd0c0ea-b54c-46d9-b0ea-68c2e487eaee"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30208599</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a95d2cba-6384-4ee4-8888-561b3adc3c72">
        <dc:identifier>HP:0000648</dc:identifier>
        <rdfs:label>Optic atrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000648</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4628cd4-2b6c-4c88-ba00-19a545896320">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d779588e-74de-411f-b4d8-d8c8032783af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/310e73a6-4284-474d-9904-65f160f76372">
    <rdfs:label>Myelopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002196</ddiem:url>
    <dc:identifier>HP:0002196</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ad885d78-507f-45b8-b5cf-a48bd697c9d6">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b72235b-4460-44d9-8858-29172c2e34d9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>Developmental impairment</rdfs:label>
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/261f2c74-7d72-41ca-8534-c10a85221903">
        <rdfs:label>Generalized muscular hypotonia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001290</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275972</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/chapter/10.1007%2F8904_2017_14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27622829</dc:provenance>
    <dc:provenance>HP:0000750</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ba7564c-28aa-467b-ad9e-229876dd8c8b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Speech and languague delay</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e298844c-a0fc-45fa-80c3-35a1d68fa67e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012011</ddiem:url>
        <rdfs:label>EEG with parito-occipital spike waves</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012011</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/274270"/>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4be676d6-0457-460a-9072-97c7a5b8abda">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/68f66ddb-f6fc-4163-9a39-6b07bcce43ac">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6fb4a942-2b64-44a5-a7fc-d1775a1453cc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/323a692f-144c-412c-a7fb-ea5ceedad0f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b377b4e2-ca1d-4900-93ef-c86a76c4314d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9195122</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dec148a-618b-41fa-a8f8-97c9c3b55202">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
        <rdfs:label>swollen joint</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001386</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b36dbfcd-ca19-4408-8fb8-b3b56786de2c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cd18812e-cc2d-4657-bf38-ac3cb655bea6">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurological abnormalitis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5012e70b-2758-404f-9e10-0c1638633578">
        <dc:identifier>HP:0100513*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal vitamin E level(Vitamin E deficiency)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100513</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d047b5e1-ae1e-4514-bf51-b026e5b86338">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Ataxia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001251</ddiem:url>
        <dc:identifier>HP:0001251</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301419</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9931538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11554913</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277460">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9fb1c5ba-195c-4acf-84c7-6b5c32c9a0d8"/>
        <dc:identifier>https://www.omim.org/entry/277460</dc:identifier>
        <rdfs:label>VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/658</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>658</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8298ff83-c7a3-4e14-a7c9-b4a829a6d2f7">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ca8fbc0-fe75-4029-a9f0-f36bc3725053">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b22bf1-b919-4eec-a25a-31d179aca71f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59c306bd-9efa-4bbb-83ae-9b4aac6ec653"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95ea81b1-f283-4d3f-a994-73fd054417e7"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6438798d-8eb7-4b11-a58c-0e302bac5b0b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <rdfs:comment>THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Benazepril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00542</ddiem:url>
    <dc:identifier>DB00542</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96a38e85-bb4c-411a-b9f8-5bd487addb66">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9c7957c1-602e-40e0-936a-d61d2e013629">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdfs:comment>Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25001633</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a68a6ab6-1342-4b5a-b239-10b8272d888a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b17d9c23-4d5d-4a87-a81d-b4694004b76d"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00114</dc:identifier>
    <rdfs:label>Pyridoxal phosphate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5f2b5a1-e300-4eed-be2a-55b3c657435c"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/fd199ca8-e56a-431f-b264-8fbe4dda4732">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12747882</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/71aea9fb-5d64-4454-a18f-174158f99aaa"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a68a6ab6-1342-4b5a-b239-10b8272d888a"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00114</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0ce42c1-2de5-411c-84cd-7d78ed2851c9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Periodic fever</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001954</ddiem:url>
    <dc:identifier>HP:0001954</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/eefaa8bc-df48-4b9b-9a6f-07b45236b1b3">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/92011b3e-284b-4281-9418-4032f2eac206">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/22b9c749-e700-48dd-bbad-dd31fd9eef05"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/226a0843-5e2d-47a4-bc3c-266b1d7e5423">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased plasma triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/343fdd8a-e84a-448e-9ab9-392b59e9ee3e">
    <rdfs:comment>The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/</rdfs:comment>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28976817</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28200172</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/46f125fd-42dc-4762-ae64-064d96ed0eb8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/171507c1-3935-45b9-bee7-38639ac80e99"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1048fe2b-3e96-4572-a0ea-4418f07d92b3">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003455</ddiem:url>
        <dc:identifier>HP:0003455</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated long chain fatty acids</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03196765</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2154b6dc-9275-4fab-a4da-12a35de7f38b">
    <rdfs:label>abnormal fat metabolism</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004359</ddiem:url>
    <dc:identifier>HP:0004359</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3f78336-d4d6-4e72-bba6-e789c268cd25">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01146197</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12975208-ce3f-49ac-90f4-5594f99ebadf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b6858ee9-8364-4b4f-a74d-56c7be8c0556"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8802f2b3-2e62-4f40-bf02-e75e778abf22"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17665eaf-0b98-4c82-b63e-eb3b08f11a39">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66a4ea33-3c61-47f8-bc7c-0b214e23f1d5"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e58f883d-2a48-456b-9ef2-3628780ccdb3"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dfc9e1b5-8054-460d-a9b0-7bf4aa9492c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/0556ec44-5840-44bd-ad95-5e74ca37b60f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/203500">
        <rdfs:label>ALKAPTONURIA; AKU</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/23</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/203500</dc:identifier>
        <ddiem:iembaseAccessionNumber>23</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d860afed-c913-4606-ae9b-f20358673630"/>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26891864</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8fbf0d2a-523a-4f57-bfcc-e9895a06e45c">
        <rdfs:label>High circulating HGA (homogentisic acid)level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78ff97bc-6709-44b8-82eb-30936047770b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/08a3bb42-e1a6-40b7-b5a0-1df31cbc1090">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/52223770-44e4-4654-a93d-2783e7b6086b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7abd52d6-1bd4-4e57-a584-b29b5ffeaedc">
        <rdfs:label>Joint disesae</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001367</ddiem:url>
        <dc:identifier>HP:0001367</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00107783</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59c68aef-6c46-448b-a3c9-afc3562f46f3">
    <rdfs:label>Cholic Acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/31ad6586-b984-4910-bc75-cdc46a18a7de">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/02ef9132-ba61-4796-bfe7-1def8bd6b871"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/78ce5c3f-14f4-467e-be30-de326f1290df"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3b9f7993-83df-4029-8be6-e9540ff1e2a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4aac123d-f5d0-4969-9cfa-aa405e2155ed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7905ebbf-3423-492e-9015-8ddf2bea8d35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70905bda-ead9-499a-b2ac-5bfc318f33bf"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/423bd000-7da9-4e5b-9121-71831d98fb1c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc5b4324-9b55-413e-acdf-8c4131bb0682"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/61a7858b-737c-4885-9b1c-88c2ac49a481"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fae9e610-c3f0-4206-b37b-8ea053f96921"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d4835a03-a21b-4387-870b-267926c3f7bd"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d386c195-3fbe-4d4c-8daf-78858c6d663b"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cda6cc8e-9537-41a5-9f87-0b1dbae7368f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/294ce3f8-b6ce-4681-9070-70317df4d0ad">
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1</dc:provenance>
        <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cdb1984-3929-4104-9556-088e0e895f05"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac441691-78c4-4316-9591-92a5b45b4c83"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16819396</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373615</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cda6cc8e-9537-41a5-9f87-0b1dbae7368f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bc5b4324-9b55-413e-acdf-8c4131bb0682"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6279362e-35af-484c-bfdb-a7dfacd0549d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e70f7efd-f8f4-445b-a1e5-705f250d2f3e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b05ccd7a-2b31-43dd-b98b-cca6f6576f49"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4aac123d-f5d0-4969-9cfa-aa405e2155ed"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e8c2df8a-cdd8-436f-8a88-d65ac757e60d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f6aef839-5bcf-4425-8edd-813366c074f5"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d90bc663-e685-4f3b-89f4-22d71200f3bd"/>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02659</ddiem:url>
    <dc:identifier>DB02659</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/c89e8f83-4fcb-4088-bbeb-c561e047c01e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602398"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/97633f78-be14-4738-9620-13eed1576352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07e534a8-978e-460c-aa7e-2644dace1268"/>
    <dc:provenance>https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d55c2577-a8bb-4cb4-a094-01abe7a2afcc">
    <rdfs:label>Neuronal death</rdfs:label>
    <dc:identifier>HP:0002529</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002529</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3a5916db-39c6-4094-9a83-eefe5fcb16af">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b64653f-76c1-4aec-893c-d3a275bbf8bd">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal serum Methylfolate Level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b4db1a5-13ff-437e-81d6-b11a4fa5e28f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
        <dc:identifier>HP:0040087</dc:identifier>
        <rdfs:label>Abnormal Folate level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ddbd07d6-76af-4a44-9ff5-6806c8af0686">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e531ab64-319d-4ed4-9bf4-959693eaab82"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11916316</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ac8abbcc-ced8-49e1-8292-d8da27359314">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03425539</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/268d82bb-06ee-4460-934e-b437f8b52154">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99e8aeb5-6b23-4bea-9d27-c88e6ef4904a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28088251</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03737214</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29982630</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02930655</dc:provenance>
    <rdfs:comment>Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d5391484-dc53-4abe-ba20-d82ecbce0a03">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High Gb3(globotriaosylceramide) accumulation.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c390b9b0-41d6-4dd1-ab27-fa7433fc4081">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/308b2567-811b-46a2-bc70-8716b1ff13f0">
        <dc:identifier>HP:0045010</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0045010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormality of peripheral nerves</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231530">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/236</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/46ead6fb-54f6-4d72-998e-03cb224b9717"/>
        <rdfs:label>3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/231530</dc:identifier>
        <ddiem:iembaseAccessionNumber>236</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT00840112</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a958cf0-d984-4609-9259-30738ef309f0">
        <dc:identifier>HP:0009830</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
        <rdfs:label>Neuropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e7f23225-ca9c-4068-9f6a-c9599e02fde4">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5cbfc79c-f1d4-4ddd-828f-110530d7a850">
        <dc:identifier>HP:0001324</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mueculoskeletal dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30788385</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b7b13f29-a1a7-431b-ba9d-481e9ce3202b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d2b64e89-917f-4bf2-b41e-a2aa2f4b7cec"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be13f4db-a1e3-4d3f-9eb1-19d50d2d1127"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc0d3c65-8a18-4a58-8b44-d2b3fef4b04b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal cardiac protein (TAZ) expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/badd9703-a5ea-4bed-a0af-3c520566ed58">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High serum amyloid A protein</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5379dfc5-455e-4f36-b153-dfc7f75b7fbd">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23364648</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22219566</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29572946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26958680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efe48826-7fc4-4e52-a435-0fc78f3e91d6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18768530</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14593474</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d18a1a41-b771-4155-b3fd-137c84b67def"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d97c1858-34fb-4510-a602-86effc5a4e56">
        <rdfs:label>Hyperpigmentation</rdfs:label>
        <dc:identifier>HP:0000953</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000953</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27942180</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/31b0bf52-388e-4f97-a553-e63a79395c23">
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Increased liver enzyme activities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6315721e-390e-482c-8eff-25b3e9030278"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24222293</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc2f05b9-c638-48b0-afc2-eda31b076a77">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9fb0bba9-2002-4109-a6a4-a295966e6c0c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5df7b718-3146-4610-b90a-5c18b48c8ede"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26040326</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66c5dd62-6f05-45bd-aeac-5113bbc709b6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cdf8a350-7a3e-4557-beef-dd8359a95fb8">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31da70bc-0263-47ba-91e3-39c93b430b7c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2ed0aeb6-60b4-426d-809d-a48b439afd5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25851806</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eed8ff37-f279-4a83-9ff2-ce5ab172ff61">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000952</ddiem:url>
        <dc:identifier>HP:0000952</dc:identifier>
        <rdfs:label>Jaundice</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad5831b9-f98c-4f89-9299-e5ca38f34506">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <dc:identifier>HP:0003234</dc:identifier>
        <rdfs:label>Carnitine deficiency</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/002cda75-d58b-400c-94ba-d1de02bc0e8b">
        <dc:identifier>HP:0100786</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hypersomnia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100786</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d8f8dbd-bdee-4cae-90b6-994075590e4e"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/549860b2-6602-4333-baa4-b08966a3d18c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12d510e7-c7d1-47ef-ac9f-caea5a30588d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
        <dc:identifier>HP:0001959</dc:identifier>
        <rdfs:label>Polydipsia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c6c81a3-151b-4ffb-b0a9-6715c53e1fcf">
        <rdfs:label>Elevated circulating parathyroid hormone level</rdfs:label>
        <dc:identifier>HP:0003165</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003165</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16882283</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28459040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f247bc9a-0853-4131-bea3-847e5fb19407"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c6eacad-3e2f-4510-a2f2-4f2f894c923a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17803689</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145980">
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/145980</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7029596a-95f8-4ee9-90c3-cad5c037c8df"/>
        <rdfs:comment>In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78d608ce-f0b9-4c5d-90a9-e284cc23d1b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003072</ddiem:url>
        <dc:identifier>HP:0003072</dc:identifier>
        <rdfs:label>Hypercalcemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9a59578d-1a26-45c6-b020-7353f5fd9781">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22916340</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102949</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c906e34-909b-46ac-80b3-16276be2c782">
        <rdfs:label>low bone marrow fat fraction value</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5931e5f5-d51f-4fd7-8c6e-12dbe691c4a3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6aa48d42-2bfc-4e9c-8143-1dc38614edfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27839981</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05c6e6e-4ae2-454c-87d4-3c99e759c8cf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2205b10-bb77-4b74-909d-373fee813f2b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025547</dc:identifier>
        <rdfs:label>low mean hemoglobin concentration</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025547</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dca81e5-835f-4f62-b660-a590d2a35ae4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b83be83d-f995-4fe8-9473-feda8cd760c8"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01422187</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03021941</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30066229</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23860343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28131618</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29388611</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9f35dfe7-d583-49a9-8280-b4d5fa06adad">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/072472c2-05e1-438c-91e1-79ec102f7ca5">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>Abnormal  protoporphyrin enterhepatic circulation</rdfs:label>
        <dc:identifier>HP:0012187</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7445d6df-bfa0-4428-8e34-9affdff04ff2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3baceaeb-263d-4d56-97ba-c322710045e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0374010c-53c0-455b-a552-2e298c25e672">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310fc5bc-d29c-4b9a-9858-abe9d7e28cb0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16549399</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95a2681e-6b44-4870-865d-b28f01a40657"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241510">
    <rdfs:label>HYPOPHOSPHATASIA, CHILDHOOD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/241510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6da2ec29-acf5-4098-8449-0d492cd8357c"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/599cdab9-6ac2-420b-85b5-da2e56eb7561">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1ef2663c-0c51-421d-93a3-5d79469abaa6">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c763332-72ab-423c-9f7f-3e68f7d56969"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ea6a07f3-3b0d-4a5e-a932-0620c799f6e4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3527b688-fd43-43a4-b1f8-003d3ca66e82"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00603</ddiem:url>
    <rdfs:label>Medroxyprogesterone acetate</rdfs:label>
    <dc:identifier>DB00603</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc84cb6a-839b-4bae-94d4-ef4dca5de136">
    <rdfs:label>abnormal muscle phosphorylase activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3082ff4f-b31b-4b81-a11c-dc77d406fc08">
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10453735</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10969108</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606762"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2235f2db-9bce-40af-840c-3f3985e7d57a">
    <rdfs:label>Orlistat</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/565c4171-6dd4-49df-8c24-ca485e15f571">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93214685-c3aa-4af4-a3d9-aabcc4ba9a7a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd2a2223-cc3a-4d06-9edd-d1e46c9425d5"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfbfacbe-bcf9-41a8-9b9f-5594572b392f"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2f0623a-b0d8-4ebd-9235-dfbef0cbaa54"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB01083</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01083</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c600ed72-30a1-4ef3-a015-1a2ef259cf78">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00461799</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dd2a2223-cc3a-4d06-9edd-d1e46c9425d5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17957158</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93214685-c3aa-4af4-a3d9-aabcc4ba9a7a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14517515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <rdfs:comment>Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.</rdfs:comment>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d0c6e050-bb6e-49f0-8bc4-0c3f6ce921c0">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/045ed8b9-5236-4104-bba8-e9f7abb787e4">
        <rdfs:label>Recombinant apolipoprotein A-I</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01c50bb4-5dd5-4570-8da8-d81b43f92484"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9324189e-3439-4d9b-83dd-c89618f8d421">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>phospholylation of RET</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6af06d59-0452-46ba-86f1-9765566cf60b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002071</ddiem:url>
    <dc:identifier>HP:0002071</dc:identifier>
    <rdfs:label>Extrapyramidal movement disorders</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cecbc850-2f6c-4c07-97c8-15c0036f62e4">
    <dc:identifier>DB00163</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2bd800a7-46dc-4cba-951e-b81ccbbec92c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b36dbfcd-ca19-4408-8fb8-b3b56786de2c"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/51ea604a-2881-4460-b1ee-6455d5b81196">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8715f9-e0c4-4c9f-9c3c-fd3cff4fd5ad"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4a62df03-5589-4e3f-825d-4fc8174bbe87">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/53bf820a-1368-49bd-a45b-4c45f329c729"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7eb0f82e-33e7-4d1b-9dca-c1fa300c406d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17206463</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7798705b-4e66-4805-be98-beb472162443"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cc2c46d2-afd5-4866-a855-bccb21f4ec2e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64e1a981-09f0-4258-b36a-029010c63f0d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a546c4f6-d18d-40a2-bef6-5ec1a1ed8fe0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7375069</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93b2533c-7f2a-4984-9d4a-4620d4b3447e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1305dd7-0890-41f2-ae29-7b2e0d99375b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07c8c54e-fcf6-4220-aa24-2a8c9cfde8a6"/>
        <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
        <dc:provenance>an enzyme-replacement therapy</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
        <dc:provenance>NCT00744042.)."</dc:provenance>
        <dc:provenance>"ENB-0040</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Vitamin E</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/28754e45-cf2e-459e-a6f0-44a08cb39c92"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3ad0f324-4273-4785-93be-9b19ee6c38d0">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/84cb5a24-221b-4e5a-966a-ecedcbb7ce57"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea1cd9b5-d853-471f-b67c-60c83f7161c4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615558"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/502c68e5-5ed7-4b0b-992d-5960528527f6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55c871ca-b617-42e0-ad14-8174b751c3c3"/>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c390b9b0-41d6-4dd1-ab27-fa7433fc4081"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00163</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5fb0e68a-cfd8-4509-bf0d-5ebc4d63faaf">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01828463</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28813744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1ca5c673-3ee5-4f25-8743-2320337fe5e1">
        <rdfs:label>apoptosis induced in chondrocytes</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria "for more information please check http://www.developakure.eu/index.html</rdfs:comment>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/159c4c62-8c0b-4ccd-9673-68b28896134c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f6424dc-6f68-462a-bf33-a7ff3927da91"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2454293-0d5d-4e51-86b6-51ed5984a252">
        <rdfs:label>lymphopenia</rdfs:label>
        <dc:identifier>HP:0001888</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001888</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://adisinsight.springer.com/trials/700243447</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a40af7c1-0d59-466a-ab6d-85bf2bbbd676">
        <rdfs:label>Low weight</rdfs:label>
        <dc:identifier>HP:0004325</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8fe68fe-8848-4ae0-a992-1b7fb6b4e6bb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001433</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hepatosplenomegaly</rdfs:label>
        <dc:identifier>HP:0001433</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/126cb3cf-f468-4956-a8e7-4f318b6f4596">
        <rdfs:label>Hemolysis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001878</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001878</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb0b2bff-3fdb-4cc4-82c7-3306f8249293">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal eosinophil counts</rdfs:label>
        <dc:identifier>HP:0001879</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001879</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/102700">
        <dc:identifier>https://www.omim.org/entry/102700</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/142</ddiem:iembaseUrl>
        <rdfs:label>SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/58bc2f4e-7b10-4199-9234-8a616a2ec6cb"/>
        <ddiem:iembaseAccessionNumber>142</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2db1a9c9-73be-493d-a8aa-ff71e2290bba">
        <dc:identifier>HP:0002960</dc:identifier>
        <rdfs:label>Thyroid antibodies (autoimmunity)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002960</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfe4b200-6644-41ea-b15a-2b5f1ebd3038">
        <dc:identifier>HP:0011123</dc:identifier>
        <rdfs:label>dermatitis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/74898971-93ff-49b9-8b28-7bd04e9c1a79">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da37feed-4433-41b2-996c-d729f5ae5915"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/350bd54b-a38b-4c8b-9e71-88013ee043b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010978</dc:identifier>
        <rdfs:label>Abnormal immune function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/af98e9cd-520a-46f3-88ff-741484fb07f0">
    <dc:identifier>HP:0003107*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:label>dystonia</rdfs:label>
    <dc:identifier>HP:0001332</dc:identifier>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/bb6b35b9-bcb9-4088-912d-f1af1d905ead">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8c15183d-562d-458f-b979-9645a5763091">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/20bf7360-b612-403c-89f5-74b8277b5011"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc2bc088-ec20-419e-b6d5-ae4c105560b9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decline of muscle strength (Muscle weakness)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001324</ddiem:url>
        <dc:identifier>HP:0001324</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a73d752e-fef7-4abb-968f-d1f562cdc4a7">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abfe36fd-4021-452f-9888-5737a439c7bf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1275520</dc:provenance>
    <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a331fe4d-2fb5-407c-aeba-2300b66bdbb6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027, HP_0002017</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"(abdominal pain, nausea, vomiting)"</rdfs:label>
        <dc:identifier>HP:0002027, HP:0002017</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23605132</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a77622e-6d0a-4c85-920d-e574ed3b2c81"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c00816b3-e82c-46af-a298-3c34a4fe2547">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b056520c-8dd3-447d-8c88-4568fc25a844">
    <rdfs:label>Renal rickets</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
    <dc:identifier>HP:0002748</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00f3fd0e-1018-4517-bcd5-a8e7d0dfd61e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/25a0c679-54b6-4598-9805-61d04566fd1a"/>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12351372</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10779036</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/628680ab-ba36-4563-ac88-f7eb81f4eed9"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3d1d16b-ea05-4ae8-bf96-5041c8ec7d1f">
        <rdfs:label>Reduced hematocrit</rdfs:label>
        <dc:identifier>HP:0031851</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031851</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24744655</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15795909</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17921858</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0fc5b1f9-7937-4dc8-94f7-8cd3bd708608">
    <dc:identifier>HP:0002572</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002572</ddiem:url>
    <rdfs:label>Recurrent vomiting</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e8409c23-84c0-4116-af0d-ac4e5a1d96e9">
    <rdfs:label>N-octyl-4-epi-β-valienamine (NOEV)</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/058792bc-32f7-4e38-a07a-04be66670e59">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63fa9101-db9f-4e1e-9197-be29d9c16e56"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4836ae04-51bb-4782-a374-32f2d8965ab1"/>
        <obo:RO_0003304>SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26259553</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5058a433-edef-459e-812d-aa53a2725e81">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cba8f78-1907-4950-b32d-00301c85b057"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12205338</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe166200-6574-4adc-9c9c-e8b2267b2114"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11068651</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e48d246-c33d-42d3-a200-9e4d85fd7da4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676</dc:identifier>
        <rdfs:label>Disaess progression(Progressive)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87b9261a-2c9b-4239-9d77-c4927b240d52">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:label>Mortality</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040006</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd568dc4-b4f5-458b-8036-780f5dba53cb">
    <rdfs:label>Retinal ganglion loss</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
    <dc:identifier>HP:0000479</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f39e03a-986e-4a47-bef3-768e39df7e85">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003128</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lactic acidosis</rdfs:label>
    <dc:identifier>HP:0003128</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/794551a8-8890-4f21-92e5-a51a96c5a0ff">
    <rdfs:label>High ferritin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003281</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1735ab07-9f43-4d9f-ae69-8d2227b32cab">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
    <rdfs:label>Impaired myocardial contractility</rdfs:label>
    <dc:identifier>HP:0006670</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b4aedc2b-8e06-40d8-8ef6-b5890640fbfd">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d5b75c5c-26cb-4558-a434-95cc26abc60d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01dc216a-fb8f-444d-988d-5eb19607c4c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac4b34b9-9991-43b7-9de1-2c33bb88c03b">
        <dc:identifier>HP:0002148</dc:identifier>
        <rdfs:label>Hypophosphatemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2017228</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7fa6b583-d928-4a18-8bb2-a334557b96a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b49130fe-dcf3-40f6-94bb-72f9902fc76a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce62a934-8730-4149-aedf-75866a27400a">
        <dc:identifier>HP:0000867</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
        <rdfs:label>Hyperparathyrodism</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b056520c-8dd3-447d-8c88-4568fc25a844"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/181aa565-6b0b-4546-80d4-33f26c5ed268">
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41350a5b-2d6a-4722-b335-ad36ebac524e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyposthenuria</rdfs:label>
        <dc:identifier>HP:0003158</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57aef328-ef45-4afb-a83c-700b9074bc47"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884783</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c85601f-209d-4587-a5fd-3d8caf4d150d"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c94c486-1d4c-4b46-9e91-20fb0223d150">
    <ddiem:url>https://www.drugbank.ca/drugs/DB11917</ddiem:url>
    <rdfs:label>Vatiquinone</rdfs:label>
    <dc:identifier>DB11917</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7ee9c6ef-3fc9-458b-8b4e-765aff61139a">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd568dc4-b4f5-458b-8036-780f5dba53cb"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
        <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfdcf1f8-dc98-43f4-bd1a-430318d9f8ad"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/abd1a500-42a7-4134-969d-69460d7f1da0"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300753</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b0c4c36-8f34-4c48-9b83-8dfd0b7f5526"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d4ac2a6-3c08-4361-85b6-e3a9d329bbb3">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfdcf1f8-dc98-43f4-bd1a-430318d9f8ad"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79310e13-f224-451c-95ea-6aba691b767e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277410"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dfdcf1f8-dc98-43f4-bd1a-430318d9f8ad"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/35b9be77-bd2f-4ed1-bf98-318021dcef1e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/05853a58-449b-4ab7-8f0a-e83a4ff41b15">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011018</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011018</dc:identifier>
        <rdfs:label>extended G1 interval</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29660499</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fedda0c-be94-4d2e-bca8-8c77a4b612b0">
        <rdfs:label>Low cell autofluorescence</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/204200">
        <dc:identifier>https://www.omim.org/entry/204200</dc:identifier>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/4fe7da94-2aaf-4fb5-92ab-c31e95ca2f47"/>
        <ddiem:iembaseAccessionNumber>307</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/307</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cebccdb2-47c2-4151-b1af-58715662d261">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ce81f99-5051-43d9-af4d-fa9f38b11453"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfdbdd53-54c9-4f56-af7b-daea841d76ad">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Blood-brain barrier (BBB) impairment</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91a2c94c-683e-4606-a729-0de5156ef148">
        <rdfs:label>membrane fluidity alterations</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29923092</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bf8e698e-1939-456e-abe9-3c5d1113b23e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d690b2d-7cd4-44e6-a77e-daaa4dc83bba">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005180</ddiem:url>
        <dc:identifier>HP:0005180</dc:identifier>
        <rdfs:label>tricuspid regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ad8e4521-859c-4ff4-985b-b7085a220ce9">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>white matter abnormalities</rdfs:label>
        <dc:identifier>HP:0002500</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/803c9290-867d-4e5e-802f-f575f74fea2f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Sleep apnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
        <dc:identifier>HP:0010535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/96c0d1d0-314b-4c9c-8176-794e4db71a9b">
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <rdfs:label>low quality of sleep</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6cd61ff3-23bd-411d-be5d-3539f3439faf">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010444</ddiem:url>
        <dc:identifier>HP:0010444</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pulmonary regurgitation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/97ff0cee-b907-4575-9e61-b49450db6237">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002877</dc:identifier>
        <rdfs:label>Nocturnal hypopnea</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002877</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31630958</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8695369a-432b-4179-9fc8-09a071f215bf"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f606d17d-12eb-4934-b3d5-9e99c1181b22">
        <rdfs:label>brain MRI abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002500</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09c71b88-3bd8-4508-8e6f-510b99877453">
        <rdfs:label>low exercise endurance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607014">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>HURLER SYNDROME</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/607014</dc:identifier>
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a7f5a96-2208-476b-affb-88283e09e668"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19748810</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/db35583a-d553-412c-b3ad-d8dba29475f6">
        <rdfs:label>Abnormal apnea–hypopnea index</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddc6b4ef-bd37-4e20-af88-662e60b01cfc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/27ef9429-54e2-4354-b52b-a3775f6c87c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2aeb99c2-f7b2-4c37-a6ee-dba236b8e5d3"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c86b1cec-a4d9-4a06-9174-17274cd48f2c">
        <dc:identifier>HP:0003541</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003541</ddiem:url>
        <rdfs:label>Urinary glycosaminoglycan excretion</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e7dc2978-2da4-4c13-af68-c5febd829969">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>pitting edema</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dfc1b96-dd0f-4615-8658-e1d9ed3a8168">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000613</ddiem:url>
        <dc:identifier>HP:0000613</dc:identifier>
        <rdfs:label>photophobia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93143915-0f87-481a-bbfa-6baef9a9052d">
        <rdfs:label>dyspnea at rest</rdfs:label>
        <dc:identifier>HP:0012763</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012763</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4678935d-b8fa-4430-b935-bd0f3eba4b5f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11172140</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e30e20-698c-4367-80aa-b0049a7b77a6">
        <rdfs:label>Abnormality of joint mobility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011729</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011729</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e431be5c-a616-49d1-94a0-2e9d325784ce">
        <rdfs:label>Daytime somnolence</rdfs:label>
        <dc:identifier>HP:0002189</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002189</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1601764c-f15e-4461-b92a-f7d8194a53f3">
        <dc:identifier>HP:0002119</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002119</ddiem:url>
        <rdfs:label>brain ventricular dilatation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6438798d-8eb7-4b11-a58c-0e302bac5b0b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000083</ddiem:url>
    <rdfs:label>Kidney failure</rdfs:label>
    <dc:identifier>HP:0000083</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b2756a98-5ac0-42ef-98d8-8c9e2350c065">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001942</ddiem:url>
    <rdfs:label>metabolic acidosis</rdfs:label>
    <dc:identifier>HP:0001942</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3347922-da0f-4f4a-9e48-7d9aa15d63ab">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2c1898af-8b00-437f-92e8-8f56dce6943d">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/303ad54d-8af6-4a5e-b812-c405b4b7ddf4">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002446</ddiem:url>
        <rdfs:label>Astrocytosis in cerebral cortex</rdfs:label>
        <dc:identifier>HP:0002446</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1dcf0c2-0bff-43ae-9ae2-b8447119033c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26537923</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/23d02a12-4a12-4216-8d7a-bdf16601dece">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pyramidal neuron loss</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002062</ddiem:url>
        <dc:identifier>HP:0002062*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8f047d81-ba0e-4123-a4c6-7c34e3aa8249">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/eb4a17e1-79b7-43ab-95eb-07ef4a9beaa7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d09596ed-dbde-4ef3-a784-fb6ba6ff1dc8">
        <rdfs:label>Hypomyelination</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0013438</ddiem:url>
        <dc:identifier>MP:0013438</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a3c7a7d-851b-4fef-9968-712a8445be96">
        <rdfs:label>Astrocytosis</rdfs:label>
        <dc:identifier>MP:0003354</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0003354</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21575633</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/046c67cd-5d47-404f-af4c-dc2ba0031f01">
        <rdfs:label>Purkinji cells apoptosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0000880</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>MP:0000880</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c692ba64-385e-4551-a82b-5b3c1dd74a52">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neuronal vacuolation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ccc24d79-f63f-4c53-8a7a-a7b2c21c69de">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Microgliosis</rdfs:label>
        <dc:identifier>HP:0100708</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100708</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/490fd378-55f0-4526-842d-c54d59deeb0d">
        <rdfs:label>High level of fucosyl-linked oligosaccharide accumulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7971e08a-7398-49a3-8e83-24c3998a1d9b">
        <rdfs:label>Oligodendrocyte loss</rdfs:label>
        <dc:identifier>HP:0100709</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100709</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230000"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56b5a8c8-2c87-4e87-bc10-81a70796b6ff">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
        <rdfs:label>Lysosomal expansion in neurons of deep cortex</rdfs:label>
        <dc:identifier>HP:0004356*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b300ce9f-471f-4c5d-93e8-57d7f878a4c9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00993</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4868a76e-a133-470d-a2bd-ab2e4e11f76a">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3373bc80-3e51-49b6-99b2-10ba6a4b29ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Azathioprine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d9f9d7c0-0471-4ac4-89d8-047daa282df6"/>
    <dc:identifier>DB00993</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/46582432-ef51-4a77-a55b-14131beccfcf">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608747"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d34dfcb-6c9a-4224-aeb5-82657e6ad418">
        <rdfs:label>Low serum ICFBP level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78cb32d5-b42c-4913-aa49-ee260c5b6830">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f3fce6da-7b83-4872-884f-2c18ee743fdd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ab95aa79-4b40-4e36-bb8b-f61f1518e14b">
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b5cea068-0073-4a9d-b372-96fa1cd1a12a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f9169bc-d8ea-450c-8fe6-7ef94239eb77"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301653</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a4ae849-cc1e-4f5f-af63-df2420edea3e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/100e11cb-1b24-41c9-a7ba-cebc0c1833be">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f39e03a-986e-4a47-bef3-768e39df7e85"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/603358">
        <dc:identifier>https://www.omim.org/entry/603358</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/83f99ecb-9785-4fa9-86cc-00c40053e17c"/>
        <rdfs:label>GRACILE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/208</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>208</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22970607</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261600">
    <ddiem:iembaseAccessionNumber>1</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/261600</dc:identifier>
    <rdfs:comment>Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub</rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3adac8d7-db8b-4569-b777-9b837a9497f5"/>
    <rdfs:label>PHENYLKETONURIA; PKU</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aab1a052-4045-46c3-b9ad-b553566c06fc">
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca3d56e8-a19a-4117-84d8-593ab6f5d9d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b97a4ffe-6a20-4d0b-9fca-b89f7e85ebb6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/65baefdf-6e49-448a-820a-3bc53dcf7d2b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000164</ddiem:url>
        <rdfs:label>Dental Defects</rdfs:label>
        <dc:identifier>HP:0000164</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22397652</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1f367b8c-73e6-4860-838c-54a2f6ddb12c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55b71242-659e-4d7b-883f-184b384eb953"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d93766c1-2e80-4758-b69b-9d9db0e393f4">
        <dc:identifier>HP:0012759</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal developmental milestones</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241510"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c35545a5-c177-4e89-8456-01ac2e5f14f5">
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:label>failure-to-thrive</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/793753ac-1bee-42dd-96bb-900040c53767">
        <rdfs:label>deteriorating pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7e0be34-f829-44ef-8d84-8da54e5698a2">
        <dc:identifier>HP:0025142</dc:identifier>
        <rdfs:label>Decreased physical function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b38024d-1339-489b-9eef-8f9fb39f70b3">
    <rdfs:label>Abnormal reticulocyte count</rdfs:label>
    <dc:identifier>HP:0004312</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004312</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4c27e3a3-7f3b-4667-b59c-ae57d80ac3fc">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7121aa2-b69f-4d64-aa4e-04e4c071c6bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00a7a046-9b17-407a-8d85-4a21fde868a1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/062ef1c0-3beb-43ef-a52b-c0e74b99d216"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03128905</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b377b4e2-ca1d-4900-93ef-c86a76c4314d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115</dc:provenance>
    <rdfs:comment>Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea65ddc2-d564-41dc-b605-7df8788ec3eb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001260</ddiem:url>
    <rdfs:label>dysarthria</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001260</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01f0ef64-b7bf-47e2-8878-19ac9daa7fdf">
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f82d095f-76e2-4e2a-b245-707d62db2af9">
        <dc:identifier>HP:0001270</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Delayed motor development</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2578f55c-f587-4017-8ad8-bc78bec49183"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/491af8d2-a9ef-434f-82fd-f2e392a6eb2a">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002540</dc:identifier>
    <rdfs:label>inability to walk</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28d48256-2fdc-4ef0-aaef-e47eef5238aa">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00393</ddiem:url>
    <rdfs:label>Nimodipine</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/045cac24-0ba5-4e42-b437-a28eaabd8612">
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49cfac0a-cc1f-4ae1-b090-6414ab3f4e57"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/70dd3cd0-cf2c-4709-87e0-09e24266ef7d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <dc:identifier>DB00393</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d4835a03-a21b-4387-870b-267926c3f7bd">
    <rdfs:label>Histologic abnormalities in liver(Abnormal test result)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <dc:identifier>HP:0500014</dc:identifier>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/9aa5587c-80cd-4bac-b8b2-81e1332edf59">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16518877</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9930336</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208400">
        <rdfs:comment>As by 2016 Banning et al. mentioned "Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/9e68b4ed-854f-4620-99c4-f2af93470ddc"/>
        <dc:identifier>https://www.omim.org/entry/208400</dc:identifier>
        <rdfs:label>ASPARTYLGLUCOSAMINURIA; AGU</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/258</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>258</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40226f5a-c349-4003-9374-445ce9367695">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e06dbd8b-955e-48e5-8db2-f81b53e2c324"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0fd6426-45d3-494b-9992-fca2c4a8c5de">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low expression of AGA enzyme</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8509bd9c-597f-47d8-a117-d52236429974">
        <rdfs:label>Brain lysosomal storage disease</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6408986-a103-4f4b-a11f-5e9554d69d81">
        <rdfs:label>ipsilateral brain neuronal storage abnormalities</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a82ea63-5efb-4f45-ad40-629a501173a9">
        <rdfs:label>Liver lysosomal storage abnormality</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c668b923-d9d2-4267-a61a-186856a30650">
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514</dc:provenance>
    <ddiem:failedToContributeToCondition>Del ex20–23</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <rdfs:comment>The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011</rdfs:comment>
    <obo:RO_0003304>N1304S</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652413</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51bba55c-1d54-4cc9-8dd3-05e595861ae7">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002353</dc:identifier>
        <rdfs:label>Abnormal brain electrical activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4bdb2d4a-9331-4454-a0c5-ce0767386c10">
        <rdfs:label>Rapid disease progression</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003678</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48a36958-46cc-42b5-912c-08979269da34">
        <dc:identifier>HP:0002344</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Neurologic burden</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/949cad85-a683-40a2-aa7a-8ef3de5b95bc">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002224</ddiem:url>
        <dc:identifier>HP:0002224</dc:identifier>
        <rdfs:label>Woolly hair</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8223785</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/915f1354-074b-4126-ba3e-8e245a215580">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025373</ddiem:url>
        <rdfs:label>Eplieptic discharge (Interictal EEG abnormality)*</rdfs:label>
        <dc:identifier>HP:0025373</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dbe65e89-a3b8-4084-b630-d25a373575d4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/37e37323-5252-4fbd-858c-ca7557017fbd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00cfc9c9-19c9-4651-80fd-1f523dfeaa30"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/addf3f3d-c697-4347-bbe0-6f2bde12e786">
        <rdfs:label>Neurological abnormalities.</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/238f4f8e-d60f-4232-9583-4dd4c23c6933">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001010</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001010</dc:identifier>
        <rdfs:label>Hypopigmented skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d62add5c-6c44-40dd-858d-6e1406d962b3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001290</ddiem:url>
        <dc:identifier>HP:0001290</dc:identifier>
        <rdfs:label>Low muscular tone</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4ad14395-545d-4536-b60e-28462f3dccb6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012389</ddiem:url>
        <dc:identifier>HP:0012389</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Appendicular hyoptonia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>G666R</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Q1385X</ddiem:failedToContributeToCondition>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001262</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272</dc:provenance>
    <ddiem:failedToContributeToCondition>2757delAG</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>"IVS9,DS,+6T→G"</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10401004</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e211ae8f-b246-4f0c-a3ac-4c287507afd7">
        <dc:identifier>HP:0012759*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
        <rdfs:label>Socio-cognitive abnormality(Neurodevelopmental abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75227ae7-1348-4d0e-a986-b6f55bb89472">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946</ddiem:url>
    <rdfs:label>Ketosis</rdfs:label>
    <dc:identifier>HP:0001946</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2b660aa3-4ddb-4634-95b8-d3709e54e6ef">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://musculardystrophynews.com/resolaris-atyr1940</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6599357-9565-4e3a-989f-34aa1a910bee">
        <dc:identifier>HP:0011804</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <rdfs:label>Abnormal muscle function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02579239</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12f53e3f-39cb-43c3-9a2d-f72c5d1e945c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3b458c28-8776-45cc-92cb-791b4fc8722e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253601">
        <dc:identifier>https://www.omim.org/entry/253601</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8bdee6e8-33fa-47c8-8a49-b9c6a44aeffd"/>
        <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d90bc663-e685-4f3b-89f4-22d71200f3bd">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0500014</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0500014</dc:identifier>
    <rdfs:label>Histologic abnormalities in liver (Abnormal test result)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d15866a7-1599-4fe4-be7d-0c33eebbc1f0">
    <rdfs:label>osteopenia</rdfs:label>
    <dc:identifier>HP:0000938</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/406eb11d-fca7-4dbe-ba66-cc0c6dc3e871">
    <rdfs:label>oxidative injury*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0025463</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025463</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7d4c23a2-6f81-48af-a921-5429a8d53ef5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608158">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CoQ-RESPONSIVE OXPHOS DEFICIENCY</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b066539-7726-40bf-99cc-ee56bb326b4b"/>
        <dc:identifier>https://www.omim.org/entry/608158</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54e35da9-72ac-4194-a9fa-fa47a5a250b2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7ac6d770-de3d-431c-8ae6-70906fb8cd30">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>defected excertion of 3- MCG</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5e714de-a18e-4299-b28c-ef72fbdcf1e6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a455bfb5-e335-4d52-9add-790fc86ae8aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2c1dcc9-7e45-453e-b042-18f47a588823"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14690254</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dd658c19-79ad-4d6c-bc90-56318c7692dd">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012592</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012592</ddiem:url>
        <rdfs:label>Albuminuria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0c9bb0bd-6ba8-4143-b139-f33398489b26">
        <rdfs:label>glomerular proteinuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000100</ddiem:url>
        <dc:identifier>HP:0000100</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1def0545-3cbe-4a64-ac90-e1d2ec1f143f">
    <dc:identifier>HP:0011167*</dc:identifier>
    <rdfs:label>tonic seizures ( Focal tonic seizures)</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011167</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/70e93c72-9872-452a-b9d9-4b6db249345c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9a9aec1-b383-489a-912b-6f045b66f323">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <rdfs:label>Decreased hemoglobin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3648469a-7854-410c-beb3-8238e545dc4b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d2c331c-64f5-4442-9104-183e91000c33">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/dbbcc76e-00b3-4b0c-98a6-b4f4e7bfa983"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/02f276ea-910e-4f98-9677-7d94d57b22b8">
        <rdfs:label>high liver volume</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231005">
        <dc:identifier>https://www.omim.org/entry/231005</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccb1642b-043a-40df-aa5b-8240a4fe6c8c"/>
        <rdfs:label>GAUCHER DISEASE, TYPE IIIC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03519646</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01685216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dca81e5-835f-4f62-b660-a590d2a35ae4"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/485be3a2-9afb-46d3-867f-c682bee77fbb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9b202fcb-f19f-45ad-92b7-0b78e188cbf4"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/360ea2f6-9bca-45f3-8a49-698eac52e844">
        <rdfs:label>Poor sleep quality(Sleep disturbance)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
        <dc:identifier>HP:0002360*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/240600">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/497</ddiem:iembaseUrl>
        <rdfs:label>GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/240600</dc:identifier>
        <rdfs:comment>GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c3cc4e8-c9e1-49f0-a12f-a592e9974a49"/>
        <ddiem:iembaseAccessionNumber>497</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02054832</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/69527f20-c346-427e-a82d-ac99a5455150">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Nocturnal Hypoglycemia(Hypoglycemia)*</rdfs:label>
        <dc:identifier>HP:0001943*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f61bba77-98f7-4456-96a8-5453edc8747d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07c8c54e-fcf6-4220-aa24-2a8c9cfde8a6">
        <rdfs:label>steatohepatitis</rdfs:label>
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/275630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc2998d6-b08b-4d23-8796-58ce2e0f91c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/79b24b60-0a84-4664-a71b-6b6fffe3da55"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a09fe803-070a-400b-9afc-d4f154c035ef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77c906ed-bc26-419c-b398-31e7acbbcb3a">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002900</dc:identifier>
        <rdfs:label>Hypokalemia Metabolic Alkalosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/EC:0007121">
        <dc:identifier>EC:0007121</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/EC_0007121</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45cf0b26-55b0-4ca0-9096-95b276235f09">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7b0e8396-8ed8-4bf3-b093-a82d50ef6a4d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/results</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae0e5a18-854b-49fa-9c6f-f158bef60604">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0200114</ddiem:url>
        <rdfs:label>Metabolic alkalosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0200114</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601678"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/171507c1-3935-45b9-bee7-38639ac80e99">
    <ddiem:url>https://www.drugbank.ca/drugs/DB07425</ddiem:url>
    <dc:identifier>DB07425</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/343fdd8a-e84a-448e-9ab9-392b59e9ee3e"/>
    <rdfs:label>Sobetirome</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0b376d3d-effa-475d-a2c7-70e44cd9965c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29651749</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/63bf7fed-e2aa-4f3c-aef9-36b41cfbcd69">
        <dc:identifier>HP:0001298*</dc:identifier>
        <rdfs:label>Relapse of hyperammonemic encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f735eae1-f6f4-4ef6-bf79-4145108a498d">
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High blood ammonia level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26427088</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d7ec77e-d444-4367-88e4-26133c3f5662">
        <rdfs:label>low plasma glutamine levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0010903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010903</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e474d2e-66da-4c9c-b20e-50a41d44fabe"/>
    <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a083564c-77ea-4309-a8fe-9839aaae52d1">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/925d7d7c-67e5-4e18-9024-00c00d851fec"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28624580</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17124037</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bdea9ec-5994-4181-933d-7ba4acae5d35"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602390"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a64e86fd-5362-4055-ab00-522ac200e9ac">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e60e6a-b0d3-440a-b81d-98486980fef6"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/37db3fc1-3f65-4853-ac6b-0f4ff7ba36ef">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a0b045b-3ff0-4a3a-ba10-cac3513d8529"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25b68a24-cc54-4cd0-9f6e-e02a369b29c5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0b97e3aa-08ce-4e6c-8fe7-e3e18d47c5b1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d3dbbcb-1bc3-42f1-bc00-f02c29d419fe">
        <rdfs:label>Defective argininosuccinic acid excretion</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/668730</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de6cb76a-7dea-44ec-8117-8b444860f5db">
        <dc:identifier>HP:0001987</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001987</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High blood ammonia levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cbb2d6af-77ae-4f1b-8d4f-963bad8800f7">
    <dc:identifier>DB02209</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/51b3fff7-3e15-4afc-b889-369d684ac13c">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7d0b2e92-e624-487a-b654-87d0c1451467"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24173411</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Pyridoxine phosphate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02209</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44f02a50-267a-4956-af36-5939c7031a14">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/92ea3aac-6817-409b-8569-821ee6a65e75"/>
    <rdfs:label>Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM</rdfs:label>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/3cb16118-8996-4060-afa1-c68304e28a11">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0be2dd99-386d-42a8-a4b8-e150373fd17c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4541af0b-5b2c-4bed-a29e-cfdc94a08a94"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26827607</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609458"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02998879</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d18a1a41-b771-4155-b3fd-137c84b67def"/>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8065fd17-71a7-4bcc-bf3a-8d5a90c69c97">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9bfc0cbc-5891-4752-8005-b9d5a4f0327d">
        <dc:identifier>HP:0002167</dc:identifier>
        <rdfs:label>speech impairment</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002167</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02520934</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17433057</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/04172f94-e611-4b95-9cd6-e9e810c31fee"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/41304f63-6c0b-4cc8-bf08-2b058540bd55"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c40f1a0-99ff-4f02-9a8f-dd1c7c85a5a9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40c9abc8-e6c9-4d40-b542-e42fe2788b42">
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:label>generalized tonic-clonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1676cbc1-0117-4611-9053-cffc30ed150e">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b841ceb-25c7-4db7-a491-ac3035020444"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253280">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/354</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3b957ba5-d557-43ad-91ce-249418e9eddd"/>
        <ddiem:iembaseAccessionNumber>354</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/253280</dc:identifier>
        <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15184894</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/68d9252a-0a48-4c3f-a702-9b5f88e81db7"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f0cd8ae-dfc6-43d2-abf0-0bcedf85311b">
    <rdfs:label>Bone pain</rdfs:label>
    <dc:identifier>HP:0002653</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002653</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5c8baede-8961-4d9a-9bde-7cf0f6c17769">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f7d8246-e9a8-4e3c-911f-22768209e65e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/91eabce4-b060-45d6-bca1-3e4f940db468"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7ac6d770-de3d-431c-8ae6-70906fb8cd30"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7474896</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8831079</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cee77840-7869-4ec2-a434-6d2dbc188d90">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
    <dc:identifier>HP:0003645</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal activated partial thromboplastin time</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7efd16f0-ad2a-4c9a-b2aa-afa5f5e7cfb5">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/14c3bb0c-4e7f-43ed-9aed-9225abdf4f53">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <rdfs:comment>Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd93d4de-4d91-47ea-bab8-4b6ca2cbaa3f"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b22bf1-b919-4eec-a25a-31d179aca71f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/da86d321-8c1a-4fef-9735-9e8097d33c2f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e595ba0-e2e6-4c65-aa65-e7ec50c844ca"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb327687-a3e0-41be-acbe-d2a0d28ba065"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2caa12c8-f806-4083-adfa-2213fb0c48d8"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02922413</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/85e21b6d-7b24-4aa6-bc7a-fabf15d97e2a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24175354</dc:provenance>
        <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d56c333c-e311-4c63-81a4-747c5de1a5ff"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24652768</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd93d4de-4d91-47ea-bab8-4b6ca2cbaa3f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0fc0552-3e2a-411d-b806-a58a2577d9fe"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <dc:identifier>DB03404</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03404</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/e1eee279-f8e8-4640-9d74-3399a4f73c7f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bd93d4de-4d91-47ea-bab8-4b6ca2cbaa3f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23016163</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/938d49db-90bf-44f4-834b-3b6622f8b9ea"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <rdfs:label>Hemin</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/fc103c33-be6d-4676-aa38-4ff5dc45005d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/00337d16-e052-462f-a89b-a062cc25b656">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1d4874d0-3ac9-4765-9ffe-8cbd9dcf173b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc4b76c4-6e62-49fb-890f-948666216694">
        <rdfs:label>Low dopamine level</rdfs:label>
        <dc:identifier>HP:0012656</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601776">
    <rdfs:label>EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/601776</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/786a2ff6-8240-4b54-8cab-70e6e056f188"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1130</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1130</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/46506264-a20e-46a6-b7c4-51b0ce1f6fc7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
    <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300438">
        <rdfs:comment>Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558</rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2db7297e-3281-4b39-8d55-773d4cee1d47"/>
        <ddiem:iembaseAccessionNumber>64</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/64</ddiem:iembaseUrl>
        <rdfs:label>HSD10 MITOCHONDRIAL DISEASE; HSD10MD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/300438</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13163618-4d2e-45d1-83c1-47510d7a2213">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
        <dc:identifier>HP:0011804</dc:identifier>
        <rdfs:label>Abnormal muscle physiology</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e515dd4-2064-491d-82b8-b45c30c073ac">
    <rdfs:label>Angiotensin II receptor blockers (ARBs), plain</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09CA</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/991684cc-65fd-4db6-8b18-fa67436e1014">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/76c2e63d-8a5a-4bc5-b69e-f527894d3f84"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4acba8c3-3793-4a46-8f7c-0a0b5aa7aee6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43b10b89-0785-4db5-8f04-96b4518c273c"/>
    <dc:identifier>C09CA</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e1f2d6d1-8872-4038-9a41-f378937ff1c7">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/817e4b56-66b0-46a7-9a5b-ed19e1470f1f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21726969</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4689a9d6-a6fe-411c-af5e-d157a0320bbf"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e887823-7346-4ad6-a55a-5a49af7d25e9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e00342f-2711-4f30-b0b6-fa4337e85d03"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Amcinonide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00288</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f1850807-efa4-4fc8-8572-08fb758d457b">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e887823-7346-4ad6-a55a-5a49af7d25e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2145ac1-9d39-498e-9e8a-7a57e4e65d04"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
        <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d1465ba4-ff85-4350-9cbd-e5a64044d02d">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9683d038-53a6-4547-b072-8efb19bdf42d"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19744342</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27139922</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e887823-7346-4ad6-a55a-5a49af7d25e9"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/848e82ca-5707-40b9-8650-8a89d22cfb54"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25402764</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/03726808-d097-42f9-9f19-1472b81b4258">
        <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611105"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7e887823-7346-4ad6-a55a-5a49af7d25e9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23644316</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be6e452a-dff9-41e3-8207-e5ab68f1007e"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00288</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3b9db926-4fac-45a0-9ba6-e2492bc0ea9f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17065067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c94a1e43-4220-4d40-8f95-20fd016198ae"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe166200-6574-4adc-9c9c-e8b2267b2114"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a766a14-1797-4bee-858e-85f0c4f6aa92">
        <rdfs:label>gouty arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001997</ddiem:url>
        <dc:identifier>HP:0001997</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/19fc155f-0f78-4f03-8da4-9fecb6480df2">
    <rdfs:label>Norleucine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6bd90be7-d40f-4b1c-8c08-d2f7430e24d0">
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e57dea33-bf87-447e-be28-1961f56e2b16"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c14e05f6-b684-4aa6-9cd3-d67466315313"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b8175fc2-3b4f-42a7-ad17-ff329f905e10"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1378a8ca-865f-46b6-b682-4743072704bf"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9ef6d88f-dc91-4b07-b15c-96d5a6a2062a">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03726996</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256600"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1fadc37-8b5e-4994-988a-65734d49897a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29909971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e0a4101c-c26f-45ac-b7ed-d1db36e95e21"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a165145-6d85-4e72-998d-9f10a613c3eb">
        <rdfs:label>Lysosomal stress (Abnormality of lysosomal metabolism)*</rdfs:label>
        <dc:identifier>HP:0004356</dc:identifier>
        <rdfs:comment>In the mouse model syudy</rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f7242e8e-176a-439c-b7ee-8c83e3a40960">
    <rdfs:comment>Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/73a97379-1a48-40b2-a9bc-8321ce3b3e35">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002160</ddiem:url>
        <dc:identifier>HP:0002160</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High total homocysteine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ed5eec07-2b54-4735-9371-07ab42d72934">
        <rdfs:label>High total cysteine levels</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <dc:identifier>HP:0010918</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae93d1aa-d9bd-4343-a754-407d1109f8f1">
        <rdfs:label>high blood S -adenosylhomocysteine level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3321c90-8b9e-4df7-b7bf-af8ab8bc1930"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/247a1502-1b7f-4c7f-aa01-77afa398086b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e63587d-2237-4f75-9c96-e381b8608b61"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41dc8657-2552-4b02-b7ce-c911d189e489"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8854af46-a910-440b-85db-1ddca9f788fd">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20943885</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22410442</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26448041</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4695a915-fa81-41ec-9a45-ac47bf6b413f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e875bd6a-42e3-4772-9298-ce97c81cad0c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be13f4db-a1e3-4d3f-9eb1-19d50d2d1127"/>
    <rdfs:comment>Author: "The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/08659e08-3395-4a87-9ae8-4a59f3f0cbf4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3643f55c-fe29-4796-b398-c1bccc6af553">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/74075977-c9ee-4c36-a6a1-98e2c404293b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28708224</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81959ed2-a627-4208-8ab4-49796ba034ee"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8804323-19d7-4539-bf17-949c5a7f8b38">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/15796a1c-633c-439e-b33e-c73fdf14d94a"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0e4a6653-fd93-4104-8b1b-656a1335a0d0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef528711-ef61-4178-8c97-8679e967527a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ca9b250-6791-495e-87a5-09c0491de2bb">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01403</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5321e651-2811-4c2b-91e3-79b8becdb479"/>
    <rdfs:label>Methotrimeprazine</rdfs:label>
    <dc:identifier>DB01403</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b00127b5-8440-4c16-a121-d1c183b12f93">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cba8f78-1907-4950-b32d-00301c85b057"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8842764</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301530</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fbf1401-0663-47de-8b6b-ef5b06bdc136"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07f9164c-3573-45b0-a08f-17ec0c661aad">
    <dc:identifier>DB13191</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ecdc891-9ddc-4153-8b39-8a4752a25133"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13191</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0b04ee2f-d241-4371-8d1a-805b8937b1bd">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/20ec6858-55d3-4e64-9086-933c8746623a"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c17ce80-c32b-425c-a841-c3a90d002cfe"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Phosphocreatine</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4e153c4e-0ee7-4544-99b0-176ef15973ef">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0588b367-a70c-4656-a33c-3191f7faebe0">
        <rdfs:label>Hyperuricemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
    <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9ad1934-8b8c-49a1-9bd6-0ae9dbbeb830">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Growth failure</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7909f59d-0cef-4301-9758-dac0c5ac505b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/675de7c6-eefe-4edb-9ef4-bf9c3740ff23"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00533</ddiem:url>
    <rdfs:label>Rofecoxib</rdfs:label>
    <dc:identifier>DB00533</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/963090b1-b505-459c-95af-e20683129e12">
    <dc:identifier>DB00166</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e153fdae-9827-4032-a592-d9da65edb8b7">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d9ef854a-4a19-436e-9886-0fef83266e30"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d55c2577-a8bb-4cb4-a094-01abe7a2afcc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Lipoic Acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4b86afd2-4729-4ab9-9c7d-f69403ffa591"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f6dac04-3691-4f86-a17f-e8f5799c7541"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00166</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/78e88010-df56-4481-8c9d-0046a96773b9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3483883</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0"/>
    <dc:provenance>https://www.nature.com/articles/pr19842087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61dd01c9-255f-479a-b670-cd56436bc144">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
        <rdfs:label>Increased erythrocyte glycogen content</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/37cbe96a-05b2-477c-acba-211aefce366d">
        <rdfs:label>Hepatomeglay</rdfs:label>
        <dc:identifier>HP:0002240</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/49d0364c-7836-47d9-8dc7-2893961a65bc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ec821df8-b17b-4912-92bc-ac85bc224f70"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86021ead-2790-4022-acc4-de6f6008bb0e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4a0306b-626a-4409-9751-ef7e8be5452f">
    <dc:identifier>DB11563</dc:identifier>
    <rdfs:label>Sebelipase alfa</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11563</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/92518c51-8830-476b-b266-c2736a79cf8e">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/576abc89-a2b5-44dc-9f98-40ec6a2fa171"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29773783</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca248bc-d124-44fe-b94e-8e651c77ee30"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/00f802ef-ef87-4117-9677-e144bf5b6bd9"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02376751</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27878737</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/04d9975a-f601-47bc-8555-7401cf0bdbee"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/25758b58-5e32-441c-8216-c6421062ce04">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/21f06a20-f420-4a13-aa38-8095f42cb2c4">
        <rdfs:label>AAV2/5-PBGD</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d62949ae-2861-4e3b-8132-d2cef6ec1be3"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d23dd204-7c95-4422-87ea-a78856449317">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13149f42-53c8-48de-8dfe-23a7f35cfe31">
        <dc:identifier>HP:0100022*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Voluntary movement abnormalities (Abnormality of movement)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bf7b5926-4d7f-487b-b788-e1b1e1f21116">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5baea3ce-dfc1-4291-b443-643bbd7fc2d1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7c49e4-6222-476e-9c9c-378a42e16a93"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee9272c6-2940-459e-a51e-56ccefe1c6e3"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa6a5fb-f153-405d-bd9e-4b99317b5411"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d8f8dbd-bdee-4cae-90b6-994075590e4e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9e7b7cd-37da-433a-affd-e2c2ba3d0cc8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21126241</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4513f90-f7ad-4ac8-baa9-2164f87c93aa">
        <rdfs:label>anxiety</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000739</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000739</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/765c6c3c-e7ff-4303-bad1-eb4b2e52f819">
        <rdfs:label>Abnormal muscle tone</rdfs:label>
        <dc:identifier>HP:0003808</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003808</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0eef0dd6-fdf3-4e96-92fa-e2f610be76d1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c058fe5a-ad06-4a7a-879c-3e83412a06f1"/>
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/049b920b-a3ae-4137-b24b-f9c1a3ffb7e5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0003304>Spa</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64f8389c-00a0-4d77-b86f-a27a05578e08">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <dc:identifier>HP:0003287*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20557e1e-538b-4bb8-9102-eeb0a6f2e7d2">
    <dc:identifier>DB00437</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b9db926-4fac-45a0-9ba6-e2492bc0ea9f"/>
    <rdfs:label>Allopurinol</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/930590e4-1501-42f8-a203-56bed027b5b1">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02752633</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK100238</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/57cd992e-2e0d-4df5-b7aa-337ff635ec1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f675eb22-0e0f-4b52-b402-7cbe1ad54b0e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6482f37e-6e30-4e67-b844-b9ec8e8dca82"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a98c085e-ddbc-4016-83d0-3e08787b39d6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614723"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af4d2944-a2bb-4a82-80d2-d21e1d98581b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ac99f9e-bf7e-4202-b2ef-8ba8c0a35b75"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2c9f4bc5-f999-4aa6-bf77-0443e59aa21a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe166200-6574-4adc-9c9c-e8b2267b2114"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ac959b2-9566-4044-9796-6ccdc698db73"/>
        <dc:provenance>https://academic.oup.com/ckj/article/9/6/800/2709623</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00437</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5058a433-edef-459e-812d-aa53a2725e81"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79d134b9-908b-4ac5-a850-d547e7995694">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fe166200-6574-4adc-9c9c-e8b2267b2114"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce766f15-8df1-4c41-9d2f-da6567d9a3a5"/>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e758e15f-1d61-405e-929c-354bee1e45c8">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a"/>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15326254</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617069">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/193ccddd-29d6-40f8-99bf-0770c6ee1782"/>
    <dc:identifier>https://www.omim.org/entry/617069</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3</rdfs:label>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/18961026-edfd-434a-b221-2d089643041d">
    <dc:identifier>DB01563</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4ec8435d-8cb5-486f-92d2-35e859cfad25">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8881997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/282c0dc8-df61-4851-8114-b4235cd2df9f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95a2681e-6b44-4870-865d-b28f01a40657"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8a0bfaf9-954d-4451-98d2-2fe77b6623ae"/>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01563</ddiem:url>
    <rdfs:label>Chloral hydrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50f6d73b-1a5c-4a7e-a0a5-38519c6007d2">
    <rdfs:label>High calcium excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002150</ddiem:url>
    <dc:identifier>HP:0002150</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d22f3cb8-971f-4b0d-9493-818c2c3d5aec">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c4219f8-7a91-447a-9534-84da40051c57"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.nejm.org/doi/full/10.1056/NEJM197807132990214</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602522">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/602522</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/34d7fac6-6674-4f91-99a0-2f562f6f27b5"/>
        <rdfs:label>BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f46a2f94-9235-40a8-8c3f-c75e13dd0ebb">
        <rdfs:label>hypokalemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002900</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002900</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d327cd36-518f-4858-b193-3fb8feb3dbee">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03514420</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5a851db-a245-4786-9150-7a1022f2a15b">
        <dc:identifier>HP:0002155*</dc:identifier>
        <rdfs:label>high fasting triglycerides</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/246953f3-a0d5-47ef-8ec9-ccee7e0fa052">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6b5b1baf-ad21-4c36-ae9f-12ac001bac5d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abd1a500-42a7-4134-969d-69460d7f1da0">
    <rdfs:label>Visual loss</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000572</ddiem:url>
    <dc:identifier>HP:0000572</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a4726b6-b83a-4303-8666-1627f3f09be8">
    <dc:identifier>HP:0002180*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>neurodegenerative astrogliosis</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d09dc50d-9cfd-4f62-8d67-000d771e62fc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001714</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ventricular hypertrophy</rdfs:label>
    <dc:identifier>HP:0001714</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ed2cc7e-c0b7-4f3c-89ba-d48bb01396d8">
    <dc:identifier>HP:0007166</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:label>Paroxysmal movements</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f7bf35f6-f09a-4cb9-9908-a0c22d5077bc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16803637</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0494351f-30a5-4c12-95fa-efc0128372e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/af1f9dc1-092e-4aa7-ad42-be55dc95be0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10574582</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfea4701-5949-4ace-a4b3-fccb30a54dec">
        <dc:identifier>HP:0012514</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012514</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Lower limb pain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d32f705-18e7-4385-b2a6-424b59e1977f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35d24af6-ebad-4f23-8ac8-e970567b3356">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal walking distance</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/640c2660-0185-4676-b506-1d6618e1a7e3"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/8adf534b-8d25-4306-b654-fd0c7e0c6889">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fea1572-0d96-41e7-bf2e-ca1c89827deb">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>abnormal liver function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <rdfs:comment>While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28697823</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75417b0e-97d7-4956-949b-1eb64ac91f86">
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hepatomegaly</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/235555"/>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c59849b1-2c48-460b-9673-cbf550901d55">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
    <rdfs:label>Elevated VLDL-cholesterol,serum TG ratio</rdfs:label>
    <dc:identifier>HP:0003362</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ac971648-d9d8-419b-bfe9-017dc242e301">
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. "Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28895280</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/209300">
        <dc:identifier>https://www.omim.org/entry/209300</dc:identifier>
        <ddiem:iembaseAccessionNumber>206</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/206</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ATRANSFERRINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/36e50ad3-5cdf-471a-84f6-a3756a80fd32"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1013dac6-76d3-45db-bbe9-2ca12ecaa869">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07c44b20-0aa4-49d2-bbb7-b0aba6054f0b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9a9aec1-b383-489a-912b-6f045b66f323"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/794551a8-8890-4f21-92e5-a51a96c5a0ff"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d136b8c1-205d-4676-8d72-5e24929967c0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24220f0e-c783-4665-bbc7-41de584d7169">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000742</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000742</dc:identifier>
        <rdfs:label>Self-mutilation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8870064</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22198833</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/65f26957-43cf-4b2f-a6e3-97f0b742dfa9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f7995872-01e3-4d9f-a160-8db1cc116d98"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/735237a1-ef6f-467b-b3af-1bb2f7821fa3">
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs00726-017-2462-x</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ec70b507-c181-4c77-ad79-7a227879132e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ac8f0e3-806b-4432-964a-5bdfe2a36b46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237400">
        <rdfs:label>HYPER-BETA-ALANINEMIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/570ae277-9f7d-4dcb-a7ed-7ec894977c13"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/161</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>161</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/237400</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c0aa673d-eaf8-4cc3-83d3-ff90f3942882">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012103</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
        <rdfs:label>mitochondrial toxicity*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27023909</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/3f7abe64-e32e-4af7-ac41-c5c9b38e206d">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/301835">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a8b57ea-0b20-410d-bd87-fa1a73f952ee"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>ARTS SYNDROME; ARTS</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/301835</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/666c257f-cd01-43e5-b26e-a716fde2e56a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0002929707613470</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/811e47b4-f52f-42c9-89ac-c640b80cd861">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>frequent hospital admission</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/827454b8-27ac-4fa0-b2ff-f9c46866f77a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <rdfs:label>Ataxia Progression(Rapid progression)</rdfs:label>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c978f798-b1be-4dc8-aea8-0ea14dc5fa0f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004369</ddiem:url>
        <rdfs:label>low levels of purines</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23190330</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fa86fc31-4613-45b8-9fb7-014181c60040">
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:label>Progression of retinal degeneration ( Rapidly Progressive)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20380929</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e6d3d4b-2b32-45dd-8e2b-4ab92acbc2cb">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
        <rdfs:label>Hearing impairment progression(Rapid progression)*</rdfs:label>
        <dc:identifier>HP:0003678*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/99cd2b8a-fc39-4afd-9422-59a406d9e310"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a8197d1-f300-4bf1-bc9f-1bb45e8ba656"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17701896</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c94bcbe2-224d-4093-a588-dc0ca3c4a40f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b0c4c36-8f34-4c48-9b83-8dfd0b7f5526"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01267422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c03b485f-6d1f-467c-a41a-7500dddbad5e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/26f5cde1-6a8d-48da-acb3-d4382a1cc701"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03153293</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f7e01f88-dfec-4b54-ac76-439c87aa6a64">
    <rdfs:label>stress fractures(Pathologic fracture)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002756</ddiem:url>
    <dc:identifier>HP:0002756*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/19486efa-184d-4b9c-9c5d-be1cbb85b4d3">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010977</dc:identifier>
    <rdfs:label>defected phagocytic function</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010977</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bb9b291d-c95c-49b5-bd59-18a3837d8fbf">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7c49adbf-6fca-4ac8-8da9-4f1ae2c612ff">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96383228-d11e-462f-bdf9-525c7bbfb9b2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7bba22e7-2562-4274-91fc-fa92e4ef2781">
        <dc:identifier>HP:0002715</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002715</ddiem:url>
        <rdfs:label>immune dysfunctions</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/583f4fc4-fd48-4521-8905-e9cbca4474cb">
        <rdfs:label>neurological malfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7df2af08-0418-4922-8d35-470f62502cd2">
    <rdfs:label>Deferoxamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a083564c-77ea-4309-a8fe-9839aaae52d1"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c0124ce6-dcde-4c6a-92a5-7e49114b1608">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c4ed0f7-ad69-4ee4-a633-9396050d150b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bdea9ec-5994-4181-933d-7ba4acae5d35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00746</ddiem:url>
    <dc:identifier>DB00746</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/df516630-6ff7-49bb-8cbd-3aa76f653f62">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bdea9ec-5994-4181-933d-7ba4acae5d35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/14199d67-c79c-416a-8953-0b0f30d97cc8"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8187613</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b5a0d2df-64e8-4c7f-ab22-17e956cca9b8">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/925d7d7c-67e5-4e18-9024-00c00d851fec"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5bdea9ec-5994-4181-933d-7ba4acae5d35"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29134618</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/704ad167-92fd-4a12-bc66-5109e8a12d9f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6656f936-0b55-45a4-9cbb-a8ddd224b75b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11400757</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/250950">
        <ddiem:iembaseAccessionNumber>58</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/58</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/bfdc6684-cd64-48fd-97f9-1a2077a9893e"/>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/250950</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/607295dd-088c-4d71-b344-1779b0fec665">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <rdfs:label>Abnormality of movement</rdfs:label>
        <dc:identifier>HP:0100022</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/269f97fe-7a06-4c25-bb56-a445e660e24c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <rdfs:label>Metabolic Decompensation</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3fb6e97-f58b-48ef-802f-aa34b9a45b6e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21744491</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3904230-201f-4f68-8692-620055bed4e4"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/601776"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/689fcdb5-e742-46d8-8d8f-0a924091cdc7">
        <dc:identifier>HP:0002019</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002019</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>constipation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a17b6793-2adf-4ef2-886e-010410d15211">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c856bb88-6126-473a-ad5d-9b33e7fdf4c9"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d1dec021-ed1b-4e62-9914-222c19ea0b6b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Proteinuria</rdfs:label>
        <dc:identifier>HP:0000093</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8aba81b-7fdf-4dac-b868-cf649b748894">
        <dc:identifier>HP:0012211</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012211</ddiem:url>
        <rdfs:label>Abnormal renal function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36d92818-0128-4cbd-acd8-9d05e32c62a3">
        <rdfs:label>Low serum HDL-cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/136120">
        <rdfs:comment>Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146</rdfs:comment>
        <ddiem:iembaseAccessionNumber>528</ddiem:iembaseAccessionNumber>
        <rdfs:label>FISH-EYE DISEASE; FED</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ec7f2a5c-5fe5-44a6-b378-b8bbe2921cfe"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/528</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/136120</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b4e50a0-d9e7-4245-b78c-fac47f2a0fd3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010979</ddiem:url>
        <rdfs:label>Abnormal lipoprotein profile</rdfs:label>
        <dc:identifier>HP:0010979</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was accomapined with fat-restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23522979</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8945aee6-b07f-4344-97ac-0071a25e4ef5">
    <rdfs:label>Uridine triacetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/678dd3b0-302a-4bfb-8df7-07b060939f86"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09144</ddiem:url>
    <dc:identifier>DB09144</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3862a8a-82f6-459f-87aa-b5539ae2e95d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f89c2cb2-a2bd-494b-b9cc-ac19cab526c3"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ed170404-b292-46fe-b472-76b16a0f01b7"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6955aa7f-e11c-49c6-b06f-0b31c6a8a30b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/301500"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25561459</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/study/NCT02795676</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25885911</dc:provenance>
    <rdfs:comment>Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152</rdfs:comment>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT02697136</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4805828c-3de5-4c65-a253-76d5eae7e9e3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7ef8e5d-4414-4577-bfb6-bdcfd341d122">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/385bff8d-d0a8-4c29-88b6-18c405263a62"/>
        <dc:identifier>DB00555</dc:identifier>
        <rdfs:label>Lamotrigine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00555</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000006 rdf:about="http://ddiem.phenomebrowser.net/dddf590d-8674-4f98-aaf2-c186bfab5d12">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70b78671-c034-43d2-b146-cb649c1b3770"/>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c4c82e8-c3a5-47a3-9410-41e3c9773f10">
        <rdfs:label>High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003254</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cf2c624f-f81e-4a3b-98d7-276d6b875f62">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
        <dc:identifier>HP:0003287</dc:identifier>
        <rdfs:label>Low NADH,NAD ratio(Mitochondrial dysfunction)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/794551a8-8890-4f21-92e5-a51a96c5a0ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17702040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4521de55-9f92-415a-bad1-5c6e8688ebc8">
        <rdfs:label>Low Frataxin expression level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16269021</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229300">
        <dc:identifier>https://www.omim.org/entry/229300</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1241</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1241</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2982ba66-ea5a-4723-9ef0-4a31a6ae059a"/>
        <rdfs:label>FRIEDREICH ATAXIA 1; FRDA</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/66eda23f-d169-422a-8ae5-b5aef85e3816"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10254206-85b0-4854-9316-8e4831b57448"/>
  </obo:DDIEM_0000006>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/59487f39-b7c2-4e9c-8ab5-e72718496654">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/906f371c-a3d2-4ce7-8c9e-daa1d461d0de">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d8185b4-36f4-4aff-80a9-353d07b486a0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53a52edd-9fd1-4770-a465-2e122c07058c"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3725c103-a9eb-4cc7-911c-abef6ca07e1d"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB14644</dc:identifier>
    <rdfs:label>Methylprednisolone hemisuccinate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14644</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52b5c5f5-726b-4348-a127-08e146378d3a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012051</ddiem:url>
    <dc:identifier>HP:0012051</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MorningHypoglycemia (Hypoglycemia)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66294415-4e29-4db6-b733-ff955561405c">
    <dc:identifier>HP:0000707</dc:identifier>
    <rdfs:label>Abnormality of the nervous system</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/110bf34a-7a92-41ae-a8a1-a6d2038b8eef">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9749b986-99e8-4835-a075-8c33f274f282"/>
    <dc:identifier>DB13961</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13961</ddiem:url>
    <rdfs:label>Fish oil</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/98eac9a8-a69d-4f34-8ee8-7f4bbea90cb2">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b57e3445-bf2c-4588-a6e5-4fbb750d66d3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/376db4c5-bd07-4b83-bb7c-5c42e4b8b49d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <dc:identifier>HP:0004305</dc:identifier>
    <rdfs:label>Involuntary movement</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6d98ae23-a1c0-4b7e-a861-8391972d4a76">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09115</ddiem:url>
    <dc:identifier>DB09115</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0884b9a4-ee91-4835-bb17-f81ca3dd1b6e"/>
    <rdfs:label>Diiodohydroxyquinoline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb7b9a4b-26e8-435c-9a6c-ff0dd2a66491">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000127</dc:identifier>
    <rdfs:label>Renal salt wasting</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4f9a8801-5e03-401e-93cb-2a96febef047">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/045dfc3c-3b2f-4aec-b023-b68e27bbb531">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/81ef6e72-10bf-46c6-90db-ec48f6714aee"/>
        <rdfs:label>Methylene blue</rdfs:label>
        <dc:identifier>DB09241</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB09241</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/d7010c92-b701-4ba5-b903-a7db28531c0f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31331814</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01399047</dc:provenance>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69c76e11-3fe3-4e0e-84f4-0bc1a8422ec3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/77b87be8-c12b-48a8-8112-a78fcce943b4"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02725580</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601780">
        <dc:identifier>https://www.omim.org/entry/601780</dc:identifier>
        <ddiem:iembaseAccessionNumber>311</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/311</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7f8a1f50-55f8-4db1-8431-de64b07035b4"/>
        <rdfs:label>CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/66499f03-c8c4-4aa7-8f4c-cefd8f87a30a">
    <dc:identifier>HP:0004364</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004364</ddiem:url>
    <rdfs:label>Abnormal renal nitrogen elimination</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/55d87946-dc22-4c77-9aaa-4465f14ca9f9">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e2499d3-6f7c-49cf-87cd-7a2891de26b5">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040144</ddiem:url>
        <rdfs:label>L-2-hydroxyglutaric aciduria</rdfs:label>
        <dc:identifier>HP:0040144</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615182">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2a0c6510-762c-4590-9c89-8583100c8264"/>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615182</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/924</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>924</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24687295</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d6f7d43a-931c-4359-99c9-6b373a8380bf">
        <rdfs:label>low urinary excretion of TCA cycle intermediates malate and succinate</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0fe3b349-e3f5-4c2f-8375-4d7b992c2dd2"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef6ab66e-3ed1-4e45-b1f6-ff7b554c50ac">
        <rdfs:label>Hypocitraturia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012405</ddiem:url>
        <dc:identifier>HP:0012405</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bb9b7402-ede7-4939-9a21-9586a3b5da32">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012321</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012321</dc:identifier>
        <rdfs:label>D-2-hydroxyglutaric aciduria</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6f596aa7-3993-4c54-932a-abaa022ecf9e">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/88113b40-5046-47f0-9d32-7c59e4850345">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected ClC-Kb expression</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23772144</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb994bdb-a3fb-4e61-8dc1-8c10ced442de">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/05b5ffc9-9c36-4e18-84a2-05075d13ff5e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0003304>W610X</obo:RO_0003304>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a73368a9-f9ba-4bc1-97ba-83efa36a51fd">
    <dc:identifier>HP:0100851</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Behaviour abnormalities</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100851</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc30824d-aa7d-4f56-91a2-e31cc0c3e50b">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1ec8e01f-da75-40a2-9578-008cac4dee04">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66c39715-79a4-47e8-8423-e05500b45c68"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59372e12-ae41-4249-ab54-dfd1da16e51b">
        <rdfs:label>sleep cycle disturbance</rdfs:label>
        <dc:identifier>HP:0002360</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/15c6c0ee-5fbb-43d1-881a-7cc791e726b4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000964</ddiem:url>
    <dc:identifier>HP:0000964*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Nummular eczema (Eczema)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67f2c891-a8ff-41fd-9283-1aaebe24b08c">
    <dc:identifier>HP:0001386</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001386</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>joint swelling</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/228e626a-6b08-4448-886a-3d24c8e74967">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14513</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7c6b01eb-0c9f-4846-84f3-e9f25ef7cf6e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3904230-201f-4f68-8692-620055bed4e4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11046879-3624-472d-930e-7b3a409febc5"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895</dc:provenance>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d1b14f7-9efc-4a17-bba0-69cc36b7cd14"/>
    <rdfs:label>Magnesium</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5cb6c8b3-8a43-46e6-b3be-f737ac47057d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3fb6e97-f58b-48ef-802f-aa34b9a45b6e"/>
    <dc:identifier>DB14513</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/093bbbc4-73a3-4d0c-8a29-a30c1e7e918f">
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/b3037c6b-2a5f-4b19-a6d7-9c14055c8571">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03395704</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001203</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3dafc1b1-bf6e-4b62-8ff3-252553c0aaa5"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9f217f22-04a9-4951-af9b-6b5b4c9da1ed"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>LJPC-401(Synthetic human hepcidin)</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fb04219b-8e06-427d-a22b-d587398a615a">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/052b19ee-077e-4560-8736-172d2a5247df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7eca1db-05dd-4c48-a529-222a4e31eb66">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f311ba6-384c-4bb4-aae1-e5fea92e4335"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109037980800010X</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/61a7858b-737c-4885-9b1c-88c2ac49a481">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
    <rdfs:label>fat soluble vitamin malabsorption (Fat malabsorption)*</rdfs:label>
    <dc:identifier>HP:0002630*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0f1e1ac7-8ed6-4ea9-b669-2acb300559ff">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74a9c043-5128-4b32-bf35-a210bb66d66a"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0025f921-19cb-494a-9b02-8c8d5a6f3d0c">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:label>High triglyceride levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/268200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30420558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eb042e05-ef73-473f-94f8-9833c1c7cd00">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a3f2c28-a2c6-4aac-b106-0277a566a92e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4923cbdc-2d2a-4413-8c20-f4f3d9d6bcd8">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/eeb918af-f9ae-4789-859a-290c70fe12bb">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d00f407-cf02-46a2-9c6b-e64caccd8a69"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Phenylacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09269</ddiem:url>
    <dc:identifier>DB09269</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e9a3c51-a9e9-40fb-bfbf-ebbaf0c76601">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
    <rdfs:label>abnormal aspartate transaminase</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002910</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2fb53ec7-aaec-4343-8807-99ab77da6636">
    <dc:identifier>HP:0004356*</dc:identifier>
    <rdfs:label>Lysosomal enlargment (Abnormality of lysosomal metabolism)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004356</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/c5560b0a-8830-4cad-95bb-76f54f611a51">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f7f69b26-db27-4dd4-ac94-6c1ca9360ec5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/76c2eb73-c500-4e07-92dc-b64e9e5ec8c2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8011d37f-af0b-43d6-9dba-11645d0effc0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0588b367-a70c-4656-a33c-3191f7faebe0"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f3f6cd9-5832-41b9-9d2e-18268054e316"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10625614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59efefb8-b40d-4b52-83d7-1ee65a21adba">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000105</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000105</dc:identifier>
        <rdfs:label>Enlarged kidney</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/648b1e26-c6be-49ca-b8dd-32dfd4626b9b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01034592</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/038aa330-e02a-4f03-b2ed-b69cec15aa6e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8759a28b-cfa2-48b3-b40e-448721347e67"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5574e1a1-81f8-46d2-b8a6-84fd5c20ec27"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb65565c-f1b9-43a3-be5d-523fc452a7b3">
    <dc:identifier>DB00951</dc:identifier>
    <rdfs:label>Isoniazid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00951</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/5f80ed8d-77fb-4ac7-acb1-059fee0fb11a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31395332</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01550705</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fdedcdf3-f20a-4486-8bc4-a64d9e4f090d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5c0bb9ef-3e35-4462-8801-f53afa87f984"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d2e4277-bf11-483d-a434-8b8c6c25d5f7">
    <dc:identifier>HP:0000002*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
    <rdfs:label>linear growth velocity(Abnormality of body height)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a183f5fe-8df5-442f-8ae4-2a3e9bec1536">
    <dc:identifier>DB00672</dc:identifier>
    <rdfs:label>Chlorpropamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00672</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cf1095c2-66b9-444d-b0ed-b8264a0e0840"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3d646b3d-b8dd-4d1a-9e04-a27433379402">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/576dcbaa-b7e0-4ae0-9de6-978b1187eec9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/83c7b4a5-cd6f-4dd2-96ad-8d02cfcb26ce"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a4726b6-b83a-4303-8666-1627f3f09be8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28958576</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a858afd4-87f0-4a66-8184-785617dd2280">
        <rdfs:label>glycosaminoglycan accumulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004371</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004371</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607015">
        <ddiem:iembaseAccessionNumber>241</ddiem:iembaseAccessionNumber>
        <rdfs:label>HURLER-SCHEIE SYNDROME</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/241</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/8a7f5a96-2208-476b-affb-88283e09e668"/>
        <dc:identifier>https://www.omim.org/entry/607015</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/35798258-a619-45e6-8acb-acb72de2ed44">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25835550</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6e1f29ba-9923-4495-8f68-2ea8ead75048">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/95270213-b44b-49c9-9ae0-3fc8a2e80149"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5d056551-4033-4deb-a4a0-e558205bc37e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Palmitate plus lactate-induced cell death</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/157640">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/281a64eb-af70-464b-ac4b-607d2f081765"/>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/157640</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4803e14d-6e3a-4bab-9a7a-db103d0b4209">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23ad66a8-dab7-414b-b899-d267bab17241">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16be7a75-7ff2-49ca-9a5a-62350dd43323"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1220254</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ac6a44f3-48e5-4151-8957-0e4aba31a8e7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c85601f-209d-4587-a5fd-3d8caf4d150d"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9e6e245-27c6-4131-849c-166fadfcd574">
    <rdfs:label>Low tetrahydrobiopterin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040210</ddiem:url>
    <dc:identifier>HP:0040210</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c705bbf1-08a0-40bc-9fdc-7198991e9728">
    <dc:identifier>DB00099</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/afce3ff9-43fd-48fb-90ee-a733b8c0c190"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00099</ddiem:url>
    <rdfs:label>Filgrastim</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/163beef5-7a4e-4761-9fe8-55ee3f307fc6">
    <rdfs:label>cognitive impairment</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <dc:identifier>HP:0100543</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55c68595-123e-4da3-89ee-46cc6c0c0742">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04815</ddiem:url>
    <dc:identifier>DB04815</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/44e645ca-bcc9-49e8-bc39-aeec26121869"/>
    <rdfs:label>Clioquinol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8b74dd1d-8189-4f2b-b95f-b56ea7c397f7">
    <rdfs:label>FIV-hAAT-G6Pase</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/a5d9aec7-90e7-4efe-a17f-4ef7ec7380b9">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3832a154-e9b0-4cc0-933c-74326f7ad95b"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b2e1892-0f06-4129-a52e-74dc17a6592c">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/246450">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/62</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>62</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/246450</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7ad82b40-861a-4d28-951f-0cd4456eefcb"/>
        <rdfs:label>3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1feb9203-3988-4465-bced-ed1fa9dad43b">
        <dc:identifier>HP:0003234</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
        <rdfs:label>Decreased plasma carnitine</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/430a403f-9b47-437f-ba99-f02c10cd5f99">
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da733d5a-5e32-47fb-8413-b4eb9383b767"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8549489f-d3b5-4e13-849b-21ddf6208b60">
        <rdfs:label>Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02023866</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14e712f7-c352-4cdf-8fd0-55937fa31eaf">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00103</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3862a8a-82f6-459f-87aa-b5539ae2e95d"/>
    <rdfs:label>Agalsidase beta</rdfs:label>
    <dc:identifier>DB00103</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8de1704-f658-43f0-b910-ca62ba45053f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39a99bc2-4b6d-42a2-9434-52913bc4b98e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8dd85d0-c877-4cec-8a21-fbc9e99c4760"/>
    <rdfs:label>Selenium</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11135</ddiem:url>
    <dc:identifier>DB11135</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f92ae2b9-ce50-49b9-b1ad-d86d35acc5d4">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/000d1edb-133a-4d3b-9e6d-8bff05bc48c8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/11ece21c-c063-406c-ba4d-6c883789e529"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/69af3283-85f4-4520-ac75-4f7cde0677bd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/136120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20605907</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b4e50a0-d9e7-4245-b78c-fac47f2a0fd3"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/156f5300-77ae-4f7a-92b2-c778623bc8a7">
    <dc:identifier>HP:0007166</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007166</ddiem:url>
    <rdfs:label>Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6574ff20-1e19-4273-beb3-3269d9e7dcd0">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/47da417d-0949-41fd-adc3-fec1e7e255ef">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ecea289-3741-4ab5-8826-56cf291756f0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82b7726f-9206-4b56-9ede-ef7906f6c87c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7fcdac3d-895c-4b16-83f6-b1852fb1a006"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25707872</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e263e1b-29c5-4fb9-96df-af71b4bbb188"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22325981</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27423595</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/39b1629c-e454-4cef-8d04-27efe83038f9"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00413</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/46bb2e7b-ede0-436f-9fea-96a027b1c389">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82b7726f-9206-4b56-9ede-ef7906f6c87c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca13d019-5d26-492f-a066-c5d39dc86ab0"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3639e2c-32b6-4a2b-9b7c-b90ff054bdb1"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1416f9d-a187-4485-b4b0-01f567f03b73"/>
        <rdfs:comment>The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/071a9e7b-387f-43b0-bbc1-c408e74576af"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19704083</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <rdfs:label>Pramipexole</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00413</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a0a2d62b-dc79-4b16-aa02-c929647d322f">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c9ce4f48-37e5-4a90-aa7d-2a12a9d07619">
        <rdfs:label>Subcortical calcification</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007346</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0007346</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59fd0a5f-44c4-4144-930c-607085995f6c"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23138986</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2785251</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0fded11-a870-488f-a83b-6c5b0405c4a9">
        <rdfs:label>Seizure</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
        <dc:identifier>HP:0001250</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c346eff-a290-43fc-8fe4-8870c4979947">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002135</ddiem:url>
        <rdfs:label>Progressive basal ganglia calcification</rdfs:label>
        <dc:identifier>HP:0002135</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/86e2aebf-76d4-413b-ac69-f858e8b1a8bc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ba9e5a8-f9de-4050-9264-319d3e3fa95b"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6017e57f-f220-48bf-a1b5-39a5f3a45db6">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8b689283-8ab4-42d0-8e43-0f26d969f1f0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30090842</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/249900"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/088789949190052M</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/16064da9-11f1-459f-bf70-b46ba5f1e32a"/>
        <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>No medical treatment is available in DDIEM</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e51e557-2f81-4439-bc2d-9cc0f03cc352">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f85def6d-ec4b-4122-a79d-90f2d239b8ef">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5efdacf0-1a00-4c72-b3b8-4c7ecb51a5ef"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f2437e3c-4048-4e33-95f6-21f46ef73020"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02430077</dc:provenance>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/295babd2-7803-459d-8fa8-5049881d99d3"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Obeticholic acid</rdfs:label>
    <dc:identifier>DB05990</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05990</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/674e44e9-c69f-4d76-aa81-817941e83072">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1ec8e01f-da75-40a2-9578-008cac4dee04"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8b8f51a0-b1c5-4785-84f8-d8311ef1565d">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12fbf029-cad8-4836-bff9-ba823d00021d">
        <rdfs:label>polyuria</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <dc:identifier>HP:0000103</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f14f35e6-de06-4d76-a0b6-40a03e26249e">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000103</ddiem:url>
        <rdfs:label>Increased urine output</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/626447</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/520c92a1-1d52-4b35-8808-c394077bdef0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f646c92-0898-4b51-a9ea-c39814264b12"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01280188</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/6b367286-a32b-49b2-9cd3-3805a295a1cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20938027</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615395">
        <rdfs:label>COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16</rdfs:label>
        <dc:identifier>https://www.omim.org/entry/615395</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/961</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0adc44b6-77d5-4260-98c1-9d2ce24f025b"/>
        <ddiem:iembaseAccessionNumber>961</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ae41f07-d5be-4c5f-a278-13d2398cac20">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>Low physical capacity (Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d7937361-01e4-459d-8968-9be35d54c15e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a59c62b1-5e67-42f3-bfbb-db82424c1dd9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb01f80e-3b9b-4ecf-83e7-fc1c45056ced"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/274e13d0-8559-43d4-a433-3350016822f1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Intraretinal cystoid spaces (Retinal disease)*</rdfs:label>
        <dc:identifier>HP:0000479*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000479</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44de1c34-edcb-40df-b8e2-757a7afa4677">
    <rdfs:label>Ubidecarenone</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/62b31ed0-3814-46e2-8642-9246a752c947">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27442316</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26118651</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b84d4a5f-4a2b-470f-9302-c93127780f71"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/f9fb7122-f5e8-4446-945f-03f364bd83e6">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22990144</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3d10d77d-86fe-4e05-8708-09b1a76101a3"/>
        <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609056"/>
        <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/150d8650-df67-4822-a51b-57ea6a6ec966"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/c2a1ecea-d27e-4a88-8d2c-2302467f3a3a">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608158"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12948744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8cbbe891-e2d0-4cc4-a93b-ed652f46fe5c">
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208920"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f4c7f46-4d9d-49ae-b8fa-8fec6d3f3fbf"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28277561</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB09270</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dd156efb-f5a4-4757-8871-ef2dc5e170b3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d48ec4e9-363c-4f2b-b71b-42942b4b3060"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09270</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4062ef0-5460-43be-b83b-5f6c98c83ce8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/57a392d5-a450-4960-80a2-265e4f026d7e"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9ff466df-9290-4abe-ab8b-bc655a7ade32">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301583</dc:provenance>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/213700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b41e9f7-1c69-418b-8062-7bdb363aae18"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4a0ddebd-1cdd-4c7c-8b5d-052ed9ee314d">
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994</dc:provenance>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6e3a9473-c5f9-4e32-ab2b-41cbe84a8d2e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10601810</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26823911</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e63537-1f01-439b-9695-1a1610807136"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c8701d82-41e0-4db7-95a8-992436ba78be">
        <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19323589</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e628672f-a0fe-4eb6-ac8b-23325e5a96cf">
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/243cc7d5-5624-4db4-92f4-617b55feb1f0">
        <rdfs:label>elevated intraneuronal cholesterol</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/50021bef-bd48-4c84-b6d7-4d1397a8f2a4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85990567-3ad9-4ea6-a16e-ddf991bdc752">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300559">
    <ddiem:iembaseAccessionNumber>563</ddiem:iembaseAccessionNumber>
    <rdfs:label>GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/563</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e6a61423-013f-4868-9ee8-94656ed4f967"/>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/300559</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7243f72e-8da8-4ffa-9702-b11722f08571">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25832663</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/855c0cad-b4e5-4d3b-a296-c7fbba08d369"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f15fcde2-bd96-4660-9772-29b5580b501c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/be7ac3f0-65dc-45a5-b7fd-7548f512a07d">
    <dc:identifier>HP:0000819</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Diabetes mellitus</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000819</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9e8d6f5e-ab04-4a41-b59c-c0acdd02405b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac81e757-4841-44e7-992f-3927a0e0dc26">
        <rdfs:label>Low serum testosterone levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_004017</ddiem:url>
        <dc:identifier>HP:004017</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec88b708-c253-452f-b7dd-5b0054d18753"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19217094</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4583189b-952b-4fe7-a131-73836697783c">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2e5f13c-84c9-4231-bdde-7dd6b2558e3a">
        <rdfs:label>enanthate</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72a48ee4-1d4d-42fc-96f3-79393aeedb1b"/>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32362</ddiem:url>
        <dc:identifier>CHEBI_32362</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b17d9c23-4d5d-4a87-a81d-b4694004b76d">
    <rdfs:label>boost residual AADC activity with a cofactor excess</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/161690f4-7058-4127-81ec-4a3720783fff">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002066</ddiem:url>
    <dc:identifier>HP:0002066*</dc:identifier>
    <rdfs:label>paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia )</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0c693843-7b38-41e6-9f9e-1b3b589bdf74">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/99336071-5c9f-4372-80de-bb38d5044b44">
        <dc:identifier>HP:0000114</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
        <rdfs:label>proximal tubule salt losses (Proximal tubular defect)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f84cf29-e99d-4ba4-a752-5665ec8f9211">
        <dc:identifier>HP:0000127</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:label>renal salt wasting</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12fbf029-cad8-4836-bff9-ba823d00021d"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cfdc3989-1a1c-4852-9751-b5400ca3ea11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b313594c-c670-410f-a437-71b91bcd17af">
        <dc:identifier>HP:0004324</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004324</ddiem:url>
        <rdfs:label>weight gain</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/090b43e6-ed23-4217-99ce-1c5b25dd17da">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c1a1a94b-53a9-42a5-9fa4-47a9e245ca88"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2455472</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6f84e1bc-50a9-447f-a348-253eda700407">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/41db42bb-19cf-4f2d-8aec-839aecc71702"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12593632</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/34f0423e-7d53-4a0b-8af1-9621802df23e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drug used as an aternate therapy with (Metronidazole+Acetylcysteine)</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f99b74cd-d231-4c58-bd9f-cda82d0370cc"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9f2393d-9f2d-4678-aa15-bff46433a045">
        <rdfs:label>abnormal thiosulfates level</rdfs:label>
        <dc:identifier>HP:0011943</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e38529eb-cb9a-4522-b16b-e64b0869d934">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f45c6ccb-6b71-46d9-84ba-875086703dc4">
        <rdfs:label>Decreased serum IGF‐1</rdfs:label>
        <dc:identifier>HP:0030353</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030353</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f7a81e0-200b-44d2-8981-f027063e79d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0a8b201-2354-4b92-a566-42e46043979c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2c5bca5-635c-4c83-b578-7523c7272b3f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/976b406f-3a7d-48c3-ba8d-3a655f26ee6a"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/684d0f97-b672-4e69-9290-8d0e1dde7f09">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1480</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/60697430-9869-4ac1-9772-11c1dd4f6843"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/604445c3-cdb0-42aa-acb4-59b8659a6f55">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e37d1846-f7ff-4d00-bfeb-edef61f1fbfe"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <dc:provenance>https://link.springer.com/article/10.1023%2FA%3A1024031714659</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/45d818f9-787f-434f-9571-882ec7fc3b00"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b2e1892-0f06-4129-a52e-74dc17a6592c"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8e2e1698-8e72-45fd-91eb-d518bdc7644c">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b01fdd76-a7a9-49ca-86ab-852e4a65a9c9"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e97ec6d-5306-44a6-9650-1bf1c6c17adf">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/406eb11d-fca7-4dbe-ba66-cc0c6dc3e871"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28396261</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bdf0338d-332d-4879-a574-d669cce0f37f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600721"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/baf8211f-f64d-4c6a-970b-bd693dde7bd0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1716d4c2-9015-4f88-82b5-627c58fb2e23"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9b657e4c-7be7-4c4f-bcb0-a7a5ddc21eef">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64f8389c-00a0-4d77-b86f-a27a05578e08"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/79f77412-efb7-4912-8613-5089bc1d6a09">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/117eef77-e571-4740-8c76-bb356e0cd683"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f785512c-bb8d-4177-a0d5-aace69bf1361"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7648dee9-447a-4d30-ab5d-ec07936759d1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2dce2996-642f-45fd-b918-1da216bc0b75"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/82e00398-7797-4e99-93ef-e8877f10deab"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b769f205-41b9-483d-a9df-ebc3a0d97707">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24ae58a8-ee94-43ec-9bbe-9338d2d7b385"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e48e09ad-4b95-4c26-a29b-ed29bedf39fa">
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e72c59eb-a6df-4a84-8075-440eb8e86341"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bac5ce7b-453c-4381-8cd9-9c08f12a64aa"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/163beef5-7a4e-4761-9fe8-55ee3f307fc6"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3a4c56fd-9eb6-4776-8d80-ccccba25d90a"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606175"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b2bb6c7a-3626-413f-b0f6-b62ff92b5c68">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/611283"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9889013</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ad5831b9-f98c-4f89-9299-e5ca38f34506"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19210957</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12359132</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28053874</dc:provenance>
        <rdfs:comment>1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46506264-a20e-46a6-b7c4-51b0ce1f6fc7"/>
    <dc:identifier>DB00583</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9403fba-fb34-424b-9303-4d9befc018ac">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51b9357d-269d-48ab-9cb8-31030a454f7b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28317891</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000009 rdf:about="http://ddiem.phenomebrowser.net/d0733b69-27c8-4e88-86d5-3bb2d4ccdcbb">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6490d7e1-4601-455b-a0eb-582e175f4687"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610006"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
        <rdfs:comment>The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day)</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddcef8aa-f26c-4201-b1f4-5a1cc4b82a06"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12837870</dc:provenance>
      </obo:DDIEM_0000009>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00583</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/704ad167-92fd-4a12-bc66-5109e8a12d9f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/da1642be-579a-4a83-a957-db26c71f2798"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fa89e751-0118-4533-b6ca-b66001b94e84">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c748c9d8-1cc2-41bf-8ae1-914e7272063f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e2499d3-6f7c-49cf-87cd-7a2891de26b5"/>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70b78671-c034-43d2-b146-cb649c1b3770"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <dc:provenance>https://n.neurology.org/content/70/13/1051</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4b2ebf43-7544-4cf7-b38f-2e51a336762f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/22076e59-afaa-4a96-834e-3295186a829d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18362286</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e13e6bd6-1c9f-4389-9ad3-b6a11d12f8f1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd5724dc-6774-4420-8df9-797376effc74"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b62440b8-e577-4976-846a-323692bf1bd5">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <rdfs:comment>The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her age‐mates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c13a1cda-6fb7-451d-85c2-58fa16944f4e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Levocarnitine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2e3d129-1e4d-44a5-8299-271f7fa1dfa5">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
    <rdfs:label>defective heart function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7651536a-c8ff-4d98-89d6-4a604326efb8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14933</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4b81d0ee-f008-468d-880e-eab1699a6246">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fc74e7d3-a305-45bd-b8d3-a63725a63f29"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30373890</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ad445b8-12e8-4601-a24b-a190a84a01ee"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
        <rdfs:comment>A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892</rdfs:comment>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Nicotinamide riboside</rdfs:label>
    <dc:identifier>DB14933</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/65c6915a-3ba6-4b8f-8e0f-c5eb99320add">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3725c103-a9eb-4cc7-911c-abef6ca07e1d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318010</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/666c257f-cd01-43e5-b26e-a716fde2e56a"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e24ef934-6dc6-4cd6-b3ee-935dd406080a">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d7a0acdc-6f87-4992-ae04-56b378a8242f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/378e6f25-164f-4380-8775-110c158b4711"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d85a2693-d47e-4cf7-89b1-2ccae2647501">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>behavioural disturbance</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0757caeb-8651-485c-9412-efb39e7b1d2c">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab4f673e-3b7d-4cb0-94e5-8408a90a11c1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>tissue damage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f21fabb-6955-4763-a238-2556dc016f60"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a88ac36d-8bfe-4c3c-b263-036c8a039abf">
        <dc:identifier>HP:0001410</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001410</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Liver dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1493</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14371919-a1cc-4722-9503-4e1e48fa9e8b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>pancreatic dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001738</ddiem:url>
        <dc:identifier>HP:0001738</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604290"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/3bcbebc8-c5d2-4b77-8ccb-cad7964be12b">
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d07912ab-ccba-41a4-99a3-71201658bee6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/07e534a8-978e-460c-aa7e-2644dace1268"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b9412dea-a33a-422f-91e3-a8f4c98d6672"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43b54b4e-5327-4c8f-ba09-290d1e300509"/>
  </obo:DDIEM_0000015>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a87a5ef2-a936-4f17-83c7-2d92a15a473f">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86d908c2-77eb-483a-980a-96ff7c18b111"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22132097</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614921">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/600</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2119e47b-1a9e-4f1c-b977-1f57648c3215"/>
    <dc:identifier>https://www.omim.org/entry/614921</dc:identifier>
    <ddiem:iembaseAccessionNumber>600</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d340b8d-33b7-4085-8e56-b6e0b79cd1e4">
    <dc:identifier>HP:0010975</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010975</ddiem:url>
    <rdfs:label>Abnormal number of b cells</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebdb6e0f-21a2-4bd7-9290-3be57c924237">
    <rdfs:label>Pulmonary Alveolar Proteinosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0006517</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006517</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55c871ca-b617-42e0-ad14-8174b751c3c3">
    <rdfs:label>Retinal degeneration</rdfs:label>
    <dc:identifier>HP:0000546</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000546</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/107568a3-3ed7-41c9-a158-acb47a037398">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100712</ddiem:url>
    <dc:identifier>HP:0100712</dc:identifier>
    <rdfs:label>changes in lumbar spine (LS)</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/41297aa4-857e-4a51-a863-8f0eba3b4e57">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8bdb02d-1b31-43e0-afdf-0c65beb2953c">
        <rdfs:label>Unstable AGA enzyme</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ce60ab1-f887-4aa7-ae2e-73cc4a0aeafd">
        <rdfs:label>Abnormal AGA processing</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0003304>T122K</obo:RO_0003304>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a26dfad2-d2be-4e55-a2f8-d35f904cd8db">
        <rdfs:label>Misfolded AGA</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f82f05d7-b73d-4497-bb30-b5005b0dd436">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low AGA activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/9c3d4485-e326-41b6-978c-f97291b3b9be">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bcc68f6-d97e-443d-beb6-8fcd234f9fdc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/57aef328-ef45-4afb-a83c-700b9074bc47"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a5125bbd-2030-45de-9c7c-a4399ac49ed4">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/611105">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/446</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>446</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/668f6568-24a6-4a71-a24a-70f69d40ddba"/>
        <dc:identifier>https://www.omim.org/entry/611105</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21749991</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45cf0b26-55b0-4ca0-9096-95b276235f09"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/161690f4-7058-4127-81ec-4a3720783fff"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a05f715d-7839-4a17-a132-680389bf4607">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <rdfs:comment>The combination of three antiepileptic drugs and LGIT"modified KD" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610131"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56aa4f70-9c80-410a-aa22-c222d6e46a28">
        <dc:identifier>HP:0002015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002015</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>dysphagia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8b2e979b-914c-4bee-9dcf-5d1bb776befb">
        <rdfs:label>neck muscle weakness</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000467</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000467</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25674260</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ea65ddc2-d564-41dc-b605-7df8788ec3eb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3eda2d08-8763-431a-bdb8-542c91f1027e"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dc628bd-dd09-4b09-a2e7-aaa699a0e106">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009071</ddiem:url>
        <dc:identifier>HP:0009071</dc:identifier>
        <rdfs:label>Inflammatory myopathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/708b6cfc-10e2-4db8-bc32-7f8ecbe4c613">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.semanticscholar.org/topic/amlexanox/510418</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <rdfs:comment>Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. "This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. " It posses the ability to cross the BBB. "Our data show for the first time that Amlexanox might provide a valid therapy for AGU." https://www.ncbi.nlm.nih.gov/pubmed/29247835</rdfs:comment>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0003304>Ser72Pro/Trp168X</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/275f8a4c-7151-452b-95d0-80f1dfc7f92a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/61e01cc4-4c6b-4f86-9f54-aed04b4dd1fc"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f82f05d7-b73d-4497-bb30-b5005b0dd436"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee7ae02b-4cce-43b9-910e-5c20bf2e4764">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002630</dc:identifier>
    <rdfs:label>Malabsorption of lipid-soluble vitamins (Fat malabsorption)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c3d1acbb-b9b3-4b74-addf-54345a5ff235">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6eafdc74-6b2f-4e4d-83f6-0b6302e4c00b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000982</dc:identifier>
        <rdfs:label>Palmoplantar keratoderma</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000982</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21393975</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ca6bb274-0d88-4a0b-980a-31f670f9e622">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c578feef-f1bb-4eee-a28c-527474bc1b6d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9415ba47-e341-4712-857f-af4607967df6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/60444919-ff02-4688-a561-0f1613294f91">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/08a5b06d-22eb-43be-a2f6-9f04081a281c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4954b14-db79-49da-a788-168ef604a860">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Periodontitis</rdfs:label>
        <dc:identifier>HP:0000704</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000704</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/77390cdc-82eb-4d80-aaea-773fec3b15a1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3bf8c8c7-29cb-4f16-9dd4-491fc2cdfa36"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/082156e9-884f-4166-8206-de03a85adb5f">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
        <rdfs:label>decreased visual acuity</rdfs:label>
        <dc:identifier>HP:0007663</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15159649</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3d328af-c44b-472f-894c-6ad8113ea826">
        <dc:identifier>HP:0000504</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000504</ddiem:url>
        <rdfs:label>abnormal central vision</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28560651</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ba1603cf-4eef-42af-b764-518fb7a07cc5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/43a6bc41-4333-48d9-bd0b-e0fe97031af8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9e62c57a-e1ab-42c1-bc37-b1a98f623bd9">
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8582405</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66499f03-c8c4-4aa7-8f4c-cefd8f87a30a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/26f55ff2-7fd3-48e1-8f53-8346e04e9ddb"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ab4a12a7-1c94-4c4d-8285-ef14fa36b9bf">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03269045</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e853763f-a77f-4763-9f72-9c8dc97577ba"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a0b045b-3ff0-4a3a-ba10-cac3513d8529"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/530a2993-9539-4f2a-bcdb-1ebc96242705">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e628672f-a0fe-4eb6-ac8b-23325e5a96cf"/>
    <rdfs:label>cyclodextrins</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_23456</ddiem:url>
    <dc:identifier>CHEBI_23456</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/973dbbf2-8adb-489d-9d59-42d05a52bd9e">
    <rdfs:label>Abnormal serum folate</rdfs:label>
    <dc:identifier>HP:0040087</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040087</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6b5b1baf-ad21-4c36-ae9f-12ac001bac5d">
    <rdfs:label>ISIS 703802 (AKCEA-ANGPTL3-LRx)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d327cd36-518f-4858-b193-3fb8feb3dbee"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e15cbc8f-91d4-49c6-b753-d49d36f5a511">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>DNA hypermethylation</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/f505e3a2-df22-409a-a645-0e97eea156cc">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/691919c0-b5ee-4693-a39d-a805cfdaaf67">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e716f283-8605-4cc5-8cf6-cdc9b2c4b1ab"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b089c1f-e1f7-41e6-9184-07e266fc3f53">
        <rdfs:label>Low pulmonary function</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
        <dc:identifier>HP:0005952</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebdb6e0f-21a2-4bd7-9290-3be57c924237"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b2fb4c0d-6955-4a67-979b-0328df8cabf9">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9e6e245-27c6-4131-849c-166fadfcd574"/>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb753fe0-510b-4e42-817a-4985fefba6f9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/492b15a2-a9a2-4686-9a17-20a32837369f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/546de381-524e-4b23-a7f3-b164adac7226">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23543666</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27650489</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e63b2887-8672-43af-8586-75fd029cbdfb">
        <dc:identifier>HP:0003199</dc:identifier>
        <rdfs:label>Low skeletal muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003199</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9a212957-056d-47b8-b2f6-cca10664754a">
        <rdfs:label>disease control rate(  Rapid disease progression)</rdfs:label>
        <dc:identifier>HP:0003678</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39f8acea-f527-4b74-950c-e380d1cf70fc">
        <rdfs:label>low quality of life ( Constitutional symptom)*</rdfs:label>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2ebcac5-2571-449a-bb5d-55b7b160c96a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/07832ee3-e2b7-4761-b2e8-39880b6f8bb5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20371662</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/25766c7c-8cca-48ba-85e1-ae451c48634d">
        <rdfs:label>Increased plasma CEA</rdfs:label>
        <dc:identifier>HP:0031029</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031029</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f0cd8ae-dfc6-43d2-abf0-0bcedf85311b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22025146</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23766359</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd211887-bff2-4b6e-9e39-c91d0c25597f">
        <rdfs:label>Objective response rate (ORR)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>M918T</obo:RO_0003304>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9683d038-53a6-4547-b072-8efb19bdf42d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00514046</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c6da6877-c6fb-4f5b-91fb-3e902a9be04e">
        <dc:identifier>HP:0003528</dc:identifier>
        <rdfs:label>Elevated calcitonin</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003528</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9e112792-a268-496d-8885-8577e1b0e68d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22354cf1-5ffc-42db-8acf-b5e98d4e4e15">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0040063</dc:identifier>
        <rdfs:label>Decreased adipose tissue</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040063</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22665903</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d0eb7a3c-d86d-4054-91b7-b0c7a02aa919">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003158</ddiem:url>
    <dc:identifier>HP:0003158</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced urinary osmolality</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4d177625-0431-4cea-84bb-bfe503b2a1c8">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/602541">
        <dc:identifier>https://www.omim.org/entry/602541</dc:identifier>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/e2d81cb9-c4d1-4dfc-b4de-9f0952cb5a9f"/>
        <ddiem:iembaseAccessionNumber>1047</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1047</ddiem:iembaseUrl>
        <rdfs:label>MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64f8389c-00a0-4d77-b86f-a27a05578e08"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0504eb97-ea16-490e-abd0-e12e8c4900ed">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32479e6a-0adf-4c9f-804d-75455835804f">
        <rdfs:label>Poor eye contact</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000817</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f17723b7-ca5d-4d6c-a122-6891d246a38d"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f60453e3-594e-460d-934b-b521688ae361">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/611250b3-31cb-4837-a9d7-a39e3f351ee9"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2ef89716-cc81-48ef-9e9d-9b53f6e17961">
    <rdfs:label>Imapired muscle function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
    <dc:identifier>HP:0011804</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/19f3d4c0-28ef-47be-b6d3-7ce684a38e0f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08830</ddiem:url>
    <dc:identifier>DB08830</dc:identifier>
    <rdfs:label>Dehydroascorbic acid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/63997e78-f078-4cdc-a252-3071b135d0f5">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ee05895b-a435-4a1b-96ea-3457132e01cd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17712735</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ab285914-a53c-474e-8142-71d25edf356a"/>
        <rdfs:comment>It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7fcdac3d-895c-4b16-83f6-b1852fb1a006">
    <rdfs:label>dopamine deficiency</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012656</ddiem:url>
    <dc:identifier>HP:0012656</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610006">
    <dc:identifier>https://www.omim.org/entry/610006</dc:identifier>
    <ddiem:iembaseAccessionNumber>63</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/0cfb1338-fe89-4ac2-88f8-616c15a6fdf5"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/63</ddiem:iembaseUrl>
    <rdfs:label>2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY</rdfs:label>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/07b621b4-5955-44e6-bc52-2a6902b76145">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a12a4761-013c-43f0-b4d4-5808e73bdaa8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/01fc2544-b84a-42f1-8176-798ff9cd6ba7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/77b49913-98ab-48f0-8f85-03b383e48690">
        <rdfs:label>Alveoli damage ( interstitial pulmonary abnormality)*</rdfs:label>
        <dc:identifier>HP:0006530</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006530</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea9aa039-28bb-4d3a-b3ac-3e4fbbef7528">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002098</ddiem:url>
        <dc:identifier>HP:0002098</dc:identifier>
        <rdfs:label>Difficulty breathing</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15978931</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1c40a9f-5594-4e06-8f76-2229d8c7baf7">
        <rdfs:label>Lung inflammation (Abnormality of respiratory system)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002086</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002086</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22282548</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3961ea1b-8023-4dd2-9d5e-2efd781e4472">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/80ab8eb6-a2e9-4050-830d-10ee9f7c7623">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5fdc6be8-dff1-4f4d-9910-cc446ae6c53e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <rdfs:comment>Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30170069</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e41091f-6ef1-44c6-9b16-fbf378127dc5">
        <dc:identifier>HP:0006670*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>left ventricularc contractility abnormalities</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0006670</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e72c250-f772-4f5d-ae52-41c418e138e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d09dc50d-9cfd-4f62-8d67-000d771e62fc"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8d7b5927-b54a-4230-905d-212394a4fdba"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607014"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8ca5ec7-1563-4bb7-8a6a-d4b57335fc65">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>cardiac dilation, Heart enlargment, cardimegaly</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8700879</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f63b3b3b-bf85-42e1-aba3-d8e37569d783">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00133</ddiem:url>
    <dc:identifier>DB00133</dc:identifier>
    <rdfs:label>Serine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/036705c2-7896-4817-81b1-689596205ef9"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/47dd31fa-9976-4df0-8a9d-a5af912385f6">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5ef8f4d-d885-40e6-8390-a90a0210a1e0">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26bc67c9-9c3b-4800-bbc0-06bf9c251e49"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00159</ddiem:url>
        <dc:identifier>DB00159</dc:identifier>
        <rdfs:label>Icosapent</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/235a8e9f-a97a-4cf1-87e1-7db391d122cc">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/12757858</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97da23ce-a9b5-4313-94ee-a9d346a6668d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6de0d5be-79e5-4f0f-ad30-21314190c5db"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/231950">
        <dc:identifier>https://www.omim.org/entry/231950</dc:identifier>
        <rdfs:label>GLUTATHIONURIA</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4278b4f-d515-47c2-a0ae-a4b75994da7f"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/214</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>214</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c4efbb6-226a-45a2-987b-f357c228f335">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010918</ddiem:url>
        <dc:identifier>HP:0010918</dc:identifier>
        <rdfs:label>low intracellular cysteine*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f461ad7-ceeb-4109-9b00-de59548db665">
        <dc:identifier>HP:0003343</dc:identifier>
        <rdfs:label>GSH deficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003343</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78946aca-7c2e-42ce-8982-5628f7361c5d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
        <dc:identifier>HP:0000708</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>behavioral abnormalities</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/76ee865e-e955-490a-a805-a75a5e50c7cd">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10581232</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c8e9c736-1d6f-43b5-8a2d-7b89a44d4fcd">
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:label>Rhabdomyolysis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4cb21b7e-013d-44c8-86aa-d719a76acf86">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/56159e5a-9e0a-4fbd-9969-f4e6fc1d5a7e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/31079757-0b22-4c84-85ff-1fc33ece503f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d97dec37-3db2-4c54-8827-d39fe411cb96">
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/605b9e73-58b5-4a93-acfb-e2ccc4ab3088">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a9fe75b5-4470-45b4-9f8a-8203b5ae1b83"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/66294415-4e29-4db6-b733-ff955561405c"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6922c2dc-85d5-44f2-8d45-6a6d6786c11c">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/925d7d7c-67e5-4e18-9024-00c00d851fec"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <rdfs:comment>Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7afee2f0-012b-413e-8cab-2f4d6310bade">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e1e8382-f71d-47f7-8f66-1ffb8a2880cf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03453918</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d2911cf5-d4eb-473f-b510-75c84f25bcac">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bf101c38-fad7-49c0-ba82-d6b7748bd955">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0310b768-01c3-419d-aa0c-d2d9165ca67f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d86ee2c7-c540-4537-90b2-03248f689178"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7d7af7ce-0c76-4479-8ee4-46a27d3d5442"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/76c2eb73-c500-4e07-92dc-b64e9e5ec8c2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c5560b0a-8830-4cad-95bb-76f54f611a51"/>
    <rdfs:label>Ad-mG6Pase</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/2d15e70e-4768-4baf-b06d-3766b0c2f3db">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26922636</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd2f1a76-a184-4899-8ee7-2a2272cdc880">
        <rdfs:label>No result was added</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27179999</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300322"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c5e27cb8-3b09-4be2-a15d-de12c883024c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a826b8f3-a700-4296-a682-090f344c6557"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004314</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT01065558</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
  </obo:DDIEM_0000007>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/19d7c699-c097-440f-ae29-63c3f47746f9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8810b34-bb08-4372-b055-3b0060b69af6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03466463</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0dfaedd-db97-4242-aaf3-ac639cb82539"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/5a21ce62-ac9b-45a7-a10d-df8ab6c66442">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59fd0a5f-44c4-4144-930c-607085995f6c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/973dbbf2-8adb-489d-9d59-42d05a52bd9e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8864759</dc:provenance>
    <dc:provenance>https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eef9e8b6-f7e7-44a4-b4c5-c99743dbe99d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c5987181-23a0-47e6-b1b9-107a40fc20da"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee7ae02b-4cce-43b9-910e-5c20bf2e4764"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9145952f-695e-47ce-a04a-6dac63108535">
    <dc:identifier>HP:0010836*</dc:identifier>
    <rdfs:label>Copper accumulation in kidney(Abnormal copper levels)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7cf4dd25-1641-40b5-96a7-fd370defe03a">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45cf0b26-55b0-4ca0-9096-95b276235f09"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d19ddbd-5626-4fa9-8f59-11db8ad3bd38"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615398">
        <dc:identifier>https://www.omim.org/entry/615398</dc:identifier>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1147</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f50f123d-9cb2-440c-8533-438cd7e839d7"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>1147</ddiem:iembaseAccessionNumber>
        <rdfs:label>MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69745203-dbe5-4629-b4e0-f40aabf67455">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4ad24154-d289-477d-9b8e-38e2c1efb56f">
        <rdfs:label>Dexamethasone</rdfs:label>
        <dc:identifier>DB01234</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8955d514-02e1-45f7-bc2e-b3f7e68b1713"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01234</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3949387-bc2d-473e-8e04-3b31eab6dbba"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74e695ab-52b9-43b4-806a-2fb44b9cb594">
    <rdfs:label>abnormal carbohydrate metabolism*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011013</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011013</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/606664">
    <rdfs:label>GLYCINE N-METHYLTRANSFERASE DEFICIENCY</rdfs:label>
    <ddiem:iembaseAccessionNumber>25</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cb205b0d-be14-4133-bcdf-5eff47431e41"/>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/25</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/606664</dc:identifier>
    <rdfs:comment>Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.</rdfs:comment>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81198963-b159-4228-871f-2e6cc5812dde">
    <rdfs:label>Disease progression (Rapid progression)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003678</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5dcac541-9991-4282-9d6e-f8da28d55ca9">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e088253-ec29-43f5-bcdd-94130c531deb"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1def0545-3cbe-4a64-ac90-e1d2ec1f143f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e3ff65fa-b36f-4261-bde8-4c50de430777">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16141353</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/15804998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/224120"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/539fdd05-1775-4246-9a9a-ebbc6bea83c9">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35d2bffc-ee50-4327-9082-c0a9dd3f9aa8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/86d5bae6-1eac-4f1d-a909-ecaee28f02de">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <rdfs:label>Elevated serum ferritin concentrations</rdfs:label>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ff4f31fa-fa56-432d-b9d6-8077c06de572">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
    <rdfs:comment>Citrulline should be given in "Low-dose" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b7e25611-5b15-47cd-b59f-8020f82da1bb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27567650</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9a62dcaf-2b88-40fc-873b-9c9db24abe47">
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/92134f51-3c77-4cae-a046-010b13f06616">
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca248bc-d124-44fe-b94e-8e651c77ee30"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5aaa7abe-82b3-4bd1-850d-44736a933ff7"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <dc:identifier>DB00973</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00973</ddiem:url>
    <rdfs:label>Ezetimibe</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e82b071-8ed5-4a94-90e0-972c2270dfb2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>ER-associated degradation of R8L</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6113383d-bad5-462d-8315-cc2a86df74c1">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151800">
        <dc:identifier>https://www.omim.org/entry/151800</dc:identifier>
        <rdfs:label>LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/3c6fb7d4-447d-4085-b509-f2a1242c3060"/>
        <rdfs:comment>The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/</rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/29be4724-15af-443e-97fc-fcb0e919a6a6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Rapid progression in body fat mass( Abnormality of adipose tissue* )</rdfs:label>
        <dc:identifier>HP:0009124*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21bdbd00-d6a8-476e-a0ae-1c3e7dfc2689">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008993</ddiem:url>
        <dc:identifier>HP:0008993</dc:identifier>
        <rdfs:label>Increased intraabdominal fat</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fadeb535-fc95-4ad9-8bf9-6aca1865f8b0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/777071e8-2bab-4636-89d0-cd8e55d14806"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2897261</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a7b9982b-8a7c-42c7-8727-f463583dc3fe">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16830281</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92011b3e-284b-4281-9418-4032f2eac206"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e5f69f7c-a01a-4017-9ca2-927629799970">
        <rdfs:label>Drug wasn't effective (Insignificant effect)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/0856caf9-8fb3-47cd-9063-23ac7db6041e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27783330</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9b089c1f-e1f7-41e6-9184-07e266fc3f53"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21110863</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/05292c5f-bf6f-4623-8cf3-1015cf1cd217"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ebdb6e0f-21a2-4bd7-9290-3be57c924237"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29058386</dc:provenance>
    <rdfs:comment>The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3395630f-5340-4e32-8bc1-b94966d94e5a">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b004865a-9bd5-461f-b017-c5fc9350cdd5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2cf1e0fb-3706-4663-8053-3189fbc15fcd"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237300">
        <rdfs:label>CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c40fdbfb-aaaf-4896-b3d7-3a93bbd5bceb"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/11</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/237300</dc:identifier>
        <ddiem:iembaseAccessionNumber>11</ddiem:iembaseAccessionNumber>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e263e1b-29c5-4fb9-96df-af71b4bbb188">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
    <rdfs:label>hyperprolactinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000870</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d675be77-2bc1-498f-9877-dcf20bb47703">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd050ac3-0abf-48ba-97db-6147c740bb43">
        <dc:identifier>DB01041</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c6d9241-e530-474c-a3dc-b7e6fcb18b13"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB01041</ddiem:url>
        <rdfs:label>Thalidomide</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a44ce51d-06df-468a-a66b-bace6a2efbc4"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/83c7b4a5-cd6f-4dd2-96ad-8d02cfcb26ce">
    <rdfs:label>GNeo-IDUA</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d646b3d-b8dd-4d1a-9e04-a27433379402"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c53279e4-cb05-4dde-a04e-a99f9ec32433">
    <rdfs:label>Abnormal circulating porphyrin concentration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010472</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/263b0eba-c1f1-4ae7-886a-d5cdc8bf150a">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26835382</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13abf97c-8da2-4f43-ab21-67e3eac23a5d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d3bf32ac-beda-43cf-9c35-41da24ff1b74">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14555</ddiem:url>
    <dc:identifier>DB14555</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7402da98-9488-47df-af18-29de0e1ce023"/>
    <rdfs:label>Ursadiol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b458c28-8776-45cc-92cb-791b4fc8722e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b660aa3-4ddb-4634-95b8-d3709e54e6ef"/>
    <rdfs:label>Resolaris (ATYR1940)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/88976df4-009c-46a0-b14d-323209e91406">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a2152b2-acaf-454a-b347-05e73725684a">
        <rdfs:label>Propranolol</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af398923-04b8-47f6-8859-731cc26887cb"/>
        <dc:identifier>DB00571</dc:identifier>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00571</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c95121ac-7cdb-4d69-94b0-b85e98cf7e1b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100022</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>deambulation</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14f15a76-ccf7-439d-ae7a-f59e36336e88">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01f0ef64-b7bf-47e2-8878-19ac9daa7fdf"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00083</ddiem:url>
    <dc:identifier>DB00083</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/299de850-0809-4144-829b-318fabb3c5d4">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/793caade-6cc0-4b93-a82d-a195127406e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2578f55c-f587-4017-8ad8-bc78bec49183"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1637b817-2e0d-45bd-82a1-9300ece0b7f0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253280"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29555514</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Botulinum toxin type A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fcd54381-975a-4409-90a4-f85225c8805a"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1bea0a5b-c02f-433d-97ff-d706ddd1a12f">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/189d26c5-18f1-457b-83b4-86d6f429f7aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bd44d35e-3e4c-4356-9319-238a6856e789"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/767635c0-f90b-4318-a050-8ce82d5bff32">
        <rdfs:label>Abnormality of metabolism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a8810b34-bb08-4372-b055-3b0060b69af6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fafc969d-04cc-46e9-b421-3bf6a7b6cc1d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012649</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased inflammatory response</rdfs:label>
        <dc:identifier>HP:0012649</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a88bc1c2-b64d-46b5-8b77-409cd7504769">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e70f7efd-f8f4-445b-a1e5-705f250d2f3e"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc2998d6-b08b-4d23-8796-58ce2e0f91c5"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/40e13fb6-98f2-40f6-9461-033855e4d264">
        <rdfs:label>Abnormal gait</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
        <dc:identifier>HP:0001288</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0804790f-cee2-41a5-b82b-642d14210a0a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8efc1c8f-74e6-40d2-925d-43d3ce3d7773">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/519ceb44-06f7-49b0-a9b6-e0946dfb0589"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a63cd4c0-98aa-4f55-9302-fa28cb2504ab">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28833550</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c6eacad-3e2f-4510-a2f2-4f2f894c923a"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145981">
        <dc:identifier>https://www.omim.org/entry/145981</dc:identifier>
        <rdfs:label>HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7736fdea-04f0-44f8-98da-d05540b8131b"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6d72f20-772b-454b-8aba-62086a19aee9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0c169b68-c628-4732-8740-9b0d6fe295d5"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d479243f-6e6b-4af4-ba16-5f5eeb5d78ec">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c59849b1-2c48-460b-9673-cbf550901d55"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3aca313c-ef5f-4768-ac09-b61ba7d60675"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac610b21-63d0-4f6a-a05f-7087aa7e4916">
        <rdfs:label>High remnant-like particle (RLP)-TG</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12801620</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eed3e36-8d91-4692-9ef9-c7305d97379a">
        <dc:identifier>HP:0031798</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031798</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Elevated apolipoprotein B level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/220bd0cb-eae7-4164-882f-1b7cd40563bb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High remnant-like particle (RLP)-cholesterol</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e59add31-1b0c-48b1-8772-fab2c64bee53">
        <dc:identifier>HP:0002155</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum triglyceride</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b1f9b00-2298-4333-869c-9cf9be6a1a35">
        <rdfs:label>High serum total cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9b3646a6-8897-4877-b60b-2e171de312c6">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/601987">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/904b407f-6f21-4c0a-adaa-3cce78351cdd"/>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/601987</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dae3544a-9631-4ee5-9274-de86e18be9ad">
        <rdfs:label>neurological damage</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000707</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15796a1c-633c-439e-b33e-c73fdf14d94a">
    <dc:identifier>DB00586</dc:identifier>
    <rdfs:label>Diclofenac</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08659e08-3395-4a87-9ae8-4a59f3f0cbf4"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00586</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d154d5c-3463-4619-8286-af4af5add837">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15c6c0ee-5fbb-43d1-881a-7cc791e726b4"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cd3a760a-10b1-43b1-b8dc-3da12491d3d3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/068e47e2-976f-4f60-a09c-b1c7565d4072"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/29835465-9bc6-4c99-9b17-24da15f6644f">
    <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16365882</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84ef3ac8-9b85-4bbe-b74a-efa97a0e6dbc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low 5‐MTHF level</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c95121ac-7cdb-4d69-94b0-b85e98cf7e1b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/45076fa7-2034-4a3a-9ffa-9d91a9332b79">
        <dc:identifier>HP:0002500</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002500</ddiem:url>
        <rdfs:label>White matter alteration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000011>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9c799369-fd69-4bf5-9d1d-0b0600024bef">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8931bf76-69a6-4e96-89bc-bc0b4ecf1a18">
        <rdfs:label>Calcium makes phototherapy more efficient</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10603107</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19752526</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26692114</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ed0262d-971f-40cb-a6b9-a5c78e707774"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ca95c71d-a53f-47f3-bf06-5a3faaff7232">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17a9cde9-7baf-48fc-91fc-5c2f85dbbd03">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3417d8b2-9466-4fbf-a48d-8a622df9f91d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b9052557-3af6-416c-a3dd-9ab6479e959d">
        <rdfs:label>Low muscle mass</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce118352-e66e-42bb-8b51-8f78df1b5452">
    <dc:identifier>HP:0012103</dc:identifier>
    <rdfs:label>Mitochondrial oxidative stress</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012103</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b22e530-b6df-4b45-89ab-5fc52a89cebf">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87039fd7-3f1c-4790-8894-e94930b90ee8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01115</ddiem:url>
    <rdfs:label>Nifedipine</rdfs:label>
    <dc:identifier>DB01115</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a759aa5a-a359-469a-86b6-15b8db12c9a0">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/577e4ff8-a5f3-440c-a318-c664b7b57357">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832064</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d07c736e-6be5-49cf-ab93-74bad9334cca"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83a106eb-b538-438a-8084-21571ef79b08"/>
        <obo:RO_0003304>"c.84−322A&gt;T, c.163 + 695_163 + 751del57, or c.164−712A&gt;T"</obo:RO_0003304>
        <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21542064</dc:provenance>
        <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Antisense morpholino oligonucleotides (AMOs)</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/21ae0f48-d5ce-461d-8d37-7c0da0a175a4">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6d1e8269-da0e-447b-84f9-83e173748dfe">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0008281</ddiem:url>
        <dc:identifier>HP:0008281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acute hyperammonemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21207059</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21403788</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/243500"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59f04063-4da6-4482-aba7-8be8eba7bc96"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/22ce15f4-b174-4ce6-92ba-9f1a539991a1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16214240</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76b8ffa7-58ef-4603-904a-1a4c40207f3a">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a13c4d18-9cb1-444f-bd8f-47429bad9f54"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7356db0f-8746-4171-980f-5d33f02fbbf4">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>cerebral cortex acetylcholinesterase inhibition</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3895de8f-e979-4b23-8700-a9398e8f204b"/>
    <rdfs:comment>α-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de310c97-80f1-47cd-b18f-dc6ed346b8a8">
        <rdfs:label>impairment of reference</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b52e56c9-429f-4f59-b453-63d89d92afcb"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6509881-780a-4055-a2e4-7b1bb9dee4b8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"hippocampal Na+, K+-ATPase reduced activity"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e531ab64-319d-4ed4-9bf4-959693eaab82">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a5916db-39c6-4094-9a83-eefe5fcb16af"/>
    <rdfs:label>5-methyltetrahydrofolic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04789</ddiem:url>
    <dc:identifier>DB04789</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/558262ea-fff1-467f-8480-4c144d8bdc6c">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719218300210</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1525001605000845</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6b7e483f-e192-41ab-a5f7-50305b640b4b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/da043740-d120-42ba-8f87-c19f3cb76f15"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b66e3cd-607a-4b89-8ffa-bb159ddc6db6">
        <dc:identifier>HP:0004923</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal blood Phenylalanine levels</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261600"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/51371311-2aac-4006-b9d2-93b1ff39a8bd">
    <rdfs:label>Lithium citrate</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1318d07d-f68c-4e7d-b12f-e6d5be982206">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c29a259a-c2f0-4adb-aebc-e9ca767b8cac"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0861bba1-5644-44e5-9f1d-7a5ebc62e54c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14507</ddiem:url>
    <dc:identifier>DB14507</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f0baa43c-66cd-4b4f-bcc0-912c2a9bde5b">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/68e98751-5c2b-49d8-a883-532f74d5015d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15637709</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10fa0655-d863-4e29-858c-3cfbeba8c268"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0d298a5-d565-400a-a47f-58ba42db41bb"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Cortisone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14681</ddiem:url>
    <dc:identifier>DB14681</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d11f3d2-447c-4664-ad06-9c6bf4f3f673">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19861948</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef68786e-e549-46ef-b0ae-f3f9a17d2c6c">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hepatic metabolic abnormalities ( Metabolism abnormality)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9dfd2e3-e573-4742-99d1-35d568091f64">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e712f7c-16d9-4aeb-a6e7-a88fb32a9f16"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64e3abc0-f0ac-4a93-b268-be0e7c592e6b">
        <rdfs:label>Abnormal neuromotor function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002333</ddiem:url>
        <dc:identifier>HP:0002333</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/87402942-1d17-4cde-923f-1d8cd4181786">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28057010</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25335805</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/600b3775-2861-4deb-b002-790642663806"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16868861</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6777479</dc:provenance>
    <rdfs:comment>The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/954cd9fc-e352-4d4b-981b-9aca8c6cbe64">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000938</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Osteopenia</rdfs:label>
        <dc:identifier>HP:0000938</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22402328</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0da45d00-84ca-4bf9-82eb-30a482d9134b">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af07731e-d8ae-4fee-9605-7e4d0da10cf9"/>
    <rdfs:comment>There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28919799</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/6ff7b366-7e43-4610-aeff-f7a16bcfb510">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d039b330-2213-41ac-81b2-806ea6b44c14"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a4ae849-cc1e-4f5f-af63-df2420edea3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24189473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/97b12ebd-564e-4bad-acbb-97f568130203">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c62b9f9a-afb9-42d3-b7e9-3852b3a841c8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e82b071-8ed5-4a94-90e0-972c2270dfb2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2637b605-74fe-4388-9203-19b28e7e4a6b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Mislocalization of R8L</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae0e5a18-854b-49fa-9c6f-f158bef60604"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c14864f-e758-46fb-873a-9009bd0d36cf">
        <rdfs:label>Sensorineural hearing impairment</rdfs:label>
        <dc:identifier>HP:0000407</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000407</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/96383228-d11e-462f-bdf9-525c7bbfb9b2">
    <rdfs:label>Inositol</rdfs:label>
    <dc:identifier>DB13178</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13178</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb9b291d-c95c-49b5-bd59-18a3837d8fbf"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e18bb3f-c2c0-4e44-9a88-c545af9c0756">
    <rdfs:comment>Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/</rdfs:comment>
    <dc:identifier>MP:    ....</dc:identifier>
    <rdfs:label>overall survival( premature death)</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_    ....</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8cc02b1-9c50-4ffb-9c06-ebf5cc35ba45">
    <rdfs:label>Probenecid</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/237c72c9-41e9-42b0-915b-85f6a06a7552">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7520501</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0a5ca1d5-bc1d-457b-886e-26c5da66278d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6fbf1401-0663-47de-8b6b-ef5b06bdc136"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01032</ddiem:url>
    <dc:identifier>DB01032</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b00127b5-8440-4c16-a121-d1c183b12f93"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/220ed301-c08b-46e2-8f72-29b0ea150c4c">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal lecithin:cholesterol acyltransferase activity</rdfs:label>
    <dc:identifier>MP:0011598</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0011598</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f56d8cc6-edc7-41b2-9383-c0d28475c0ba">
    <rdfs:label>high ornithine level</rdfs:label>
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44799c76-d36a-4c81-a36b-95f24ad98bc3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43b10b89-0785-4db5-8f04-96b4518c273c"/>
    <rdfs:label>BETA BLOCKING AGENTS</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C07</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9956bfdd-ee6a-475d-8d48-66ce14ed71c1">
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26067811</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4d84cd0b-0a13-4662-a29f-e0fb730d6b0c"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50b9b6b4-3646-4205-a9ee-032560cd1cfb"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da4941a7-ce2a-40e7-9a39-245e6e2f91e3"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>C07</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/991684cc-65fd-4db6-8b18-fa67436e1014"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/058a1df2-0032-43d0-9fc0-4991125420d3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ef31a7f2-a2de-42a7-afa4-1c37eca9b8c0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0a3c2bf7-ca87-42ee-8d44-391cea1e98c0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd6783e8-269d-4e76-886a-b7662eb14e7e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e0fe7f5b-f247-49e5-9359-032318ab930a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c856bb88-6126-473a-ad5d-9b33e7fdf4c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/610198">
        <dc:identifier>https://www.omim.org/entry/610198</dc:identifier>
        <ddiem:iembaseAccessionNumber>1012</ddiem:iembaseAccessionNumber>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1012</ddiem:iembaseUrl>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1907f093-9d0b-4e01-baa4-291343ed7221"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27928778</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c67aae04-5741-4509-892c-4c8952c9778b">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low Brain Copper (Abnormal copper levels)*</rdfs:label>
    <dc:identifier>HP:0010836*</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1d9df80-6058-4913-bb97-b71030b14915">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002275</dc:identifier>
    <rdfs:label>Poor motor coordination</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/25e8fcaa-a62c-4f26-9297-15553b8f690b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2610fee-abb6-4dc9-804e-8913beba831c"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1afa557-dbd7-4d4a-a2d4-99e36111ebfb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4d2e4fff-a5c4-4f03-881f-63195fc68861"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25620325</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b87b97b8-77d4-4400-803c-42b7000f632d">
        <rdfs:label>Decreased activity of mitochondrial complex I</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011923</ddiem:url>
        <dc:identifier>HP:0011923</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1a5421cf-dc34-453f-8c49-d255221490a6">
        <dc:identifier>HP:0025464</dc:identifier>
        <rdfs:label>Increased ROS production</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2348be2f-3d7d-40a7-9898-9ec0429d06f0">
    <rdfs:label>Recombinant human palmitoyl-protein thioesterase 1 ( PPT1)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48483bb9-ad37-4659-9715-9a39e3cf0b08"/>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/b68abdfd-8416-4039-83fa-52325c0272f2">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dcaf122a-1b9b-40f9-aa2f-d079aaeb6804">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>premature degradation of misfolded UROS mutants</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24145442</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/263700">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/111</ddiem:iembaseUrl>
        <ddiem:iembaseAccessionNumber>111</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a4dee27e-da3c-4212-b86c-c0d04fa69a7f"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/263700</dc:identifier>
        <rdfs:label>PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5946ae7d-eef1-4d87-be83-f54ae4812e63">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010473</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal porphyrin accumulation in urine</rdfs:label>
        <dc:identifier>HP:0010473</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcf810c3-9728-4cfc-a7b7-4ef087e79f51">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012187</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012187</ddiem:url>
        <rdfs:label>high porphyrin accumulation in circulating RBCs</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1f3f9f90-a9a4-4467-bb81-5d5f42303193">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:label>skin photosensitivity</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334762</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/61a30360-9e4b-4df9-9be2-58cbf5962aa0"/>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ef3faa05-d722-4f80-8e2c-e3e517cd3799">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b41e9f7-1c69-418b-8062-7bdb363aae18"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1f367b8c-73e6-4860-838c-54a2f6ddb12c"/>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29405935</dc:provenance>
    <dc:provenance>https://cdn.intechopen.com/pdfs/56869.pdf</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/75e14054-20e5-4b21-acad-f9578c9f15e0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000002</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000002</ddiem:url>
        <rdfs:label>delayed growth(stature)</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/46a21544-8b44-49ca-84b3-0cca9e140bf5"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/163beef5-7a4e-4761-9fe8-55ee3f307fc6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9dbe630-9270-4358-b6d8-3a46f36a989e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4778763-5d74-464e-a95c-eec305e38d80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/91255e43-7bc0-4d7e-8299-dde41423317e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>fine motor dysfunction</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
        <dc:identifier>HP:0007010</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a72fa2c6-1c85-48a0-bd1c-df800a715446">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002748</dc:identifier>
        <rdfs:label>rickets</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002748</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a8fa4d88-db63-420c-a631-e37e2cc7d929">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>respiratory insufficiency</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002093</ddiem:url>
        <dc:identifier>HP:0002093</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1d9d99f-0e2f-419e-86d8-138994fd8418">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>gross motor dysfunction</rdfs:label>
        <dc:identifier>HP:0007015</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007015</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/10d123a3-2e7b-4b6f-9ad4-c155cd758077">
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:label>growth delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X18300174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30083035</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dfc9e1b5-8054-460d-a9b0-7bf4aa9492c0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3f78336-d4d6-4e72-bba6-e789c268cd25"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00328</ddiem:url>
    <dc:identifier>(DB00328</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4a8335d-ada7-41e6-8cc6-e5f10811eb88">
    <rdfs:comment>In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011990</ddiem:url>
    <rdfs:label>Partial correction of neutrophil dysfunction</rdfs:label>
    <dc:identifier>HP:0011990</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d7712904-4aaa-4573-bca2-a0998f105cf7">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a41df7fa-ae37-45e0-bc23-63b972b1dcc9">
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>myoclonic seizures</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29739138</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/491af8d2-a9ef-434f-82fd-f2e392a6eb2a"/>
    <rdfs:comment>The treatment regimen resulted in neuroleptic malignant syndrome.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125370"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24816443</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28856097</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/53fa10d8-f0ba-4d1c-8f57-157d8080a862">
        <rdfs:label>Diminished intellectual abilities</rdfs:label>
        <dc:identifier>HP:0001249</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5a0524f9-9dbb-4204-acb4-d0878467552c">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f62cece0-8cd5-4c87-a5b3-26ebc36bd011"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66c39715-79a4-47e8-8423-e05500b45c68">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/674e44e9-c69f-4d76-aa81-817941e83072"/>
    <dc:identifier>DB00909</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc30824d-aa7d-4f56-91a2-e31cc0c3e50b"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/113a7e64-2273-46c4-b90b-141752ea669b">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14981187</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f13692ab-044b-40a8-bfd2-7ea67cbd7cab"/>
        <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9d00cdff-94ef-4c52-9e01-4b1f08a1a188"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Zonisamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00909</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/32f1e446-8519-4b28-810b-63b0f551dbb6">
    <rdfs:label>Slow background activity in the EEG(EEG abnormality)*</rdfs:label>
    <dc:identifier>HP:0002353*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002353</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e0159cb-c8f3-40b7-930a-f83104cb7c52">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5145a23-32af-4132-b8d0-d88a3f229437">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007103</ddiem:url>
        <rdfs:label>White matter changes</rdfs:label>
        <dc:identifier>HP:0007103</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29565174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0ddc0e67-c987-4d28-95fe-774430c584b2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5a9661bf-f0d4-44bd-ba9a-ba6107600f9e"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3b3b8fc7-e4be-4a74-a355-03065e5dd62e">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81d8be46-bd18-4be9-b0d5-32eb9e251f80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30264864</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c732f489-b144-41bf-83b8-618bbd9c977b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003656</ddiem:url>
        <rdfs:label>abnormal glucocerebroside level</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003656</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dca81e5-835f-4f62-b660-a590d2a35ae4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28935503</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231005"/>
    <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30247105</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29680197</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ddc6b4ef-bd37-4e20-af88-662e60b01cfc"/>
    <obo:RO_0003304>CYP2D6</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>http://clinicaltrials.gov/show/NCT00358150</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2205b10-bb77-4b74-909d-373fee813f2b"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52711171-ee01-4d08-bb1e-5f2636c04ee5">
    <rdfs:label>rAAV-GPE-G6PT</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37120c55-ca06-46c4-94cb-edca1eb09531"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/26767d9d-b452-4499-a4dd-136e2db48de1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64e4c4d9-2287-460d-8a8a-4c9d3e79c199">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012212</ddiem:url>
        <rdfs:label>Glomerular hyperfilteration (Abnormal glomerular filtration rate)</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012212</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15963056</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c856bb88-6126-473a-ad5d-9b33e7fdf4c9"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7da15996-05fd-4f10-b9a1-0b6f4564780f">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a30aca4a-12b8-43f0-b039-72adf58cb5a0"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28766015</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5dceb7dc-c98c-4b20-bdb0-7627160476df">
        <dc:identifier>HP:0001271</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001271</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Diabetic polyneuropathy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/341bc4f4-24da-40ad-a5a4-0c7cc25465dd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b8b5cb7e-1aae-4e57-ba83-c03d5af6b613"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d921f42c-a85f-4ca4-83cd-1cdb1f86d416">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010876</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010876*</dc:identifier>
    <rdfs:label>Defect in protein synthesis (Abnormality of circulating protein level)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/378e6f25-164f-4380-8775-110c158b4711">
    <dc:identifier>DB00996</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00996</ddiem:url>
    <rdfs:label>Gabapentin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e24ef934-6dc6-4cd6-b3ee-935dd406080a"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ceedbf10-2a96-4135-a49d-1f6b5cdbfc56">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b2366acf-41c2-4bf1-980c-299cf3059092">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/47bc4775-d7a1-4fae-8ef5-eb4a30fb547d"/>
        <rdfs:label>rAAV-PPCR</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d153d05c-68ac-4a6d-a608-a61cc19ae26d">
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1c3f963c-b8d0-4d8f-8f81-c6be0d302bbb">
        <rdfs:label>low β2 microglobulin,creatinine ratio</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/10d123a3-2e7b-4b6f-9ad4-c155cd758077"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/140350">
        <rdfs:label>HAWKINSINURIA</rdfs:label>
        <ddiem:iembaseAccessionNumber>22</ddiem:iembaseAccessionNumber>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f6a6ccde-995a-4b9e-b39b-f38c0f0179d4"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/22</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/140350</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb6dedaf-d8c9-4ccc-aa75-f842cfab889c"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/753bf00f-c130-4ed8-ae8a-11b182866dd8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
        <rdfs:label>failure to thrive</rdfs:label>
        <dc:identifier>HP:0001508</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6e68f27c-a71f-4946-a48e-0372d628c069">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b9d1c257-8621-4524-9f06-2ce362d74eaa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5b375a13-2e6d-4fa1-a160-df398320456d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4a8335d-ada7-41e6-8cc6-e5f10811eb88"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4dc61a73-9c4b-40e6-9161-2dba94fb0751">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ebf9a445-dc24-4cda-b645-4cd435d8840d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28126686</dc:provenance>
    <rdfs:comment>To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/7ebf7769-1fa1-404b-92ae-204038d2ac1b">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9073a3c2-81b6-4166-be9b-8041b05d7624">
        <rdfs:label>Splenomegly</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001744</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12064906</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16285070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01463215</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16199246</dc:provenance>
    <rdfs:comment>The drug was used in a pilot study.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b94e9fb-502d-41e9-b750-55d0af304614">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001873</ddiem:url>
        <rdfs:label>Thrombocytpenia</rdfs:label>
        <dc:identifier>HP:0001873</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/21443527-0fd3-4111-973e-73d1f09a1bc1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/49761585-89ab-4716-8b2f-3f86d38cdb41"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d40b6f66-a291-462b-a64f-46013bf91666"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e43d1abc-8d23-482e-8c77-a9c67974a287">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001903</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
        <rdfs:label>Anemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11227045</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a3eb6a3f-a9df-4478-acb1-a9fc818e029b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:label>hepatomegly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05c6e6e-4ae2-454c-87d4-3c99e759c8cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15505381</dc:provenance>
  </obo:DDIEM_0000012>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/00bc36f4-a308-4e3e-a2cf-89bc3b34dd4a">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/abc4842f-f053-4bb6-870b-4c018ef2c7b8">
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:label>abnormality in bone mineral density</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29503270</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d2c331c-64f5-4442-9104-183e91000c33"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00391625</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b8fe68fe-8848-4ae0-a992-1b7fb6b4e6bb"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8cda6bc-fc2b-4a0b-86a7-65253628e63d">
        <rdfs:label>avascular osteonecrosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010885</ddiem:url>
        <dc:identifier>HP:0010885</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f0cd8ae-dfc6-43d2-abf0-0bcedf85311b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b83be83d-f995-4fe8-9473-feda8cd760c8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7dca81e5-835f-4f62-b660-a590d2a35ae4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25801797</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02574286</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/107568a3-3ed7-41c9-a158-acb47a037398"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a97e983e-5a27-40ca-b925-0a55401098d2">
        <rdfs:label>growth faliure</rdfs:label>
        <dc:identifier>HP:0001510</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d3aa16f3-b2a8-4c13-976b-d1831c755489">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK442019</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12975208-ce3f-49ac-90f4-5594f99ebadf"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f46a2f94-9235-40a8-8c3f-c75e13dd0ebb"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3cca4a8-fc3a-4c56-95a2-4009aa66fee0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01609</ddiem:url>
    <rdfs:label>Deferasirox</rdfs:label>
    <dc:identifier>DB01609</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1c534d8-d2c5-4074-ae36-c6d22e9aecaa"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a3b96a4-39b7-455b-af28-dd8438e2a9f3">
    <rdfs:label>Glutathione</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1aea4fce-61e8-4a14-aff2-7ad087d958c8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00143</ddiem:url>
    <dc:identifier>DB00143</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0341e517-a386-4978-9d19-da3c63bc554b">
    <rdfs:label>The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/145750">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/773169c4-5012-4901-a15c-5e73b8adf910"/>
    <dc:identifier>https://www.omim.org/entry/145750</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>HYPERTRIGLYCERIDEMIA, FAMILIAL</rdfs:label>
  </ddiem:Disease>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6b81b717-c345-45c0-961a-66bda6e8fa08">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3731bc25-dded-454f-a1bb-7506422adb20">
        <rdfs:label>acute arthritis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001369</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118610"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17541659</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5c4219f8-7a91-447a-9534-84da40051c57"/>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0dc86461-7b02-4431-96eb-41cc6233fbe5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/723536fc-6aa9-4e42-a757-fe7b7957ab5e">
        <rdfs:label>pyroglutamic aciduria(Organic aciduria)*</rdfs:label>
        <dc:identifier>HP:0001992*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001992</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d63a20e8-38a5-4228-b42b-7e8d2d0ad202">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/238c1c25-b750-4855-b0e0-6ea207281dc9">
        <dc:identifier>HP:0004396</dc:identifier>
        <rdfs:label>decreased appetite</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004396</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2756a98-5ac0-42ef-98d8-8c9e2350c065"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1852fd19-e42a-4a0b-81c4-9665384dccf1">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eb0b1d8e-69d1-4218-a092-15ebb13c9c79">
        <dc:identifier>HP:0001977</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Thrombosis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001977</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/94af40d8-a7fc-48ca-8526-94ef2e271b6e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1c0eae31-aaa0-432a-8557-c01f4c54f536"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16767100</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/307030"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4b7bf1d5-f96b-4f02-9f3f-b1e11e27bba1">
    <dc:identifier>DB00697</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aff709bd-b144-4093-a5f2-40695810c0e0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
        <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b0f8029c-d735-43be-bcaf-23dcfb8329f4"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4aa9b35b-460e-49c9-824d-2439a69851a2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21735565</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612319"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00697</ddiem:url>
    <rdfs:label>Tizanidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/777071e8-2bab-4636-89d0-cd8e55d14806">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01001</ddiem:url>
    <rdfs:label>Salbutamol</rdfs:label>
    <dc:identifier>DB01001</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6113383d-bad5-462d-8315-cc2a86df74c1"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/72a889d0-ea87-44b5-9e28-925034a62bac">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26161337#</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4695a915-fa81-41ec-9a45-ac47bf6b413f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c763332-72ab-423c-9f7f-3e68f7d56969"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a4e9eecf-3c3d-459b-bbc8-2b0da5288c90">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High Apnea,Hypopnea Index(sleep apnea)*</rdfs:label>
    <dc:identifier>HP:0010535*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010535</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16be01ff-3fd6-4e48-9c9e-7bd436658248">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f80b7a77-2856-4e3f-91ac-bcbd930b0d6b"/>
    <dc:identifier>DB09210</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09210</ddiem:url>
    <rdfs:label>Piracetam</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/124da49e-3366-48e1-bfca-8310949bf0e5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23601642</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/srep37583/figures/5</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0f7d8246-e9a8-4e3c-911f-22768209e65e"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29247835</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <rdfs:comment>The trial was done on cell culture not model animals, authors of this paper " https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/" have mentioned that " Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system".</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f82f05d7-b73d-4497-bb30-b5005b0dd436"/>
  </obo:DDIEM_0000012>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/906f2e50-25a6-418f-be43-3592b917ffbb">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c67aae04-5741-4509-892c-4c8952c9778b"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d5f74f1d-524c-4e1d-b59a-f97c6b68a6ac"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22815746</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbefa83a-2fec-4af2-8ead-0051d211f5b5"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309400"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c13ed41d-63f7-4f62-ba5a-8129b1c2a393">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d02a7c01-11c1-408e-a8e6-3ec5cfe1a027"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9145952f-695e-47ce-a04a-6dac63108535"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30384011</dc:provenance>
    <rdfs:comment>However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.</rdfs:comment>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/298ec289-ce86-4af9-9598-bf0c8386c6cf">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15251700</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a2bd349-e4b9-462c-a6d3-44182df1afbb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2d07c692-ee69-47cb-931e-7066577f8356">
    <dc:identifier>DB01076</dc:identifier>
    <rdfs:label>Atorvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d8b462f-4bd9-46f9-96db-ea7725ca32e1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4cfff86-b3c7-42aa-8eaf-613a038d33fa"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/42dff221-d191-4ad4-b55d-6c8cca1c3ef1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01076</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d479243f-6e6b-4af4-ba16-5f5eeb5d78ec"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1267ccf-2167-41e1-a5b9-969af33733a2">
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16601879</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23690520</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261640"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8a65036a-7470-48b0-a05d-bd57378b1f68">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003117</ddiem:url>
        <dc:identifier>HP:0003117</dc:identifier>
        <rdfs:label>Abnormality in serotonin turnover (Abnormality of circulating hormone level)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25304915</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc8507d2-1b62-49e6-8056-10ee4d5594d7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/807c60e5-ecbf-4d87-825b-c8bc001a73d1">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5d2e4277-bf11-483d-a434-8b8c6c25d5f7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20631546</dc:provenance>
    <dc:provenance>https://www.nature.com/articles/gim201069</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/266ca317-978e-495e-9648-b50143a7fc18"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6fd4837-c501-4212-95df-168be14629ac">
        <dc:identifier>HP:0002240</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Enlarged size of the liver</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25153581</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ae570ff-1561-48ad-89c2-9601b81b9a2c">
    <rdfs:label>Metoclopramide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01233</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00f3fd0e-1018-4517-bcd5-a8e7d0dfd61e"/>
    <dc:identifier>DB01233</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/72a48ee4-1d4d-42fc-96f3-79393aeedb1b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24997711</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92efee6e-c0a5-4108-a0cf-13602d59b0a3">
        <dc:identifier>HP:0003236</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003236</ddiem:url>
        <rdfs:label>Elevation of creatine kinase</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4583189b-952b-4fe7-a131-73836697783c"/>
    <rdfs:comment>The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/731798ea-d192-4c68-91e2-3a2fc334efc4">
        <rdfs:label>Exercise-induced muscle cramps</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003710</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003710</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
  </obo:DDIEM_0000010>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1b355f63-829b-43db-8fd9-61ba83c241a7">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16848116</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1f3f6cd9-5832-41b9-9d2e-18268054e316"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba581f67-45af-4e4a-9680-4a233d1f036a">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0ba8b0b2-9a17-48fb-898e-00d0de499bdb">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d9ed12e0-5528-4085-ac25-c43c0e31841e"/>
        <rdfs:comment>https://www.ncbi.nlm.nih.gov/pubmed/8370580</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24137761</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/aad5f9d0-0c15-45db-adcc-8499950d01b0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26744272</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30811537</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <rdfs:comment>Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1fef71a-f930-4321-b257-66a351861db0"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11094</ddiem:url>
    <dc:identifier>DB11094</dc:identifier>
    <rdfs:label>Vitamin D</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5e8cb58-54cf-4f89-9cb6-b6df4151b530"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/778a5016-137f-4ad4-90be-870d414b8ef6">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f7a81e0-200b-44d2-8981-f027063e79d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/a1fa7d69-e76d-44c9-bf9d-5e6e87cca9e4">
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee7ae02b-4cce-43b9-910e-5c20bf2e4764"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
        <rdfs:comment>It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/034ac432-c930-4574-be19-6ba350c56e4b">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf20cc38-bdb6-47da-ab5f-c419e5c8e70e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d15866a7-1599-4fe4-be7d-0c33eebbc1f0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/623eaaf7-39cc-4524-a654-cca5921e32e4">
    <rdfs:label>Omega-3 fatty acids</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11133</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/933ce3be-e61d-4a10-8051-8ce9123a5490"/>
    <dc:identifier>DB11133</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/71ace21e-7d00-4514-a0f8-b1d713683b52">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1a5cefa-8cf5-4331-ad9b-1c623a310034"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10925336</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/3324a2c4-1808-49b4-becf-ac78bf2e4725">
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f97b9806-f9c4-4f6f-88b4-a00fbcfebb88">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012335</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal folate homeostasis in the CNS</rdfs:label>
        <dc:identifier>HP:0012335</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/758e197b-38c7-4d1a-acf6-1c23fde2ae5f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>depletion of cerebral folate</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012446</ddiem:url>
        <dc:identifier>HP:0012446</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d464f13a-bcba-44d8-a786-c3731daa73eb">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal muscle function</rdfs:label>
    <dc:identifier>HP:0011804</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011804</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e25b051b-0466-438b-8de1-eb986d6b9dd9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00026</ddiem:url>
    <dc:identifier>DB00026</dc:identifier>
    <rdfs:label>Anakinra</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9100c012-aa89-4b75-8582-a3e0531371e0"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4394b384-3e42-43fe-a899-b361604622cc">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/23089857-f554-4e21-af50-dc6af397b92f"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20712835</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67f2c891-a8ff-41fd-9283-1aaebe24b08c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b377b4e2-ca1d-4900-93ef-c86a76c4314d"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95694d82-ee2d-48b7-b8a4-3883bfa93404">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000992</dc:identifier>
    <rdfs:label>Cutaneous photosensitivity</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9a1426f2-4026-4c97-aba2-d7a62bff9e07">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43b54b4e-5327-4c8f-ba09-290d1e300509"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/226a0843-5e2d-47a4-bc3c-266b1d7e5423"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f107351c-80bc-4361-992d-b662a9f8d49e">
        <rdfs:label>Elevated urine mevalonate levels</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/78d54d3a-551a-4c3b-b43d-c5f60b81a367">
        <rdfs:label>Increased LDL cholesterol</rdfs:label>
        <dc:identifier>HP:0003141</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2092c2bc-f114-4bec-a890-3ae2391ab096">
        <dc:identifier>HP:0003124</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased total cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01371825</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7eb0f82e-33e7-4d1b-9dca-c1fa300c406d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000556</ddiem:url>
    <rdfs:label>retinal dystrophy</rdfs:label>
    <dc:identifier>HP:0000556</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b14cfb5f-07bb-4f78-8ae5-24e39fa0c501">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7938d5d8-6c77-4220-8e54-ca05337b6817">
    <dc:identifier>DB00679</dc:identifier>
    <rdfs:label>Thioridazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ec8435d-8cb5-486f-92d2-35e859cfad25"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00679</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/304d38d1-aac4-4614-98ea-06422be2c29a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74ec3a2c-13cf-407b-bfc3-7d7464fd164a">
        <dc:identifier>HP:0004322</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <rdfs:label>short stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/86021ead-2790-4022-acc4-de6f6008bb0e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8872ba0e-93f0-4884-8c12-f81de41ac1a0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301760</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b074ae59-c03e-4182-a076-c8954d68efae">
        <dc:identifier>HP:0011015</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011015</ddiem:url>
        <rdfs:label>Abnormal blood glucose concentration</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68e152d5-c15d-4b29-9ece-3cc0c385aae0">
        <dc:identifier>HP:0012378</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>Low energy level(Tiredness)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6aa48d42-2bfc-4e9c-8143-1dc38614edfe">
    <rdfs:label>Taliglucerase alfa</rdfs:label>
    <dc:identifier>DB08876</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08876</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a59578d-1a26-45c6-b020-7353f5fd9781"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3baeee1-ccd6-42e8-9453-a79f7239739c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00121</ddiem:url>
    <rdfs:label>Biotin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab4a12a7-1c94-4c4d-8285-ef14fa36b9bf"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/55546394-759c-4363-b373-7ee80e92936f">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e853763f-a77f-4763-9f72-9c8dc97577ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16773504</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <ddiem:failedToContributeToCondition>MCCB-(IVS16þ1G&gt;A)/ MCCB-missense mutation E99Q Homozygous mutation</ddiem:failedToContributeToCondition>
        <rdfs:comment>Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30b49202-1676-4ed6-89f0-84fdfcd0baec"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15877210</dc:provenance>
        <obo:RO_0003304>MCCA-R385S(heterozygote mutation)</obo:RO_0003304>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1213858b-58b3-4872-99a6-48a21cf6796d"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/210200"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e609a182-f092-4ef0-b8ca-b33b7d7a8eed"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0003304>"heterozygote missense mutation, MCCA-R385S"</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18155630</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00121</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/61988bcc-0a48-49df-8db5-264d86daab7e">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/45cf0b26-55b0-4ca0-9096-95b276235f09"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/241200">
        <rdfs:label>BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/fd0d3ec4-d641-47f4-8cc8-b1d187e5a78d"/>
        <dc:identifier>https://www.omim.org/entry/241200</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cab58010-8246-448b-a3ce-e68559c4b55d"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bd2d3746-84a9-421a-b154-1c436fc30106">
    <dc:provenance>http://www.scielo.br/scielo.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220120"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26247153</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/48f732b5-f9ed-41a8-b19f-a3b70e24e075">
    <dc:identifier>DB00123</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2dd313b5-cc2e-4708-a617-748835096f76"/>
    <rdfs:label>L-Lysine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00123</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b36c48c8-79cd-430b-89fa-bd09cf726aef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79f77412-efb7-4912-8613-5089bc1d6a09"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/015fff50-30c1-471b-98ae-a082f1a5f295">
    <rdfs:label>Sargramostim</rdfs:label>
    <dc:identifier>DB00020</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00020</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0856caf9-8fb3-47cd-9063-23ac7db6041e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0d185a9e-2dd5-45d6-bd9a-068792e3fb83"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4778d7c-a777-4575-859d-4b6e450f1280">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f222476c-a072-4a62-bb2b-2bb00159f35d"/>
    <rdfs:label>Amino acids</rdfs:label>
    <dc:identifier>DB09393</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09393</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/60949155-56ee-4c07-9cc2-15154a82df1c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a88cd3b4-352a-437f-80fc-48a993af8901">
        <rdfs:label>subclinical hypothyroidism</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000821</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000821</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26396722</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17132287</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0310b768-01c3-419d-aa0c-d2d9165ca67f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f8ce08fb-2743-4345-b3eb-c5af16d570e8">
    <rdfs:label>Fructose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04173</ddiem:url>
    <dc:identifier>DB04173</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7243f72e-8da8-4ffa-9702-b11722f08571"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d8b8f39f-1cea-4122-be32-4c299c8c57cd">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001943</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
    <rdfs:label>https:,www.ncbi.nlm.nih.gov,pubmed,19336674</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f9578226-e65f-4f79-bf42-d82bcae71805">
    <rdfs:label>Abormal liver size</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002240</ddiem:url>
    <dc:identifier>HP:0002240</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e875bd6a-42e3-4772-9298-ce97c81cad0c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8854af46-a910-440b-85db-1ddca9f788fd"/>
    <dc:identifier>DB00783</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72a889d0-ea87-44b5-9e28-925034a62bac"/>
    <rdfs:label>Estradiol</rdfs:label>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/d62949ae-2861-4e3b-8132-d2cef6ec1be3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/25758b58-5e32-441c-8216-c6421062ce04"/>
    <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24933563</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/568999e5-6a06-43ec-9a3d-53a988750de1">
        <rdfs:label>Low PBGD expression in liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c0eae31-aaa0-432a-8557-c01f4c54f536">
    <dc:identifier>B01</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1852fd19-e42a-4a0b-81c4-9665384dccf1"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B01</ddiem:url>
    <rdfs:label>ANTITHROMBOTIC AGENTS</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/628ce737-23ab-4303-af89-53e4413e27a2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001712</ddiem:url>
    <dc:identifier>HP:0001712*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High left ventricular mass index ( Left ventricular hypertrophy)*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d62c402-fd98-432e-a985-441766bcc642">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f1b3fb3a-974c-494d-aa74-a051fccb6bd4">
        <ddiem:url>https://www.drugbank.ca/drugs/DB08875</ddiem:url>
        <rdfs:label>Cabozantinib</rdfs:label>
        <dc:identifier>DB08875</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/38d8e494-1fd1-4439-b0e9-a144cad756e4"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/83bf1740-6894-4ea7-b89b-f3e5c91915a7">
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cf90e243-7fd8-4434-a678-1079aa338892"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31061755</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/355c6e73-75d2-4c10-a116-7a7666c73841"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7288a0b-afa8-421e-a0a3-91efb8150ef8">
        <dc:identifier>HP:0001298</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>encephalopathy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27749535</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da80a791-78b3-4431-8d0c-b283afdcdff3">
        <rdfs:label>signal abnormality of the cortex</rdfs:label>
        <dc:identifier>HP:0030178</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030178</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607483">
        <rdfs:label>THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/929a7de0-efec-4bc4-b7f9-83773738212e"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/607483</dc:identifier>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e853763f-a77f-4763-9f72-9c8dc97577ba"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/36e4e4a5-d74c-4bbf-bcfa-f39b99ba1c2a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal movement</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
        <dc:identifier>HP:0100022</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bcb2c169-9df3-461b-9352-7d47b069ea03">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18276179</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/666e482b-c704-42ec-b8e7-38d053b72494">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>levodopa‐induced choreic dyskinesia(Dyskinesia)*</rdfs:label>
        <dc:identifier>HP:0100660*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15389992</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/446d8a13-2d1a-4ee7-8f7a-86b1e1b051fa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ad0ce876-fc00-445b-b94c-f97329e5cc0d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/2b8bde74-4a08-4369-bbc0-73051a183097">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9686828</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11749046</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fa6de61f-98c1-447e-b7c8-c7f8213f2cb3"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8c72e16c-b970-49fa-9b2c-0002d22359a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002453</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*</rdfs:label>
        <dc:identifier>HP:0002453*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec394a12-b33c-4cbc-81a5-402cbef1b7e8"/>
    <rdfs:comment>A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/32f1e446-8519-4b28-810b-63b0f551dbb6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
  </obo:DDIEM_0000015>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/cdc49bbb-5a81-4c1b-8f1b-7a77d9414f19">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a2bd349-e4b9-462c-a6d3-44182df1afbb"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9493705</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9826fd07-d2d3-4408-b039-569331b67f83">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <rdfs:label>Low HDL cholesterol concentration</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a4a1c51-27cc-4fb8-8a86-026f54508d39">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b1ef97ea-3d89-4960-8e7e-a3f11b1fc4a6">
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e9897f46-d775-469e-b7a0-4ceca6f83355"/>
        <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_32030</ddiem:url>
        <rdfs:label>Kaliumbromid</rdfs:label>
        <dc:identifier>CHEBI_32030</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3a507886-4bac-4898-8b49-d631629e7151">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8011d37f-af0b-43d6-9dba-11645d0effc0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e3d386f-a07c-4edc-bdd5-a439f043e1f0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000127</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Salt wasting</rdfs:label>
        <dc:identifier>HP:0000127</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/82338e2b-0b02-4031-8afa-a7a98116455f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased life expectancy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49d7a246-fe50-44b5-87e2-39b8d3715c6a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Deleterious prognosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/378fe7e8-485a-4d26-a85c-d9f1d3ce7abc">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f11ccbaf-b22c-4d3f-a71e-d85c900afe3b"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b251f889-2857-4e9c-b169-4ca977667d52">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/09ec988c-e528-47bc-af29-485f723f92db">
        <dc:identifier>done</dc:identifier>
        <rdfs:label>"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level."</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/done</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03517085</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f571e97e-de23-4983-93fa-1a305d37a7e3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4a11183-6e74-495d-9f0f-87028e23d25f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20163245</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/f8d264c3-d6aa-4920-b582-86f6de40c5c0">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e8741c71-1f60-40c6-a392-39033310cbcf">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c14a030-851d-40f4-b12e-2fe96025dd93"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62d2d8a8-bf32-4ed0-b7cd-4b27954a5105">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002540</dc:identifier>
        <rdfs:label>loss of ambulation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002540</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9484cece-4888-476d-9947-2db1b26a10eb">
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>neurological disease</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3532ad7-9c34-4931-98a7-a268a5366daf">
        <rdfs:label>neurologic deficits</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29688815</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a031bb8-ec01-4e04-a561-7131dde39d35"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ffa7346d-1705-43f4-b3b5-79ecb8914d20"/>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94da83a7-92a1-47a2-8776-69391416a7f3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00186</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d8d3c95-85c1-4e0d-84cb-1b20cb2b199b"/>
    <dc:identifier>DB00186</dc:identifier>
    <rdfs:label>Lorazepam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e712f7c-16d9-4aeb-a6e7-a88fb32a9f16">
    <rdfs:label>rAAV8-mediated gene therapy expressing murine HMB-synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d11f3d2-447c-4664-ad06-9c6bf4f3f673"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c5243eb-0c17-4734-8eb9-bc79cd0761b3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01277</ddiem:url>
    <rdfs:label>Mecasermin</rdfs:label>
    <dc:identifier>DB01277</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9841c54-f937-455d-abf6-aef1f900037b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/39b1629c-e454-4cef-8d04-27efe83038f9">
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>behavioral disability</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eacd383d-63af-4433-a7d9-f0626cdb0a44">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <rdfs:label>low HDL-C level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/256540">
    <ddiem:iembaseAccessionNumber>319</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/256540</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/319</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GALACTOSIALIDOSIS; GSL</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d015184d-9310-47c5-a503-6b1452978a60"/>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/70a18b54-66a4-4a4e-9295-d4eacd178917">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a885e43c-769b-4399-925d-1c8c80eedf35">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004325</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low weight,growth</rdfs:label>
        <dc:identifier>HP:0004325</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f29ca0b1-b53b-46ed-b0d5-62e2397d9f34"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b93cc8e-ef27-4555-bd63-23246b92d6df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0929693X16302044</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/404774c2-7ec0-4ba8-b0a4-8781856e6e00">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/615558">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/25d10eda-f59d-4432-b96b-02558a75f895"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/615558</dc:identifier>
        <rdfs:label>HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0804790f-cee2-41a5-b82b-642d14210a0a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b9797c4-2bb3-4d8a-a30b-3225a29f0390">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Fat soluble vitamin  Malabsorption (Fat malabsorption)*</rdfs:label>
        <dc:identifier>HP:0002630</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26086616</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3083e06c-d491-4e35-9f40-cb812644922a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
        <rdfs:label>Fat soluble vitamin  Malabsorption</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002630</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cfef77d-b573-4cae-876a-873156a85949">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000488</ddiem:url>
        <rdfs:label>Progressive ataxic retinopathy</rdfs:label>
        <dc:identifier>HP:0000488</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24751931</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9dac01a5-6576-4c87-91bc-81cc38a518c7">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>http://www.jbc.org/content/282/14/10762.long#ref-14</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1c518db-f8e5-4725-b561-7a5b651b11a8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal Golgi located fucosylation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/19486efa-184d-4b9c-9c5d-be1cbb85b4d3"/>
    <dc:provenance>http://www.bloodjournal.org/content/94/12/3976.abstract</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d11f2377-b094-4f72-8459-075317bd2a05">
        <rdfs:label>low neutrophil count</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875</ddiem:url>
        <dc:identifier>HP:0001875</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35b2270e-df7e-4693-8985-2a18aba83d1a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal fucosylation state of glycoconjugates.</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/266265">
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c4158b3a-1e29-4449-a91b-115a1916e223"/>
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/341</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/266265</dc:identifier>
        <ddiem:iembaseAccessionNumber>341</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b59f7fa8-d1aa-4e83-8291-3b9e53fb2d3d">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b0eb7737-13b3-401a-9fa4-56bfb67b0c46"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a546c4f6-d18d-40a2-bef6-5ec1a1ed8fe0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fe09ff83-44ee-48d9-b756-c8691bb424e5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal expression of E- and P-selectin ligands</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29702557</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>the patient showed significant psychomotor improvement while on fucose therapy."</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d35855ae-860f-4201-b06c-98799abb8a9b">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>atypical psychomotor development</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II)</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7aa87e7-2ff4-41b4-b3b0-623d92d98c3a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002719</ddiem:url>
        <dc:identifier>HP:0002719</dc:identifier>
        <rdfs:label>recurrent infection</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17276979</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>correction of the delayed psychomotor development was expected to be more difficult to achieve. However</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/13a83ee5-7e18-4fee-8522-43f4d14089f5">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal selectin ligand function</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/156bf446-3546-426b-a35d-9fa385ddd126">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca05f8e9-2c45-4fe8-a158-5f7f3e5cddcf">
        <rdfs:label>Abdominal pain</rdfs:label>
        <dc:identifier>HP:0002027</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002027</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2aa45d7-53a2-4183-93ae-d71c741fe4c2">
        <rdfs:label>Hepatotoxicity</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3473dd3-f776-4c25-acb0-c12e6e9998b8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e7d872c-a594-4785-b3ea-d5ccab181146"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6723327b-1dc5-45c3-b859-288ce9e264b1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <dc:identifier>HP:0002910</dc:identifier>
        <rdfs:label>Abnormal liver function test</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3335288</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d3f8dc86-d4c1-424d-bac4-08643c8fb4dd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20375647</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7758200</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/576037d4-752d-4dd3-ab3d-e29f5f13735e">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
        <dc:identifier>HP:0000969</dc:identifier>
        <rdfs:label>Fluid retention</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10189233</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/460d0ca1-bb1d-4415-bffd-3b2e0e56203b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:label>Photosenstivity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/35144459-2e30-4769-9b65-bf088ee1ddcb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:label>anemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001903</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/76c2e63d-8a5a-4bc5-b69e-f527894d3f84">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8ba37bb5-4970-463a-b8dd-e34fb08ad9e3">
        <rdfs:label>ACE INHIBITORS, PLAIN</rdfs:label>
        <dc:identifier>C09A</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/636793ff-bf83-43f5-9317-0659c6cebf62"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43b10b89-0785-4db5-8f04-96b4518c273c"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09A</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/991684cc-65fd-4db6-8b18-fa67436e1014"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e515dd4-2064-491d-82b8-b45c30c073ac"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44799c76-d36a-4c81-a36b-95f24ad98bc3"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca9161e8-3a85-434c-b7d2-0db837b58c2c">
        <dc:identifier>C03</dc:identifier>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03</ddiem:url>
        <rdfs:label>DIURETICS</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/236d23a7-0e36-4d9f-8f67-4efecdd2c0ed"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/991684cc-65fd-4db6-8b18-fa67436e1014"/>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/190e74ab-8b65-4ff6-8a4c-cd81931ec409"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/acd8fab2-f214-45ac-9df9-d3f889c764eb">
    <dc:identifier>HP:0012759</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012759</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Developmental abnormality</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3417d8b2-9466-4fbf-a48d-8a622df9f91d">
    <rdfs:label>(r) AAV2/1-mediated calpain 3</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ca95c71d-a53f-47f3-bf06-5a3faaff7232"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/56daa45b-9cc5-4824-94d2-5dd0820f03f2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30081189</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/acd8fab2-f214-45ac-9df9-d3f889c764eb"/>
    <rdfs:comment>Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20356773</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f8a862f2-5cb8-48fd-8b76-299748266658">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4911235-89a3-4bd3-a798-68c734a88a2f"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00638547</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603174"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/476f4540-ae83-42d4-8a34-37490823362e">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24524914</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92011b3e-284b-4281-9418-4032f2eac206"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/547c211f-9044-43fe-b825-9b100a5dec78">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ecb4f36-123d-4e10-84ac-913f728b559b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09046</ddiem:url>
    <dc:identifier>DB09046</dc:identifier>
    <rdfs:label>Metreleptin</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/38d8e494-1fd1-4439-b0e9-a144cad756e4">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e18bb3f-c2c0-4e44-9a88-c545af9c0756"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a85e416-3acf-40c6-9925-b774daf4df3b">
        <rdfs:label>Low tumor response rate</rdfs:label>
        <rdfs:comment>The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501</rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdfs:comment>Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6da6877-c6fb-4f5b-91fb-3e902a9be04e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21606412</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9324189e-3439-4d9b-83dd-c89618f8d421"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2ebcac5-2571-449a-bb5d-55b7b160c96a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d62c402-fd98-432e-a985-441766bcc642"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00215605</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24002501</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/89ca44e6-99bb-47ca-96e3-e6a058d65ce4">
    <dc:provenance>http://www.medlink.com/scripts/mpdf/print_friendly.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef528711-ef61-4178-8c97-8679e967527a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <rdfs:comment></rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b9bf1663-f897-4fbb-989e-25431e07aaa9">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0edc4d2d-d760-44eb-b102-2b1ae1864a10">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d5e96940-e51f-4b00-ae2e-cc15c9e4a1ac"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/59c306bd-9efa-4bbb-83ae-9b4aac6ec653">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8298ff83-c7a3-4e14-a7c9-b4a829a6d2f7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/aee6c829-ce72-4fc9-afac-d08058afd682">
    <rdfs:label>Glycosade</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/485be3a2-9afb-46d3-867f-c682bee77fbb"/>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/ae2ad46e-f21f-4988-bf22-e3ef86b49d6d">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/45b83ef9-4976-40d7-a592-92e299fa2021">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/184b1fdb-96b1-49a1-abc7-91cf02107b20"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01161576</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000009">
    <dc:creator>leechuck</dc:creator>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is depleted in molecules closely related to the products or end processes of a genetically defective protein which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:24+00:00</dc:date>
    <rdfs:label xml:lang="en">dietary exclusion</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7efc4091-c48a-49bf-af8a-d35a0f68f43d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No result is  added</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/906ea95c-f88d-4cb0-84f7-af7801ed9155">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/73851382-ce75-49f6-b9f0-0e9f2843503f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cee77840-7869-4ec2-a434-6d2dbc188d90"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/774a8b11-d731-42dc-8c68-e7bf4298e21b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003645</dc:identifier>
        <rdfs:label>Abnormal aPTT level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003645</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae19cc9d-63b2-47a2-9005-0de3da7ddfb0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001976</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal Antithrombin-III levels</rdfs:label>
        <dc:identifier>HP:0001976</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0b468030-d214-4860-9e94-5e9b26ef4380">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal nucleotide sugars</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28617415</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614921"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b3c1e67-12b7-4e03-949c-c0f411b5f94b">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal ALT level(Abnormal liver enzymes)*</rdfs:label>
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9d1c257-8621-4524-9f06-2ce362d74eaa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24499211</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71de8254-635d-49dc-a722-5ed5ad20a0ff">
        <dc:identifier>HP:0002910</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002910</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>"abnormal alanine transaminase,"</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5e9a3c51-a9e9-40fb-bfbf-ebbaf0c76601"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fea19929-ce0c-41bf-af15-a2bb793a46ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12756558</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/75ad5bef-c038-48c5-a45f-e4a56ebc8165">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f98437-5ac2-4723-a925-725225e80625"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d53bd1e-f302-4a3f-b014-301b94a26dfc"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9fba1654-e531-45df-8fe8-ee98c72de6e4"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26954033</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ffcbd91b-900a-446d-a595-04a24fdd0d7b">
        <rdfs:label>Stroke-like episodes</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002401</ddiem:url>
        <dc:identifier>HP:0002401</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15728297</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f70f2c81-445b-48c4-a8c9-57b63b079902">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Painful neuropathy(neuropathy)*</rdfs:label>
        <dc:identifier>HP:0009830*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009830</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/736141f9-7f4b-4c50-9167-ff16007ca890">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/69fcef0c-1f73-41ce-85e0-4157229784d0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/962bab8a-e944-4b4b-949b-78475fb19720"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <rdfs:comment>Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9185508</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b39db228-0dea-4e00-ac0c-1ff91d5bd5a2">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002621</ddiem:url>
        <rdfs:label>Atherosclerosis</rdfs:label>
        <dc:identifier>HP:0002621</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/162e5d97-a0ad-4b21-b1ea-abe2138ff385">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756475</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e088253-ec29-43f5-bcdd-94130c531deb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/376db4c5-bd07-4b83-bb7c-5c42e4b8b49d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/61203e1a-869b-4313-9f98-d325e1951f31">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23527792</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02363946</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdfs:comment>The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3a56d0d3-2171-416d-b65a-51e9142f6740">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2bda0be5-ab01-4600-9560-43bd10998392"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02900183</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613490"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30477028</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30049652</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f565214a-1db8-4d12-8b52-9db6c6a0d694">
    <rdfs:comment>Further data gathering is necessary to determine overall outcome of patients on long-term therapy "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/78d33c56-d102-4cba-a439-145d794593b3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/98b7bcfe-9109-44fb-b591-140d83d047b7"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0d340b8d-33b7-4085-8e56-b6e0b79cd1e4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7107cad7-7649-4d7b-908c-d835ef5781b1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd3a44a4-3711-43eb-84a1-efa6be3a6ae1"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/666c257f-cd01-43e5-b26e-a716fde2e56a"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/350bd54b-a38b-4c8b-9e71-88013ee043b1"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cc218516-baf5-4c86-8b06-b5507446beef">
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/165cb61e-5e33-430e-bc92-5eb126015d06">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/848eb0f5-8b24-46d8-bd69-53f626c23348"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/600890"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16040264</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1a10ef5-8ef9-4885-bd0f-6374451dddda"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cf1bbd3b-9c15-4dbf-890e-4af8511bfe28"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03756</ddiem:url>
    <rdfs:label>Doconexent</rdfs:label>
    <dc:identifier>DB03756</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/26bc67c9-9c3b-4800-bbc0-06bf9c251e49">
    <rdfs:comment>Poor compliance to the treatment was noticed</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/92011b3e-284b-4281-9418-4032f2eac206"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1a5cefa-8cf5-4331-ad9b-1c623a310034"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19820022</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/47dd31fa-9976-4df0-8a9d-a5af912385f6"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cf1bbd3b-9c15-4dbf-890e-4af8511bfe28">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cc218516-baf5-4c86-8b06-b5507446beef"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9c6d9241-e530-474c-a3dc-b7e6fcb18b13">
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <rdfs:comment>All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004450</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0f1c4364-5fad-4591-87b7-26dfead22c79">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>NO revealed clinical benefit</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10870849</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d675be77-2bc1-498f-9877-dcf20bb47703"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eea2e652-0ff2-47e1-b816-8f2e4b7d1bad">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/86000f7b-1ce9-4976-bee9-dd11a8cfdff0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300100"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e8bf113f-38af-4f73-8462-6ed8ed0a8c95">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f22bee7-9c00-4d15-a063-d9d856e094a7"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/8efc1c8f-74e6-40d2-925d-43d3ce3d7773"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/87c9a228-e22b-4bfa-a11c-27a5ffe59083">
        <rdfs:label>Bleeding tendency</rdfs:label>
        <dc:identifier>HP:0001892</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001892</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5bcc7568-f84f-4612-9eec-7b21464ac4ef">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31f3550d-6e39-47e2-b652-43af14c9bb4f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ca69b4a8-1a77-4d3c-804b-e256b8b7f1e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7783847c-7672-45f9-8db8-bce3c71138cd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <rdfs:comment></rdfs:comment>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0b3f50af-9565-458f-8883-2dbda762ebf8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613933</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bf7b5926-4d7f-487b-b788-e1b1e1f21116"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
    <rdfs:comment>It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1181</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612953"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5ee4a2c-778d-42b7-9457-24f694d598bb"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3f6e3d0-828f-4d3b-951a-a2d6e231cd94">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0001426</ddiem:url>
    <dc:identifier>MP:0001426</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>polydipsia</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f28ab07d-4807-479f-b6d2-1803e3f0aa50">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9b5a585a-e25e-49b7-86ba-7ec2de20864a">
        <rdfs:label>volanesorsen (IONIS-APOCIIIRx)</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7905b4c0-3815-4699-ace9-1cb374fbd537"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/bc02a4bc-648d-46e8-9cba-0d26ea65ebc1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
    <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/53d26fab-5080-40b0-83c9-db4dde088169"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000005">
    <rdfs:label xml:lang="en">mechanistically predicated therapeutic procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T17:59:32+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure which directly addresses the effects of a protein defect produced by the mutation, its structure, activity or end product. Therapies which target the local interaction or regulatory network or pathway in which the affected proten lies are also regarded as mechanistic therapies. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2436c0be-9b6b-483e-81ca-ef9b305e79f3">
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/02e286d8-3761-468a-9954-d523f0c56ebb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cf69db97-2867-422f-9388-c7c54aafaa79"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11723211</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4a1e2edc-7bf7-40e9-873f-48b513e8d6bb">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5291c6e7-e9c5-4ff6-9811-540a05dab633"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5a4dfeca-6768-4ec1-88ac-0530961209ed">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001129</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Large central visual field defect</rdfs:label>
        <dc:identifier>HP:0001129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d8daf8c6-8bab-40be-95ab-0d519fcc0409">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f56ea74b-8173-4162-b5d2-56433b7f8ad9">
        <dc:identifier>HP:0005952</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased pulmonary function</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0005952</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f2645623-1ac1-40a4-881e-1b8206bf40f0">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Six Minute Walk Test</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a4e9eecf-3c3d-459b-bbc8-2b0da5288c90"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dab8fa5a-d9bc-4382-b421-6da0522eef87">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:label>Limitation of the Joint range of motion</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27ef9429-54e2-4354-b52b-a3775f6c87c8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8ca3f762-2c3e-41af-8a9d-7cfed79c3b49">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002111</ddiem:url>
        <rdfs:label>Low Forced Vital Capacity</rdfs:label>
        <dc:identifier>HP:0002111</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00912925</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a4fad6e-f875-43f4-a80f-df4a048cbf86">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/7ef27135-58c0-43b5-8773-5c0512c9fd4c">
        <rdfs:comment>The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602473"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16376514</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d2e3f39b-d674-4410-a8ef-d1554afa717e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29526615</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27830356</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15352507</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dc86461-7b02-4431-96eb-41cc6233fbe5"/>
    <dc:identifier>DB06151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95018197-9fb3-43f0-a56f-cdb2b89c90e7"/>
    <rdfs:label>Acetylcysteine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5fb0e68a-cfd8-4509-bf0d-5ebc4d63faaf"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/016d646e-a2f0-451f-8b2d-400fd332be8d">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11095909</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bac5ce7b-453c-4381-8cd9-9c08f12a64aa"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11089562</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20868666</dc:provenance>
        <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231950"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/c628074e-cc43-4a13-bffc-045930598729"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e4147282-f661-496b-838e-7863319d9c58"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/95210585-9a07-4310-839f-7c26e3834b56"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d71ae1a-f87f-4c09-bf1d-5e2565d706e0">
    <rdfs:label>high serum bilirubin level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002904</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002904</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/592e2f7b-1b5e-445b-946e-93c84b8caf45">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28967191</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10657992</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208400"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2796be0-3c89-4ab1-ad7f-45db86527cd1">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
        <dc:identifier>HP:0001939*</dc:identifier>
        <rdfs:label>High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*)</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc7d9973-c771-4252-bc2e-513c608744c3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>accumulating substance aspartylglucosamine from ( Metaboic abnormality)*</rdfs:label>
        <dc:identifier>HP:0001939*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <rdfs:comment>There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f79775dc-ec00-4d52-9792-77b90c543dd7"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03181963-a443-4f04-bf99-17eb27d1704e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5154719e-c58a-4b4a-83cd-2db13e7e4524"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15342551</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8fc55dd2-43a1-4bb5-a9f8-1543e6e129e4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20607610</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a44ce51d-06df-468a-a66b-bace6a2efbc4">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/24deefd0-e6f1-4455-9427-7638ea414556">
        <rdfs:label>Limited Efficacy of the drug.</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d675be77-2bc1-498f-9877-dcf20bb47703"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11504824</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dd2522d3-7c80-4ec6-8dc4-3e6710578efa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/158797ba-2930-41f6-8de0-d6d8f770b428"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01012</ddiem:url>
    <dc:identifier>DB01012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a63cd4c0-98aa-4f55-9302-fa28cb2504ab"/>
    <rdfs:label>Cinacalcet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/549860b2-6602-4333-baa4-b08966a3d18c"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01630429-3fbd-4e29-befe-28d0abdb7fd1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20981509</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28314c5a-ed3f-4667-b00a-647bba447840">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001263</ddiem:url>
        <dc:identifier>HP:0001263</dc:identifier>
        <rdfs:label>Developmetal delay</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1d6a9a02-34c8-46e9-b704-98498428bd15">
        <dc:identifier>HP:0001640</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001640</ddiem:url>
        <rdfs:label>Cardiomegaly</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef31a7f2-a2de-42a7-afa4-1c37eca9b8c0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b2ea7da-fa38-4f5a-933e-a8f63748bbb9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18632498</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9578226-e65f-4f79-bf42-d82bcae71805"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cd6783e8-269d-4e76-886a-b7662eb14e7e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30070157</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f04e9a32-7a8e-4493-a638-94f739ef50a7">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/380b6ef1-acee-4859-88cb-79a35b56b8c6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3ea8285f-859e-441d-aeb2-1598138bad9b">
    <dc:identifier>CHEBI_28384</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eef9e8b6-f7e7-44a4-b4c5-c99743dbe99d"/>
    <rdfs:label>vitamine K</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_28384</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8e2815e4-bc85-4e59-96ab-2671a6b002ed">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ef528711-ef61-4178-8c97-8679e967527a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/07c8209e-eea1-48a9-a03f-bb9b05ec58f7">
        <dc:identifier>HP:0007359</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007359</ddiem:url>
        <rdfs:label>Focal seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10590041</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e5dd34a-76fd-445c-8990-bc2a25c49797">
        <dc:identifier>HP:0002069</dc:identifier>
        <rdfs:label>Generalized tonic–clonic seizure</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002069</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/267e6792-3216-472b-a18f-14a5f61cdd21">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1b6c3de7-bf41-4d91-9561-532867cf657a"/>
    <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a1ea280d-cf7c-4b15-aa9e-0ca32b28e428"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310e73a6-4284-474d-9904-65f160f76372"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c3cfae03-dd57-4854-85b0-5761aff7ac31">
        <dc:identifier>HP:0002317</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Gait instability</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002317</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0ecbc3e5-d9d3-40a4-8134-938cb5542d98"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7357085</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c7e5344c-3284-41f7-9a8a-f6c035778392"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6749192</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/45289a2f-c8f1-4d7d-854d-d51839898d6c">
    <rdfs:label>Duloxetine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b265420c-1264-4031-89b6-e1931596b50c">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a5b32c6e-7a10-46c1-876e-e264e6f11ec4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ba78866-59fc-4d10-9f17-88bb50177fdd"/>
        <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00476</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00476</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ece4588-0d68-4fd2-b0dc-1274ec75ffaf">
    <rdfs:label>Bromocriptine</rdfs:label>
    <dc:identifier>DB01200</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01200</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01266b17-e319-4d0f-a42a-071419785b6c">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5f4eaf68-7f84-4f31-88eb-0616377e6469"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6579cf0e-0aae-4409-bd6c-a9aa7ee2b451"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc74ce41-028c-4e50-bea3-21e06ba1fac1"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/03a245fe-d65c-4052-9ff7-87ca3c627b5a"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/31e32232-8719-4002-a9a6-619d39b1d59d"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6fbb3341-1500-403a-88e8-5141502184a7"/>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d493817-2ade-46e0-a225-d202c36aebff"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa6a5fb-f153-405d-bd9e-4b99317b5411"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee9272c6-2940-459e-a51e-56ccefe1c6e3"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94c8575f-2edc-4ff0-b37d-ca8b6692d5cc">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00742</ddiem:url>
    <dc:identifier>DB00742</dc:identifier>
    <rdfs:label>Mannitol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bccbd83e-a4da-46ab-a78d-e0ad5c78905e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43dfa170-99c8-4be0-a11b-6415c3210e62">
    <dc:identifier>DB13959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/441b1e41-d576-4db2-baed-23bfee14441c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e153c4e-0ee7-4544-99b0-176ef15973ef"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13959</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d153d05c-68ac-4a6d-a608-a61cc19ae26d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b376d3d-effa-475d-a2c7-70e44cd9965c"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b723b66e-1527-4729-8034-a6de603d2c4f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20357432</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7cba8f78-1907-4950-b32d-00301c85b057"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f9ad1934-8b8c-49a1-9bd6-0ae9dbbeb830"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9b25e941-a313-42e3-80bb-9cc18745540d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614308</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/212138"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19452263</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb066d4-d587-4fec-bd89-aa23900bafdb"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70a18b54-66a4-4a4e-9295-d4eacd178917"/>
    <rdfs:label>Medium-chain triglycerides</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/8bb0583c-ffd9-4064-aefb-6cd183bac25f">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649527</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28781843</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aeb8cd51-8113-4697-ba26-10b3207fc6af"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26858006</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24886114</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba9efbc6-b149-4e58-a6a2-c69620637e55"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248360"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b5312f6a-b2cd-469f-b68d-67a692c89e12"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8832e3ca-f229-40d5-942e-def1b420b12f"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/01d2c943-7ea3-4d8f-b875-a578e0f21e16"/>
      </obo:DDIEM_0000008>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b3646a6-8897-4877-b60b-2e171de312c6"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64e1a981-09f0-4258-b36a-029010c63f0d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007367</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>CNS damage progression</rdfs:label>
    <dc:identifier>HP:0007367</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/198d9bb6-530f-4b89-80e3-5ad81d535449">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>Abstract</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/203750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75227ae7-1348-4d0e-a986-b6f55bb89472"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a77622e-6d0a-4c85-920d-e574ed3b2c81"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a6876a44-943e-44ef-b713-99fd1dcb5e1d">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001249</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001249</ddiem:url>
    <rdfs:label>Poor intelligibility</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9d00cdff-94ef-4c52-9e01-4b1f08a1a188">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002123</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
    <rdfs:label>Myoclonic epliepsy</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3bb61825-13a8-4543-a9c0-949490c795f6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB02772</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9f666618-e6f3-495c-9dfe-f77d3b055baa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f15fcde2-bd96-4660-9772-29b5580b501c"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d93b319c-7c68-4cd9-bd62-fabefdd22a25"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
        <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB02772</dc:identifier>
    <rdfs:label>Sucrose</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b709afc2-3a3d-46be-9a37-5ba0fb6ec0cf">
    <rdfs:label>High total plasma cholesterol leve</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51b9357d-269d-48ab-9cb8-31030a454f7b">
    <rdfs:label>mitochondrial dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003287</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003287</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fcfc709a-8264-4ad6-88ac-e57a95bd8ef6">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Voice tremor</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012477</ddiem:url>
    <dc:identifier>HP:0012477</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67f2cfd0-7556-4e27-963a-f3657f73496c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00016</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72534857-6c28-44f1-ad9f-df814d2cb78b"/>
    <dc:identifier>DB00016</dc:identifier>
    <rdfs:label>Erythropoietin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dddf590d-8674-4f98-aaf2-c186bfab5d12"/>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3be7c9db-1237-4003-8df7-0df6a2e227a1">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/840e1ef6-8299-42b5-85a5-794bcecc6775">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypoalphalipoproteinemia</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
        <dc:identifier>HP:0003233</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18993152</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9826fd07-d2d3-4408-b039-569331b67f83"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604091"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9494790-1cb2-4e6a-bf33-f54ba0aea29f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01942291</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5602c0e-8ddd-40e4-ba1b-edd6c9721046">
    <dc:identifier>DB15066</dc:identifier>
    <obo:RO_0000056>
      <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/20579f5f-1bfd-4dba-b878-b9cfdbbaf94b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30726693</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02452372</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30766957</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c53279e4-cb05-4dde-a04e-a99f9ec32433"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24821812</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/64e0ddad-e026-4de0-88a4-79a5b7355264"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
        <rdfs:comment>There is a study for "Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317</rdfs:comment>
      </obo:DDIEM_0000015>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB15066</ddiem:url>
    <rdfs:label>Givosiran</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/16804c09-f2d7-4eca-874a-3b4d4aaa3cee">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0022202X15441491</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176100"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4811840</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e97ac4e2-1e80-43a1-9000-7ac04624f667">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012465</ddiem:url>
        <dc:identifier>HP:0012465</dc:identifier>
        <rdfs:label>Increased liver iron level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <ddiem:failedToContributeToCondition>C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation)</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7324107</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6173993</dc:provenance>
    <rdfs:comment>The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cb179ee4-ba58-4ba0-bdbf-5cce6d70edb6">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0012463</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012463</ddiem:url>
        <rdfs:label>Elevated transferrin saturation</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5080345</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/71316f17-6be3-49aa-ad0d-47ea713cafe4">
        <rdfs:label>Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
        <dc:identifier>HP:0010472*</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0facf12-d718-4377-a283-3942f90c2cb6">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
        <dc:identifier>HP:0003281</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Increased serum ferritin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12622622</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5208dfca-4900-45e1-848e-716cdc3c5234">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e75573cb-267c-4243-acb1-118eb0ce4fc1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4739135</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/799cc5c9-34ad-4385-9587-2370fc795dde">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003452</dc:identifier>
        <rdfs:label>Increased serum iron</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22985607</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/04abc49f-1fdd-4a40-8064-81b92f4f980d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3324a2c4-1808-49b4-becf-ac78bf2e4725"/>
    <dc:identifier>DB00650</dc:identifier>
    <rdfs:label>Leucovorin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c482c83e-08ef-4df0-8d5a-ceff9b3b44e2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d98196c3-6421-45d5-bc71-b8d97bba0999"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/29835465-9bc6-4c99-9b17-24da15f6644f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e83104c1-d8ec-470e-994f-c94fbb0f0dc8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00650</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/498e87a6-13f6-43ab-9e71-0927e27dc2a5">
    <dc:identifier>DB00034</dc:identifier>
    <rdfs:label>Interferon Alfa-2a, Recombinant</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00034</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4674c66-053f-4959-a0d1-33a27ae6399c"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d698d9e3-da4d-41cc-9924-88ae7b962d02">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be7ac3f0-65dc-45a5-b7fd-7548f512a07d"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23456528</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e4b75ff0-c587-497d-a40d-cafa0e7ffd87">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fa0ed094-3a3c-4650-824c-78a85003fab8"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/29116606</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/235200">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/203</ddiem:iembaseUrl>
    <rdfs:label>HEMOCHROMATOSIS, TYPE 1; HFE1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/235200</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c9cb58c7-fef3-4b22-a651-0469cf570339"/>
    <ddiem:iembaseAccessionNumber>203</ddiem:iembaseAccessionNumber>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/069744d2-e093-4be9-be9a-92bbf43ea273">
    <dc:identifier>DB00145</dc:identifier>
    <rdfs:label>Glycine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/124da49e-3366-48e1-bfca-8310949bf0e5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00145</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5c8baede-8961-4d9a-9bde-7cf0f6c17769"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4f3d872a-2fed-4472-9743-a3f5719473f9">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0ec8a9e-6300-4db5-9efe-a95871d3067f">
        <rdfs:label>low proximal tubular reabsorption of bicarbonates</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0004910*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004910</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bbb04ad0-e1a6-451b-b623-1580209a36cc"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/930dd6ce-ef36-4149-9561-d529ebf9ef58">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11767031</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <rdfs:comment>Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a631293a-8e1b-4c1c-beaf-91e6b5a45a80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14749227</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/55c871ca-b617-42e0-ad14-8174b751c3c3"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0804790f-cee2-41a5-b82b-642d14210a0a"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/208920">
    <rdfs:label>ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/95016809-9cba-4bc4-859d-6e5c860689ba"/>
    <dc:identifier>https://www.omim.org/entry/208920</dc:identifier>
  </ddiem:Disease>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/cc9dedf6-887b-41eb-bfea-51d87189ab83">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e27abeb3-07c9-4b39-acf0-dde68edc6c0e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7a10a125-b9c9-442c-b30d-df2ed44bac36"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1800965</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47043c3f-475e-4ece-a84b-22987b7dad7c">
        <dc:identifier>HP:0001735</dc:identifier>
        <rdfs:label>Acute pancreatitis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001735</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/03a245fe-d65c-4052-9ff7-87ca3c627b5a">
    <rdfs:label>Oculogyric crises</rdfs:label>
    <dc:identifier>HP:0010553</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010553</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/f2ba6bbb-ab48-4402-9055-f104425801f7">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dcc4c654-f88b-42a5-b9a8-64df7bd50d5f"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e031c8ac-12ae-42c8-9b12-465b430489aa">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009051</ddiem:url>
        <rdfs:label>high glycogen levels in muscles</rdfs:label>
        <dc:identifier>HP:0009051</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8991475f-07bf-4297-a6d8-da9b044b41c4">
        <rdfs:label>liver fibrosis progression</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001395</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24509886</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9ed8d2a0-edf7-4587-b824-9c0b511eb0a1">
    <rdfs:label>Copper</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09130</ddiem:url>
    <dc:identifier>DB09130</dc:identifier>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/189e4af0-739b-4d59-bb6e-fabdfcf0f987">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/121270"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/678bc98f-ac87-4c9d-80da-1305651dd1b8"/>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719215300895</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dbefa83a-2fec-4af2-8ead-0051d211f5b5"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55f510a0-8e8a-44fd-9e39-c41a5b72adb0">
    <rdfs:label>hepcidin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95f83d4d-ba1c-4132-9ede-9d4671237315"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/519ceb44-06f7-49b0-a9b6-e0946dfb0589">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01022</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a88bc1c2-b64d-46b5-8b77-409cd7504769"/>
    <rdfs:label>Phylloquinone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8bf113f-38af-4f73-8462-6ed8ed0a8c95"/>
    <dc:identifier>DB01022</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3edaa723-7ec0-4a07-90ff-2ba4fa6b5cb1">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b704ebe9-7659-4e39-8555-fe9c1ccf05ed">
        <rdfs:label>Nanotechnology-based gene therapy</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ebcad338-5dbd-4558-af45-7bc1126aef3c"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/14be4523-65a8-4abe-88b9-b4b944bd3bf9">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/816d15f1-1f50-4d37-8283-9255171e5a3f">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/74d73684-b101-4d05-96fc-b5fbd8faf6f4"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
        <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01306</ddiem:url>
    <dc:identifier>DB01306</dc:identifier>
    <rdfs:label>Insulin Aspart</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/b7a70794-8896-4301-b815-688616961493">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/adf62036-1a0f-4f8e-82d7-7bdfb2218c27">
        <dc:identifier>HP:0001397</dc:identifier>
        <rdfs:label>Fatty liver</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9fa66223-ed2f-45f2-9271-afe7bec0e92c">
        <dc:identifier>HP:0001397</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001397</ddiem:url>
        <rdfs:label>Liver steatosis</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27207470</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e4a9cf5-a2ea-45c8-9e9a-9d9dec91305f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606664"/>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ebc3566c-3e14-4eac-a80a-c26e875011c7">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001395</ddiem:url>
        <dc:identifier>HP:0001395</dc:identifier>
        <rdfs:label>Liver fibrosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e15cbc8f-91d4-49c6-b753-d49d36f5a511"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20578266</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4978602-229c-4175-821e-7648c3fe1c38">
    <rdfs:label>CER 001, a recombinant high-density lipoprotein (HDL)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/13f6d838-e255-4dca-b40d-cb551c03db30"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/efffd0f6-21fa-4ca0-ad6d-30d5ff4456f3">
    <dc:identifier>HP:0002155*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal fasting triglycerides</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3baceaeb-263d-4d56-97ba-c322710045e5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01432</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/bfafe7f8-4651-4f5b-bcef-470963688fc4">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/278000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29374495</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23432031</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca248bc-d124-44fe-b94e-8e651c77ee30"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Treatment success with statins has been mixed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28804516</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31239752</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7445d6df-bfa0-4428-8e34-9affdff04ff2"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3ca97369-a1f5-4bff-91b5-a21a12843f1b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1521691810001101</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1801793</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <rdfs:label>Cholestyramine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f35dfe7-d583-49a9-8280-b4d5fa06adad"/>
    <dc:identifier>DB01432</dc:identifier>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000010">
    <rdfs:label xml:lang="en">dietary supplementation</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:04:54+00:00</dc:date>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000008"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with foodstuffs containing molecules closely related to the products or end processes of a genetically defective protein, which occur naturally in the diet. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/618098">
    <ddiem:iembaseAccessionNumber>1336</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1336</ddiem:iembaseUrl>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/618098</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/c73d6539-c0bd-4efb-84f9-aabdd306348f"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5baea3ce-dfc1-4291-b443-643bbd7fc2d1">
    <dc:identifier>DB01186</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01186</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b3f50af-9565-458f-8883-2dbda762ebf8"/>
    <rdfs:label>Pergolide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d23dd204-7c95-4422-87ea-a78856449317"/>
  </ddiem:Drug>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/1191e60b-6efe-483a-a092-5fd917325d5e">
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <ddiem:failedToContributeToCondition>G167A / F213A</ddiem:failedToContributeToCondition>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20649569</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0003304>"L155A, G345S and A349E"</obo:RO_0003304>
    <obo:RO_0003304>L155/ G345/ A349</obo:RO_0003304>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602522"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bfb5eb7f-2081-474d-94a1-cbaf10f2dc6f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d6339b65-1503-422e-bf3a-e50fb7f3d47c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e07ed0a-c1fb-499d-a4a5-3ac7ec5f1a78">
        <rdfs:label>Abnormal ClC-Ka function</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:DDIEM_0000007>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac7f8c1f-8862-4d6e-a751-5f5fa6ca6499">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012450</ddiem:url>
    <dc:identifier>HP:0012450</dc:identifier>
    <rdfs:label>Chronic constipation</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0694ba35-df24-4b64-9859-777b881c1f56">
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>an enzyme-replacement therapy</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29392821</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/308050"/>
    <dc:provenance>NCT00744042.)."</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f36b91cb-cf64-4275-a357-30ed1fa108e4"/>
    <dc:provenance>"ENB-0040</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7687fbe-4d35-490c-9fc0-ce31239eb28f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/631b1ffc-1242-4c09-a069-b51abfb676af"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number</dc:provenance>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fa0ed094-3a3c-4650-824c-78a85003fab8">
    <rdfs:label>Insulin Human</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/72258a59-6997-4ae9-a09c-a84352dcd97f">
        <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7b07908b-6355-4f81-8e94-995d7576da80"/>
        <rdfs:comment>Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4b75ff0-c587-497d-a40d-cafa0e7ffd87"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28756474</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fac312ef-321a-42c1-9776-50fe13d61fb4">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be7ac3f0-65dc-45a5-b7fd-7548f512a07d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25092642</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e4b75ff0-c587-497d-a40d-cafa0e7ffd87"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27709644</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d698d9e3-da4d-41cc-9924-88ae7b962d02"/>
    <dc:identifier>DB00030</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00030</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a3a38408-abee-433e-aeb1-355c604cc06a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bcc68f6-d97e-443d-beb6-8fcd234f9fdc"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/43b54b4e-5327-4c8f-ba09-290d1e300509"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6ceda83a-cf47-4afe-8bd2-ed0778f4bea7">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9494790-1cb2-4e6a-bf33-f54ba0aea29f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs11883-014-0440-2</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25079293</dc:provenance>
    <rdfs:comment>clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5c0bb9ef-3e35-4462-8801-f53afa87f984">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Study was Terminated (Interim analysis demonstrated the treatment was not effective)</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f0b3a33-a14a-424a-9056-dea112723ab4">
    <rdfs:label>Ornithine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00129</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2b8bde74-4a08-4369-bbc0-73051a183097"/>
    <dc:identifier>DB00129</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a1fef71a-f930-4321-b257-66a351861db0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000867</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000867</dc:identifier>
    <rdfs:label>secondary hyperparathyrodism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9eb86c31-2218-4baf-ba50-32cb6f78a05c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/836106ad-3c70-49c1-9feb-0e03fc582145"/>
    <rdfs:label>Potassium cation</rdfs:label>
    <dc:identifier>DB01345</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01345</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/762a1cf2-9a06-49b2-9bf9-15f7ad9415a5">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bf2a85d7-5fff-4462-859a-b7cb629a8559">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9ed0262d-971f-40cb-a6b9-a5c78e707774"/>
        <dc:provenance>https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20975743</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/6c97820f-d5c7-4385-93ce-1dc360bfe22a"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/423fd858-2700-4ed9-90c6-063cde8137b0"/>
        <rdfs:comment>Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Cholecalciferol</rdfs:label>
    <dc:identifier>DB00169</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00169</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/89945d02-961b-4016-8d05-e89132138b63">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/05b9cfac-21d7-4e30-be0b-cc9d1490bd8a"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/efe3629a-91cd-4b4c-9a21-b54568b106d8"/>
    <rdfs:comment>All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day)</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e700f222-7cb2-4b9a-ad8e-f99e696123f4"/>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://reader.elsevier.com/reader/sd/pii/S0140673615000768</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aaf5615b-ee70-4143-b79f-d208cb483d3d">
        <dc:identifier>HP:0007340</dc:identifier>
        <rdfs:label>Lower extremity weakness</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0007340</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c3cfae03-dd57-4854-85b0-5761aff7ac31"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5d676772-4ab0-4285-b4c0-33a1af554eb2">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4468191d-227e-4e45-adee-b2c2fd3ac803"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aa690da1-2c9f-4e9b-a03e-59aa476dcad3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Fukutin function</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/58c712b9-33f4-4fb7-b094-1118f4042d42">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23806424</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ddc37dd9-9704-4aaa-ba4d-e750f8fc4500">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9203a319-044b-4d66-b699-12d324ea90a5"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59337670-c402-45e0-bb75-019e4b3abfe6"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be13f4db-a1e3-4d3f-9eb1-19d50d2d1127"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6d691c47-deb5-4f83-9515-66dc76adc6e5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d02d4f58-8e93-45a7-be57-691d0b281158"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/74e1a091-80d0-4075-bca0-bd12fb7d9ef0">
    <rdfs:label>Decreased activity of cytochrome C oxidase in muscle tissue</rdfs:label>
    <dc:identifier>HP:0003688</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003688</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42d695bf-ecf3-49d3-9428-3661c8e1230c">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/dbbcc16e-c709-41c2-af00-6a390e8965c3">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e2f82b04-0f7b-4bfd-890d-6e92e2383230"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3de5c41b-3ceb-4795-b492-83b1c1059e2d"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11320193</dc:provenance>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <rdfs:comment>Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Warfarin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00682</ddiem:url>
    <dc:identifier>DB00682</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f83cf61d-6953-4c12-b945-280630f98b0a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/647d1c8f-4a1a-45f2-9e56-0f6e314ad5a0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/94281f91-e37f-4dcd-86ca-16d08d0f4f56"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/420ff2cc-b244-4cef-b1c5-6c7344bba5a0">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002902</ddiem:url>
        <rdfs:label>Hyponatremia</rdfs:label>
        <dc:identifier>HP:0002902</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/261750">
    <ddiem:iembaseAccessionNumber>1258</ddiem:iembaseAccessionNumber>
    <dc:identifier>https://www.omim.org/entry/261750</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1258</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>GLYCOGEN STORAGE DISEASE IXb; GSD9B</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/356e723f-b5a9-4705-9ee7-df0f053c3607"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3be5e7d1-d3cc-489b-8fef-f58d9aa0b64b">
    <rdfs:label>insufficient anaerobic glycolysis of skeletal muscle</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/beabab32-cd69-4cb3-afb1-ee0c20a2f797">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12069112</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1db41fa1-41f3-48e4-9069-3adeabcec1b8">
        <rdfs:label>Saccadic ocular movement abnormality (Abnormality of saccadic eye movements)</rdfs:label>
        <dc:identifier>HP:0000570</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000570</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2e1f6e3c-b16c-4b7c-998e-340834e32d9d">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000639</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000639</dc:identifier>
        <rdfs:label>Nystagmus</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/628ce737-23ab-4303-af89-53e4413e27a2"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/47259d9e-4562-4965-8ff7-c1610aaa3446">
        <rdfs:label>Cerebellar dysfunction</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/792efedc-61c2-44df-958d-c3e7b5354b3b"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4cb3fd6-8f60-4d79-a27c-928d5d331f99">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0010438</ddiem:url>
        <dc:identifier>HP:0010438*</dc:identifier>
        <rdfs:label>Interventricular septal thickning (Ventricular septum abnormality)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17826341</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81198963-b159-4228-871f-2e6cc5812dde"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12368988</dc:provenance>
    <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d047b5e1-ae1e-4514-bf51-b026e5b86338"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18234531</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11907009</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12771265</dc:provenance>
  </obo:OGMS_0000112>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/01eba44d-46ad-4022-af05-58017afb3cb2">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/238585a5-c4b3-4a7a-87fc-0adf3bf19146">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e7c98425-622f-4cf1-b10a-9bb1318f71de"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f97e613-6ba2-4406-b626-5d6c067828f6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>neurotoxicity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a031bb8-ec01-4e04-a561-7131dde39d35"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25474440</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23388701</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8715f9-e0c4-4c9f-9c3c-fd3cff4fd5ad"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba4bb3a0-8bc1-4f72-9266-799c0d50c884">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0006462</ddiem:url>
    <dc:identifier>HP:0006462</dc:identifier>
    <rdfs:label>defect in skeletal mineralization</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/515ac014-d8cc-4d73-8297-608e0abd77f4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007010</ddiem:url>
    <rdfs:label>Poor fine motor skills</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007010</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/412d0bd8-390c-4669-93ef-344820ba2204">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01914</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/263b0eba-c1f1-4ae7-886a-d5cdc8bf150a"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9da76476-ad3f-469f-942f-729a8bcc8a4b">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29390242</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29203193</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229700"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13abf97c-8da2-4f43-ab21-67e3eac23a5d"/>
        <rdfs:comment>Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains &lt;7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27491218</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01914</dc:identifier>
    <rdfs:label>D-glucose</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/622a9eba-7791-4827-8b8b-2cf4fe744bc9">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300559"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef41d703-b6a0-4300-ba97-cff2fdd75fdf"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18401027</dc:provenance>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13abf97c-8da2-4f43-ab21-67e3eac23a5d"/>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/0f5debb9-64da-447b-8663-04ef0fa36cf3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220407</dc:provenance>
        <rdfs:comment>The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26997609</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f5557700-608c-4987-a74b-960620cd1e89"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246450"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/13abf97c-8da2-4f43-ab21-67e3eac23a5d"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/81240203-20a5-4cb6-8386-0419000c8ef4"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2443756</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17628222</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1886403</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d528d1d1-3d59-4f1e-aa02-a70432dfeaba">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025464</ddiem:url>
    <dc:identifier>HP:0025464</dc:identifier>
    <rdfs:label>Oxidative Stress</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/15bf5764-dd32-4399-a8d9-4baea628e835">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/91323a08-2832-4999-bf91-c1be981db98e"/>
    <rdfs:label>Pantothenic acid</rdfs:label>
    <dc:identifier>DB01783</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3b9f7993-83df-4029-8be6-e9540ff1e2a2">
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>production of bile acid toxic intermediates</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/ecddb4b9-d643-43a8-8899-21610430470e">
    <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17330087</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/de4b7393-f0b3-45fa-bd44-4e20a2afc1f8">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Muscle atrophy</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003797</ddiem:url>
        <dc:identifier>HP:0003797</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9e963576-6ca8-4cd0-bb16-8441575a1506"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bb9c8dae-8e5f-4653-bc8d-1df559a7e69f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b7b91a10-be6c-4931-b169-400ca7337481"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000007>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/0a500a1b-619d-45ea-840a-aebb11654cb3">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5326725d-06b0-4d68-a526-f2ec7677beb3">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/1f4f06d6-d045-4390-8a09-d46d8e2b323d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04e40fe5-c787-4908-988d-311a8e26cb0c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
        <rdfs:label>progressive leukodystrophy</rdfs:label>
        <dc:identifier>HP:0002415</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>Synergism inmproves results</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12727399</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1735ab07-9f43-4d9f-ae69-8d2227b32cab"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b70b2f96-cb35-4a57-8d3b-4d408591df05">
        <dc:identifier>HP:0003470</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>paralysis</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003470</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231680"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d747cc32-4b85-4818-b27d-9e237ae62bbd"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000007>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a7d21250-5bc4-4d18-9274-0f0a5f667aa9">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/585e8be7-83c0-493c-ab67-fef220cb068c">
        <dc:identifier>DB02053</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/103cde05-cb93-4ef3-9a4b-94f3a59de337"/>
        <rdfs:label>Ribose-5-phosphate</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB02053</ddiem:url>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/21debbb8-43a0-4586-af30-8e5a5a9fae4f">
    <dc:identifier>HP:0001832</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001832</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>metatarsal stress fractures</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4dbe84cd-5488-4801-9f7a-4c810ae89af1">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/280544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50d472e7-28d1-4ff4-89ba-9a2b7fd6b38f">
        <dc:identifier>HP:0001943</dc:identifier>
        <rdfs:label>Mild asymptomatic hypoglycemia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001943</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/49d0364c-7836-47d9-8dc7-2893961a65bc"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/4ccb3344-7a2a-4441-991a-c2c3a7b38e5b">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19011501</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a0ce42c1-2de5-411c-84cd-7d78ed2851c9"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f576693b-98be-4820-b431-f073a146f486">
    <rdfs:label>Axial dystonia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002530</ddiem:url>
    <dc:identifier>HP:0002530</dc:identifier>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/c14fd92b-1a2a-4bcd-8068-ab05fa003ef1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b17d9c23-4d5d-4a87-a81d-b4694004b76d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
  </obo:DDIEM_0000012>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dd2a2223-cc3a-4d06-9edd-d1e46c9425d5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2235f2db-9bce-40af-840c-3f3985e7d57a"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a9d51e99-ea6c-4c38-a181-7816471323f4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/22b72fe2-2ab0-472f-9cd4-d8f1a275e03f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca545d69-1663-40d9-9bc2-0240d38d65db">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*</rdfs:label>
    <dc:identifier>HP:0003119</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b79f8bc9-7527-426d-8241-2ab23f5fc10d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18570303</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc2998d6-b08b-4d23-8796-58ce2e0f91c5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8225213</dc:provenance>
    <rdfs:comment>Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to " prominent dyskinesia " as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607765"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7f1e691c-d41d-40f1-8b2f-daa27af6515a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20619503</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19087156</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2072042</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7915305</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/489352d5-7869-4a93-8d04-0b22ff64bdf1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040134</ddiem:url>
    <rdfs:label>elevated liver iron concentration</rdfs:label>
    <dc:identifier>HP:0040134</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b3949387-bc2d-473e-8e04-3b31eab6dbba">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa1c40ae-893e-4d2a-bd83-680900efda08"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702#</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a4ae849-cc1e-4f5f-af63-df2420edea3e"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c10e961-3cd8-471c-bbf1-7ad572a910df"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18458702</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/360bd36a-5ec6-400f-9d54-f926e728a970"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69745203-dbe5-4629-b4e0-f40aabf67455"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bf9d69e9-74a5-49dd-8541-8dc85f31d4bc">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Bone mass loss</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27853336</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/161a2f10-daee-44f2-8914-8c9bc2dca8f2">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/13149f42-53c8-48de-8dfe-23a7f35cfe31"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23390030</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8a7c49e4-6222-476e-9c9c-378a42e16a93"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1fa6a5fb-f153-405d-bd9e-4b99317b5411"/>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1d8f8dbd-bdee-4cae-90b6-994075590e4e"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <rdfs:comment>In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7f1d98d7-f2d7-48ae-b46b-7ded78a8053d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ee9272c6-2940-459e-a51e-56ccefe1c6e3"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9f4f34be-daa5-4426-9e00-70df96531e19">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/539fdd05-1775-4246-9a9a-ebbc6bea83c9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/489352d5-7869-4a93-8d04-0b22ff64bdf1"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00350662</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/604250"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d3639e2c-32b6-4a2b-9b7c-b90ff054bdb1">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000870</dc:identifier>
    <rdfs:label>High prolactin level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000870</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7e7be8d-a1f4-410a-a8df-a186151bf89c">
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/6f1abed3-9b8f-4570-9aa2-79aeef56122e">
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f1d9df80-6058-4913-bb97-b71030b14915"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/883f2884-e259-4eae-8d88-5b6cd073ced2"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22391998</dc:provenance>
        <rdfs:comment></rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236792"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e2499d3-6f7c-49cf-87cd-7a2891de26b5"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24321868</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/53a20050-994b-4431-9b9b-a5401809ae39">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25251739</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ef41d703-b6a0-4300-ba97-cff2fdd75fdf"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/83e63537-1f01-439b-9695-1a1610807136"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/70f62010-bed7-47ed-bd05-da3fb1623c87"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1567724914001299</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0deafe0d-d52c-4136-bd23-d3cedf187dae"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f77db5b6-2b22-43cf-997f-9be6905f8be4"/>
        <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12927581</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/9009400a-929f-4cd4-8d4a-8c6bf1637df0">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/64f8389c-00a0-4d77-b86f-a27a05578e08"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602541"/>
        <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26006750</dc:provenance>
        <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9bd1256e-587e-476c-bbad-0bb4a81f79b9"/>
      </obo:DDIEM_0000007>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a8464ee8-6d24-4b88-bf4a-dc495c730b17"/>
    <dc:identifier>DB00140</dc:identifier>
    <rdfs:label>Riboflavin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76ee865e-e955-490a-a805-a75a5e50c7cd"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00140</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/01c50bb4-5dd5-4570-8da8-d81b43f92484">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2065040</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3162680</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11425766</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b39db228-0dea-4e00-ac0c-1ff91d5bd5a2"/>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12181212</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d0c6e050-bb6e-49f0-8bc4-0c3f6ce921c0"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2983ec0c-8ae7-40a5-9c3d-e28537a9200d">
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f1dfa3c1-2ae0-44d4-b0af-28ab63e48262"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00465751</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c533026-4dc0-4d16-8370-aa866b0f4c9f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000657</ddiem:url>
    <dc:identifier>HP:0000657</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Oculomotor apraxia</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/082f7657-ae04-4755-9be0-1e8f7b638ffb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21310277</dc:provenance>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610090"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bc6534e4-448b-4568-88dc-5dc960087044">
    <rdfs:label>L-Leucine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00149</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e2067846-7d9e-4006-85fd-bacebdbf7f15">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10959439</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d921f42c-a85f-4ca4-83cd-1cdb1f86d416"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01362595</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2dc05724-5405-4547-b52c-c3560834775f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/848b3de2-23ba-407c-b332-3f856ff6ab92"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02386267</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba5696ac-34fb-479e-94ae-dcfd7d253a0f"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00149</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/68df942a-c606-4eef-bd86-16b244a336bc">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
    <rdfs:label>Lack of energy</rdfs:label>
    <dc:identifier>HP:0012378</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b66e7239-a55d-4c29-9962-4967e07eabac">
    <rdfs:label>Oprozomib</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/311ee1a6-97a4-41e9-bb9a-48d56f9a7c1c">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e6c2fcaa-1615-44ee-a9df-c7c2798ef726"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3afdc73c-cd56-40e2-8231-71d10d207a0c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4a8e2bd8-5b83-422c-9812-2fbc5da2e532"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0003304>S466L /I278T</obo:RO_0003304>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11991</ddiem:url>
    <dc:identifier>DB11991</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d33d7f46-915d-4ba6-9d7a-8aa0d3b2b280">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26669244</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29340523</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6751392a-404e-461e-83df-b08f904a5df8"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/266130"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <rdfs:comment>An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5c14a030-851d-40f4-b12e-2fe96025dd93">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f8d264c3-d6aa-4920-b582-86f6de40c5c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13173</ddiem:url>
    <dc:identifier>DB13173</dc:identifier>
    <rdfs:label>Cerliponase alfa</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5338b68b-8a58-4894-86af-3ca69f6b1ffa">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd8aeade-f5fb-4d6e-a188-6f686b2ec04c">
        <rdfs:label>Trial is no longer available</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29471850</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/30226cb5-17d6-4217-b920-fd1cb8b71034">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/23a2d12b-1088-4f99-a8f3-3940282ac620"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00705939</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e37d1846-f7ff-4d00-bfeb-edef61f1fbfe">
    <rdfs:label>high  short chain acyl-carnitine metabolite level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f5557700-608c-4987-a74b-960620cd1e89">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001958</ddiem:url>
    <dc:identifier>HP:0001958</dc:identifier>
    <rdfs:label>Nonketotic hypoglycemia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f5a5093d-3082-4ab2-a7e9-d5b847fcfdb2">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3be5e7d1-d3cc-489b-8fef-f58d9aa0b64b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/dc84cb6a-839b-4bae-94d4-ef4dca5de136"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f15fcde2-bd96-4660-9772-29b5580b501c"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22334182</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1dc00347-118c-4700-9f0d-eac9ca0f2890">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ec852c47-e251-4674-b4f4-d34bf6f79bb3">
        <dc:identifier>HP:0000508</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000508</ddiem:url>
        <rdfs:label>Ptosis</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/dc297c75-b0c4-4faf-98e1-8ced720f517e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20652410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0fc5b1f9-7937-4dc8-94f7-8cd3bd708608"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0003304>p.I480M</obo:RO_0003304>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2602d864-e5c1-4a70-9b47-2282ca3b4e07"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10448086</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/8e6307ce-85ce-4b66-98f4-c7b8c662ca40">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23592311</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c0aa3af-4127-4ea5-8d57-f63ea6d27966"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
    <obo:RO_0003304>I278T</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/61a30360-9e4b-4df9-9be2-58cbf5962aa0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <rdfs:comment>These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f73f306-23dd-4070-a361-d71cb81b2ac8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/be49032f-46f0-4c68-8bd1-122174a334c9"/>
    <rdfs:label>Ademetionine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00118</ddiem:url>
    <dc:identifier>DB00118</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3f7abe64-e32e-4af7-ac41-c5c9b38e206d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b9a7f34-ba55-4ff5-8fb5-9e66b9c60f1d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15bb4c9c-bc86-45e6-b91b-6ea10b6649f0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0c625d2e-99f5-4cdf-9e14-2a1836281fd0">
    <dc:identifier>DB00331</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00331</ddiem:url>
    <rdfs:label>Metformin</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/93f6f533-7ac3-4d81-9156-500720a8f958">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
        <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f3e0bc8c-790f-43e1-8ffc-43d89dcd6588"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17994020</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246650"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d4ae96d7-5b61-42ac-b7f3-de7ecacd52cb">
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0c335e82-469a-4122-a0f3-69c47908bc08"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01793090</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/236270">
        <rdfs:label>HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/f3d31e82-7b22-4f80-a4df-1a906362951c"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/31</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/236270</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseAccessionNumber>31</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28210839</dc:provenance>
    <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7c4ed0f7-ad69-4ee4-a633-9396050d150b">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003281</dc:identifier>
    <rdfs:label>high plasma ferritin</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d56c333c-e311-4c63-81a4-747c5de1a5ff">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low pancreatic zymogens</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3832a154-e9b0-4cc0-933c-74326f7ad95b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8b74dd1d-8189-4f2b-b95f-b56ea7c397f7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/396a1b36-f6b6-481a-a037-8ba044da459a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09449</ddiem:url>
    <dc:identifier>DB09449</dc:identifier>
    <rdfs:label>Sodium phosphate, monobasic</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/9b54abd5-016a-45ba-a3d5-d60302a06c3d">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27102039</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8444253</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/219800"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3550461</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/142ab802-1aae-40da-b1ed-142f411d88a3"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4a245a1-a5b6-4788-b2ba-710ce0bab52c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5d17ec2f-ef14-4520-ae5e-c755327b98e2"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a833151c-7322-4f96-b284-38ccd668f283">
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00887562</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b774cbe2-b759-40b9-92fd-342cf2e0531a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6bf901b-fb07-48ad-9eb5-9b87394da8ba">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Decreased activity of mitochondrial ATP synthase complex</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011925</ddiem:url>
        <dc:identifier>HP:0011925</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8757046</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60697430-9869-4ac1-9772-11c1dd4f6843">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003234</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003234</dc:identifier>
    <rdfs:label>secondary carnitine deficiency (Carnitine deficiency)*</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b2a98847-95ef-4588-b7be-6d6532bae34a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8e331004-166e-4efd-a9b8-d971a0b2d15e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f73ce8e-2a1f-4fd2-a608-3fcfd0fc4d93">
    <rdfs:label>Nicotinamide</rdfs:label>
    <dc:identifier>DB02701</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c348aeae-cdf6-4199-ab7f-1f5b50b5ee34"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/493bd9e1-5b86-4b3a-8275-baa58b8e89cc">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2e4a9cf5-a2ea-45c8-9e9a-9d9dec91305f"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/734fe216-4596-4fb7-b006-05c0a744c6d8"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
        <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02701</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7a70794-8896-4301-b815-688616961493"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4168f0a2-fdfd-4c54-a814-1d09279aadf8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01325</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b79da856-0f03-4394-89c4-13f0cba6c048">
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4137c365-9e80-41dd-be7b-9a5369824a30"/>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/50f6d73b-1a5c-4a7e-a0a5-38519c6007d2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26251718</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Quinethazone</rdfs:label>
    <dc:identifier>DB01325</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d322b4d-d115-47d5-b792-02140cac1735">
    <dc:identifier>DB12890</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12890</ddiem:url>
    <rdfs:label>Dihydrexidine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7aef978-2f92-4759-99f0-1f9424b40e27"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b32bcbcb-4d7b-4d26-8e98-a76acfcbf668">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8652022</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10970889</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/14c8bdf7-b2a9-45cf-876f-384392f88126"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11687750</dc:provenance>
    <rdfs:comment>Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25032271</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23478190</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c20db8cc-b346-486a-b581-ba5b5a58eb32"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fa817121-b70b-462a-8235-4b54fe03768c">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232220"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19066956</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/307e45d6-73dc-44ce-9da0-a309497a81b3"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/71c721a2-cd42-4c42-b128-fb6a22fb7163">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/edcecfa2-9932-4303-a144-ce553e2f1f73"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19541498</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3351e726-afa3-4f39-96b3-fa87dbba0928">
        <rdfs:label>Neutropenia with IBD</rdfs:label>
        <dc:identifier>HP:0001875+HP:0002037</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001875+HP_0002037</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25288127</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12373585</dc:provenance>
    <rdfs:comment>Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5e7d872c-a594-4785-b3ea-d5ccab181146">
    <dc:identifier>DB09278</dc:identifier>
    <rdfs:label>Activated charcoal</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09278</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/156bf446-3546-426b-a35d-9fa385ddd126"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/277410">
    <ddiem:iembaseAccessionNumber>316</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/316</ddiem:iembaseUrl>
    <rdfs:label>METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/277410</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ffc1c0a4-d407-4adc-b545-e726bb65bf9e"/>
    <rdfs:comment></rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f11ccbaf-b22c-4d3f-a71e-d85c900afe3b">
    <rdfs:label>POTASSIUM-SPARING AGENTS</rdfs:label>
    <dc:identifier>C03D</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a507886-4bac-4898-8b49-d631629e7151"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C03D</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e63587d-2237-4f75-9c96-e381b8608b61">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00165</ddiem:url>
    <dc:identifier>DB00165</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6c96e808-8611-4987-84cf-0c5661731256"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7242e8e-176a-439c-b7ee-8c83e3a40960"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5a5093d-3082-4ab2-a7e9-d5b847fcfdb2"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e235620-ba11-4ae0-9ae7-93c7385b4308">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0fded11-a870-488f-a83b-6c5b0405c4a9"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17395561</dc:provenance>
        <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/263112b9-6839-4fa7-8aff-8419ff9c5093"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/ef6e432f-71cf-4692-9ace-175d0ee13953">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29654911</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17565677</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24082780</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29757052</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f56d8cc6-edc7-41b2-9383-c0d28475c0ba"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7028650</dc:provenance>
      </obo:DDIEM_0000012>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e2399d99-fa40-43c1-a03c-8a0306e4d505">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237400"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/6198500</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1589f711-e220-41ec-a2bf-c5f8edd4706d"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
        <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7936305</dc:provenance>
        <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Pyridoxine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9655f745-5a52-4876-9ec9-48309abd8bdf">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
        <obo:RO_0003304>"P49L, A114V, I278T, R266K, or R336H"</obo:RO_0003304>
        <ddiem:failedToContributeToCondition>"R125Q, E176K, T191M, T262M, or G307S"</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30755342</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236200"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16619244</dc:provenance>
        <rdfs:comment>pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29119254</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14739681</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24355692</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7c0aa3af-4127-4ea5-8d57-f63ea6d27966"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/95a3831b-1947-4556-a5ee-b6920099a897"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c14fd92b-1a2a-4bcd-8068-ab05fa003ef1"/>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/ec27e630-5538-4756-a2bc-dd6b833bb91e">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890588</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4c3c75ed-4fbc-486c-a454-89b56c87874b"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9cb6b597-5cd5-43e7-ae50-c048c499a51b"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/716a1c04-ecca-4583-85bb-0c5dcae453eb">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9874bf37-fc06-42c4-bb49-62dbe3e4018e">
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b2756a98-5ac0-42ef-98d8-8c9e2350c065"/>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bd2d3746-84a9-421a-b154-1c436fc30106"/>
    <dc:identifier>DB01390</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/100e11cb-1b24-41c9-a7ba-cebc0c1833be"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2f2a3792-c604-4d32-a79f-2210e69d6b5f">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42e2d94c-70da-4304-978d-be50f0cb007f"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7564233</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24912437</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/227810"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01390</ddiem:url>
    <rdfs:label>Sodium bicarbonate</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/120a155f-87ca-48fb-8a5e-5c409b169c37">
        <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5159e670-0bcc-41e1-90f1-d130cae38878"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ce6d80e7-9d5b-4a93-a4f0-23f886f0fc79"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
        <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12937245</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d33d7f46-915d-4ba6-9d7a-8aa0d3b2b280"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/46937cba-0737-4123-8435-34110d8a7d83">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24980685</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c7b3f9a4-cddf-4c28-8719-a9458ecbdbd4">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25512a64-7637-4d16-8436-36dc05238cdf"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27589827</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d528d1d1-3d59-4f1e-aa02-a70432dfeaba"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/049b920b-a3ae-4137-b24b-f9c1a3ffb7e5">
    <dc:identifier>DB00404</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9e7b7cd-37da-433a-affd-e2c2ba3d0cc8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00404</ddiem:url>
    <rdfs:label>Alprazolam</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e7f0fd52-9166-45c5-adea-a5511de70234">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/39892a09-4a8f-4aff-a3d6-b84d2fe069d0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2767acc1-834a-45da-86cb-e37ac21d2213">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3082ff4f-b31b-4b81-a11c-dc77d406fc08"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01202</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d2911cf5-d4eb-473f-b510-75c84f25bcac"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/113a7e64-2273-46c4-b90b-141752ea669b"/>
    <dc:identifier>DB01202</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8d32f40-ff03-4a90-94a7-d1aee07807ea"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc02a4bc-648d-46e8-9cba-0d26ea65ebc1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e283375-e77b-44ed-9b3d-c738fdf1b640"/>
    <rdfs:label>Levetiracetam</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9fb0bba9-2002-4109-a6a4-a295966e6c0c">
    <dc:identifier>DB03614</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03614</ddiem:url>
    <rdfs:label>Methylcobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5379dfc5-455e-4f36-b153-dfc7f75b7fbd"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e72c59eb-a6df-4a84-8075-440eb8e86341">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:label>cardiac dysfunction</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d86ee2c7-c540-4537-90b2-03248f689178">
    <rdfs:label>Levothyroxine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf101c38-fad7-49c0-ba82-d6b7748bd955"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/60949155-56ee-4c07-9cc2-15154a82df1c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00451</ddiem:url>
    <dc:identifier>DB00451</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35761893-660e-44c3-89e6-4ef8bfe220aa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75ad5bef-c038-48c5-a45f-e4a56ebc8165"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00125</ddiem:url>
    <rdfs:label>L-Arginine</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6d46dfe5-0a55-4e8f-8291-1390c373c82e">
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/63f98437-5ac2-4723-a925-725225e80625"/>
        <rdfs:comment>Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749</rdfs:comment>
        <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c14e05f6-b684-4aa6-9cd3-d67466315313"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/603471"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18958581</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cb16c8c1-1a3b-447c-8316-71f2929911de"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15670720</dc:provenance>
        <dc:provenance>https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9ff76a33-9a69-4270-817c-1e7af48c6db8"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/79f77412-efb7-4912-8613-5089bc1d6a09"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e253828-d716-413c-9e8e-7755c2315515"/>
    <dc:identifier>DB00125</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ee418253-16a9-4b2e-be46-d00976d558f1">
    <rdfs:label>High plasma phenylalanine level</rdfs:label>
    <dc:identifier>HP:0004923</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/613077">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/017d9159-66c0-4733-b5dd-b30c59a757f4"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/613077</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/603f8e8c-d173-4799-b893-280abfd1f831">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bac2de75-9d74-4be2-afb5-2e52966b5168"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d9c7603-a35e-4727-bc63-681420f823ec">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012379</ddiem:url>
        <dc:identifier>HP:0012379</dc:identifier>
        <rdfs:label>Abnormal enzyme,coenzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
    <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9414260</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00001735</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7713647-3aa6-4f96-87b6-2e3a9df1d484">
    <rdfs:label>AAV9-MCK-fukutin</rdfs:label>
    <obo:RO_0000056>
      <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/45a93c77-7326-45e1-9732-c17a2884d9da">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12849431-df94-495a-b230-343cdf007cd7"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2ef89716-cc81-48ef-9e9d-9b53f6e17961"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
      </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
    </obo:RO_0000056>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/448bb407-cd7a-46ad-89a9-4034693495c0">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/eeffcdda-3185-4006-be13-83cd3d53d381">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d00c4263-9dd6-413a-9ac4-22c7d435625b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce118352-e66e-42bb-8b51-8f78df1b5452"/>
    <obo:RO_0003304>G11778A</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17296905</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <rdfs:comment>Dietry treatment supplementation</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30107658</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fff579e7-c064-407f-8860-1134377ee827">
        <dc:identifier>HP:0001138</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001138</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Optic nerve damage</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2ab3eaa2-e8a3-4a41-b810-3a4116ee8c45">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e250047a-6eca-40e4-8dc5-f1a97dee9753"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24718477</dc:provenance>
    <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12044538</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f21fabb-6955-4763-a238-2556dc016f60"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bc8a3452-0b9c-4723-828c-e9a1fc85455b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/201100"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4eb34ca8-abca-4f6c-9708-44e8c55ec71b">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000712</dc:identifier>
        <rdfs:label>emotional disturbances</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000712</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aca4371e-ec70-4e4b-9e91-f42ba375bcb5"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a2479b43-8244-4634-bd22-212b6ed7d902"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2334bbe7-23ef-4c95-ad2a-8a607c67d9d8"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5f953195-4031-45f6-9931-13ea2eee2595">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7748366</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3eda2d08-8763-431a-bdb8-542c91f1027e"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231530"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16835865</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d9f3f643-ad7b-4e3a-aecf-187d7a922093">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040129</ddiem:url>
        <rdfs:label>Impaired nerve conduction</rdfs:label>
        <dc:identifier>HP:0040129</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.jci.org/articles/view/11948</dc:provenance>
    <dc:provenance>https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency</dc:provenance>
    <rdfs:comment>Effect of glycine in treating the condition is variable among literatures.  "Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5f31fd6e-7495-4e96-a6f0-384e3be1b7d6">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected neuronal plasma membrane</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1644114-7465-41de-b567-e9fbffc6b830">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Defected mucle plasma membrane</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/088789949400109F</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4468191d-227e-4e45-adee-b2c2fd3ac803">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89945d02-961b-4016-8d05-e89132138b63"/>
    <rdfs:label>Vitamin B-complex, plain</rdfs:label>
    <dc:identifier>A11EA</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9cd05b41-0031-46e9-8866-3d17eabe391d">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2e04ac1b-864f-454c-9472-77fd4972856e">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28318733</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>MCT should be at least 70% of the total fat content of the diet.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27718492</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9c1b7e01-3128-450b-87ba-dee6c8fe1d20"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/530000"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e38529eb-cb9a-4522-b16b-e64b0869d934"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aeab8d77-53a0-4be6-b88d-5049aefdd9ec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4413c208-e78a-431e-a176-8190bcf770d7"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a296013c-d621-48bb-a195-f7eb384e42f0">
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16775724</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301535</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23430827</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/222700"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25614305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25859380</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f0f79a85-3a3b-4b27-946c-103d01b0e4b3"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6f7a81e0-200b-44d2-8981-f027063e79d8"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdfs:comment>Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00052</ddiem:url>
    <dc:identifier>DB00052</dc:identifier>
    <rdfs:label>Somatotropin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1668c603-77b0-4b6b-9a83-78d324651eb0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
    <rdfs:label>Myositis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100614</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d1bad9b4-3a95-4a2c-9171-7f7f22ab19f4">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bbc68ee2-237a-4635-af78-48d77f7771b6">
        <rdfs:label>Complex Carbohydrates</rdfs:label>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2dcfebd5-6d9d-4bbd-99b6-1fda287b159b"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07c44b20-0aa4-49d2-bbb7-b0aba6054f0b">
    <rdfs:label>Ferrous sulfate anhydrous</rdfs:label>
    <dc:identifier>DB13257</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac971648-d9d8-419b-bfe9-017dc242e301"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13257</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/23a2d12b-1088-4f99-a8f3-3940282ac620">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/cce54e5f-72ed-46af-9d81-1b2d4a3ab2ef">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
        <rdfs:comment>The treatment was done via convection-enhanced delivery</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7efc4091-c48a-49bf-af8a-d35a0f68f43d"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/30226cb5-17d6-4217-b920-fd1cb8b71034"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23085429</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230900"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00244582</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24441827</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18952590</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://link.springer.com/article/10.1007%2Fs11011-018-0236-1</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06667</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5338b68b-8a58-4894-86af-3ca69f6b1ffa"/>
    <dc:identifier>DB06667</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/7221ece1-603f-44bd-a028-7db07415e99c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/85e40dd5-6375-4038-8ce5-bcd4586c1d1f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18425437</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7760062</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ff5edb79-21f0-4ad2-9ce4-133947571cf5"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/17401a4a-7999-4947-9e34-469803fc77aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ced62a12-94fb-40c2-9871-ddb710ed9eb1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261630"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26817292</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f33f0ea1-419a-4689-8986-a31da8b83394"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25667865</dc:provenance>
  </obo:DDIEM_0000011>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/32f2b6cf-4251-493b-a2f8-6d8f3fddc593">
    <dc:identifier>DB00073</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1c6bb7f-bca0-4245-b0e0-b8c84fc1c66b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00073</ddiem:url>
    <rdfs:label>Rituximab</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2da67f29-39dd-40fc-a2eb-0d2808e08b72">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fe2a29dc-ba62-47fb-933b-027955d4ae1d"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f56e8372-a04a-486d-a6b1-4e0e5d791c7b">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
        <rdfs:label>High atherogenic lipoprotein(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00733811</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/58e86572-fa42-48f1-8579-9efdaf842073">
        <rdfs:label>High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*</rdfs:label>
        <dc:identifier>HP:0003119*</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26194979</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14632789</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12547874</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22798447</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/151670">
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/30cc24f2-ddc0-43a6-a6d9-7828d6b5b794"/>
        <dc:identifier>https://www.omim.org/entry/151670</dc:identifier>
        <rdfs:label>LIPASE, HEPATIC; LIPC</rdfs:label>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e60e6a-b0d3-440a-b81d-98486980fef6"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8ba3023b-bd12-4fd8-8b83-e52c8a159d84">
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ac4b34b9-9991-43b7-9de1-2c33bb88c03b"/>
    <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7fa6b583-d928-4a18-8bb2-a334557b96a8"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27488560</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/85d3df8f-2634-478a-ba48-00db45e15c54">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <rdfs:comment>The drug has some effects but hyponatremia is a troublesome side effect.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3e20e64e-bbf3-4c2d-aa6a-29b64237e1a6">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031951</ddiem:url>
        <dc:identifier>HP:0031951</dc:identifier>
        <rdfs:label>Short nocturnal tonic seizures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/0ba9e5a8-f9de-4050-9264-319d3e3fa95b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c3a399d4-8c32-429b-bed3-79275ce8739c">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/236800"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/258ed8d8-217d-4ba4-a027-07c07f66e299">
        <rdfs:label>sensitivity to sunlight</rdfs:label>
        <dc:identifier>HP:0000992</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14169454</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26516243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24561416</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a9494790-1cb2-4e6a-bf33-f54ba0aea29f"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10540864</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17334708</dc:provenance>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/65aab3f6-9c90-4103-80c6-481d08f9f8c4"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/cfe4b200-6644-41ea-b15a-2b5f1ebd3038"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8f147fed-d810-4782-b536-36448a8c95f2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000726</ddiem:url>
        <rdfs:label>dementia</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000726</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6761cbb-2845-4d8f-b03e-f574e5736b23">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/64f81324-ed1e-4a2e-8b09-5af6fd363b66">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/614080"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00923247</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30297385</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec240001-0e05-4680-91c8-48bfad890484"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00704730</dc:provenance>
        <rdfs:comment>Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64980eb9-5ac1-4da3-803c-dc73c0d40544"/>
    <dc:identifier>DB00273</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64c12ba2-e995-4ea9-8acc-5725f1ef6cc6"/>
    <rdfs:label>Topiramate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00273</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6be32d14-ba84-44c9-b5a0-352213e73899">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c799369-fd69-4bf5-9d1d-0b0600024bef"/>
    <dc:identifier>DB01373</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01373</ddiem:url>
    <rdfs:label>Calcium</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6de2b764-00b7-4854-a3ce-17f8a6da3e53">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6417016e-f13d-489d-a70b-c5831f829a80"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b1a84a34-532f-41d5-b111-89b2ebff9ec9">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29624790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22812641</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29303961</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <rdfs:comment>The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02014883</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/06fabca2-fc9f-412d-a7cd-be5de9f0bb56">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8810bfab-d6ae-4dc3-9814-79d6236c122a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b987539b-9421-4572-b101-3aa39b83a274"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/156f5300-77ae-4f7a-92b2-c778623bc8a7"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02000960</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4de61461-934e-4397-a020-e14b11a0b657"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606777"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25eb2e89-7f9f-4f93-8cd8-256922a84260">
    <obo:RO_0000056>
      <obo:DDIEM_0000008 rdf:about="http://ddiem.phenomebrowser.net/80ac9550-a80e-4a8a-b979-1fac1782f147">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d747cc32-4b85-4818-b27d-9e237ae62bbd"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24613482</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c76a3c21-98ca-434e-88c3-fe8ea92d41a3"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
        <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2b4e5c17-4fef-4128-8c0c-beb55a868add"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1e28a801-213f-4488-8f4c-5df07984c501"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8245377</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232400"/>
      </obo:DDIEM_0000008>
    </obo:RO_0000056>
    <rdfs:label>high protein diet</rdfs:label>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/1e53705b-426f-45fe-9365-f50b93bd840a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a2c2053-4ef3-4c22-98ee-94b14d4c0d6e">
        <rdfs:label>high plasma RAAS activity</rdfs:label>
        <dc:identifier>HP:0000847*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000847</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb066d4-d587-4fec-bd89-aa23900bafdb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9de7fae2-d961-4d97-afd8-49ce753c5b04"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25852896</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/93556a85-6d53-45a0-9078-bbe17cf01ac0"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cfdc3989-1a1c-4852-9751-b5400ca3ea11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/089068a6-2122-499a-8ebe-e0b7753466c3">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003201</ddiem:url>
    <dc:identifier>HP:0003201</dc:identifier>
    <rdfs:label>rhabdomyolysis</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/258450">
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/281a64eb-af70-464b-ac4b-607d2f081765"/>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1</rdfs:label>
    <ddiem:iembaseAccessionNumber>418</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/418</ddiem:iembaseUrl>
    <dc:identifier>https://www.omim.org/entry/258450</dc:identifier>
  </ddiem:Disease>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2dcfebd5-6d9d-4bbd-99b6-1fda287b159b">
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d1bad9b4-3a95-4a2c-9171-7f7f22ab19f4"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9c1b7e01-3128-450b-87ba-dee6c8fe1d20">
        <rdfs:label>Short Stature</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004322</ddiem:url>
        <dc:identifier>HP:0004322</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/81ef6e72-10bf-46c6-90db-ec48f6714aee">
    <obo:RO_0003304>A354V</obo:RO_0003304>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <obo:RO_0003304>A354V and C12775STOP</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220111"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1712e1ca-956c-44c3-8702-cc0f3eab01a3">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>acidotic crises</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
        <dc:identifier>HP:0001941*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22202226</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ceb3fe8e-00b2-431e-ae83-cf2b0eb5c317">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Low COX content and activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4f9a8801-5e03-401e-93cb-2a96febef047"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
  </obo:DDIEM_0000011>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/abcb887b-6d34-4c20-8d55-b0f0a734b3d1">
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607091">
        <rdfs:label>CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/cf4cf392-ba60-4367-ab2a-aeef251fa407"/>
        <rdfs:comment></rdfs:comment>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/338</ddiem:iembaseUrl>
        <dc:identifier>https://www.omim.org/entry/607091</dc:identifier>
        <ddiem:iembaseAccessionNumber>338</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02955264</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b9d1c257-8621-4524-9f06-2ce362d74eaa"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/6370e6ef-dd91-439e-adb3-fa810a8d644f">
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a540b87-8e63-488b-9a07-e89d17ae4d68"/>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7a4ae849-cc1e-4f5f-af63-df2420edea3e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7861588b-9bce-4c84-b7b1-c2ce8564ebd8">
    <rdfs:label>GM3 ganglioside accumulation (Ganglioside accumulation )*</rdfs:label>
    <dc:identifier>HP:0004345</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004345</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/482a04bb-974e-4b49-b050-37582ecd4978">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/89ca44e6-99bb-47ca-96e3-e6a058d65ce4"/>
    <dc:identifier>DB01080</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e4a6653-fd93-4104-8b1b-656a1335a0d0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0dbe5966-8363-4d99-a893-0db636adf376"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01080</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e2815e4-bc85-4e59-96ab-2671a6b002ed"/>
    <rdfs:label>Vigabatrin</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ba683889-8fa1-4712-8dd8-ac1c40f3e97e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04076</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/485a39b7-f3cf-430e-a85f-c4daab8973cc"/>
    <dc:identifier>DB04076</dc:identifier>
    <rdfs:label>Hypoxanthine</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b1ff8091-73fe-4557-a901-8079e739b27e">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/12975208-ce3f-49ac-90f4-5594f99ebadf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f46a2f94-9235-40a8-8c3f-c75e13dd0ebb"/>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/263800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23196212</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25012174</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/04d9975a-f601-47bc-8555-7401cf0bdbee">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002155</ddiem:url>
    <rdfs:label>hypertriglycemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002155</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/13054d20-cdfd-48b9-beaa-18778f3e242a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3a399d4-8c32-429b-bed3-79275ce8739c"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ceda83a-cf47-4afe-8bd2-ed0778f4bea7"/>
    <dc:identifier>DB00627</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7cf58ca-8527-4fae-b5bb-f79a248e8e72"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3be7c9db-1237-4003-8df7-0df6a2e227a1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a74553fa-5bcb-408b-9cf6-5c93f2ad2759"/>
    <rdfs:label>Niacin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00627</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7e06a5ae-5723-46cf-a850-36d77c7c759e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK6803</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30723321</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612073"/>
    <dc:provenance>https://www.nature.com/articles/s41436-019-0451-z</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00925301</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01218659</dc:provenance>
    <rdfs:comment>The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of α-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/86d908c2-77eb-483a-980a-96ff7c18b111"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01458119</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27834756</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ca21a54f-b0b9-487c-b0bc-ee7147440773">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <dc:identifier>HP:0003326</dc:identifier>
    <rdfs:label>muscle pain</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/70905bda-ead9-499a-b2ac-5bfc318f33bf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>production of toxic bile acid metabolic intermediates</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/117eef77-e571-4740-8c76-bb356e0cd683">
    <dc:identifier>HP:0003218</dc:identifier>
    <rdfs:comment>The drug works through preventing the aciduria and the hyperammonemia rather than treating it.</rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003218</ddiem:url>
    <rdfs:label>orotic aciduria</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/ebcad338-5dbd-4558-af45-7bc1126aef3c">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3edaa723-7ec0-4a07-90ff-2ba4fa6b5cb1"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31434105</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/direct_complementation_of_a_genetically_defective_protein_by_gene_therapy"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31211405</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/77cd63a5-a291-42b8-8ebd-c5832783e3d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31082797</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607015"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31196723</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29122734</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4db1ca12-c8ca-41c4-ba91-db3624d60600">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23337983</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0deac219-83c5-4d65-8cad-2778f3daa7d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/72685c8e-cd2f-4179-b0d5-ae3b8732fadb"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b72169f1-7dc7-43b3-830c-507a8799a2e9">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Brain pathology</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298</ddiem:url>
        <dc:identifier>HP:0001298</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230600">
        <rdfs:label>GM1-GANGLIOSIDOSIS, TYPE II</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6476d1c0-0624-47f4-8787-895b071ae02a"/>
        <dc:identifier>https://www.omim.org/entry/230600</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e8c363db-14b0-4780-959d-ff14f3ceb63d">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/341955</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19656325</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4459235b-2d2f-4987-96c9-a582143b8e1f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c4075988-7b9c-4bc1-9b88-edb503b02b3a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baf1a819-1e2f-4c4e-b8d3-49cf1a22fdc4">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000992</ddiem:url>
        <dc:identifier>HP:0000992</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>intolerance to sunlight</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791288</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d372e996-2410-4b15-ad10-fed66a3fa079">
        <dc:identifier>HP:0025280*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025280</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Pain in the skin</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
    <rdfs:comment>Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/</rdfs:comment>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01fc2544-b84a-42f1-8176-798ff9cd6ba7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/07b621b4-5955-44e6-bc52-2a6902b76145"/>
    <rdfs:label>Tretinoin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00755</ddiem:url>
    <dc:identifier>DB00755</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05b5ffc9-9c36-4e18-84a2-05075d13ff5e">
    <rdfs:label>Geneticin</rdfs:label>
    <dc:identifier>DB04263</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04263</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6f596aa7-3993-4c54-932a-abaa022ecf9e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6dd48dc1-7266-4ee2-8520-0087af4b8f04">
    <dc:identifier>DB02691</dc:identifier>
    <rdfs:label>Glycocholic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb0e1afe-314e-4b38-b510-64dd8493add2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02691</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/aaf3e595-76a8-4a16-a529-af494f3e9b92">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22142470</dc:provenance>
    <rdfs:comment>In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25993639</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/40fff2bb-5f1a-47e4-96b0-b892429e99f5">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/60089421-5b36-453d-a494-5a5f377f4052"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16390715</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8365ee00-20d0-40d5-9389-a8d3838671c4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e8d6f5e-ab04-4a41-b59c-c0acdd02405b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0b7b0d3a-41ce-44fe-9939-9927db31d7ef"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00624</ddiem:url>
    <rdfs:label>Testosterone</rdfs:label>
    <dc:identifier>DB00624</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff72eb5b-a932-48e9-a899-7c9493cda578"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/247ff6e0-4bc6-42ca-9867-42c1428c47ba">
    <rdfs:label>High ornithine plasma level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012026</ddiem:url>
    <dc:identifier>HP:0012026</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1a4f35a-052d-45be-93b2-9ed9c6e7618b">
    <dc:identifier>HP:0025201*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
    <rdfs:label>low APO A level</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/21a1bb0d-49a9-4028-ac48-5582cf5c1931">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.nature.com/articles/srep44408</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17514432</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/48a7ca53-a9ab-48fc-aed9-84ae9dd00825">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003676*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
        <rdfs:label>Renal disease progression( Progressive disorder)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/af94adf7-c03d-4043-bf96-00cf970f3013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8aba81b-7fdf-4dac-b868-cf649b748894"/>
    <obo:RO_0002558>
      <ddiem:Evidence rdf:about="http://ddiem.phenomebrowser.net/ECO:0005242">
        <dc:identifier>ECO:0005242</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/ECO_0005242</ddiem:url>
      </ddiem:Evidence>
    </obo:RO_0002558>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18996862</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20195241</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/bae95a97-2e86-4490-a618-a3551f8b317e"/>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3fdf32f-0231-447a-a034-395e2278ee14">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ae9fc07f-1f33-4ed3-ba94-b1b5252f0f90"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21503667</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28381550</dc:provenance>
    <rdfs:comment>Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083</rdfs:comment>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/81d8be46-bd18-4be9-b0d5-32eb9e251f80"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20439622</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00376168</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f05c6e6e-4ae2-454c-87d4-3c99e759c8cf"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2d975d04-808d-4fca-bffe-916301592a87"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608013">
        <rdfs:label>GAUCHER DISEASE, PERINATAL LETHAL</rdfs:label>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccb1642b-043a-40df-aa5b-8240a4fe6c8c"/>
        <dc:identifier>https://www.omim.org/entry/608013</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01074944</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27499018</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f23ccd05-e74d-463f-ac88-ca7c41ba09b2">
        <rdfs:label>Low lumbar spine bone mineral density(bnormality of bone mineral density)*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0004348</ddiem:url>
        <dc:identifier>HP:0004348</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00962260</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9868107e-4ea8-48d4-aac9-f425f6e70adb">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/520c92a1-1d52-4b35-8808-c394077bdef0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23890587</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16544179</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/610768"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/12fbf029-cad8-4836-bff9-ba823d00021d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a91034ca-c966-4f0d-83fd-30bc6af52c18">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
        <rdfs:label>affected functional activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9732974</dc:provenance>
    <rdfs:comment>Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/85b52695-8d0f-4de9-a408-d7b92271ee50">
    <dc:identifier>HP:0003155</dc:identifier>
    <rdfs:label>high serum alkaline phosphatase</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003155</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/6f878a34-0c22-4c78-81a5-195a02d71902">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/014067369192373A</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9511979</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19585268</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1fe9d259-a9d7-45fc-989c-32d3e5b11c4b">
        <dc:identifier>HP:0002123</dc:identifier>
        <rdfs:label>Myoclonic epilepsy</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002123</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <rdfs:comment>Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/250850"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
  </obo:OGMS_0000112>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e9897f46-d775-469e-b7a0-4ceca6f83355">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a4a1c51-27cc-4fb8-8a86-026f54508d39"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1def0545-3cbe-4a64-ac90-e1d2ec1f143f"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/10fa0655-d863-4e29-858c-3cfbeba8c268">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0baa43c-66cd-4b4f-bcc0-912c2a9bde5b"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ac51ec91-7b47-4255-828c-9fe39474644b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5c827ae0-34fe-4a00-a655-768de728d776"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2c1dcc9-7e45-453e-b042-18f47a588823">
    <rdfs:label>Spirapril</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01348</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5e714de-a18e-4299-b28c-ef72fbdcf1e6"/>
    <dc:identifier>DB01348</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c578feef-f1bb-4eee-a28c-527474bc1b6d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3d1acbb-b9b3-4b74-addf-54345a5ff235"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01015)</ddiem:url>
    <dc:identifier>DB01015)</dc:identifier>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3503f5c9-59fc-44dd-8d4b-e87addf80083">
    <rdfs:comment>If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood &amp; urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/423fd858-2700-4ed9-90c6-063cde8137b0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26899bb3-cc52-4308-84b8-5af161763a16">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002148</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0002148</dc:identifier>
        <rdfs:label>Hypophosphatasia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ef34ecf-c29f-4ee6-a05b-d199d42c2eca">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/17a46e5e-64eb-4897-8020-929aad794bfe"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/309000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/72bca5c6-7052-48f6-bc4f-27763b956b29"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19773212</dc:provenance>
    <dc:provenance>https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/7905b4c0-3815-4699-ace9-1cb374fbd537">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/151660"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02300233</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f28ab07d-4807-479f-b6d2-1803e3f0aa50"/>
    <rdfs:comment>Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet</rdfs:comment>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/efffd0f6-21fa-4ca0-ad6d-30d5ff4456f3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02211209</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/49761585-89ab-4716-8b2f-3f86d38cdb41">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ebf7769-1fa1-404b-92ae-204038d2ac1b"/>
    <dc:identifier>DB06742</dc:identifier>
    <rdfs:label>Ambroxol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06742</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f004f834-db36-40f1-aef8-e3ce1e429cf0">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/863f25cd-217e-4119-9ac1-0fd828b59013">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e3ac891-6352-4aeb-b5a3-060d04d3fd6a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/da733d5a-5e32-47fb-8413-b4eb9383b767"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdfs:comment>Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/</rdfs:comment>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00847</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/48c643e1-7436-4def-b27d-f5ca559c0a7b"/>
    <rdfs:label>Cysteamine</rdfs:label>
    <dc:identifier>DB00847</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54d9c939-6951-4508-a6fc-9eb0083c771f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/430a403f-9b47-437f-ba99-f02c10cd5f99"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f6cec2cb-aaed-44fa-b152-1c64cebb123f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dbf4ed8-8d86-46b9-9ad4-1813568cb25f"/>
    <rdfs:label>Pitressin tannate in oil</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1c331788-66ef-4d23-8230-d88f8c29ac02">
    <rdfs:label>Oxcarbazepine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86e2aebf-76d4-413b-ac69-f858e8b1a8bc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85d3df8f-2634-478a-ba48-00db45e15c54"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00776</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/11a86e20-bed2-4fed-a181-ab543fdd1831"/>
    <dc:identifier>DB00776</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f9495a7-9b51-4ad2-92fe-261e13cd1c32">
    <dc:identifier>DB08809</dc:identifier>
    <rdfs:label>Dichloroacetic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08809</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b32bcbcb-4d7b-4d26-8e98-a76acfcbf668"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dd9ec7c2-44aa-4884-9a71-35a0efa944c5">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c12cb433-742b-41d1-af36-e1aa6d87a236"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151710</dc:provenance>
    <dc:provenance>https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19755409</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/202110"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea0b2ca2-1c74-4933-9db6-7e68e5dfb4e0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f239e781-3a83-4442-8562-01738d9997c6"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa1c40ae-893e-4d2a-bd83-680900efda08"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/38d2ce6e-ffad-4eb9-96e7-50f14076b2a0">
    <rdfs:label>Muscle cramps</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003394</ddiem:url>
    <dc:identifier>HP:0003394</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/3310ab16-3553-4f40-8c8a-ff49354c362e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22840416</dc:provenance>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11102558</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7783847c-7672-45f9-8db8-bce3c71138cd"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0303846712003952</dc:provenance>
    <dc:provenance>https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300438"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/de5374d0-da1b-418c-87b0-5456a9e24d4b">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c9d69d8-9bec-433a-991e-c1d534ee520f"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3de5c41b-3ceb-4795-b492-83b1c1059e2d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/42d695bf-ecf3-49d3-9428-3661c8e1230c"/>
  </rdf:Alt>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/0e27a2a1-c72c-4b9f-bf6c-03ca97e8a3c5">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/608643"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0a6faaad-bbcc-4620-9258-dba6d772ea11">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/89883f93-c6b7-479b-beff-a2cdee16df62"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02926066</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01395641</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5e4d3401-f635-4c8c-b4dd-b0eb838b0be9">
        <rdfs:label>increased dopamine and serotonin levels (neurotransmitter levels)</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012654</ddiem:url>
        <dc:identifier>HP:0012654</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/92b7a68c-a754-4c72-954c-363103731246">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0002275</ddiem:url>
        <dc:identifier>HP:0002275</dc:identifier>
        <rdfs:label>motor malperformance</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/999d2f84-756c-4dd7-8f36-cbb324ac9499">
    <rdfs:label>gait abnormality</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001288</ddiem:url>
    <dc:identifier>HP:0001288</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d00ede78-ff45-4715-96bf-cd473848f33b">
    <rdfs:label>abnormal SF-36 physical composite scores</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/103cde05-cb93-4ef3-9a4b-94f3a59de337">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8056e68c-ad16-4d28-8aaf-141ee5acf3e7">
        <rdfs:label>Exercise-induced muscle fatigue</rdfs:label>
        <dc:identifier>HP:0009020</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0009020</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/38d2ce6e-ffad-4eb9-96e7-50f14076b2a0"/>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b3eebc1e-8b41-4380-86bf-cde71e8b7945">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003690</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Limb muscle weakness</rdfs:label>
        <dc:identifier>HP:0003690</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615511"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c2eb12be-0a6b-479b-9eb8-4db0858419a3">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003738</ddiem:url>
        <rdfs:label>Exercise-induced myalgia</rdfs:label>
        <dc:identifier>HP:0003738</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a7d21250-5bc4-4d18-9274-0f0a5f667aa9"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/17a46e5e-64eb-4897-8020-929aad794bfe">
    <rdfs:label>Pamidronic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00282</ddiem:url>
    <dc:identifier>DB00282</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3503f5c9-59fc-44dd-8d4b-e87addf80083"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/2db47e8b-ed37-4a38-a6b7-ae00d6f0cfa3">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27884013</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301746</dc:provenance>
    <rdfs:comment>The drug is occasionally effective especially when started early in status epilepticus.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ca3d56e8-a19a-4117-84d8-593ab6f5d9d8"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5159e670-0bcc-41e1-90f1-d130cae38878">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000114</ddiem:url>
    <rdfs:label>Proximal tubular dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000114</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4e7f52e6-ecfe-4c65-bf0a-bd70f9d92b8f">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207900"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S109671921200265X</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/be7a09b1-a4ed-4434-a1de-d14684760b78">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/692af4ce-3ee6-4dfe-bdd9-6823425fd394"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/26f70df4-9c9c-4f32-a10a-fbc86c026955">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>absence of flow-mediated dilatation of brachial artery</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22541557</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52165af4-0fc6-4d84-b2c8-44f1b59682eb">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>endothelial dysfunction</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fb565377-ffd7-4e19-98b4-ce08d09e38c1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Cardiac hypertrophy</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a5b22bf1-b919-4eec-a25a-31d179aca71f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypertension</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000822</ddiem:url>
        <dc:identifier>HP:0000822</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
  </obo:OGMS_0000112>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000008">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <rdfs:label xml:lang="en">dietary regime modification</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the diet is supplemented with or depleted in molecules  closely related to the products or end processes of a genetically defective protein which occur as natural products in the diet. [PNS]</obo:IAO_0000115>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:52+00:00</dc:date>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f646c92-0898-4b51-a9ea-c39814264b12">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9868107e-4ea8-48d4-aac9-f425f6e70adb"/>
    <rdfs:label>Desmopressin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00035</ddiem:url>
    <dc:identifier>DB00035</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8b8f51a0-b1c5-4785-84f8-d8311ef1565d"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/77701cd3-55f9-4834-9c69-6f5351a980fa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5337dfcb-ac7e-4504-86ab-7c656ca5fac2"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a97c8e50-9442-4393-bf82-f9f9b9d54173">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0be27dcf-f4bb-4b59-8e3b-013088d30f74"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5f953195-4031-45f6-9931-13ea2eee2595"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a05f715d-7839-4a17-a132-680389bf4607"/>
    <dc:identifier>DB00635</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00635</ddiem:url>
    <rdfs:label>Prednisone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15011668-6ff0-47db-a625-9b1f3ed3bc3d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61f70be4-8444-465d-8294-2b1629f668d0">
    <dc:identifier>DB06819</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/373c11d0-ccc4-4aff-bd46-8191a5d44c2e"/>
    <rdfs:label>Phenylbutyric acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06819</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/20753467-2329-45b4-a915-63be978965ac">
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
        <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/b817ee35-93cd-4ddd-bd7f-a01a072fd78c"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
        <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eebcdf2d-38a3-4919-b71d-e9037668f169"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b98194e6-5784-4f76-a259-74e1c1f527df"/>
  </ddiem:Drug>
  <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/09ea77be-128d-4eae-afb3-7053e4dfbbb3">
    <dc:provenance>PMC2676979</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/255120">
        <dc:identifier>https://www.omim.org/entry/255120</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5e67b4cf-cfbc-48e4-b841-5d38eed9aac9"/>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/228</ddiem:iembaseUrl>
        <rdfs:label>CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY</rdfs:label>
        <ddiem:iembaseAccessionNumber>228</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15669684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a7e17ab4-3b6a-483e-9dd4-1283f3935198">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001507</ddiem:url>
        <dc:identifier>HP:0001507*</dc:identifier>
        <rdfs:label>Low growth rate (Abnormal growth)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:DDIEM_0000010>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f20bb48-1480-4c7a-994a-380b91f72269">
    <rdfs:label>Droxidopa</rdfs:label>
    <obo:RO_0000056>
      <obo:DDIEM_0000011 rdf:about="http://ddiem.phenomebrowser.net/e517319a-b95c-4842-b4fd-44de7fe65aa7">
        <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
        <dc:provenance>https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fd8144ca-93da-46bd-ac4a-34732ef3a410"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f3890bb-95d3-44af-ade3-bafd9d6873ac"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00889135</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/223360"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20301647</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
      </obo:DDIEM_0000011>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06262</ddiem:url>
    <dc:identifier>DB06262</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b6858ee9-8364-4b4f-a74d-56c7be8c0556">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d3aa16f3-b2a8-4c13-976b-d1831c755489"/>
    <dc:identifier>DB00761</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00761</ddiem:url>
    <rdfs:label>Potassium chloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1ff8091-73fe-4557-a901-8079e739b27e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e876f230-9f5f-499c-b111-25c89921dc35">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98eac9a8-a69d-4f34-8ee8-7f4bbea90cb2"/>
    <rdfs:label>NA</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ae1d41a0-3f3e-4623-b17e-d56e3d4e3b5f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/921eb4a0-0c08-4596-ac58-6269759fe498"/>
    <rdfs:label>Modified Atkins diet</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ef971b86-96e4-4624-9719-9a6c7b9964f3">
    <dc:identifier>DB02952</dc:identifier>
    <rdfs:label>Alpha-Aminoisobutyric Acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02952</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/8cd88180-4199-4678-9806-a778084822aa">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28883274</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1755734</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/247ff6e0-4bc6-42ca-9867-42c1428c47ba"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1bf9e72f-3409-4fc3-9904-f25b3afdb011"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/258870"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7356686</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7254778</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0e6019ac-c30d-460e-b0c4-a53db62946f0">
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
    <rdfs:label>High cermaide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>MP:0020582</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b69427ed-84dd-4702-b4cb-25ec56e4bbd7">
    <dc:identifier>MP:0002647</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0002647</ddiem:url>
    <rdfs:label>decreased cholesterol absorption</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bd5b60e1-d138-423a-a4a4-0b2bdc6eb183">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <dc:identifier>HP:0003119*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Lipid accumulation( Abnorality in lipid meabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8a7bd5c0-bb86-472f-9854-ae75b63df0de">
    <dc:identifier>DB00151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00151</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/79ac3941-3cc2-4bfa-90c8-a625964a248b">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/177000"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22092997</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23884489</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12535027</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004831</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26979527</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00004940</dc:provenance>
        <rdfs:comment>Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9a3f9fb8-0490-4718-a327-654ef5196c24"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/11987230-4dad-4360-892e-3036c9110da1"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>L-Cysteine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d8acc1f-2647-4279-b924-43fe64077193">
    <dc:identifier>DB00860</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d9f9d7c0-0471-4ac4-89d8-047daa282df6"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00860</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eb1c1174-72a4-4634-bf16-8fe15c412536">
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17446099</dc:provenance>
        <rdfs:comment>Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/8b841ceb-25c7-4db7-a491-ac3035020444"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1668c603-77b0-4b6b-9a83-78d324651eb0"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5ebcbba4-03a5-4534-ab6b-c9dee31b357e"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007764"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607155"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23817215</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6599357-9565-4e3a-989f-34aa1a910bee"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4976393f-0dcf-46a8-b880-75214a2ca57c"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28334834</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ac6f019-2738-4d2a-9717-737de462fbbc"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25048216</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/15df652e-b287-43a6-a6be-8f9381c566e1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28480302</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28107841</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28931339</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Prednisolone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/594e369f-2d39-4f3d-b815-b7622b91ff2b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cda6cc8e-9537-41a5-9f87-0b1dbae7368f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <dc:identifier>HP:0001396</dc:identifier>
    <rdfs:label>Bile flow defect</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c4030b69-ed08-4950-825c-42905ee93200">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001369</ddiem:url>
    <dc:identifier>HP:0001369</dc:identifier>
    <rdfs:label>Joint inflammation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28df9898-fa24-4312-93f9-6795a4bf0cc8">
    <rdfs:label>Ad5-LARGE-eGFP</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1676cbc1-0117-4611-9053-cffc30ed150e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/94f253fa-4ddf-48c1-84b9-9e05bc6f5e2e">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010863</dc:identifier>
    <rdfs:label>Receptive language delay</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010863</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41dc8657-2552-4b02-b7ce-c911d189e489">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41297aa4-857e-4a51-a863-8f0eba3b4e57"/>
    <rdfs:label>Glycine betaine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06756</ddiem:url>
    <dc:identifier>DB06756</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7242e8e-176a-439c-b7ee-8c83e3a40960"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/5837c000-6876-4e80-8e08-43fcb502f3a2">
    <rdfs:comment>The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e51de5dd-2162-44a2-bc85-350b0b6cb374"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c5d6bf37-d491-4c25-b75c-8256782b4023">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0025142*</dc:identifier>
        <rdfs:label>low quality of life(Constitutional symptom )*</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16be7a75-7ff2-49ca-9a5a-62350dd43323">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4803e14d-6e3a-4bab-9a7a-db103d0b4209"/>
    <dc:identifier>DB00999</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00999</ddiem:url>
    <rdfs:label>Hydrochlorothiazide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bd44d35e-3e4c-4356-9319-238a6856e789">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1bea0a5b-c02f-433d-97ff-d706ddd1a12f"/>
    <rdfs:label>AAV-mediated gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/962bab8a-e944-4b4b-949b-78475fb19720">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01599</ddiem:url>
    <dc:identifier>DB01599</dc:identifier>
    <rdfs:label>Probucol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/736141f9-7f4b-4c50-9167-ff16007ca890"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ae1cae6d-8381-4769-a130-460397d6b1bf">
    <rdfs:label>Paroxysmal nocturnal hemoglobinuria</rdfs:label>
    <dc:identifier>HP:0004818</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004818</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b0eb7737-13b3-401a-9fa4-56bfb67b0c46">
    <rdfs:label>Alpha-D-Fucose</rdfs:label>
    <dc:identifier>DB03485</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03485</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9dac01a5-6576-4c87-91bc-81cc38a518c7"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b7c716d5-e070-4a5d-9056-121d5a79223d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/246700"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e7c3cfcf-4b17-425d-bfc5-5068ebdfd737"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691</dc:provenance>
    <dc:provenance>https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4120eb9d-0186-459f-8d2b-e2b6e4d97ccd">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2e01243-950e-4485-afb8-1e7bc10d147b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23329770</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ce8715f9-e0c4-4c9f-9c3c-fd3cff4fd5ad"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/611250b3-31cb-4837-a9d7-a39e3f351ee9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00472</ddiem:url>
    <rdfs:label>Fluoxetine</rdfs:label>
    <dc:identifier>DB00472</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0504eb97-ea16-490e-abd0-e12e8c4900ed"/>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/404d3354-01c5-4b1f-b44c-520e2d7646d8">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/786010dd-719a-41e5-b77d-01102eb81eb7"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/987955d5-71f0-4ccc-a689-cd5c5eaf6ee0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee58517d-e207-4af0-a3e0-b3a01f3687aa"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8900123</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd4d816d-1e8c-4f13-bb14-2494ea37a31d">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B05BB01</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/44a18245-bf16-4631-8180-3a656d38acd3">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fb7b9a4b-26e8-435c-9a6c-ff0dd2a66491"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/300971"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27120771</dc:provenance>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
        <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/297dd15f-c89e-41e0-b6ba-0794646ac9aa"/>
        <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>electrolytes</rdfs:label>
    <dc:identifier>B05BB01</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fae9e610-c3f0-4206-b37b-8ea053f96921">
    <dc:identifier>HP:0001396</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Defected bile flow(Cholestasis)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/47bbefcb-cc39-499d-863f-cecb95c40e8e">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00067</ddiem:url>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/47c2941f-282d-4f9c-9678-b5e3314e20de">
        <dc:provenance>https://academic.oup.com/jcem/article/98/10/3958/2833930</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7ac76d4c-c656-42f4-b698-b9087a4f5845"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1316120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/67ac24a0-c6c0-4e56-93c8-299b525fb94b"/>
        <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b3f6e3d0-828f-4d3b-951a-a2d6e231cd94"/>
        <rdfs:comment>Drug name: Treatment is under trial.</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00067</dc:identifier>
    <rdfs:label>Vasopressin</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c57f69b4-edd7-489b-a5dd-c597aac1f2b1">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/261750"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2"/>
    <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3b23f030-970b-4918-ae31-596a0702b1b6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c869e6ca-6bf4-40d4-b101-854f18b03e86"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2896e753-4ce9-4e08-b110-07d78a668351">
    <rdfs:label>AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2dc773a-6fe6-4864-b6ae-effb64b53a36"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e5351f1d-6abd-448c-8817-6089fc56fa80">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1fad1424-9bdc-43c6-88e4-7ce41662981d"/>
    <rdfs:label>Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/85946b43-3414-460c-8d5e-218785524618">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04581989-489c-49a8-95fd-7e0947ca3033"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00936</ddiem:url>
    <dc:identifier>DB00936</dc:identifier>
    <rdfs:label>Salicylic acid</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a36eb57f-a8fc-43e2-92b9-5f7fb4f7ba68">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/acccba5e-7034-4b0e-9a23-f6d1f8421187">
        <rdfs:label>Canakinumab</rdfs:label>
        <dc:identifier>DB06168</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8788abbe-fa26-4b15-aed4-56d74450c588"/>
        <ddiem:url>https://www.drugbank.ca/drugs/DB06168</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9100c012-aa89-4b75-8582-a3e0531371e0"/>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6b339151-b16e-485d-9df1-a6b46ee17ce3">
    <rdfs:label>No Studies were done on this drug.</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/b25ed3e2-6bfb-48ae-81b7-964161ec9b2c">
    <obo:RO_0003304>M197I</obo:RO_0003304>
    <obo:RO_0003304>A456V</obo:RO_0003304>
    <obo:RO_0003304>W99R</obo:RO_0003304>
    <obo:RO_0003304>G68V</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>Y214C</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f584cd7d-312b-4627-b23d-cb42a537f6c2"/>
    <obo:RO_0003304>T65I</obo:RO_0003304>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/10e4dfe8-c325-4413-a022-d4b178fcc25d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d8b8f39f-1cea-4122-be32-4c299c8c57cd"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/602485"/>
    <obo:RO_0003304>S64Y</obo:RO_0003304>
    <obo:RO_0003304>V452L</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>GK-Y214C(De novo muttation)</ddiem:failedToContributeToCondition>
    <obo:RO_0003304>(Val455Met) at codon 455</obo:RO_0003304>
    <dc:provenance>https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8410522</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/17dddd5c-6ce4-42d3-9b7e-9f83ec8c5776"/>
    <ddiem:failedToContributeToCondition>ins454A</ddiem:failedToContributeToCondition>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15133749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25781533</dc:provenance>
    <rdfs:comment>Based on their study auhors of"  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract"  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15277402</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19336674</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/55b71242-659e-4d7b-883f-184b384eb953">
    <dc:identifier>DB09105</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b97a4ffe-6a20-4d0b-9fca-b89f7e85ebb6"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ef3faa05-d722-4f80-8e2c-e3e517cd3799"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09105</ddiem:url>
    <rdfs:label>Asfotase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f01532a4-ed0d-41f0-8db4-4f165be2804b">
    <rdfs:label>High bone turnover markers</rdfs:label>
    <dc:identifier>HP:0003260*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003260</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/848b3de2-23ba-407c-b332-3f856ff6ab92">
    <dc:identifier>HP:0001903</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001903</ddiem:url>
    <rdfs:label>low heamoglobin leval</rdfs:label>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/98e0b2a4-3e5f-44fc-9fe2-9f2d36d428cd">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613153"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S152500161632250X</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d464f13a-bcba-44d8-a786-c3731daa73eb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4c3e5690-6179-47d9-8901-3920d7369610">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/16f80160-d75f-4619-84c6-b070179a831b"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fe97a45b-0629-428b-b6df-e18be7fdb5db">
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22129523</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12709436</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb4c5806-deb4-4182-82ec-d7dcdbe3e926"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c75beeff-e731-4de2-83eb-c1c9aa9f2831">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0003233</dc:identifier>
        <rdfs:label>Low HDL-cholesterol</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65b8ad2e-e97d-44b3-8f4e-ec69ee596e89"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/eebf7b0c-dd10-4ecf-a613-0c9ad33a1f77">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003362</ddiem:url>
        <rdfs:label>High level of very low-density lipoprotein</rdfs:label>
        <dc:identifier>HP:0003362</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2653622</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51a26c85-5bc4-43c2-8d6c-da886afcbe8e">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High total cholesterol</rdfs:label>
        <dc:identifier>HP:0003124</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003124</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23633496</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e035724-aac4-4529-8236-85c62dbce033">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21a1bb0d-49a9-4028-ac48-5582cf5c1931"/>
    <dc:identifier>DB12449</dc:identifier>
    <rdfs:label>Tempol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12449</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/0f8ab6d5-0b00-4cb9-a371-474a177abc75">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24093206</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02805790</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21600768</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21483849</dc:provenance>
    <rdfs:comment>The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/535000"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/600b3775-2861-4deb-b002-790642663806"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24161764</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29054473</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02176733</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c9615bb1-845b-4050-92a0-e3921eff9379"/>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c03c5596-fe2b-44a7-a54c-27f235482666">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26095523</dc:provenance>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/be13f4db-a1e3-4d3f-9eb1-19d50d2d1127"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec70b507-c181-4c77-ad79-7a227879132e"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <dc:provenance>http://ichgcp.net/clinical-trials-registry/NCT03432871</dc:provenance>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29596118</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c3c9163-2c8e-4016-b99c-c2cdf5d33fa0"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/540000"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e51fd94b-d55f-4ed3-9046-9e5fd9471650">
    <rdfs:comment>rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0e6019ac-c30d-460e-b0c4-a53db62946f0"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b21b7566-9f10-449c-9093-060d79b94e67">
        <dc:identifier>MP:0009587</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0009587</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>abnormal sphingosine level(Abnormality of lipid metabolism)*</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a9847569-1b39-4328-9bbb-0d0add316d62"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23681708</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bac5ce7b-453c-4381-8cd9-9c08f12a64aa"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/228000">
        <ddiem:iembaseAccessionNumber>1297</ddiem:iembaseAccessionNumber>
        <dc:identifier>https://www.omim.org/entry/228000</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>FARBER LIPOGRANULOMATOSIS; FRBRL</rdfs:label>
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1297</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/360f4f51-fd06-42a0-a1ca-26925c8997be"/>
      </ddiem:Disease>
    </obo:RO_0002599>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3c588b0d-e15d-434f-b28e-f613b666b00f">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/555ec245-4242-417e-a29c-901aeadac03a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/51a9ffb3-71a5-4d37-87fa-cb81d1eb61d1">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High intracellular cermaid level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/MP_0020582</ddiem:url>
        <dc:identifier>MP:0020582*</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d48164b1-6af2-424c-993e-4ce3a7340075">
        <dc:identifier>HP:0001744</dc:identifier>
        <rdfs:label>Abnormal spleen size</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001744</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c4030b69-ed08-4950-825c-42905ee93200"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ca545d69-1663-40d9-9bc2-0240d38d65db"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/0fba7177-4dc6-4fb5-8152-df60a3d44d48"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0cb2994d-9160-4d4f-9ed0-b7095c7a3ab5">
    <rdfs:label>Limb dystonia</rdfs:label>
    <dc:identifier>HP:0001332</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001332</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4577c623-0aec-4c48-b6d2-92969ef172a5">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2681858</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b1329595-e8c2-463d-b65d-de2e9923d52c">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012238</ddiem:url>
        <dc:identifier>HP:0012238</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Hyperchylomicronemia</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4883477</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29695967</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1a170d33-82ae-4578-be5a-94491050baea"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2702860</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e04c8ebd-ae6f-4677-aed8-23f904f7d53a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/2a2bd349-e4b9-462c-a6d3-44182df1afbb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/30367039-6958-42fb-b0ab-765d72c8bbec"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b709afc2-3a3d-46be-9a37-5ba0fb6ec0cf"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6c5669a2-c2a9-48e8-9f6e-9f7b08f01d0d">
        <rdfs:comment>The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860</rdfs:comment>
        <dc:identifier>HP:0001013*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001013</ddiem:url>
        <rdfs:label>Tuberoeruptive xanthomas</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/faaa6c9f-edac-4ff4-99ee-8ab5ed57b33a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01151</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9852323-e37a-46b2-b640-7cc7968f06e3"/>
    <rdfs:label>Desipramine</rdfs:label>
    <dc:identifier>DB01151</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9ef6d88f-dc91-4b07-b15c-96d5a6a2062a"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a3f2c28-a2c6-4aac-b106-0277a566a92e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f1e1ac7-8ed6-4ea9-b669-2acb300559ff"/>
    <dc:identifier>DB08834</dc:identifier>
    <rdfs:label>Tauroursodeoxycholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08834</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba9efbc6-b149-4e58-a6a2-c69620637e55">
    <dc:identifier>HP:0031544</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0031544</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High blood malonylcarnitine level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/230900">
    <rdfs:label>GAUCHER DISEASE, TYPE II</rdfs:label>
    <rdfs:comment>By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.</rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/230900</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/ccb1642b-043a-40df-aa5b-8240a4fe6c8c"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d0464d6-bc71-4dac-89db-35f377bdf6a5">
    <dc:identifier>HP:0025548</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025548</ddiem:url>
    <rdfs:label>High RBC's mean corpuscular volume</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/385bff8d-d0a8-4c29-88b6-18c405263a62">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16635485</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>A low fat regimen was added to metformin while treating the patient.</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17339125</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ec240001-0e05-4680-91c8-48bfad890484"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4805828c-3de5-4c65-a253-76d5eae7e9e3"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24777537</dc:provenance>
    <obo:RO_0002599>
      <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/614462">
        <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/836</ddiem:iembaseUrl>
        <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/7928fe18-04f4-4500-ab2e-c39002e8b86c"/>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>https://www.omim.org/entry/614462</dc:identifier>
        <rdfs:label>HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS</rdfs:label>
        <ddiem:iembaseAccessionNumber>836</ddiem:iembaseAccessionNumber>
      </ddiem:Disease>
    </obo:RO_0002599>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1d4874d0-3ac9-4765-9ffe-8cbd9dcf173b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fc103c33-be6d-4676-aa38-4ff5dc45005d"/>
    <rdfs:label>Isocarboxazid</rdfs:label>
    <dc:identifier>DB01247</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01247</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/86125bd0-8305-4ef1-a9dd-4a244f1cdec8">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28281899</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/59f04063-4da6-4482-aba7-8be8eba7bc96"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7cdb1984-3929-4104-9556-088e0e895f05">
    <rdfs:label>Atypical bile acids</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/40d426f0-5c11-455b-bf8b-046891754c8e">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/03b10ead-9b5b-497b-b997-9afdb94dd06e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/96b8c5b5-9b5d-4a19-99a3-9fbbac9fcaf9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/22b9c749-e700-48dd-bbad-dd31fd9eef05">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a7b9982b-8a7c-42c7-8727-f463583dc3fe"/>
    <dc:identifier>DB01039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/476f4540-ae83-42d4-8a34-37490823362e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01039</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/eefaa8bc-df48-4b9b-9a6f-07b45236b1b3"/>
    <rdfs:label>Fenofibrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/249900">
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/2c7e5d5f-e927-47ee-abd6-b0c9dee27018"/>
    <ddiem:iembaseAccessionNumber>293</ddiem:iembaseAccessionNumber>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/249900</dc:identifier>
    <rdfs:label>METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY</rdfs:label>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/293</ddiem:iembaseUrl>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ba5696ac-34fb-479e-94ae-dcfd7d253a0f">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012133</ddiem:url>
    <dc:identifier>HP:0012133*</dc:identifier>
    <rdfs:label>Decreased red blood cell production</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/e1fb609a-a30e-412e-a8d4-534c7becab9f">
    <rdfs:comment>A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to α-GAL A and GLB1, so it has improved selectivity for α-NAGAL and makes it superior to DGJ.</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23045655</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/EC0:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26884075</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bc3ef82d-b6c6-4cf7-9f8c-3ab4b25eb713">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>Abnormal enzyme activity</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02473445</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9cadde21-d49c-4b9b-9804-bdd13262b7b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee712e11-4939-49d5-bf27-ea3d97ade3f2"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/609242"/>
  </obo:DDIEM_0000012>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b05ccd7a-2b31-43dd-b98b-cca6f6576f49">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>production of toxic intermediates</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f974e2f3-bb3b-4215-9dc9-ae2e0e440919">
    <rdfs:label>Fenofibric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/15c60d20-bac5-4fc7-a6d1-f7b8e9632ed8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe97a45b-0629-428b-b6df-e18be7fdb5db"/>
    <dc:identifier>DB13873</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13873</ddiem:url>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/223360">
    <dc:identifier>https://www.omim.org/entry/223360</dc:identifier>
    <rdfs:label>ORTHOSTATIC HYPOTENSION 1; ORTHYP1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>101</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/101</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6133cc0e-076f-470e-9763-3ae94be4970b"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e280d5ff-7a64-47bb-a6a3-fdd70eec525d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/267e6792-3216-472b-a18f-14a5f61cdd21"/>
    <dc:identifier>DB00200</dc:identifier>
    <rdfs:label>Hydroxocobalamin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00200</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3a5916db-39c6-4094-9a83-eefe5fcb16af"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d4ae96d7-5b61-42ac-b7f3-de7ecacd52cb"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4cfb54d-f829-41e0-8d92-2b4746cbb74e"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/69a8750e-b461-4106-ac8a-f753e7cfb7e0">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10078749</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12003346</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20818608</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719208000048</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8578fac1-4d6f-4672-b216-4a245c30dc23">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012535</ddiem:url>
        <rdfs:label>Defected neurotransmitter homeostasis in the CNS</rdfs:label>
        <dc:identifier>HP:0012535</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d6b65fe8-119b-47cc-b75b-9b9c81f80745"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1dbd5f6a-23fb-440a-9640-1084c945844a">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001270</ddiem:url>
        <rdfs:label>abnormal motor development</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001270</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aa9b35b-460e-49c9-824d-2439a69851a2">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001257</ddiem:url>
        <rdfs:label>spasticity</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0001257</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19234759</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/233910"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bc1fd59a-3f5b-49df-8e8b-bcf34faad7e6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f566493b-6adb-48d7-b855-6cb91701625c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729</dc:provenance>
    <rdfs:comment>Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22729819</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/12849431-df94-495a-b230-343cdf007cd7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c7713647-3aa6-4f96-87b6-2e3a9df1d484"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c2e01243-950e-4485-afb8-1e7bc10d147b">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/60773e7f-4dbe-428d-ba6b-f8eabbde0043">
        <rdfs:comment>A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4120eb9d-0186-459f-8d2b-e2b6e4d97ccd"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00028262</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bd5b60e1-d138-423a-a4a4-0b2bdc6eb183"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256730"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e34d7b82-1bee-440b-a3fa-32275851692e"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2fb53ec7-aaec-4343-8807-99ab77da6636"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/86944b03-72c6-467d-a6f9-d170f850adae">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4120eb9d-0186-459f-8d2b-e2b6e4d97ccd"/>
        <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
        <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e34d7b82-1bee-440b-a3fa-32275851692e"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29631617</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>Tocopherol</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11251</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b7c716d5-e070-4a5d-9056-121d5a79223d"/>
    <dc:identifier>DB11251</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5be07c82-a8d4-43fe-8ce6-16586262b3fa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/beabab32-cd69-4cb3-afb1-ee0c20a2f797"/>
    <rdfs:label>Idebenone</rdfs:label>
    <dc:identifier>DB09081</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09081</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a833151c-7322-4f96-b284-38ccd668f283"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e758e15f-1d61-405e-929c-354bee1e45c8"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/142ae25f-d9c6-4b0a-9300-b91516d63f05"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/283bb79a-cacc-4d22-8656-736712d62c99">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/5707897</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/613163"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29480352</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19428278</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/94c1c31a-af7a-4eb1-ab64-53f61d4a3fe5"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/70dd3cd0-cf2c-4709-87e0-09e24266ef7d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/28d48256-2fdc-4ef0-aaef-e47eef5238aa"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/2fd6e9c0-d762-4531-a39c-c3e9b35ad486">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdfs:comment>In this study"https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28098593</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f993856-dbab-4d32-9be5-bc1a5bef81e7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10385780</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2137a684-5177-43b8-aa4d-fd83d9d12d4f"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0021915015001379</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9bcc68f6-d97e-443d-beb6-8fcd234f9fdc"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/617347"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25768710</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/793caade-6cc0-4b93-a82d-a195127406e2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000486</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>strabismus</rdfs:label>
    <dc:identifier>HP:0000486</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83530693-72e4-4059-bcfb-3dc37814f7f2">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003326</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Myalgia</rdfs:label>
    <dc:identifier>HP:0003326</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/e3c287b5-49db-4c51-9627-f03df26ff638">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
    <rdfs:comment>The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000015"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/228000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27155573</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a0885aef-e8e5-475b-b480-9bc6d77391a8">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/40906b57-1763-4033-8f93-0419755c0807"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/30034be1-7840-4716-8a6a-fdb1a9cb53b5">
        <rdfs:label>Abnormal pulmonary ceramide level</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000305"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28275553</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18376404</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94f4d26a-8918-45f0-aac2-1cbc8cf78eab">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00390</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab900e0b-7191-4d8c-acf3-52d6fb40c848"/>
    <rdfs:label>Digoxin</rdfs:label>
    <dc:identifier>DB00390</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/006c5a50-65f6-4ab3-88da-a45bd7578e8c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b68abdfd-8416-4039-83fa-52325c0272f2"/>
    <rdfs:label>Bortezomib</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8e6307ce-85ce-4b66-98f4-c7b8c662ca40"/>
    <dc:identifier>DB00188</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00188</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5973b326-8e74-4a85-b88d-1a3fad228ade">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/56b746c5-52de-4693-85f0-88ee87ca59e7">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/306000"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/fab294ec-9c41-4af6-92cf-2bb07fab98f1"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6cb0cc44-4d0d-47eb-83b7-534b64b002f2"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
        <rdfs:comment>Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <rdfs:label>CoCarbs + HPro</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af398923-04b8-47f6-8859-731cc26887cb">
    <dc:provenance>https://link.springer.com/article/10.1007%2Fs10048-015-0444-2</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e9982ec3-a78f-49d4-bd5d-c7b362ce3eba">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
        <rdfs:label>low physical capacity</rdfs:label>
        <dc:identifier>HP:0012378</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/88976df4-009c-46a0-b14d-323209e91406"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25797485</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615395"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f341a011-addc-47e6-a11c-d9aee9d249ac"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/8a0bfaf9-954d-4451-98d2-2fe77b6623ae">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7938d5d8-6c77-4220-8e54-ca05337b6817"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/d02fbd34-3b1b-482d-9484-996a68bdcffe">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1723602e-35da-4fa5-a136-7b85b472ad53">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000707</ddiem:url>
        <rdfs:label>Neurologic abnormalities</rdfs:label>
        <dc:identifier>HP:0000707</dc:identifier>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27750150</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/289c4c82-6224-49f4-b2b2-40a6ac51adc0">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9577b1ff-d188-4fd6-9e5f-de3fac5b221c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230500"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c6033562-a089-43a0-8c99-331ce08c8de3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03256</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5a21ce62-ac9b-45a7-a10d-df8ab6c66442"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0a2d62b-dc79-4b16-aa02-c929647d322f"/>
    <dc:identifier>DB03256</dc:identifier>
    <rdfs:label>(6R)-Folinic acid</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f1c62323-710b-41a3-8d8c-3ac586237674">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25391139</dc:provenance>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17490880</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f15fcde2-bd96-4660-9772-29b5580b501c"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24493026</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/28932990</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/911fc3a2-8fe6-4bf8-823f-a344f22049e0">
    <dc:identifier>HP:0004305</dc:identifier>
    <rdfs:label>involuntary movements</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004305</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a0a114db-254b-41c2-9695-eef011833651">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c6ce1272-bbe4-46f7-934c-705b993e6c4a"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/302060"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d1cf014d-2f2d-4f36-8226-bc97d2425974"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT03098797</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/21008e61-3a1f-450d-85b6-e88fc66aa29b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4195ad1f-46ca-4736-968c-602b7606827c"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/50b9b6b4-3646-4205-a9ee-032560cd1cfb">
    <dc:identifier>HP:0001638</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001638</ddiem:url>
    <rdfs:label>Cardiomyopathy</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fc76b781-80cc-40f4-b9c1-58956de2647f">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Parkinsonism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2bda0be5-ab01-4600-9560-43bd10998392">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61203e1a-869b-4313-9f98-d325e1951f31"/>
    <rdfs:label>ARC-AAT</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e4147282-f661-496b-838e-7863319d9c58">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000518</dc:identifier>
    <rdfs:label>Cataract</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000518</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/41842271-4657-4607-afb6-0ec7cc39cd91">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00473655</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3898712c-2e6b-403a-866f-902487395c9f">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High LDL level</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
        <dc:identifier>HP:0003141</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/bb4c5806-deb4-4182-82ec-d7dcdbe3e926"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/144650"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e60e6a-b0d3-440a-b81d-98486980fef6"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7dc0e113-d600-4f33-880f-d6e2f0d71f7a">
        <dc:identifier>HP:0025201*</dc:identifier>
        <rdfs:label>High Apoliporprotein B level(Abnormal abpolipoprotein level)*</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0025201</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:00007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/51a26c85-5bc4-43c2-8d6c-da886afcbe8e"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/609286">
    <dc:identifier>https://www.omim.org/entry/609286</dc:identifier>
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c1a7bd1-5476-4b06-9f6a-2598fb378875"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0a3c2bf7-ca87-42ee-8d44-391cea1e98c0">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00695</ddiem:url>
    <rdfs:label>Furosemide</rdfs:label>
    <dc:identifier>DB00695</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01630429-3fbd-4e29-befe-28d0abdb7fd1"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cfbfacbe-bcf9-41a8-9b9f-5594572b392f">
    <dc:identifier>HP:0002570</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002570</ddiem:url>
    <rdfs:label>increased fecal fat excretion</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a758951b-5abe-4df7-a06c-fe527cf989ff">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/12ce8d3b-7aa4-4b2f-8f95-c32ee599df29">
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0012217</ddiem:url>
        <dc:identifier>HP:0012217</dc:identifier>
        <rdfs:label>Eevated porphyrin precursors porphobilinogen</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15767622</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/176000"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9c6a52f4-508a-4839-a6bb-92107f934359">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7a3b433f-af3f-44c4-bd36-6f095cf6a42c"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02180412</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15208740</dc:provenance>
    <rdfs:comment>The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/23089857-f554-4e21-af50-dc6af397b92f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e25b051b-0466-438b-8de1-eb986d6b9dd9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/528291d5-5b90-4867-b48b-2a44cd23f5d1">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00396</ddiem:url>
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/fc688f86-a21c-4c36-a548-fec99a047d54">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30731125</dc:provenance>
        <dc:provenance>https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24288038</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9d9a7029-aec5-4221-a232-bc3a77543fd4"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Investigational "Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/</rdfs:comment>
        <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0378378210006055</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/56954c83-ce3e-4361-8844-1fa85df92219"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25488886</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/200100"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Progesterone</rdfs:label>
    <dc:identifier>DB00396</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4d2e4fff-a5c4-4f03-881f-63195fc68861">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/25e8fcaa-a62c-4f26-9297-15553b8f690b"/>
    <rdfs:label>Trolox ornithylamide hydrochloride</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e58f883d-2a48-456b-9ef2-3628780ccdb3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00594</ddiem:url>
    <rdfs:label>Amiloride</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3f78336-d4d6-4e72-bba6-e789c268cd25"/>
    <dc:identifier>DB00594</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7798705b-4e66-4805-be98-beb472162443">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal microtubule assembly</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/297dd15f-c89e-41e0-b6ba-0794646ac9aa">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cd4d816d-1e8c-4f13-bb14-2494ea37a31d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b0b64bca-bae0-4c90-8771-d8aa8d4bfac1">
    <rdfs:label>incoordination</rdfs:label>
    <dc:identifier>HP:0002311</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002311</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/babfd94f-34fd-4255-b7ea-96ac908b51dc">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e490828a-1a36-4853-bcec-1913c1d86524">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25098371</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22791294</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/105650"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17562599</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5574e1a1-81f8-46d2-b8a6-84fd5c20ec27"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22734070</dc:provenance>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/results/NCT00001962</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/e2265d57-88c2-4354-9cca-95d15f7f3fd5"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15813920</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <dc:identifier>DB00111</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00111</ddiem:url>
    <rdfs:label>Daclizumab</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/74075977-c9ee-4c36-a6a1-98e2c404293b">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00311</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08659e08-3395-4a87-9ae8-4a59f3f0cbf4"/>
    <dc:identifier>DB00311</dc:identifier>
    <rdfs:label>Ethoxzolamide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3a4c56fd-9eb6-4776-8d80-ccccba25d90a">
    <rdfs:label>fasting ketogenesis</rdfs:label>
    <dc:identifier>HP:0001946,HP:0025212</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001946,HP_0025212</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2805fe22-ad3c-487d-819e-d837c6275a14">
    <rdfs:label>Acidemia</rdfs:label>
    <dc:identifier>HP:0001941</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/47bc4775-d7a1-4fae-8ef5-eb4a30fb547d">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/ceedbf10-2a96-4135-a49d-1f6b5cdbfc56"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15895716</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b6fecb0c-fc74-4128-b173-28987e043503">
        <rdfs:label>edematous</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0000969</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000969</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15084520</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/999d2f84-756c-4dd7-8f36-cbb324ac9499"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/837d0b6f-914d-4cfb-9492-e8a1dfcd321a">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>infertility</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000789</ddiem:url>
        <dc:identifier>HP:0000789</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29358012</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22008912</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b0b64bca-bae0-4c90-8771-d8aa8d4bfac1"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25485164</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/7814809</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/256540"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/07c05d66-88c7-49a2-805c-0c8a2df15436">
    <rdfs:label>Hydrocortisone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00741</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b0db20a-1be9-401a-a770-7d353a821f8c"/>
    <dc:identifier>DB00741</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/fa7b5ebb-85e7-4f25-8f54-d547de24387a">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16434679</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232600"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/0cdabfc8-bd9b-411f-b47d-059b700d65d6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ee438ac7-2e7b-408a-8973-8a252189be78"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/af1f9dc1-092e-4aa7-ad42-be55dc95be0d">
    <rdfs:label>Antiinflammatory agents, non-steroids</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01BC</ddiem:url>
    <dc:identifier>S01BC</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f7bf35f6-f09a-4cb9-9908-a0c22d5077bc"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ac441691-78c4-4316-9591-92a5b45b4c83">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003678</ddiem:url>
    <dc:identifier>HP:0003678*</dc:identifier>
    <rdfs:label>progression of the disease (Rapidly progressive)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/071a9e7b-387f-43b0-bbc1-c408e74576af">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7776b2c-2087-480f-b815-88862299a965">
    <rdfs:label>Pargyline</rdfs:label>
    <dc:identifier>DB01626</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01626</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1533b579-192c-40c4-bb5a-30bec0edbea2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/16f80160-d75f-4619-84c6-b070179a831b">
    <rdfs:label>Adeno-associated Virus 9 Mediated FKRP Gene Therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/98e0b2a4-3e5f-44fc-9fe2-9f2d36d428cd"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b84da21-bca8-4f65-a004-3269172b2522">
    <dc:identifier>DB00636</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1c7ffb0a-9357-404c-ab6f-7ec824c1dde2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c3d4485-e326-41b6-978c-f97291b3b9be"/>
    <rdfs:label>Clofibrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00636</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/181aa565-6b0b-4546-80d4-33f26c5ed268"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60089421-5b36-453d-a494-5a5f377f4052">
    <rdfs:label>Omega-3-acid ethyl esters</rdfs:label>
    <dc:identifier>DB09539</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09539</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aaf3e595-76a8-4a16-a529-af494f3e9b92"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/56e37ccd-7a83-4058-87fc-c4fcc603ab7b">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/e5ee4a2c-778d-42b7-9457-24f694d598bb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d047b5e1-ae1e-4514-bf51-b026e5b86338"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/911fc3a2-8fe6-4bf8-823f-a344f22049e0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22550086</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/446d8a13-2d1a-4ee7-8f7a-86b1e1b051fa"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/2209e962-9161-4b04-8549-fb567b520a58">
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/1c40f1a0-99ff-4f02-9a8f-dd1c7c85a5a9"/>
    <rdfs:comment>The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26766614</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdc37e11-e280-4708-848f-db220dd9951d">
        <rdfs:label>High ganglioside accumulation</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/230650"/>
    <dc:provenance>https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/42605488-7c2f-4a3d-a199-9ea17d1bce0d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02030015</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </obo:DDIEM_0000015>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3b02ac1a-c1c7-4eb3-b3fd-875ead9beaea">
    <rdfs:label>N-acetylmannosamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12536</ddiem:url>
    <dc:identifier>DB12536</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b643d498-8b65-42d0-9eff-f86a804f11a8"/>
  </ddiem:Drug>
  <obo:DDIEM_0000012 rdf:about="http://ddiem.phenomebrowser.net/3bdcf55b-d521-4935-86c8-3c0fe32d750c">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23162302</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/606785"/>
    <rdfs:comment>Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d71ae1a-f87f-4c09-bf1d-5e2565d706e0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:DDIEM_0000012>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/40906b57-1763-4033-8f93-0419755c0807">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00321</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3c287b5-49db-4c51-9627-f03df26ff638"/>
    <dc:identifier>DB00321</dc:identifier>
    <rdfs:label>Amitriptyline</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fc606fb0-3d98-4230-b43b-7347570193a4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c22c77d9-28cc-4af2-8ae0-e7028353dd01"/>
    <rdfs:label>Adalimumab</rdfs:label>
    <dc:identifier>DB00051</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00051</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/121ecc03-54ab-44f5-abe9-3bc0c6fd4ec8">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/88b5e387-ac3d-48b7-978e-7109da067405">
        <ddiem:url>https://www.drugbank.ca/drugs/DB00563</ddiem:url>
        <dc:identifier>DB00563</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a27e6d5b-0ff1-438c-b24d-65d74c230d6d"/>
        <rdfs:label>Methotrexate</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d66338a5-e1da-4267-8d08-48d86d92b73f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05018</ddiem:url>
    <dc:identifier>DB05018</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b692860-9ece-420f-886d-288f95a4bdc8"/>
    <rdfs:label>Migalastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69f4dfc0-50b6-4cc0-84da-14e57bec1077"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8d4408d6-6b4f-459f-87cc-c267fb8da88c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0004355</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004355</ddiem:url>
    <rdfs:label>abnormality of proteoglycan metabolism</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2aeb99c2-f7b2-4c37-a6ee-dba236b8e5d3">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d8daf8c6-8bab-40be-95ab-0d519fcc0409"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bf8e698e-1939-456e-abe9-3c5d1113b23e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00090</ddiem:url>
    <dc:identifier>DB00090</dc:identifier>
    <rdfs:label>Laronidase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/28314b21-ec14-405f-bd81-13e02cf51b1a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:label>Asterixis-like movement(Abnormality of movement)</rdfs:label>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/984c1413-8768-4ab4-8e48-567710b61a82">
    <rdfs:comment>Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15753292</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9525311</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/218800"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/786010dd-719a-41e5-b77d-01102eb81eb7"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9156798</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/14521454-a314-4b0a-8a23-d2c33506a0a6">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d72d8a6e-10eb-44f9-9693-9aa7d4937069"/>
      </rdf:Alt>
    </obo:RO_0000057>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f01a48d6-6134-44e1-ac0b-24723c7345e2">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Trial is still in the Recruiting stage.</rdfs:label>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bfbe905d-40cb-4edf-b8c3-3c9eacb09583">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23887143</dc:provenance>
    <rdfs:comment>Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27551684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19304794</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/271245"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24639006</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c869e6ca-6bf4-40d4-b101-854f18b03e86">
    <rdfs:label>Complex carbohydrates+Beneprotein+Low fats</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c57f69b4-edd7-489b-a5dd-c597aac1f2b1"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/734fe216-4596-4fb7-b006-05c0a744c6d8">
    <rdfs:label>Abnormal levels of urine total alkanes</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9a195371-588c-4a6a-bf03-bd68f17be99d">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20030229</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/605820"/>
    <rdfs:comment>In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that "The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of α-Syn also affects retromer function and causes ceramide accumulation." https://www.ncbi.nlm.nih.gov/pubmed/29909971</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01517880</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10549306</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26546927</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19627167</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21517694</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/44ab0580-908d-46b9-97f0-09089df474ca"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00125190</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f9d70598-6484-404d-8bae-0c54c19e1715"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17192294</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f62cece0-8cd5-4c87-a5b3-26ebc36bd011">
    <dc:identifier>DB08883</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7712904-4aaa-4573-bca2-a0998f105cf7"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08883</ddiem:url>
    <rdfs:label>Perampanel</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ced62a12-94fb-40c2-9871-ddb710ed9eb1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7221ece1-603f-44bd-a028-7db07415e99c"/>
    <dc:identifier>DB00494</dc:identifier>
    <rdfs:label>Entacapone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00494</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2145ac1-9d39-498e-9e8a-7a57e4e65d04">
    <dc:identifier>HP:0010978</dc:identifier>
    <rdfs:label>hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c5edd135-e2d0-4e04-b4e7-bc36fd0e91bb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0f8ab6d5-0b00-4cb9-a371-474a177abc75"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/87402942-1d17-4cde-923f-1d8cd4181786"/>
    <dc:identifier>DB00091</dc:identifier>
    <rdfs:label>Ciclosporin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0530521b-2217-405f-b028-215a0731ccc8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00091</ddiem:url>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/b8dde397-b650-4d2e-a67a-0f3b09ff4374">
    <dc:provenance>https://emedicine.medscape.com/article/942055-treatment</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26577040</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25638506</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253260"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/95a2681e-6b44-4870-865d-b28f01a40657"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/310fc5bc-d29c-4b9a-9858-abe9d7e28cb0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28649539</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/c8c34314-7e0a-4dfe-ad9b-736d375f70d4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c204e8ca-a9f5-4c13-a81a-ef08ac03362b">
    <dc:identifier>DB12783</dc:identifier>
    <rdfs:label>Benserazide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12783</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ede574bb-fcfa-4f63-adf0-409fedfa8931"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c9198058-74c3-4b4f-b82d-9288b0cca852">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/ba4bb3a0-8bc1-4f72-9266-799c0d50c884"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22218563</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17213282</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/a0e7af47-f77b-46f0-90e9-8ef49a6ca88f">
        <rdfs:label>High urine phosphoethanolamine</rdfs:label>
        <dc:identifier>HP:0003239</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0003239</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/21debbb8-43a0-4586-af30-8e5a5a9fae4f"/>
    <obo:RO_0003304>D378V /G339R/E191K/A176T/V423A</obo:RO_0003304>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/241500"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9683d038-53a6-4547-b072-8efb19bdf42d"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f7e01f88-dfec-4b54-ac76-439c87aa6a64"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20739387</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18308659</dc:provenance>
    <obo:RO_0003304>compound heterozygotes for a p.G339R and p.E191K ALPL mutation</obo:RO_0003304>
    <ddiem:failedToContributeToCondition>N461L</ddiem:failedToContributeToCondition>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f01532a4-ed0d-41f0-8db4-4f165be2804b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20089612</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c76ae3af-5652-4f55-8922-04371b6bbfbf">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum pyridoxal 5'-phosphate</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2a755a0e-71b5-428e-ba79-e7602aeceaef">
        <dc:identifier>HP:0001376</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>mobility problems</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001376</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0003304>Ala176Thr/Val423Ala/Val522Ala</obo:RO_0003304>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dc01a4bc-f080-49f2-b43e-609893b84224">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/67e6ca70-bcd1-4f47-9e61-65229e3a7120"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/4744026</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/9110486</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27042741</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3f1d7d8-fd2d-4669-b938-810906128f1f">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0100036</ddiem:url>
        <dc:identifier>HP:0100036</dc:identifier>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>proximal femur pseudofractures</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26245849</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/63fa9101-db9f-4e1e-9197-be29d9c16e56">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e8409c23-84c0-4116-af0d-ac4e5a1d96e9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/062ef1c0-3beb-43ef-a52b-c0e74b99d216">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4c27e3a3-7f3b-4667-b59c-ae57d80ac3fc"/>
    <dc:identifier>DB01394</dc:identifier>
    <rdfs:label>Colchicine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01394</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/cc2c46d2-afd5-4866-a855-bccb21f4ec2e">
    <dc:identifier>HP:0002718</dc:identifier>
    <rdfs:label>Susceptibility to Bacterial infection</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002718</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/600721">
    <rdfs:label>D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:iembaseAccessionNumber>166</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/166</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6d156ae5-1061-49cf-a838-510ee60e725b"/>
    <dc:identifier>https://www.omim.org/entry/600721</dc:identifier>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/84cb5a24-221b-4e5a-966a-ecedcbb7ce57">
    <rdfs:label>Neuromuscular degeneration</rdfs:label>
    <dc:identifier>HP:0002180</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002180</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a27e6d5b-0ff1-438c-b24d-65d74c230d6d">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9dec148a-618b-41fa-a8f8-97c9c3b55202"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613</dc:provenance>
    <rdfs:comment>There is a contraversy about effectivness of methotrexate in treating "Condrocalcinosis 2" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b377b4e2-ca1d-4900-93ef-c86a76c4314d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21102543</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29675606</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25315665</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/121ecc03-54ab-44f5-abe9-3bc0c6fd4ec8"/>
  </obo:DDIEM_0000013>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/8832e3ca-f229-40d5-942e-def1b420b12f">
    <rdfs:label>Failurre to thrive</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001508</ddiem:url>
    <dc:identifier>HP:0001508</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93214685-c3aa-4af4-a3d9-aabcc4ba9a7a">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
    <dc:identifier>HP:0008282</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>high plasma level of unconjugated bilirubin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f4a245a1-a5b6-4788-b2ba-710ce0bab52c">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
    <rdfs:label>Phosphate imbalance (Abnormality of phosphate homeostasis)</rdfs:label>
    <dc:identifier>HP:0100529</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/43f31b37-779d-4d75-9dc3-4c936cd134ac">
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dac426d6-0823-4281-9045-9a7a26745a16">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/627372ae-1a01-47b7-817b-4221b7b9a94d"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8317485</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01797055</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/209300"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/14199d67-c79c-416a-8953-0b0f30d97cc8">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0001931</ddiem:url>
        <rdfs:comment></rdfs:comment>
        <rdfs:label>hypochromic anemia</rdfs:label>
        <dc:identifier>HP:0001931</dc:identifier>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79b24b60-0a84-4664-a71b-6b6fffe3da55">
    <dc:identifier>DB01586</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f61bba77-98f7-4456-96a8-5453edc8747d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01586</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b79f8bc9-7527-426d-8241-2ab23f5fc10d"/>
    <rdfs:label>Ursodeoxycholic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28745b0f-be91-470e-b876-986fdc1a0b98">
    <rdfs:label>Ecopipam</rdfs:label>
    <dc:identifier>DB12273</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12273</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1f9550e0-f262-4d4a-bbb8-f5f184089707"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/feea6e66-a3b8-47e3-ac75-5e0e45d7e4e5">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02534844</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19750228</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/f4954b14-db79-49da-a788-168ef604a860"/>
    <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11787939</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/9415ba47-e341-4712-857f-af4607967df6"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3fdf320d-faf0-4901-941d-a31b22dd393e">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>abnormal plasma lipids levels</rdfs:label>
    <dc:identifier>HP:0003119</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4bc5c3d7-d2ca-4ee6-9cc6-0774a1d09b30">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a17b6793-2adf-4ef2-886e-010410d15211"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09C</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/26767d9d-b452-4499-a4dd-136e2db48de1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/058a1df2-0032-43d0-9fc0-4991125420d3"/>
    <rdfs:label>ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), PLAIN</rdfs:label>
    <dc:identifier>C09C</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/042fca02-077c-4dd8-8163-c82871d5888c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005346</ddiem:url>
    <rdfs:label>Abnormal facial expression</rdfs:label>
    <dc:identifier>HP:0005346</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a58bba2-57ba-4aa8-a073-bc9ad993c3e9">
    <rdfs:label>Trimethylaminoxid</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4fdfa61a-0b72-4ca7-8656-f1e274f176df">
        <obo:RO_0003304>F364C- alpha</obo:RO_0003304>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/248600"/>
        <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7083addb-b95d-426f-88f1-65dbbf4b095a"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/7dd70f2e-70af-41b8-876d-fd6516d4416e"/>
        <ddiem:failedToContributeToCondition>A209D-alpha</ddiem:failedToContributeToCondition>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11507102</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
        <obo:RO_0003304>Y393N- alpha</obo:RO_0003304>
        <obo:RO_0003304>Y368C- alpha</obo:RO_0003304>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_15724</ddiem:url>
    <dc:identifier>CHEBI_15724</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4d1efd3-3531-4167-b248-40e8a2389801">
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f4b2550e-4716-4127-9628-d82b81674bee">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612736"/>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/6af06d59-0452-46ba-86f1-9765566cf60b"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003661</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719212002971</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8813986</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18652077</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29506905</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24268530</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3f812176-ff66-49cb-8786-83513c379945"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719213003107</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000011"/>
        <rdfs:comment>There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB00148</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00148</ddiem:url>
    <rdfs:label>Creatine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1c62323-710b-41a3-8d8c-3ac586237674"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b367286-a32b-49b2-9cd3-3805a295a1cf"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ecdc891-9ddc-4153-8b39-8a4752a25133"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e3ac891-6352-4aeb-b5a3-060d04d3fd6a">
    <dc:identifier>HP:0002344</dc:identifier>
    <rdfs:label>progression of neurodegeneration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002344</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9387b43b-67ab-4225-b7b1-3a26eb4e618d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00181</ddiem:url>
    <dc:identifier>DB00181</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0374010c-53c0-455b-a552-2e298c25e672"/>
    <rdfs:label>Baclofen</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b8dde397-b650-4d2e-a67a-0f3b09ff4374"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5542fd97-f26c-455f-ac30-f4a52520d63d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012202</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0012202</dc:identifier>
    <rdfs:label>elevated serum concentrations of bile acids</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e0d298a5-d565-400a-a47f-58ba42db41bb">
    <dc:identifier>HP:0001252</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001252</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Muscular hypotonia</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8788abbe-fa26-4b15-aed4-56d74450c588">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26962538</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fbbc994f-2bbf-4122-8814-74df2e8345b0">
        <rdfs:comment></rdfs:comment>
        <dc:identifier>HP:0011227</dc:identifier>
        <rdfs:label>Elevated C-reactive protein</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0011227</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/260920"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25758134</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4aafd563-03aa-4b9b-8f24-5b52d4403ba2"/>
    <dc:provenance>https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/a36eb57f-a8fc-43e2-92b9-5f7fb4f7ba68"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/badd9703-a5ea-4bed-a0af-3c520566ed58"/>
    <rdfs:comment>The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22740624</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000015 rdf:about="http://ddiem.phenomebrowser.net/90dc5722-28cb-44b0-8f04-a2920d468246">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b99a4271-c3fd-467a-8aee-2bc0e51d9092"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16361586</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12084887</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/d3f4891a-f298-4cf0-ad06-94384ed46771"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11346370</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/8163996</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/128230"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1899474</dc:provenance>
    <rdfs:comment>Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos disease  https://www.ncbi.nlm.nih.gov/pubmed/28529428</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1ba78866-59fc-4d10-9f17-88bb50177fdd"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16891685</dc:provenance>
  </obo:DDIEM_0000015>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4e7295ed-7c47-4a9e-88b5-1b8592fb4417">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>myoclonuic Jerk</rdfs:label>
    <dc:identifier>HP:0001336</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001336</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/baf8211f-f64d-4c6a-970b-bd693dde7bd0">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003254</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003254*</dc:identifier>
    <rdfs:label>DNA damage (Abnormality of DNA repair)*</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/1b3fcb10-0689-4a57-8350-a47d3fae3116">
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19622360</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/971536</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11067870</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/220110"/>
    <rdfs:comment>"Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22149023</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/93b2533c-7f2a-4984-9d4a-4620d4b3447e">
    <dc:identifier>HP:0001874</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001874</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>abnormal polymorphonuclear leukocyte function</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4a803c5f-2d0f-475b-a543-6f34dda25162">
    <rdfs:label>Decreased muscle mass</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d6339b65-1503-422e-bf3a-e50fb7f3d47c">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04552</ddiem:url>
    <rdfs:label>Niflumic acid</rdfs:label>
    <dc:identifier>DB04552</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1191e60b-6efe-483a-a092-5fd917325d5e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6279362e-35af-484c-bfdb-a7dfacd0549d">
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:label>Hepatic Biochemical abnormalities (Laboratory abnormality)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1b33817b-cdf7-49ae-bca5-c55d7e790fa7">
    <dc:identifier>DB12907</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12907</ddiem:url>
    <rdfs:label>Mannose</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/64cf81d2-661f-4b54-982d-e8165eea294b"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1cfb7ecf-20cd-42d1-98b6-e8c0c3aff7f3">
    <rdfs:label>Abnormal cholesterol efflux from cells</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/MP_0003193</ddiem:url>
    <dc:identifier>MP:0003193</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000004">
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">direct complementation of genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T10:19:07+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a genetically defective protein is replaced by a canonical source of the same protein, genetically as in gene therapy, or by some other means of delivery, whose completion is hypothesized by a health care provider to eliminate a disorder or to alleviate the signs and symptoms of a disorder or pathological process. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f58e279d-7d8a-480e-9730-aaf9eea38482">
    <rdfs:label>AT342</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fe122bb1-361c-4d3d-9355-0ee869a44ae0"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08a5b06d-22eb-43be-a2f6-9f04081a281c">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=(DB00440</ddiem:url>
    <dc:identifier>(DB00440</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3d1acbb-b9b3-4b74-addf-54345a5ff235"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5e892d9-4a69-4dd1-ada9-f9139fa397d5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01124</ddiem:url>
    <dc:identifier>DB01124</dc:identifier>
    <rdfs:label>Tolbutamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/36f8e7fa-ff8b-4247-8a61-a2fdda3983b7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/380b6ef1-acee-4859-88cb-79a35b56b8c6">
    <dc:identifier>DB01197</dc:identifier>
    <rdfs:label>Captopril</rdfs:label>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f7fe6a93-f16f-4dee-8649-a9677003408a">
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f04e9a32-7a8e-4493-a638-94f739ef50a7"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23391322</dc:provenance>
        <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
        <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa1c40ae-893e-4d2a-bd83-680900efda08"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01630429-3fbd-4e29-befe-28d0abdb7fd1"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01197</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d696863-a955-4685-92ff-21b6e145659a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB01026</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7a2e03aa-2c1b-4a75-8ebc-48bc9ca3a33a"/>
    <rdfs:label>Ketoconazole</rdfs:label>
    <dc:identifier>DB01026</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb01f80e-3b9b-4ecf-83e7-fc1c45056ced">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7937361-01e4-459d-8968-9be35d54c15e"/>
    <dc:identifier>M02AA</dc:identifier>
    <rdfs:label>Antiinflammatory preparations, non-steroids for topical use</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M02AA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2b4e5c17-4fef-4128-8c0c-beb55a868add">
    <dc:identifier>HP:0001510</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001510</ddiem:url>
    <rdfs:label>delayed growth</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9203a319-044b-4d66-b699-12d324ea90a5">
    <rdfs:label>Vitamin K</rdfs:label>
    <dc:identifier>B02BA</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58c712b9-33f4-4fb7-b094-1118f4042d42"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=B02BA</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1200b0e9-be5c-4809-bd1c-2168457d3f75">
    <rdfs:label>AAV-cG6PGH</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e13b6e43-1e79-411c-9008-d7c4ae152871"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/944b46c5-82fc-4d1d-9286-e7029199e334">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e0e52be-0601-4785-819e-ca2d61e234de"/>
    <dc:identifier>DB12528</dc:identifier>
    <rdfs:label>Glyceryl Trierucate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12528</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a8b87e8b-ec49-4ce6-9790-980e989dee10">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/377b244b-64bd-4adf-91f7-84d12ee38880"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/4fc07961-47a0-474c-856d-236a3eedac12">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14213380</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/13992367</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000012"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/2805fe22-ad3c-487d-819e-d837c6275a14"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c3eaa87-999d-43f7-8211-aeda2ca90d05">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/06d44991-fead-424d-a582-bd42ba16e5c1"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/31392111</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/237300"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23649895</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <rdfs:comment>Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/142ab802-1aae-40da-b1ed-142f411d88a3">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/396a1b36-f6b6-481a-a037-8ba044da459a"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/10f87349-a9ff-40d6-8ee4-83ed0e0b6c83">
        <ddiem:url>https://www.drugbank.ca/drugs/DB14502</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b54abd5-016a-45ba-a3d5-d60302a06c3d"/>
        <rdfs:label>Sodium phosphate, dibasic</rdfs:label>
        <dc:identifier>DB14502</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/e0a6fe00-83a4-40d1-bd54-cd6da4988c5a">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615181"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b25ad2ee-a0d3-42cd-97c6-0ee6c1025798"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29273094</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:DDIEM_0000013>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/c0f4315f-a1d3-4818-9d9c-098f01d53634">
    <rdfs:comment>There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.</rdfs:comment>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/fcfc709a-8264-4ad6-88ac-e57a95bd8ef6"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4e7295ed-7c47-4a9e-88b5-1b8592fb4417"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/208900"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a6876a44-943e-44ef-b713-99fd1dcb5e1d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17586848</dc:provenance>
    <dc:provenance>https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/515ac014-d8cc-4d73-8297-608e0abd77f4"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27906067</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e088253-ec29-43f5-bcdd-94130c531deb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26232052</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15300460</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5b6dcc2e-94c6-4351-a619-f26531983629">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8ba37bb5-4970-463a-b8dd-e34fb08ad9e3"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e515dd4-2064-491d-82b8-b45c30c073ac"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3f927ac9-a192-4d02-8402-84547f183add">
        <dc:identifier>C04</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43b10b89-0785-4db5-8f04-96b4518c273c"/>
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C04</ddiem:url>
        <rdfs:label>PERIPHERAL VASODILATORS</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44799c76-d36a-4c81-a36b-95f24ad98bc3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/41db42bb-19cf-4f2d-8aec-839aecc71702">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04844</ddiem:url>
    <dc:identifier>DB04844</dc:identifier>
    <rdfs:label>Tetrabenazine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/090b43e6-ed23-4217-99ce-1c5b25dd17da"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/da86d321-8c1a-4fef-9735-9e8097d33c2f">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0011009</dc:identifier>
    <rdfs:label>Acute attack</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011009</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/eaafee4d-1bb5-4279-a75c-73769cba81e6">
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <rdfs:comment>Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z</rdfs:comment>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/28314b21-ec14-405f-bd81-13e02cf51b1a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/545000"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/1490314</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5e088253-ec29-43f5-bcdd-94130c531deb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05c7c052-a969-4be2-8668-714f62d2a6d1">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A06AA</ddiem:url>
    <dc:identifier>A06AA</dc:identifier>
    <rdfs:label> Softeners, emollients</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4aea0f39-2c36-4ca2-81ca-b6c5d96a7a0d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/add205c8-ade9-4d94-bdcd-946b7192fa13"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c13a1cda-6fb7-451d-85c2-58fa16944f4e">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal circulating creatinine level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012100</ddiem:url>
    <dc:identifier>HP:0012100</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/253800">
    <dc:identifier>https://www.omim.org/entry/253800</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/642</ddiem:iembaseUrl>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4</rdfs:label>
    <ddiem:iembaseAccessionNumber>642</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/6dec3649-3d6d-4888-b50f-ad185b5b6146"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/64671cbc-8647-4b9a-aeb6-dd1e02e4fbbf">
    <dc:identifier>DB06273</dc:identifier>
    <rdfs:label>Tocilizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1d28d787-84d1-44bc-b61d-cf01171a13fc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/158a81a1-721c-4416-81a6-118f75f5ce58"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06273</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a1f9526e-d96d-4362-8efb-811094d2df87">
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01212744</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/520000"/>
    <dc:provenance>https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/92e681cf-3fc7-4cad-8d61-aafe49d84b3a"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/5b0c4c36-8f34-4c48-9b83-8dfd0b7f5526"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/274e13d0-8559-43d4-a433-3350016822f1"/>
    <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0f18cfb-3d3e-413a-801a-a5cb7110458e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a85ac05-8dcc-471b-8fc8-8708ccfcc973"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>The drug was administered through intravitreal injection.</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24746802</dc:provenance>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000007 rdf:about="http://ddiem.phenomebrowser.net/d5a11788-3f02-4dcb-b790-675933a3901f">
    <rdfs:comment>Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/9529c862-5633-47ec-b12e-70c7a3dd6b1b"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/207800"/>
    <dc:provenance>http://www.orpha.net/consor/cgi-bin/Disease_Search.php</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23494656</dc:provenance>
    <dc:provenance>https://www.clinicaltrialsregister.eu/ctr-search/search</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/54e35da9-72ac-4194-a9fa-fa47a5a250b2"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/11148549</dc:provenance>
  </obo:DDIEM_0000007>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6872991a-bca5-4314-acf8-9b75d35fc692">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03085</ddiem:url>
    <dc:identifier>DB03085</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e38b369f-a60c-46c8-8f72-872fa0f0c9b2"/>
    <rdfs:label>Glycolic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/5ebcbba4-03a5-4534-ab6b-c9dee31b357e">
    <dc:identifier>HP:0040081</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0040081</ddiem:url>
    <rdfs:label>Abnormal serum creatine kinase</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f7995872-01e3-4d9f-a160-8db1cc116d98">
    <obo:RO_0000056>
      <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/d43f61ae-01c3-49d9-bd35-4736b35da9d5">
        <rdfs:comment>Selection of this drug combinstion ""Methylprednisolone sodium succinate +
Immune Globulin "" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/65f26957-43cf-4b2f-a6e3-97f0b742dfa9"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://link.springer.com/article/10.1023/A:1005353530303</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/277400"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25511120</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3950820</dc:provenance>
        <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1096719205001733</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1e2df06a-7d9a-4876-b0dc-fe7a20effcc6"/>
        <dc:provenance>https://www.pnas.org/content/96/5/2339.short</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19821145</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17431913</dc:provenance>
      </obo:DDIEM_0000013>
    </obo:RO_0000056>
    <rdfs:label>Risperidone</rdfs:label>
    <dc:identifier>DB00734</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d136b8c1-205d-4676-8d72-5e24929967c0"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00734</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2f82b04-0f7b-4bfd-890d-6e92e2383230">
    <rdfs:label>Deep venous thrombosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002625</ddiem:url>
    <dc:identifier>HP:0002625</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d779588e-74de-411f-b4d8-d8c8032783af">
    <rdfs:label>MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd5f2709-6797-4b46-9cab-4e4f1bb69ef7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2ed0aeb6-60b4-426d-809d-a48b439afd5d">
    <rdfs:label>Cobalamin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdf8a350-7a3e-4557-beef-dd8359a95fb8"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14098</ddiem:url>
    <dc:identifier>DB14098</dc:identifier>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/871613b4-5f3b-49ab-9130-30cf49b30a1a">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28125198</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/612016"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298</dc:provenance>
    <rdfs:comment>Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24164873</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309</dc:provenance>
  </obo:DDIEM_0000013>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ca69b4a8-1a77-4d3c-804b-e256b8b7f1e0">
    <rdfs:label>Tazobactam</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5bcc7568-f84f-4612-9eec-7b21464ac4ef"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01606</ddiem:url>
    <dc:identifier>DB01606</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/029ae30e-baf4-4b72-a1c1-6e98c2e83e1e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/847f35e9-0d9d-4a54-8ff8-abc082e0d2c2"/>
    <rdfs:label>Carbonic anhydrase inhibitors</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=S01EC</ddiem:url>
    <dc:identifier>S01EC</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0ad445b8-12e8-4601-a24b-a190a84a01ee">
    <rdfs:label>Decreased niacinamide level</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3527b688-fd43-43a4-b1f8-003d3ca66e82">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000141</ddiem:url>
    <dc:identifier>HP:0000141</dc:identifier>
    <rdfs:label>Amenorrhea</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b8175fc2-3b4f-42a7-ad17-ff329f905e10">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/19fc155f-0f78-4f03-8da4-9fecb6480df2"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/28dd4a59-32b8-4611-9ffc-95bef514d65f">
    <dc:identifier>DB00230</dc:identifier>
    <rdfs:label>Pregabalin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00230</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1cdac22-50b3-4005-be6c-24965491cfb7"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ecf01806-b5b0-478c-a709-67f2621697e3">
    <ddiem:url>https://www.drugbank.ca/drugs/DB04272</ddiem:url>
    <dc:identifier>DB04272</dc:identifier>
    <rdfs:label>Citric acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e420c13-322a-45d2-839f-3fad17bc5abe"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bf1c3612-9b36-4914-b30e-75b25e67947d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB12537</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff709bd-b144-4093-a5f2-40695810c0e0"/>
    <dc:identifier>DB12537</dc:identifier>
    <rdfs:label>Benzodiazepine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1213858b-58b3-4872-99a6-48a21cf6796d">
    <dc:identifier>HP:0002521</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002521</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Hypsarrhythmia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f239e781-3a83-4442-8562-01738d9997c6">
    <rdfs:label>Pioglitazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01132</ddiem:url>
    <dc:identifier>DB01132</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dd9ec7c2-44aa-4884-9a71-35a0efa944c5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e716f283-8605-4cc5-8cf6-cdc9b2c4b1ab">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f505e3a2-df22-409a-a645-0e97eea156cc"/>
    <rdfs:label>Regramostim</rdfs:label>
    <dc:identifier>DB05386</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05386</ddiem:url>
  </ddiem:Drug>
  <obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy rdf:about="http://ddiem.phenomebrowser.net/b60721c6-5e70-49ea-ad57-584fce3b5fdb">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28589525</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://emedicine.medscape.com/article/1178391-treatment</dc:provenance>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT00151216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24938720</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdfs:comment>A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f9697a40-23d5-4bd2-a719-6f770d8fa2aa">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/469de258-3918-44f0-9307-be756ee15945"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01907087</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/204500"/>
  </obo:direct_complementation_of_a_genetically_defective_protein_by_gene_therapy>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4d493817-2ade-46e0-a225-d202c36aebff">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>axial hypotonia</rdfs:label>
    <dc:identifier>HP:0008936</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008936</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/983b4d7f-5a93-4c10-8a68-6f98121c61af">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003233</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003233</ddiem:url>
    <rdfs:label>low HDL level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e595ba0-e2e6-4c65-aa65-e7ec50c844ca">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100543</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100543</dc:identifier>
    <rdfs:label>abnormal mental status</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/9b7a6249-0e49-46e8-9c0c-a75ca016cc55">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21289269</dc:provenance>
    <rdfs:comment>Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3898712c-2e6b-403a-866f-902487395c9f"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/85315bcd-133e-433b-bcb1-400ab02bd1b0"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23323877</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/145750"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e60e6a-b0d3-440a-b81d-98486980fef6"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28225998</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20495831</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12114919</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19770656</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/50736745-81ff-48ad-a9af-34a7867d35c0">
    <dc:identifier>DB00053</dc:identifier>
    <rdfs:label>Imiglucerase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/76817761-9acf-4109-aaea-aeabc1428482"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00053</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/39e48d23-ef08-4064-9b8a-7d1f58504c6c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/816a9192-1a27-4784-a4a5-78117999f688"/>
    <dc:identifier>M01AX</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=M01AX</ddiem:url>
    <rdfs:label>Other antiinflammatory and antirheumatic agents, non-steroids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb13c699-e766-44b7-8668-f2eb65380055">
    <rdfs:label>NeuAc</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_17012</ddiem:url>
    <dc:identifier>CHEBI_17012</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a195371-588c-4a6a-bf03-bd68f17be99d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1450cff-d355-4779-be57-9526f3d1a702"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b58bc908-732e-4396-92c7-12e04368279d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00158</ddiem:url>
    <rdfs:label>Folic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/72534857-6c28-44f1-ad9f-df814d2cb78b"/>
    <dc:identifier>DB00158</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2caa12c8-f806-4083-adfa-2213fb0c48d8">
    <rdfs:label>tachycardia</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001649</ddiem:url>
    <dc:identifier>HP:0001649</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/59bf53d5-b9c3-4bb7-955e-db79868c8853">
    <rdfs:label>Atrial fibrillation</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005110</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0005110</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/52223770-44e4-4654-a93d-2783e7b6086b">
    <rdfs:label>Nitisinone</rdfs:label>
    <dc:identifier>DB00348</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0556ec44-5840-44bd-ad95-5e74ca37b60f"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/351237b9-3838-4866-b8c0-0b59f1292b05">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24683506</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19415691</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e1773c6-7f4b-461a-be24-b380dec95473"/>
        <dc:provenance>http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf</dc:provenance>
        <rdfs:comment>One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824</rdfs:comment>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/140350"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25717099</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28803710</dc:provenance>
        <dc:provenance>https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/20677779</dc:provenance>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/08a3bb42-e1a6-40b7-b5a0-1df31cbc1090"/>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00348</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d859a264-d440-4026-9725-35734cdeb214">
    <dc:identifier>HP:0000496</dc:identifier>
    <rdfs:label>Defective eye motor function</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000496</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fc74e7d3-a305-45bd-b8d3-a63725a63f29">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7651536a-c8ff-4d98-89d6-4a604326efb8"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7905ebbf-3423-492e-9015-8ddf2bea8d35">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
    <rdfs:label>biochemical abnormalities</rdfs:label>
    <dc:identifier>HP:0001939*</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/37e37323-5252-4fbd-858c-ca7557017fbd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c668b923-d9d2-4267-a61a-186856a30650"/>
    <rdfs:label>Copper Histidine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/35d2bffc-ee50-4327-9082-c0a9dd3f9aa8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB08826</ddiem:url>
    <dc:identifier>DB08826</dc:identifier>
    <rdfs:label>Deferiprone</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3ff65fa-b36f-4261-bde8-4c50de430777"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9f4f34be-daa5-4426-9e00-70df96531e19"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6de0d5be-79e5-4f0f-ad30-21314190c5db">
    <rdfs:label>OTZ (L-2-oxothiazoline-4-carboxylic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/235a8e9f-a97a-4cf1-87e1-7db391d122cc"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67ba0189-30f2-4dc2-96d2-2648b7b52b4d">
    <dc:identifier>DB09341</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09341</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a73d752e-fef7-4abb-968f-d1f562cdc4a7"/>
    <rdfs:label>Dextrose, unspecified form</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/198d9bb6-530f-4b89-80e3-5ad81d535449"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/da4941a7-ce2a-40e7-9a39-245e6e2f91e3">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2f790808-f898-4533-b681-6b5de9eb9be9">
        <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=C09</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9956bfdd-ee6a-475d-8d48-66ce14ed71c1"/>
        <dc:identifier>C09</dc:identifier>
        <rdfs:label>AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ac8f0e3-806b-4432-964a-5bdfe2a36b46">
    <rdfs:label>Taurine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01956</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c03c5596-fe2b-44a7-a54c-27f235482666"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/735237a1-ef6f-467b-b3af-1bb2f7821fa3"/>
    <dc:identifier>DB01956</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/08bde810-5c15-4c7c-adff-df785769ded7">
    <obo:RO_0000056>
      <obo:DDIEM_0000010 rdf:about="http://ddiem.phenomebrowser.net/f11b9f83-5b28-4dac-b85b-852773562152">
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/402b4f4a-b796-4744-8da6-c5595cd09e8e"/>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
        <rdfs:comment>Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/</rdfs:comment>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12794686</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/75227ae7-1348-4d0e-a986-b6f55bb89472"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29223626</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3306242</dc:provenance>
        <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/52b5c5f5-726b-4348-a127-08e146378d3a"/>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15726662</dc:provenance>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/240600"/>
      </obo:DDIEM_0000010>
    </obo:RO_0000056>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/304d38d1-aac4-4614-98ea-06422be2c29a"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11599</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/09ea77be-128d-4eae-afb3-7053e4dfbbb3"/>
    <dc:identifier>DB11599</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b14cfb5f-07bb-4f78-8ae5-24e39fa0c501"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/807c60e5-ecbf-4d87-825b-c8bc001a73d1"/>
    <rdfs:label>Starch, corn</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/fab7372b-718a-4bae-8a83-7296199bef60">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/95ea81b1-f283-4d3f-a994-73fd054417e7">
        <dc:identifier>HP:0000093</dc:identifier>
        <rdfs:label>proteinuria</rdfs:label>
        <rdfs:comment></rdfs:comment>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0000093</ddiem:url>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/b1a4f35a-052d-45be-93b2-9ed9c6e7618b"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/983b4d7f-5a93-4c10-8a68-6f98121c61af"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/4d97614b-8667-4554-a5d7-0871e1a10892"/>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1bf1bc9a-a18b-4ebf-b163-23364a789e63">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7362e630-4a5f-4433-8dfc-1649723bc9e0"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/3fdf320d-faf0-4901-941d-a31b22dd393e"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/35144459-2e30-4769-9b65-bf088ee1ddcb"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/eacd383d-63af-4433-a7d9-f0626cdb0a44"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/220ed301-c08b-46e2-8f72-29b0ea150c4c"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02527343</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/245900"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
    <dc:provenance>https://www.clinicaltrials.gov/ct2/show/NCT01554800</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1cfb7ecf-20cd-42d1-98b6-e8c0c3aff7f3"/>
    <rdfs:comment>Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/133d27d4-0daf-4157-b6ad-52f43ab9fe06"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/617070">
    <rdfs:label>PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/23aefb6b-6615-4c82-ace7-b7bebeb51952"/>
    <dc:identifier>https://www.omim.org/entry/617070</dc:identifier>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/561c40f2-fd36-4f9e-aa8a-a4ab5e497e18">
    <rdfs:label>Pitavastatin</rdfs:label>
    <dc:identifier>DB08860</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB08860</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4cfff86-b3c7-42aa-8eaf-613a038d33fa"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cd8779a5-a0b9-4e05-b7a2-17f33c5f2d68">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0757caeb-8651-485c-9412-efb39e7b1d2c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01593</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ab84f93-188c-4d40-8548-417d57aa368d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2ab3eaa2-e8a3-4a41-b810-3a4116ee8c45"/>
    <rdfs:label>Zinc</rdfs:label>
    <dc:identifier>DB01593</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aeb8cd51-8113-4697-ba26-10b3207fc6af">
    <rdfs:label>Low endurance</rdfs:label>
    <dc:identifier>HP:0025142</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0025142</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/64fb59ea-cfba-4daa-b7e1-b7b138e904aa">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001250</dc:identifier>
    <rdfs:label>epilepsy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001250</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/255224b3-3747-4bb0-9207-d260bf5cfc60">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00926</ddiem:url>
    <rdfs:label>Etretinate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04b137c4-11b9-41de-a658-6afc945a0cb2"/>
    <dc:identifier>DB00926</dc:identifier>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9d9a7029-aec5-4221-a232-bc3a77543fd4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/528291d5-5b90-4867-b48b-2a44cd23f5d1"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b38d3186-530c-4999-8656-39e94ca1d001">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4f3d872a-2fed-4472-9743-a3f5719473f9"/>
    <rdfs:label>Polythiazide</rdfs:label>
    <dc:identifier>DB01324</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c10d36cf-c1c5-42a7-84eb-6b6225869944"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01324</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c058fe5a-ad06-4a7a-879c-3e83412a06f1">
    <dc:identifier>DB00829</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9e7b7cd-37da-433a-affd-e2c2ba3d0cc8"/>
    <rdfs:label>Diazepam</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00829</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d386c195-3fbe-4d4c-8daf-78858c6d663b">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>fat soluble vitamin malabsorption*</rdfs:label>
    <dc:identifier>HP:0002630</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002630</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/67ac24a0-c6c0-4e56-93c8-299b525fb94b">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001959</ddiem:url>
    <dc:identifier>HP:0001959</dc:identifier>
    <rdfs:label>thirst</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/20b58c7c-cbf2-4092-b735-05a0f1613929">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001945</ddiem:url>
    <dc:identifier>HP:0001945*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>hyperpyrexia in case of acute encephalopathic crises(Fever)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/98b7bcfe-9109-44fb-b591-140d83d047b7">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f565214a-1db8-4d12-8b52-9db6c6a0d694"/>
    <dc:identifier>DB00061</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00061</ddiem:url>
    <rdfs:label>Pegademase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f757f83f-d920-459a-a4d4-cfb8cbd1af74">
    <dc:identifier>DB00916</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00916</ddiem:url>
    <rdfs:label>Metronidazole</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ee507423-9956-41d3-8658-fa59cbe3edfc"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000011">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <rdfs:label xml:lang="en">metabolite replacement</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:06:25+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure involving enteral, parenteral or transdermal provision of small molecules closely related to the products or end processes of a genetically defective protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f6aef839-5bcf-4425-8edd-813366c074f5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001394</ddiem:url>
    <dc:identifier>HP:0001394</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cirrhosis</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/01dc216a-fb8f-444d-988d-5eb19607c4c2">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00136</ddiem:url>
    <dc:identifier>DB00136</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b4aedc2b-8e06-40d8-8ef6-b5890640fbfd"/>
    <rdfs:label>Calcitriol</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/42e2d94c-70da-4304-978d-be50f0cb007f">
    <rdfs:label>Renal tubular acidosis</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001947</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001947</ddiem:url>
  </ddiem:Phenotype>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/dcf441a9-22c8-43d1-8c97-cccc9e2447f0">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/102700"/>
    <rdfs:comment>IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/</rdfs:comment>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/3725c103-a9eb-4cc7-911c-abef6ca07e1d"/>
    <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT01420627</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-MCC.pdf</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/29241594</dc:provenance>
    <dc:provenance>https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/666c257f-cd01-43e5-b26e-a716fde2e56a"/>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000013">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:49+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:label xml:lang="en">symptomatic treatment procedure</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/metabolic_disease_treatment"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure aimed at amelioration of one or more abnormal phenotypes generated as a consequence of a defective protein or process by a means unrelated to the immediate pathway or network environment of the defective protein. Generally working at the level of the tissue or overall organismal physiology. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ce766f15-8df1-4c41-9d2f-da6567d9a3a5">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002149</ddiem:url>
    <dc:identifier>HP:0002149</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High plasma uric acid levels</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eff3198d-974c-472d-ae03-de3ff086856c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d22f3cb8-971f-4b0d-9493-818c2c3d5aec"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6b81b717-c345-45c0-961a-66bda6e8fa08"/>
    <dc:identifier>DB00788</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00788</ddiem:url>
    <rdfs:label>Naproxen</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e9a3afc-1b79-4ec2-86f2-e9ae4735bff2"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/932ddfa6-6483-43c5-b811-dd4192accb47">
    <rdfs:label>Benzoic Acid</rdfs:label>
    <dc:identifier>DB03793</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d5a11788-3f02-4dcb-b790-675933a3901f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7d4c23a2-6f81-48af-a921-5429a8d53ef5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03793</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa62878f-cd76-49ee-a68d-62568c273bc0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d2e3f39b-d674-4410-a8ef-d1554afa717e">
    <dc:identifier>HP:0003648</dc:identifier>
    <rdfs:label>high Lactic acid</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003648</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6490d7e1-4601-455b-a0eb-582e175f4687">
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Elevated serum toxic intermediates in isoleucine pathway</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/89883f93-c6b7-479b-beff-a2cdee16df62">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0e27a2a1-c72c-4b9f-bf6c-03ca97e8a3c5"/>
    <rdfs:label>AAV2-hAADC ( Gene therapy)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/95270213-b44b-49c9-9ae0-3fc8a2e80149">
    <dc:identifier>DB03766</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35798258-a619-45e6-8acb-acb72de2ed44"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03766</ddiem:url>
    <rdfs:label>Propanoic acid</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/bdf0338d-332d-4879-a574-d669cce0f37f">
    <rdfs:label>lipid peroxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/43a6bc41-4333-48d9-bd0b-e0fe97031af8">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00112</ddiem:url>
    <dc:identifier>DB00112</dc:identifier>
    <rdfs:label>Bevacizumab</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/77390cdc-82eb-4d80-aaea-773fec3b15a1"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/504db0d5-d6b0-411b-ae2f-09182f0d6560">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/92ed5697-59a4-4a41-b52f-7601b20fed11"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2dce2996-642f-45fd-b918-1da216bc0b75">
    <rdfs:label>hyperproteinemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002152</ddiem:url>
    <dc:identifier>HP:0002152</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f3fce6da-7b83-4872-884f-2c18ee743fdd">
    <rdfs:label>Mecasermin rinfabate</rdfs:label>
    <dc:identifier>DB14751</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14751</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46582432-ef51-4a77-a55b-14131beccfcf"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5291c6e7-e9c5-4ff6-9811-540a05dab633">
    <rdfs:label>CORTICOSTEROIDS FOR SYSTEMIC USE</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=H02</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2436c0be-9b6b-483e-81ca-ef9b305e79f3"/>
    <dc:identifier>H02</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4f69335b-8fbf-4705-b160-2ae95519ec35">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/19d7c699-c097-440f-ae29-63c3f47746f9"/>
    <rdfs:label>GNT0003</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/f21cbe78-2e4a-4d8f-a985-7fc5b05db4b7">
    <dc:provenance>http://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17397529</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/231670"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/55bebabb-d326-4e2c-af27-153e2b196299"/>
    <rdfs:comment>This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10222465</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/20b58c7c-cbf2-4092-b735-05a0f1613929"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/16368216</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/05217c53-0b64-45d6-bcd2-9610619e807c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b25ed3e2-6bfb-48ae-81b7-964161ec9b2c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b5fc4cd2-be8e-4c4d-9fd7-f570df0f6f7a"/>
    <dc:identifier>DB01119</dc:identifier>
    <rdfs:label>Diazoxide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/93bfe607-b1eb-4deb-8456-6f5dc6be9ab6"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000006">
    <rdfs:label xml:lang="en">compensatory complementation of a genetically defective protein</rdfs:label>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:02:30+00:00</dc:date>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the normal product of a defective enzyme or protein is provided to alter its concentration or availability by delivery, stabilisation or modulation of turnover. [PNS]</obo:IAO_0000115>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7a3b433f-af3f-44c4-bd36-6f095cf6a42c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a758951b-5abe-4df7-a06c-fe527cf989ff"/>
    <rdfs:label>rhPBGD</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b5312f6a-b2cd-469f-b68d-67a692c89e12">
    <rdfs:label>Cardiomyopathy progrssion</rdfs:label>
    <dc:identifier>HP:0003679</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003679</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da043740-d120-42ba-8f87-c19f3cb76f15">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/558262ea-fff1-467f-8480-4c144d8bdc6c"/>
    <dc:identifier>DB12839</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12839</ddiem:url>
    <rdfs:label>Pegvaliase</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4cbe756d-4af8-4843-86d6-7d0d7e215b5f">
    <rdfs:label>Phosphorus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f5bbb73a-66b4-4725-83f2-c432bab91d90"/>
    <dc:identifier>DB14151</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14151</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3c682148-2b05-4246-a4cc-31847f40f87c">
    <dc:identifier>DB05271</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/161a2f10-daee-44f2-8914-8c9bc2dca8f2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05271</ddiem:url>
    <rdfs:label>Rotigotine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ced2fbb7-de08-469c-b224-0d1e5bdb91ba">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/820224c6-2ce5-457d-9e43-62b3a9234f85"/>
    <rdfs:label>Pegunigalsidase alfa</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3862a8a-82f6-459f-87aa-b5539ae2e95d"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14992</ddiem:url>
    <dc:identifier>DB14992</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/99e8aeb5-6b23-4bea-9d27-c88e6ef4904a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14872</ddiem:url>
    <dc:identifier>DB14872</dc:identifier>
    <rdfs:label>Lucerastat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ac8abbcc-ced8-49e1-8292-d8da27359314"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d02a7c01-11c1-408e-a8e6-3ec5cfe1a027">
    <dc:identifier>DB13245</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/906f2e50-25a6-418f-be43-3592b917ffbb"/>
    <rdfs:label>Thiram</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB13245</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/79df5a6b-11bc-4df6-8249-d295fbee306e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7729b80-fab3-4d56-87de-d99c84969134"/>
    <rdfs:label>rh-HMBS</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e9e993cf-862c-4e57-baa7-441e308f34da">
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cdc790fe-3e46-42e5-bffe-d359a4b5020e">
        <rdfs:label>Methyclothiazide</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00232</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2597aaac-4ba1-4462-b123-91c79a151122"/>
        <dc:identifier>DB00232</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1e2df06a-7d9a-4876-b0dc-fe7a20effcc6">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000708</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <rdfs:label>Psychiatric disturbance</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d60cb0b8-17e4-41c2-835e-62e2bb28d95d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9b7a6249-0e49-46e8-9c0c-a75ca016cc55"/>
    <obo:RO_0000056>
      <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/a35179e4-9ffd-4019-9f19-894b8ff65117">
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18759345</dc:provenance>
        <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21597884</dc:provenance>
        <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0007121"/>
        <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/24e60e6a-b0d3-440a-b81d-98486980fef6"/>
        <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/229300"/>
        <dc:provenance>https://clinicaltrials.gov/ct2/show/NCT02705547</dc:provenance>
        <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
        <rdfs:comment>There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044</rdfs:comment>
      </obo:OGMS_0000112>
    </obo:RO_0000056>
    <dc:identifier>DB01098</dc:identifier>
    <rdfs:label>Rosuvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2da67f29-39dd-40fc-a2eb-0d2808e08b72"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01098</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/41842271-4657-4607-afb6-0ec7cc39cd91"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a64e86fd-5362-4055-ab00-522ac200e9ac"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c4cfff86-b3c7-42aa-8eaf-613a038d33fa"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/38064bff-99de-4a01-9c73-66ebfae593c3">
    <rdfs:label>Soybean oil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56d9a815-62c5-4fa6-9389-462b60af4526"/>
    <dc:identifier>DB09422</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09422</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56466793-e9ec-463e-936c-5f3241369125">
    <dc:identifier>HP:0100660</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100660</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Dyskinesia</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/52d63561-c6a7-43c4-ab1a-86c748880642">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormal H50 (The erythrocyte resistance to oxidative stress)</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/190e74ab-8b65-4ff6-8a4c-cd81931ec409">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/21979053</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/books/NBK1520</dc:provenance>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S1059131117301243</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/27f4d3a6-9156-450a-9695-5ff0a59b30f9"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/aa690da1-2c9f-4e9b-a03e-59aa476dcad3"/>
    <dc:provenance>https://link.springer.com/article/10.1007/s11940-011-0131-z</dc:provenance>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:OGMS_0000112>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/a229982f-415c-448d-a3fe-882394c7624c">
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6465191f-a3d6-4403-a2d1-07231fb5189d">
        <rdfs:label>Decreased life expectancy (Mortality)*</rdfs:label>
        <dc:identifier>HP:0040006*</dc:identifier>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0040006</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/2646391</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28220409</dc:provenance>
    <dc:provenance>http://www.neurologyindia.com/article.asp</dc:provenance>
    <rdfs:comment>Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30387909</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/49d7a246-fe50-44b5-87e2-39b8d3715c6a"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24260777</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/7e3d386f-a07c-4edc-bdd5-a439f043e1f0"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/607364"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.orpha.net/data/patho/GB/uk-Bartter.pdf</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/cfdc3989-1a1c-4852-9751-b5400ca3ea11"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/17185149</dc:provenance>
  </obo:DDIEM_0000013>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000007">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:03:22+00:00</dc:date>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which the composition or metabolic activity of the pathway or network in which the defective protein is found is modified, compensating for alteration of activity of that protein. [PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000002"/>
    <rdfs:label xml:lang="en">functional complementation of a genetically defective protein</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/848eb0f5-8b24-46d8-bd69-53f626c23348">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <dc:identifier>HP:0003676</dc:identifier>
    <rdfs:label>Disease progression(Retinopathy)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/296c9beb-1075-4885-a0f8-3d0a51a3d27a">
    <rdfs:label>pathogenic exon trapping</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/df423442-03f4-44ef-b5c0-5bbe755c3f1f">
    <rdfs:label>Thiamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/83bf1740-6894-4ea7-b89b-f3e5c91915a7"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1dc00347-118c-4700-9f0d-eac9ca0f2890"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4d177625-0431-4cea-84bb-bfe503b2a1c8"/>
    <dc:identifier>DB00152</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0da45d00-84ca-4bf9-82eb-30a482d9134b"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00152</ddiem:url>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/3c5406c9-58e0-4b8e-b3ed-88156affa3ca">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/232700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25266922</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/74ec3a2c-13cf-407b-bfc3-7d7464fd164a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/19019309</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000010"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/14695410</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6230836f-c723-4aa5-af8e-5beea288198e">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e92590f0-74f8-4e54-8d3c-18e2ad76c48a"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <rdfs:comment>Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7228d411-f929-40d1-ac33-416bb9c129df">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c0769626-0ff6-4f88-a4d1-b208bbda744b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3d1427d-40b3-4eee-9e2d-4ecd81bc6af0"/>
    <dc:identifier>DB01592</dc:identifier>
    <rdfs:label>Iron</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01592</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/492b15a2-a9a2-4686-9a17-20a32837369f">
    <rdfs:label>Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b2fb4c0d-6955-4a67-979b-0328df8cabf9"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b375a13-2e6d-4fa1-a160-df398320456d">
    <dc:identifier>DB11735</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/abcb887b-6d34-4c20-8d55-b0f0a734b3d1"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/906ea95c-f88d-4cb0-84f7-af7801ed9155"/>
    <rdfs:label>Galactose</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11735</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/678bc98f-ac87-4c9d-80da-1305651dd1b8">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010836</ddiem:url>
    <rdfs:label>hypocupraemia</rdfs:label>
    <dc:identifier>HP:0010836</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ec821df8-b17b-4912-92bc-ac85bc224f70">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4dbe84cd-5488-4801-9f7a-4c810ae89af1"/>
    <rdfs:label>Dextrothyroxine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/78e88010-df56-4481-8c9d-0046a96773b9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00509</ddiem:url>
    <dc:identifier>DB00509</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f4911235-89a3-4bd3-a798-68c734a88a2f">
    <ddiem:url>https://www.drugbank.ca/drugs/DB6756</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56daa45b-9cc5-4824-94d2-5dd0820f03f2"/>
    <dc:identifier>DB6756</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8759a28b-cfa2-48b3-b40e-448721347e67">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/648b1e26-c6be-49ca-b8dd-32dfd4626b9b"/>
    <dc:identifier>DB00480</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00480</ddiem:url>
    <rdfs:label>Lenalidomide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/979976e0-edfa-43c9-b0b4-61a09aaee29c">
    <rdfs:label>Retrovirus</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0fe106d5-da50-45da-90bb-d85bd7e44a63"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4c17ce80-c32b-425c-a841-c3a90d002cfe">
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of cardiovascular system physiology</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/237500">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/237500</dc:identifier>
    <rdfs:label>DUBIN-JOHNSON SYNDROME; DJS</rdfs:label>
    <ddiem:iembaseAccessionNumber>554</ddiem:iembaseAccessionNumber>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/554</ddiem:iembaseUrl>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/609115ab-b96c-4291-ab27-becf78fcd1ba"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ce81f99-5051-43d9-af4d-fa9f38b11453">
    <rdfs:label>Carbenoxolone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02329</ddiem:url>
    <dc:identifier>DB02329</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/35b9be77-bd2f-4ed1-bf98-318021dcef1e"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/423bd000-7da9-4e5b-9121-71831d98fb1c">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001939</dc:identifier>
    <rdfs:label>Liver biochemical abnormalities (Laboratory abnormalities)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001939</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/93f55e89-07a9-47b3-b355-7952d5571e5b">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/99c7c71d-8cbd-4d02-be5c-356d997d3924"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c3c1149c-1f72-4835-82ee-02e4957dbc5a">
    <rdfs:label>Velmanase alfa</rdfs:label>
    <dc:identifier>DB12374</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12374</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3362d06c-116d-4a88-93f5-2da3d50b8897"/>
  </ddiem:Drug>
  <obo:DDIEM_0000013 rdf:about="http://ddiem.phenomebrowser.net/bca52d93-85bf-42c6-93f6-7cc645dc98e2">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/12016800</dc:provenance>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc99f595-d4d7-4bff-bbff-6e7e1fc20b51">
        <rdfs:comment></rdfs:comment>
        <rdfs:label>High serum osmolality</rdfs:label>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/125700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/15131757</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/26153518</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10510995</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
    <dc:provenance>http://www.bloodjournal.org/content/101/5/1705.abstract</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d0eb7a3c-d86d-4054-91b7-b0c7a02aa919"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30804055</dc:provenance>
    <rdfs:comment>Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.</rdfs:comment>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28590052</dc:provenance>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/cb8a9596-26cf-4b11-ac23-95dc788a74ce">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/d14c2b45-5115-4b62-a9f0-a59f662eeb52"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1c85601f-209d-4587-a5fd-3d8caf4d150d"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24218524</dc:provenance>
  </obo:DDIEM_0000013>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b0f8029c-d735-43be-bcaf-23dcfb8329f4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bf1c3612-9b36-4914-b30e-75b25e67947d"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4b7bf1d5-f96b-4f02-9f3f-b1e11e27bba1"/>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1e2b0e37-3693-482c-9fea-bda13ce9b9f7">
        <rdfs:label>Amphetamine</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00182</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff709bd-b144-4093-a5f2-40695810c0e0"/>
        <dc:identifier>DB00182</dc:identifier>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f311ba6-384c-4bb4-aae1-e5fea92e4335">
        <dc:identifier>DB00376</dc:identifier>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff709bd-b144-4093-a5f2-40695810c0e0"/>
        <rdfs:label>Trihexyphenidyl</rdfs:label>
        <ddiem:url>https://www.drugbank.ca/drugs/DB00376</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fb04219b-8e06-427d-a22b-d587398a615a"/>
      </ddiem:Drug>
    </rdf:li>
    <rdf:li>
      <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/44ce4be4-8d7c-4a70-92f3-3243827a8567">
        <ddiem:url>https://www.drugbank.ca/drugs/DB01219</ddiem:url>
        <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aff709bd-b144-4093-a5f2-40695810c0e0"/>
        <dc:identifier>DB01219</dc:identifier>
        <rdfs:label>Dantrolene</rdfs:label>
      </ddiem:Drug>
    </rdf:li>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a13c4d18-9cb1-444f-bd8f-47429bad9f54">
    <ddiem:url>https://www.drugbank.ca/drugs/DB14476</ddiem:url>
    <dc:identifier>DB14476</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/22ce15f4-b174-4ce6-92ba-9f1a539991a1"/>
    <rdfs:label>DL-alpha-Tocopherol</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ee05895b-a435-4a1b-96ea-3457132e01cd">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/19f3d4c0-28ef-47be-b6d3-7ce684a38e0f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0deafe0d-d52c-4136-bd23-d3cedf187dae">
    <rdfs:label>Mitochondrial proliferation in the muscle</rdfs:label>
    <dc:identifier>HP:0003200</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003200</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbbcc76e-00b3-4b0c-98a6-b4f4e7bfa983">
    <ddiem:url>https://www.drugbank.ca/drugs/DB06720</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/00bc36f4-a308-4e3e-a2cf-89bc3b34dd4a"/>
    <dc:identifier>DB06720</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/70e93c72-9872-452a-b9d9-4b6db249345c"/>
    <rdfs:label>Velaglucerase alfa</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d14c2b45-5115-4b62-a9f0-a59f662eeb52">
    <dc:identifier>DB00808</dc:identifier>
    <rdfs:label>Indapamide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bca52d93-85bf-42c6-93f6-7cc645dc98e2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00808</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3afdc73c-cd56-40e2-8231-71d10d207a0c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b66e7239-a55d-4c29-9962-4967e07eabac"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f13692ab-044b-40a8-bfd2-7ea67cbd7cab">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/2767acc1-834a-45da-86cb-e37ac21d2213"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5102282e-9dc7-4d0a-9ddb-5a6427deff97"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/66c39715-79a4-47e8-8423-e05500b45c68"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7ac76d4c-c656-42f4-b698-b9087a4f5845">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/47bbefcb-cc39-499d-863f-cecb95c40e8e"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/66a4ea33-3c61-47f8-bc7c-0b214e23f1d5">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00700)</ddiem:url>
    <dc:identifier>DB00700)</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b3f78336-d4d6-4e72-bba6-e789c268cd25"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/edcecfa2-9932-4303-a144-ce553e2f1f73">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa817121-b70b-462a-8235-4b54fe03768c"/>
    <rdfs:label>Mesalazine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00244</ddiem:url>
    <dc:identifier>DB00244</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5be0a32c-cb64-4da9-a1ee-357ff50fbab5">
    <rdfs:label>Miglustat</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2209e962-9161-4b04-8549-fb567b520a58"/>
    <dc:identifier>DB00419</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00419</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8065fd17-71a7-4bcc-bf3a-8d5a90c69c97"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d23c778d-d2fb-40dc-b987-eb5831180f95">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9e62c57a-e1ab-42c1-bc37-b1a98f623bd9"/>
    <rdfs:label>Sodium citrate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09154</ddiem:url>
    <dc:identifier>DB09154</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d69bea8f-3c3c-4f64-9f12-856b40d0cba5"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a9fe75b5-4470-45b4-9f8a-8203b5ae1b83">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d97dec37-3db2-4c54-8827-d39fe411cb96"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11E</ddiem:url>
    <dc:identifier>A11E</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb529eff-9f4e-4a03-bb9a-7dfe8a35c5ad">
    <dc:identifier>DB14778</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/75a19f98-4bdf-414e-bc80-e1c25326b8be"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14778</ddiem:url>
    <rdfs:label>Setrusumab</rdfs:label>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/5d90f67b-52b2-4116-96e2-ab7198e20873">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23022422</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/22832289</dc:provenance>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/118600"/>
    <rdfs:comment>Anakinra was administered as preventive therapy in one study" https://www.ncbi.nlm.nih.gov/pubmed/19289295". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/</rdfs:comment>
    <obo:RO_0000057>
      <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e0b7d857-40ea-424d-bd86-1fe75c96c9b1">
        <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bad7a413-3084-4991-a391-8fe7a61af333"/>
      </rdf:Alt>
    </obo:RO_0000057>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/25922564</dc:provenance>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1742948d-e751-4939-9107-28d5171ba312"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/30034506</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/18240249</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/20bf7360-b612-403c-89f5-74b8277b5011">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bb6b35b9-bcb9-4088-912d-f1af1d905ead"/>
    <rdfs:label>GNE gene lipoplex</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000015">
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure that inhibits  a component of the pathway or network in which a genetically defective protein is found, compensating for alteration of activity of that protein.[PNS]</obo:IAO_0000115>
    <dc:creator>leechuck</dc:creator>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:08:56+00:00</dc:date>
    <rdfs:label xml:lang="en">functional complementation of a defective protein by inhibition</rdfs:label>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000007"/>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a5b32c6e-7a10-46c1-876e-e264e6f11ec4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/45289a2f-c8f1-4d7d-854d-d51839898d6c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/49cfac0a-cc1f-4ae1-b090-6414ab3f4e57">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of circulating enzyme level</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011021</ddiem:url>
    <dc:identifier>HP:0011021</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/184b1fdb-96b1-49a1-abc7-91cf02107b20">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ae2ad46e-f21f-4988-bf22-e3ef86b49d6d"/>
    <rdfs:label>AAVrh.10CUhCLN2</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4aac123d-f5d0-4969-9cfa-aa405e2155ed">
    <rdfs:label>synthesis of atypical bile acids</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e57dea33-bf87-447e-be28-1961f56e2b16">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High α-ketoisocaproate level</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9ecea289-3741-4ab5-8826-56cf291756f0">
    <rdfs:label>movement disability</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bdfd1bad-24a0-40e1-8e55-9bfbff69f8f6">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00641</ddiem:url>
    <rdfs:label>Simvastatin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5873e17-570f-4feb-90c8-b53b21aa6b27"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ccb3344-7a2a-4441-991a-c2c3a7b38e5b"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2fd6e9c0-d762-4531-a39c-c3e9b35ad486"/>
    <dc:identifier>DB00641</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3176f43d-f85a-4cee-a5c1-f58e7c7885f2"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1b355f63-829b-43db-8fd9-61ba83c241a7"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/55809cf5-204e-4e2d-b0fd-49717c3766b3">
    <rdfs:label>Abnormal cardiac function</rdfs:label>
    <dc:identifier>HP:0011025</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011025</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6c9d69d8-9bec-433a-991e-c1d534ee520f">
    <dc:identifier>DB01329</dc:identifier>
    <rdfs:label>Cefoperazone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01329</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3310ab16-3553-4f40-8c8a-ff49354c362e"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/eb4a17e1-79b7-43ab-95eb-07ef4a9beaa7">
    <rdfs:label>recombinant canine α-l-fucosidase enzyme</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3347922-da0f-4f4a-9e48-7d9aa15d63ab"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7a10a125-b9c9-442c-b30d-df2ed44bac36">
    <dc:identifier>DB01109</dc:identifier>
    <rdfs:label>Heparin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cc9dedf6-887b-41eb-bfea-51d87189ab83"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01109</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8e1e8382-f71d-47f7-8f66-1ffb8a2880cf">
    <rdfs:label>flavanols</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6922c2dc-85d5-44f2-8d45-6a6d6786c11c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7362e630-4a5f-4433-8dfc-1649723bc9e0">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fab7372b-718a-4bae-8a83-7296199bef60"/>
    <rdfs:label>recombinant human LCAT (ACP-501)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/938d49db-90bf-44f4-834b-3b6622f8b9ea">
    <rdfs:label>Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010472</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010472*</dc:identifier>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/af4699f9-8926-4656-9653-a8325c07d22f">
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28202261</dc:provenance>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_</rdfs:comment>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/d85a2693-d47e-4cf7-89b1-2ccae2647501"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/28285122</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/4a032b19-7c9f-42cd-9507-8cdbf047110b"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/239500"/>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82e00398-7797-4e99-93ef-e8877f10deab">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/48f732b5-f9ed-41a8-b19f-a3b70e24e075"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f0a8b201-2354-4b92-a566-42e46043979c"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/35761893-660e-44c3-89e6-4ef8bfe220aa"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4a85ac05-8dcc-471b-8fc8-8708ccfcc973">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a1f9526e-d96d-4362-8efb-811094d2df87"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00620</ddiem:url>
    <rdfs:label>Triamcinolone</rdfs:label>
    <dc:identifier>DB00620</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6ca722fe-5021-4dbe-847d-643432808790">
    <rdfs:label>Nicotinamide Mononucleotide</rdfs:label>
    <dc:identifier>DB03227</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB03227</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7c92036c-566b-4939-a711-49d570eac29c"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/72685c8e-cd2f-4179-b0d5-ae3b8732fadb">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4db1ca12-c8ca-41c4-ba91-db3624d60600"/>
    <rdfs:label>6S-NBI-DGJ</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5b4cb137-3b00-4fda-8c4b-60934bf934d8">
    <dc:identifier>DB00119</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/54141c2c-03ba-47aa-9566-5e9659b0d09e"/>
    <rdfs:label>Pyruvic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c9362aa-390a-4a76-a528-4a2d2af55c8c"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00119</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c1d207a1-15bb-4e9d-a8a0-fd80a771e668"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee58517d-e207-4af0-a3e0-b3a01f3687aa">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/404d3354-01c5-4b1f-b44c-520e2d7646d8"/>
    <rdfs:label>Ad-hBUGT1</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dfdd596b-3d45-4d91-aade-9a7ddc3655f6">
    <dc:identifier>HP:0001635</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Cardiac dysfunction</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/42de30ab-b663-4e4c-9262-abeb63852725">
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N05A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3d027371-cb1e-421c-a61d-4cdb0bd10ea5"/>
    <dc:identifier>N05A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c7dc7f5e-b6c2-4a93-96a7-76a884496e0b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a229982f-415c-448d-a3fe-882394c7624c"/>
    <rdfs:label>Indometacin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0c693843-7b38-41e6-9f9e-1b3b589bdf74"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1e53705b-426f-45fe-9365-f50b93bd840a"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b54a51a2-09a0-41e4-93bb-620ef24682e5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00328</ddiem:url>
    <dc:identifier>DB00328</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a09d91f4-cb59-416b-933c-ea777c92f50b">
    <rdfs:label>hydroxypropyl-β-cyclodextrin (HPBCD)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/011fead1-d643-4f8b-b19e-5cad72196a93"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b49130fe-dcf3-40f6-94bb-72f9902fc76a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8ba3023b-bd12-4fd8-8b83-e52c8a159d84"/>
    <rdfs:label>Phosphate ion P-32</rdfs:label>
    <dc:identifier>DB14573</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14573</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7b0e8396-8ed8-4bf3-b093-a82d50ef6a4d">
    <dc:identifier>DB00819</dc:identifier>
    <rdfs:label>Acetazolamide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00819</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a09fe803-070a-400b-9afc-d4f154c035ef"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61988bcc-0a48-49df-8db5-264d86daab7e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a5125bbd-2030-45de-9c7c-a4399ac49ed4"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7cf4dd25-1641-40b5-96a7-fd370defe03a"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2cb28a4f-2c7f-4fd2-b8a6-16a72f680727">
    <rdfs:label>Abnormal chondrocyte growth</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7161e076-94d8-4c5a-ba19-88eca249295b">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f2ba6bbb-ab48-4402-9055-f104425801f7"/>
    <dc:identifier>DB00877</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00877</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a55dc935-5476-47a0-adeb-9e1fba55c7c3"/>
    <rdfs:label>Sirolimus</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e3492c91-7d2b-4f79-a43f-367049878be1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000989</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0000989</dc:identifier>
    <rdfs:label>pruritus</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/b121e446-9a8e-4288-9d06-46987eeb968f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3a46c556-7026-4220-857f-a5bb821ae55e"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ab285914-a53c-474e-8142-71d25edf356a">
    <rdfs:label>Sulfide toxicity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/62bbfc8d-342e-4c65-bf4c-3cba3680badb">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0011197</ddiem:url>
    <dc:identifier>HP:0011197</dc:identifier>
    <rdfs:label>EEG with focal spike waves</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/86000f7b-1ce9-4976-bee9-dd11a8cfdff0">
    <rdfs:label>Interferon beta-1a</rdfs:label>
    <dc:identifier>DB00060</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00060</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9c6d9241-e530-474c-a3dc-b7e6fcb18b13"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/31e32232-8719-4002-a9a6-619d39b1d59d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0ece4588-0d68-4fd2-b0dc-1274ec75ffaf"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3a777fa3-48b3-44bb-beb5-f87441f6c537">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d551cc6f-823e-4316-812f-d4e0bd73960a"/>
    <rdfs:label>Aminolevulinic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00855</ddiem:url>
    <dc:identifier>DB00855</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6e3a9473-c5f9-4e32-ab2b-41cbe84a8d2e">
    <dc:identifier>HP:0008972*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008972</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1716d4c2-9015-4f88-82b5-627c58fb2e23">
    <rdfs:label>Protein oxidation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41da0e94-7db2-41a2-b4ba-166b79b25dd9">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Increased low-density lipoprotein cholesterol concentration</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003141</ddiem:url>
    <dc:identifier>HP:0003141</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7083addb-b95d-426f-88f1-65dbbf4b095a">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>No phenotypes were mentioned in the study. In vitro Study.</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da973bd5-52c3-4fd7-82e5-eec3a1ea1abc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/930dd6ce-ef36-4149-9561-d529ebf9ef58"/>
    <rdfs:label>Vitamin A</rdfs:label>
    <dc:identifier>DB00162</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/404774c2-7ec0-4ba8-b0a4-8781856e6e00"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00162</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3bde17f7-b195-4961-a42c-c26613de623f">
    <dc:identifier>DB00252</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00252</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/aab1a052-4045-46c3-b9ad-b553566c06fc"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2db47e8b-ed37-4a38-a6b7-ae00d6f0cfa3"/>
    <rdfs:label>Phenytoin</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6c97820f-d5c7-4385-93ce-1dc360bfe22a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/762a1cf2-9a06-49b2-9bf9-15f7ad9415a5"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4075988-7b9c-4bc1-9b88-edb503b02b3a">
    <rdfs:label>Beta carotene</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06755</ddiem:url>
    <dc:identifier>DB06755</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e8c363db-14b0-4780-959d-ff14f3ceb63d"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/2cf1e0fb-3706-4663-8053-3189fbc15fcd">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3395630f-5340-4e32-8bc1-b94966d94e5a"/>
    <rdfs:label>Gene Therapy ??</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/332adf54-c29d-44be-98d9-cc5f19efcb73">
    <dc:identifier>DB00130</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f222476c-a072-4a62-bb2b-2bb00159f35d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/664e23dd-6b20-4850-8c89-61cd48685ee3"/>
    <rdfs:label>L-Glutamine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00130</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fab294ec-9c41-4af6-92cf-2bb07fab98f1">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5973b326-8e74-4a85-b88d-1a3fad228ade"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/22076e59-afaa-4a96-834e-3295186a829d">
    <rdfs:label>defected  L-2-HGDH enzyme activity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/627372ae-1a01-47b7-817b-4221b7b9a94d">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/43f31b37-779d-4d75-9dc3-4c936cd134ac"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_2786</ddiem:url>
    <dc:identifier>CHEBI_2786</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81863dee-874e-4452-8a7a-3116ea097654">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003676</ddiem:url>
    <rdfs:label>Disease progresssion</rdfs:label>
    <dc:identifier>HP:0003676</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fb9b7964-9908-497d-8c94-bfff79bd0be0">
    <dc:identifier>DB00235</dc:identifier>
    <rdfs:label>Milrinone</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00235</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2597aaac-4ba1-4462-b123-91c79a151122"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/068e47e2-976f-4f60-a09c-b1c7565d4072">
    <rdfs:label>CORTICOSTEROIDS, PLAIN</rdfs:label>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=D07A</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d154d5c-3463-4619-8286-af4af5add837"/>
    <dc:identifier>D07A</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cf62c67b-6751-4378-9e25-b295e37694ae">
    <rdfs:label>Olanzapine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00334</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/550400e4-ca60-463b-a51e-aee3afe1c59a"/>
    <dc:identifier>DB00334</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/af4699f9-8926-4656-9653-a8325c07d22f"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d5e96940-e51f-4b00-ae2e-cc15c9e4a1ac">
    <dc:identifier>DB00593</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b9bf1663-f897-4fbb-989e-25431e07aaa9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00593</ddiem:url>
    <rdfs:label>Ethosuximide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f09df761-60b4-4f75-a57c-d7c4d0656002">
    <dc:identifier>DB06281</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9d8b462f-4bd9-46f9-96db-ea7725ca32e1"/>
    <rdfs:label>Torcetrapib</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06281</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e75573cb-267c-4243-acb1-118eb0ce4fc1">
    <dc:identifier>DB00608</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/16804c09-f2d7-4eca-874a-3b4d4aaa3cee"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00608</ddiem:url>
    <rdfs:label>Chloroquine</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d2b64e89-917f-4bf2-b41e-a2aa2f4b7cec">
    <rdfs:label>AAV9-TAZ</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e7f23225-ca9c-4068-9f6a-c9599e02fde4"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/1589f711-e220-41ec-a2bf-c5f8edd4706d">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>somnolence</rdfs:label>
    <dc:identifier>HP:0002360</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002360</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/f3e0bc8c-790f-43e1-8ffc-43d89dcd6588">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0c625d2e-99f5-4cdf-9e14-2a1836281fd0"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/2861ff2b-9e44-4887-bc36-61c140fd9307">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002329</ddiem:url>
    <dc:identifier>HP:0002329*</dc:identifier>
    <rdfs:label>unalertencess</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/dbc56082-b832-42fc-9975-0501c0c075dc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/90dc5722-28cb-44b0-8f04-a2920d468246"/>
    <rdfs:label>Oxitriptan</rdfs:label>
    <dc:identifier>DB02959</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bca2ab94-f5af-40dd-8eb4-d64f748da2df"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f1267ccf-2167-41e1-a5b9-969af33733a2"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02959</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f77db5b6-2b22-43cf-997f-9be6905f8be4">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <dc:identifier>HP:0003750</dc:identifier>
    <rdfs:label>Fatiguability</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7e887823-7346-4ad6-a55a-5a49af7d25e9">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e1f2d6d1-8872-4038-9a41-f378937ff1c7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/469de258-3918-44f0-9307-be756ee15945">
    <rdfs:label>AAV2CUhCLN2</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b60721c6-5e70-49ea-ad57-584fce3b5fdb"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b8fae3ac-aa44-4367-a3c1-2694c94411c9">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001283</ddiem:url>
    <dc:identifier>HP:0001283</dc:identifier>
    <rdfs:label>Bulbar dysfunction</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7b166c28-e358-40cc-a46b-f70a0079887c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/e24e0fb6-d494-4363-9b19-9e7b5f1dde43"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e1e70256-965c-4751-a2c2-d875f58b584f">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010978</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormality of immune system physiology</rdfs:label>
    <dc:identifier>HP:0010978</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7a5044f5-0832-46ab-8a1b-e95c275e8671">
    <rdfs:label>Elevated Phe level in blood</rdfs:label>
    <dc:identifier>HP:0004923</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0004923</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f51d139f-6a2b-4f24-950d-d3018181c90f">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3bcbebc8-c5d2-4b77-8ccb-cad7964be12b"/>
    <rdfs:label>Cholesterol</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c89e8f83-4fcb-4088-bbeb-c561e047c01e"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04540</ddiem:url>
    <dc:identifier>DB04540</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4acba8c3-3793-4a46-8f7c-0a0b5aa7aee6">
    <rdfs:label>Heart failure</rdfs:label>
    <dc:identifier>HP:0001635</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001635</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c76a3c21-98ca-434e-88c3-fe8ea92d41a3">
    <rdfs:label>myopathy</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003198</ddiem:url>
    <dc:identifier>HP:0003198</dc:identifier>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d84cd0b-0a13-4662-a29f-e0fb730d6b0c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/44799c76-d36a-4c81-a36b-95f24ad98bc3"/>
  </rdf:Alt>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/94b8625a-56ac-4a21-b636-db141eaabab4">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/238700"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/23570448</dc:provenance>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/5a5c7bc5-d940-4232-84c1-010ca2bca269"/>
    <rdfs:comment>The drug was accompanied with lysin restricted diet</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000009"/>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/a5b63d90-63aa-455f-a869-ab45ac6bd1fb"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/24204001</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/150d8650-df67-4822-a51b-57ea6a6ec966">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012433</ddiem:url>
    <dc:identifier>HP:0012433</dc:identifier>
    <rdfs:label>abnormal interactivity</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fb52c1bc-7a84-4b52-91d5-0e176a1bf510">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b53239bb-8bc9-4357-88b1-bb2991d163cf"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7e188f77-322e-4dd7-b6d7-01dfc1b7a4c5">
    <rdfs:label>Acitretin</rdfs:label>
    <dc:identifier>DB00459</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/907ac2a9-5e8f-4dc8-a3e7-979f1a503d19"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/add205c8-ade9-4d94-bdcd-946b7192fa13"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/feea6e66-a3b8-47e3-ac75-5e0e45d7e4e5"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00459</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/fd8144ca-93da-46bd-ac4a-34732ef3a410">
    <rdfs:label>orthostatic hypotension</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001278</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001278</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d93b319c-7c68-4cd9-bd62-fabefdd22a25">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/3bb61825-13a8-4543-a9c0-949490c795f6"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9b18bb34-0a07-4967-8796-15a488fa4ee3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Thrombotic microangiopathy</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/c29a259a-c2f0-4adb-aebc-e9ca767b8cac">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51371311-2aac-4006-b9d2-93b1ff39a8bd"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ebf9a445-dc24-4cda-b645-4cd435d8840d">
    <rdfs:label>Uridine</rdfs:label>
    <dc:identifier>DB02745</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB02745</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6e68f27c-a71f-4946-a48e-0372d628c069"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/fcaeab5c-2394-4bb9-8bf2-71fe7d470b83">
    <rdfs:label>Curcumin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8f144be0-8c21-4a77-b4a9-1d419391f7f5"/>
    <dc:identifier>DB11672</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11672</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7dd70f2e-70af-41b8-876d-fd6516d4416e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4a58bba2-57ba-4aa8-a073-bc9ad993c3e9"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee712e11-4939-49d5-bf27-ea3d97ade3f2">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e1fb609a-a30e-412e-a8d4-534c7becab9f"/>
    <rdfs:label>iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/187bbb2e-6080-43a4-b131-2fabcbe8f858">
    <rdfs:label>High urinary levels of primapterin (7-biopterin)</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/58e3148d-33e5-42b4-bcd8-0bcf45eea879">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5243f7b6-c757-4280-9343-f581db4dbcd5"/>
    <dc:identifier>N06AB</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=N06AB</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bb332d6d-7b8a-458c-ac1e-b224a03cf7b1">
    <dc:identifier>CHEBI_25548</dc:identifier>
    <rdfs:label>nitrilotriacetate</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cd391c6e-ad73-4a0a-92c6-069d3cc4eca3"/>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_25548</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4541af0b-5b2c-4bed-a29e-cfdc94a08a94">
    <rdfs:label>AAV1vector expressing α-Mannosidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3cb16118-8996-4060-afa1-c68304e28a11"/>
  </ddiem:Drug>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/8955d514-02e1-45f7-bc2e-b3f7e68b1713">
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/162300"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9e6ef49e-cfd4-4b54-a9d0-21c2f77c785b">
        <dc:identifier>HP:0031377</dc:identifier>
        <rdfs:label>Abnormal cellular proliferation</rdfs:label>
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0031377</ddiem:url>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/3491070</dc:provenance>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/10947080</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/69745203-dbe5-4629-b4e0-f40aabf67455"/>
    <rdfs:comment>In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410</rdfs:comment>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/53a52edd-9fd1-4770-a465-2e122c07058c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/59487f39-b7c2-4e9c-8ab5-e72718496654"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7e1773c6-7f4b-461a-be24-b380dec95473">
    <dc:identifier>HP:0012378*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Extreme frailty (Fatigue)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0012378</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/607155">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5</rdfs:label>
    <dc:identifier>https://www.omim.org/entry/607155</dc:identifier>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/98d61ac2-3497-4d41-b6cf-2f3ac04c348d"/>
  </ddiem:Disease>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6579cf0e-0aae-4409-bd6c-a9aa7ee2b451">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Abnormalitilty in voluntary movements(Abnormality of movement)*</rdfs:label>
    <dc:identifier>HP:0100022*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/86009a68-9535-4f68-b911-32f15b9bcd2d">
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0005542"/>
    <rdfs:comment>Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/</rdfs:comment>
    <obo:RO_0002212>
      <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/b87c6690-211f-4ad7-ae45-cc5084b212db">
        <ddiem:url>http://purl.obolibrary.org/obo/HP_0030098</ddiem:url>
        <dc:identifier>HP:0030098</dc:identifier>
        <rdfs:label>Abnormal fukutin mRNA expression</rdfs:label>
        <rdfs:comment></rdfs:comment>
      </ddiem:Phenotype>
    </obo:RO_0002212>
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/296c9beb-1075-4885-a0f8-3d0a51a3d27a"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0001565"/>
    <dc:provenance>https://www.ncbi.nlm.nih.gov/pubmed/27421908</dc:provenance>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/60648970-4ae8-424c-a5d0-f8df29b423c3"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/253800"/>
    <dc:provenance>https://www.nature.com/articles/nature10456</dc:provenance>
  </obo:OGMS_0000112>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b09a89c3-bf56-422f-bbaa-344b13ea18c7">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03147</ddiem:url>
    <dc:identifier>DB03147</dc:identifier>
    <rdfs:label>Flavin adenine dinucleotide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa89e751-0118-4533-b6ca-b66001b94e84"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/25512a64-7637-4d16-8436-36dc05238cdf">
    <dc:identifier>DB14307</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14307</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/46937cba-0737-4123-8435-34110d8a7d83"/>
    <rdfs:label>Green tea leaf</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4031f921-d64a-40b3-81f5-9f3d0c9a2e1f">
    <rdfs:label>High biliary cholesterol saturation index</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/bd93d4de-4d91-47ea-bab8-4b6ca2cbaa3f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/7efd16f0-ad2a-4c9a-b2aa-afa5f5e7cfb5"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d02d4f58-8e93-45a7-be57-691d0b281158">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/58c712b9-33f4-4fb7-b094-1118f4042d42"/>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=A11EB</ddiem:url>
    <dc:identifier>A11EB</dc:identifier>
    <rdfs:label>Vitamin B-complex with vitamin C</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/94281f91-e37f-4dcd-86ca-16d08d0f4f56">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09395</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f83cf61d-6953-4c12-b945-280630f98b0a"/>
    <dc:identifier>DB09395</dc:identifier>
    <rdfs:label>Sodium acetate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/979d2741-0b42-4d41-82df-cb667d4406a8">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c3460a83-cd1c-4465-a4b1-a71aa8d20c3a"/>
    <dc:identifier>DB01241</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01241</ddiem:url>
    <rdfs:label>Gemfibrozil</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4577c623-0aec-4c48-b6d2-92969ef172a5"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/cdc49bbb-5a81-4c1b-8f1b-7a77d9414f19"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/298ec289-ce86-4af9-9598-bf0c8386c6cf"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b8b5cb7e-1aae-4e57-ba83-c03d5af6b613">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7da15996-05fd-4f10-b9a1-0b6f4564780f"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00458</ddiem:url>
    <dc:identifier>DB00458</dc:identifier>
    <rdfs:label>Imipramine</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4d00f407-cf02-46a2-9c6b-e64caccd8a69">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4923cbdc-2d2a-4413-8c20-f4f3d9d6bcd8"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4e999e09-9f1f-4d66-96cf-a0d596dd3ea0">
    <dc:identifier>DB00988</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00988</ddiem:url>
    <rdfs:label>Dopamine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2597aaac-4ba1-4462-b123-91c79a151122"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c97f7be8-8d63-4c3e-b076-0a900f8d6928">
    <dc:identifier>DB00028</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00028</ddiem:url>
    <rdfs:label>Immune Globulin Human</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/dcf441a9-22c8-43d1-8c97-cccc9e2447f0"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/65c6915a-3ba6-4b8f-8e0f-c5eb99320add"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/fdedcdf3-f20a-4486-8bc4-a64d9e4f090d">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bb65565c-f1b9-43a3-be5d-523fc452a7b3"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d00c4263-9dd6-413a-9ac4-22c7d435625b">
    <rdfs:label>AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/448bb407-cd7a-46ad-89a9-4034693495c0"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ea1cd9b5-d853-471f-b67c-60c83f7161c4">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007009</ddiem:url>
    <rdfs:label>Central nervous degeneration</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0007009</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3bfc914e-3583-4e56-956b-37b6bed5804e">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0020062</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0020062</dc:identifier>
    <rdfs:label>Low Hemoglobin concentration</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9f217f22-04a9-4951-af9b-6b5b4c9da1ed">
    <dc:identifier>HP:0003452</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003452</ddiem:url>
    <rdfs:label>High serum iron</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/121270">
    <dc:identifier>https://www.omim.org/entry/121270</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>COPPER DEFICIENCY, FAMILIAL BENIGN</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/1b066539-7726-40bf-99cc-ee56bb326b4b"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/631b1ffc-1242-4c09-a069-b51abfb676af">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0694ba35-df24-4b64-9859-777b881c1f56"/>
    <dc:identifier>CHEBI_26537</dc:identifier>
    <rdfs:label>retinoid</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_26537</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6fb4a942-2b64-44a5-a7fc-d1775a1453cc">
    <dc:identifier>DB01611</dc:identifier>
    <rdfs:label>Hydroxychloroquine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4be676d6-0457-460a-9072-97c7a5b8abda"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01611</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/81b4c384-5e18-4b94-8fb2-0144e2fc1b8c">
    <rdfs:label>mitochonic acid 5</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3e7b8e26-0ddc-4db0-a423-695ce0a415ec"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/81240203-20a5-4cb6-8386-0419000c8ef4">
    <rdfs:label>Acute decompensation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c0d1ab6d-3f77-463e-8a32-a60281ca9714">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/85f032ed-7517-4650-8510-bd5168a4709b"/>
    <rdfs:label>Prokinetic agents</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/9a3f9fb8-0490-4718-a327-654ef5196c24">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/8a7bd5c0-bb86-472f-9854-ae75b63df0de"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/67e6ca70-bcd1-4f47-9e61-65229e3a7120">
    <rdfs:label>Teriparatide</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c9198058-74c3-4b4f-b82d-9288b0cca852"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06285</ddiem:url>
    <dc:identifier>DB06285</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d48ec4e9-363c-4f2b-b71b-42942b4b3060">
    <rdfs:label>high-anion gap acidosis</rdfs:label>
    <dc:identifier>HP:0001941*</dc:identifier>
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001941</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f3557920-66b0-4e34-9cfb-54ccbe95c2f7">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0100502</dc:identifier>
    <rdfs:label>Low levels of serum vitamin B12</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100502</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/722eb1b1-b9d5-41df-b998-c32584e3db07">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <dc:identifier>HP:0100022</dc:identifier>
    <rdfs:label>movement disorders</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d07c736e-6be5-49cf-ab93-74bad9334cca">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a759aa5a-a359-469a-86b6-15b8db12c9a0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/7d000371-20ff-49f6-8e5a-48da6a4e337a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00098</ddiem:url>
    <dc:identifier>DB00098</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0530521b-2217-405f-b028-215a0731ccc8"/>
    <rdfs:label>Antithymocyte immunoglobulin (rabbit)</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/faf429f2-63da-4267-9c54-d91bb9473e0c">
    <rdfs:label>Chenodeoxycholic acid</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06777</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/82ffdc1a-4a82-46b9-995a-d5c969b768ae"/>
    <dc:identifier>DB06777</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2983ec0c-8ae7-40a5-9c3d-e28537a9200d"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/df2c5576-0263-4c9c-afcc-cdc08a108bad"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/8adf534b-8d25-4306-b654-fd0c7e0c6889"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4689a9d6-a6fe-411c-af5e-d157a0320bbf">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100614</ddiem:url>
    <dc:identifier>HP:0100614</dc:identifier>
    <rdfs:label>Muscle inflammation</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0d43a726-a9c5-46ca-a68f-556754b33340">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/152b11ac-32c6-49c1-b521-b9b02108f57a"/>
    <rdfs:label>AAV-treated βgal</rdfs:label>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/608099">
    <rdfs:comment></rdfs:comment>
    <dc:identifier>https://www.omim.org/entry/608099</dc:identifier>
    <rdfs:label>MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3</rdfs:label>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/d266cf89-a33f-4b2e-ba97-532eea78d278"/>
  </ddiem:Disease>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3f3890bb-95d3-44af-ade3-bafd9d6873ac">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/0f20bb48-1480-4c7a-994a-380b91f72269"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5f6cf3fc-7ad9-453d-bc4a-338ce27b8ad9">
    <rdfs:label>Recombinant alpha 1-antitrypsin</rdfs:label>
    <dc:identifier>DB05481</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05481</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e0bf5e5a-19c2-4b1a-b9aa-afbd24e09a58"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/229700">
    <dc:identifier>https://www.omim.org/entry/229700</dc:identifier>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/483</ddiem:iembaseUrl>
    <rdfs:comment>The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&amp;Cmd=Retrieve&amp;list_uids=29390242&amp;dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9</rdfs:comment>
    <rdfs:label>FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D</rdfs:label>
    <ddiem:iembaseAccessionNumber>483</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5c47895d-e602-4b95-aac4-25fbb314fdc4"/>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/77b87be8-c12b-48a8-8112-a78fcce943b4">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d7010c92-b701-4ba5-b903-a7db28531c0f"/>
    <rdfs:label>scAVV9.CB.CLN6</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/9dec5755-7da4-4b76-89e0-5f96df87bfa8">
    <dc:identifier>HP:0100022*</dc:identifier>
    <rdfs:label>excessive adventitious movements</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100022</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/ea6a07f3-3b0d-4a5e-a932-0620c799f6e4">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/599cdab9-6ac2-420b-85b5-da2e56eb7561"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/134b831e-38f0-4f02-a7bf-087d188f565e">
    <dc:identifier>DB04854</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04854</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7ae0ded6-c24f-4b5f-a348-362c9b95b77c"/>
    <rdfs:label>Febuxostat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/3d10d77d-86fe-4e05-8708-09b1a76101a3">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Poor eye contect</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000817</ddiem:url>
    <dc:identifier>HP:0000817</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/da37feed-4433-41b2-996c-d729f5ae5915">
    <rdfs:label>Elapegademase</rdfs:label>
    <dc:identifier>DB14712</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14712</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/159c4c62-8c0b-4ccd-9673-68b28896134c"/>
  </ddiem:Drug>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/232800">
    <dc:identifier>https://www.omim.org/entry/232800</dc:identifier>
    <rdfs:label>GLYCOGEN STORAGE DISEASE VII; GSD7</rdfs:label>
    <rdfs:comment>The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272</rdfs:comment>
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/491</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>491</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/5e8f82dc-eea0-4959-9a07-0fbd11cbacae"/>
  </ddiem:Disease>
  <ddiem:Disease rdf:about="http://ddiem.phenomebrowser.net/300818">
    <ddiem:iembaseUrl>http://iembase.org/app/#!/disorder/1141</ddiem:iembaseUrl>
    <ddiem:iembaseAccessionNumber>1141</ddiem:iembaseAccessionNumber>
    <obo:RO_0004020 rdf:resource="http://ddiem.phenomebrowser.net/a6d42cad-4114-498e-820b-08e1b65c5d70"/>
    <dc:identifier>https://www.omim.org/entry/300818</dc:identifier>
    <rdfs:label>PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1</rdfs:label>
    <rdfs:comment>PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949</rdfs:comment>
  </ddiem:Disease>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0f9169bc-d8ea-450c-8fe6-7ef94239eb77">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ab95aa79-4b40-4e36-bb8b-f61f1518e14b"/>
    <dc:identifier>DB11098</dc:identifier>
    <rdfs:label>Potassium bicarbonate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11098</ddiem:url>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/aca248bc-d124-44fe-b94e-8e651c77ee30">
    <dc:identifier>HP:0003119</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003119</ddiem:url>
    <rdfs:label>Dyslipidemia</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/692af4ce-3ee6-4dfe-bdd9-6823425fd394">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00435</ddiem:url>
    <dc:identifier>DB00435</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e7f52e6-ecfe-4c65-bf0a-bd70f9d92b8f"/>
    <rdfs:label>Nitric Oxide</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e7c98425-622f-4cf1-b10a-9bb1318f71de">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/01eba44d-46ad-4022-af05-58017afb3cb2"/>
    <rdfs:label>AAV-based gene therapy</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ee438ac7-2e7b-408a-8973-8a252189be78">
    <dc:identifier>DB04729</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/fa7b5ebb-85e7-4f25-8f54-d547de24387a"/>
    <rdfs:label>Gentamicin C1a</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04729</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/31079757-0b22-4c84-85ff-1fc33ece503f">
    <dc:identifier>DB01323</dc:identifier>
    <rdfs:label>St. John&amp;apos;s Wort</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01323</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4cb21b7e-013d-44c8-86aa-d719a76acf86"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/c7b5007e-0cc7-4966-80b6-f875517ea852">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>cortical GM2 ganglioside accumulation</rdfs:label>
    <dc:identifier>HP:0003495</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003495</ddiem:url>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7cb3c409-648e-4747-a097-c5df7cabdd3c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4e999e09-9f1f-4d66-96cf-a0d596dd3ea0"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/4637e0f6-c50c-4ba6-a48c-af9c7e48c839">
    <rdfs:label>IMMUNOSUPPRESSANTS</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/847f35e9-0d9d-4a54-8ff8-abc082e0d2c2"/>
    <dc:identifier>L04</dc:identifier>
    <ddiem:url>https://www.whocc.no/atc_ddd_index/?code=L04</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f566493b-6adb-48d7-b855-6cb91701625c">
    <dc:identifier>DB04159</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04159</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/69a8750e-b461-4106-ac8a-f753e7cfb7e0"/>
    <rdfs:label>Beta-Hydroxytryptophane</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/282c0dc8-df61-4851-8114-b4235cd2df9f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/18961026-edfd-434a-b221-2d089643041d"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/d18397bf-2d37-4d59-ac44-721ef72494ae">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0030390</ddiem:url>
    <dc:identifier>HP:0030390*</dc:identifier>
    <rdfs:label>High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/56954c83-ce3e-4361-8844-1fa85df92219">
    <dc:identifier>HP:0008222</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008222</ddiem:url>
    <rdfs:label>Female infertility</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b199fed3-9d37-460a-bb69-0777e4c3926d">
    <ddiem:url>https://www.drugbank.ca/drugs/DB09039</ddiem:url>
    <dc:identifier>DB09039</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b26ceaa-76fc-4a13-b3fe-1e06f727d94f"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3fdf32f-0231-447a-a034-395e2278ee14"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3b3b8fc7-e4be-4a74-a355-03065e5dd62e"/>
    <rdfs:label>Eliglustat</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/a826b8f3-a700-4296-a682-090f344c6557">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/2d15e70e-4768-4baf-b06d-3766b0c2f3db"/>
    <rdfs:label>aminomidazole carboxamide riboside</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5efdacf0-1a00-4c72-b3b8-4c7ecb51a5ef">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/5e51e557-2f81-4439-bc2d-9cc0f03cc352"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/767a3efd-1718-4d47-8cc4-601382397eb9">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/7e06a5ae-5723-46cf-a850-36d77c7c759e"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a87a5ef2-a936-4f17-83c7-2d92a15a473f"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00564</ddiem:url>
    <dc:identifier>DB00564</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/979eab39-b975-4130-b1a8-cfcadde0b8df">
    <ddiem:url>https://www.drugbank.ca/drugs/DB03904</ddiem:url>
    <rdfs:label>Urea</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/04581989-489c-49a8-95fd-7e0947ca3033"/>
    <dc:identifier>DB03904</dc:identifier>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4b2ebf43-7544-4cf7-b38f-2e51a336762f">
    <rdfs:label>Leukodystrophy</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0002415</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002415</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c4a11183-6e74-495d-9f0f-87028e23d25f">
    <rdfs:label>DTX401</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b251f889-2857-4e9c-b169-4ca977667d52"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ea0333b6-f59d-43b9-9763-2bbdd8d6789e">
    <rdfs:label>Lovastatin</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00227</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/1ba30851-08a4-41b7-9214-a8a84773da4a"/>
    <dc:identifier>DB00227</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9a1426f2-4026-4c97-aba2-d7a62bff9e07"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a3a38408-abee-433e-aeb1-355c604cc06a"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/metabolic_disease_treatment">
    <obo:IAO_0000115 xml:lang="en">a treatment strategy or plan which the clinician beleives will cure or ameliorate a disease caused by a deleterious genetic variation in a patient, affecting their metabolism. It may modify some or all of its signs or symptoms, or alter the prognosis and course of the disease, either by severity, timecourse or phenotypic quality.</obo:IAO_0000115>
    <rdfs:label xml:lang="en">metabolic disease treatment</rdfs:label>
    <dc:creator xml:lang="en">https://orcid.org/0000-0002-5111-7263</dc:creator>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  </owl:Class>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d13ce77f-f7bc-4071-a3dc-a280ecbb8a1f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c2d5a02e-765d-4f76-b579-e50c8335f86a"/>
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/51c95db6-fc44-42cf-bc17-ad49d7220117"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/555ec245-4242-417e-a29c-901aeadac03a">
    <rdfs:label>human recombinant acid ceramidase/human ACDase-encoding lentivector</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e51fd94b-d55f-4ed3-9046-9e5fd9471650"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7648dee9-447a-4d30-ab5d-ec07936759d1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0005961</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>intracellular defect of arginine</rdfs:label>
    <dc:identifier>HP:0005961</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/9577b1ff-d188-4fd6-9e5f-de3fac5b221c">
    <rdfs:label>(5aR)-5a-C-Pentyl-4-epi-isofagomine</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/d02fbd34-3b1b-482d-9484-996a68bdcffe"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/8810bfab-d6ae-4dc3-9814-79d6236c122a">
    <rdfs:label>AAV-GLUT1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/b1a84a34-532f-41d5-b111-89b2ebff9ec9"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1416f9d-a187-4485-b4b0-01f567f03b73">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0000708</ddiem:url>
    <dc:identifier>HP:0000708</dc:identifier>
    <rdfs:label>Behavioural Disability</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/bad7a413-3084-4991-a391-8fe7a61af333">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/5d90f67b-52b2-4116-96e2-ab7198e20873"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06372</ddiem:url>
    <dc:identifier>DB06372</dc:identifier>
    <rdfs:label>Rilonacept</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/4836ae04-51bb-4782-a374-32f2d8965ab1">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Low β-gal activity (Abnormal enzyme,coenzyme activity )*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/60d34ac9-3f99-4f28-8e4f-82b5e9889599">
    <rdfs:label>Elamipretide</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB11981</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bc690b16-c77e-4bc6-ab1c-a66763900634"/>
    <dc:identifier>DB11981</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/a0a114db-254b-41c2-9695-eef011833651"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6f6f427b-85c2-43ee-8835-7ae13aaa6254">
    <rdfs:label>Carglumic acid</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/21ae0f48-d5ce-461d-8d37-7c0da0a175a4"/>
    <dc:identifier>DB06775</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB06775</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/86125bd0-8305-4ef1-a9dd-4a244f1cdec8"/>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/06d44991-fead-424d-a582-bd42ba16e5c1">
    <dc:identifier>DB04075</dc:identifier>
    <rdfs:label>N-Acetyl-L-Glutamate</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB04075</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4fc07961-47a0-474c-856d-236a3eedac12"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/7d0b2e92-e624-487a-b654-87d0c1451467">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/cbb2d6af-77ae-4f1b-8d4f-963bad8800f7"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/d72d8a6e-10eb-44f9-9693-9aa7d4937069">
    <rdfs:label>Ad5/CMV/hUG-Br1</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/984c1413-8768-4ab4-8e48-567710b61a82"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/20ec6858-55d3-4e64-9086-933c8746623a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/07f9164c-3573-45b0-a08f-17ec0c661aad"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e8c2df8a-cdd8-436f-8a88-d65ac757e60d">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001396</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0001396</dc:identifier>
    <rdfs:label>Defected bile flow</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/6a41b890-74df-4c64-9e13-a71443ab1c56">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/636793ff-bf83-43f5-9317-0659c6cebf62"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB14500</ddiem:url>
    <dc:identifier>DB14500</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6370e6ef-dd91-439e-adb3-fa810a8d644f"/>
    <rdfs:label>Potassium</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/7f4c7f46-4d9d-49ae-b8fa-8fec6d3f3fbf">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>lack of strenght</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003750</ddiem:url>
    <dc:identifier>HP:0003750</dc:identifier>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/d6556204-8898-4cc4-a35a-fbd61ebe92c7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/544ab5fc-ddca-447b-8e0c-5df538195027"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0a5ca1d5-bc1d-457b-886e-26c5da66278d">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0100529</ddiem:url>
    <dc:identifier>HP:0100529</dc:identifier>
    <rdfs:label>Abnormality of phosphate homeostasis</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/43bd3401-f2c9-4bb9-9ea5-9582501375ca">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/fb9b7964-9908-497d-8c94-bfff79bd0be0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/a61ff704-7605-43c3-b8a3-9f69b11f85db">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa5ab7ce-da21-4827-8f56-d4e296692607"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e06dbd8b-955e-48e5-8db2-f81b53e2c324">
    <rdfs:label>Gene therapy (wild-type Ad-AGA)</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/9aa5587c-80cd-4bac-b8b2-81e1332edf59"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/567bd347-d4e5-4853-9f36-7c1d0b62dc94">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6322e27d-52cb-4d0f-ba3f-0774528ff8bb"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/62d6391b-9072-4486-a4de-272361d524cc">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ff4f31fa-fa56-432d-b9d6-8077c06de572"/>
    <rdfs:label>L-Citrulline</rdfs:label>
    <dc:identifier>DB00155</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00155</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/234b8a3f-d128-4ced-943d-87bff41c2ef5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f007d250-961c-40e3-9a36-46a96156fd43"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/2dc05724-5405-4547-b52c-c3560834775f">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/bc6534e4-448b-4568-88dc-5dc960087044"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/61e01cc4-4c6b-4f86-9f54-aed04b4dd1fc">
    <dc:identifier>DB01025</dc:identifier>
    <rdfs:label>Amlexanox</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB01025</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/708b6cfc-10e2-4db8-bc32-7f8ecbe4c613"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f1a10ef5-8ef9-4885-bd0f-6374451dddda">
    <dc:identifier>HP:0007663</dc:identifier>
    <rdfs:label>Reduced visual acuity</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0007663</ddiem:url>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/0d8185b4-36f4-4aff-80a9-353d07b486a0">
    <dc:identifier>HP:0001298*,HP:0002960*</dc:identifier>
    <rdfs:label>Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*</rdfs:label>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001298,HP_0002960</ddiem:url>
    <rdfs:comment>Doctors prescribed these drugs combination""Methylprednisolone sodium succinate +
Immune Globulin "" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120</rdfs:comment>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/cb6faedf-7a16-4d43-88fd-d2d8d378603c">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/739324f5-6f5a-4d7d-ada8-7641bcd188a0"/>
    <rdfs:label>Chimeric oligonucleotide(oligonucleotide-based gene therapy)</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/722bb76e-4fee-49c2-9c84-ebc5d43a3ae0">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9ca9b250-6791-495e-87a5-09c0491de2bb"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e2f0623a-b0d8-4ebd-9235-dfbef0cbaa54">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*</rdfs:label>
    <dc:identifier>HP:0008282*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0008282</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0ff5bd25-907a-4f6c-8da8-056a828f48b9">
    <ddiem:url>https://www.drugbank.ca/drugs/DB05294</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/546de381-524e-4b23-a7f3-b164adac7226"/>
    <rdfs:label>Vandetanib</rdfs:label>
    <dc:identifier>DB05294</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/78d9f841-2228-4030-951f-5f6f16db52e6">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/55d87946-dc22-4c77-9aaa-4465f14ca9f9"/>
    <ddiem:url>https://www.drugbank.ca/drugs/DB09125</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/08b93502-018f-4246-ba9f-cfcbb9317726"/>
    <dc:identifier>DB09125</dc:identifier>
    <rdfs:label>Potassium Citrate</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/ef41d703-b6a0-4300-ba97-cff2fdd75fdf">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003546</ddiem:url>
    <rdfs:label>Exercise intolerance</rdfs:label>
    <dc:identifier>HP:0003546</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/ad0ce876-fc00-445b-b94c-f97329e5cc0d">
    <dc:identifier>DB00915</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/bcb2c169-9df3-461b-9352-7d47b069ea03"/>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/56e37ccd-7a83-4058-87fc-c4fcc603ab7b"/>
    <rdfs:label>Amantadine</rdfs:label>
    <ddiem:url>https://www.drugbank.ca/drugs/DB00915</ddiem:url>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/dfdcf1f8-dc98-43f4-bd1a-430318d9f8ad">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6c94c486-1d4c-4b46-9e91-20fb0223d150"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/207d2bb2-3868-4dc4-be47-c1a8037c6d2c">
    <dc:identifier>DB12351</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB12351</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/61ca1b74-ca40-46d3-868a-b2691acb4197"/>
    <rdfs:label>Siagoside</rdfs:label>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/e6c2fcaa-1615-44ee-a9df-c7c2798ef726">
    <rdfs:label>Abnormal Hcy level</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0010919*</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0010919</ddiem:url>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/b7b91a10-be6c-4931-b169-400ca7337481">
    <rdfs:label>AAV2 /1-mSeAP-propmyoD76A</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/ecddb4b9-d643-43a8-8899-21610430470e"/>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000012">
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2019-07-15T18:07:23+00:00</dc:date>
    <rdfs:label xml:lang="en">activity modification of a genetically defective protein</rdfs:label>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which  generally small molecules are delivered to the organism in order to to directly increase, decrease or alter the activity or stability of a genetically defective protein.[PNS]</obo:IAO_0000115>
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000006"/>
    <dc:creator>leechuck</dc:creator>
  </owl:Class>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c62b9f9a-afb9-42d3-b7e9-3852b3a841c8">
    <dc:identifier>DB05134</dc:identifier>
    <ddiem:url>https://www.drugbank.ca/drugs/DB05134</ddiem:url>
    <rdfs:label>Tanespimycin</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/6ff7b366-7e43-4610-aeff-f7a16bcfb510"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/6482f37e-6e30-4e67-b844-b9ec8e8dca82">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>Kidney stones</rdfs:label>
  </ddiem:Phenotype>
  <obo:OGMS_0000112 rdf:about="http://ddiem.phenomebrowser.net/c42cce93-b81c-4c6e-8fee-408466364ded">
    <obo:RO_0002212 rdf:resource="http://ddiem.phenomebrowser.net/1def0545-3cbe-4a64-ac90-e1d2ec1f143f"/>
    <obo:RO_0002558 rdf:resource="http://ddiem.phenomebrowser.net/ECO:0000352"/>
    <rdfs:comment>Drugs has decreased rhe frequency of the tonic seizuress</rdfs:comment>
    <rdf:type rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000013"/>
    <obo:RO_0000057 rdf:resource="http://ddiem.phenomebrowser.net/f10fbbe9-74f4-44c7-9450-01aad23dc4ff"/>
    <obo:RO_0002599 rdf:resource="http://ddiem.phenomebrowser.net/615398"/>
    <dc:provenance>https://www.sciencedirect.com/science/article/pii/S0387760417301742</dc:provenance>
  </obo:OGMS_0000112>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/29f79d4a-e0c0-4d9a-953a-59ac6a7de2ff">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/aa479e36-2b77-4106-a61c-2f36f3dd56ec"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/68480119-ad53-4189-b972-000482e3b474">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/e3e34aad-49ba-45a2-ab66-0707a19eb160"/>
    <rdfs:label>Uncooked cornstarch+ Beneprotein</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4cc69c3b-74e2-4b9a-9a84-b404733c8d97">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/b01aeb10-c083-426e-991d-bb09e20a4f6c"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/83a106eb-b538-438a-8084-21571ef79b08">
    <rdfs:comment></rdfs:comment>
    <rdfs:label>pseudoexon activation</rdfs:label>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/6988af76-7ddf-4a06-acbc-e2a5150be625">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/55636bfa-eca3-485f-9cb3-4ef6e53097df"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/0b97e3aa-08ce-4e6c-8fe7-e3e18d47c5b1">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/37db3fc1-3f65-4853-ac6b-0f4ff7ba36ef"/>
    <rdfs:label>keto-analogues of essential amino acids</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/1f4f06d6-d045-4390-8a09-d46d8e2b323d">
    <dc:identifier>CHEBI_113373</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/0a500a1b-619d-45ea-840a-aebb11654cb3"/>
    <rdfs:label>sodium beta-hydroxybutyrate</rdfs:label>
    <ddiem:url>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_113373</ddiem:url>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5fdc6be8-dff1-4f4d-9910-cc446ae6c53e">
    <rdfs:label>Gene therapy</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3961ea1b-8023-4dd2-9d5e-2efd781e4472"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/573613b5-a103-4b96-98d5-0034a6fd336e">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/a063df6e-e58f-4ed1-922e-3b06763d6611"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/e2265d57-88c2-4354-9cca-95d15f7f3fd5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/babfd94f-34fd-4255-b7ea-96ac908b51dc"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64dbf323-2fbe-4474-bba0-5ab077276d42">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/46dc73b9-4d45-4987-9797-9a574c620fff"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/f273ba9d-610f-4c9e-935d-791fbfeb225a">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00065</ddiem:url>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4ae18680-44cf-4e91-b3ba-7a04f48d06cb"/>
    <rdfs:label>Infliximab</rdfs:label>
    <dc:identifier>DB00065</dc:identifier>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/3e347ab2-7bea-40b2-b6aa-af09c25eb35e">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/24e829c5-b8e0-4aaf-a63c-4fee30669579"/>
    <rdfs:label>β-galactosidase:RTB lectin fusion</rdfs:label>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/16064da9-11f1-459f-bf70-b46ba5f1e32a">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6017e57f-f220-48bf-a1b5-39a5f3a45db6"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1e28a801-213f-4488-8f4c-5df07984c501">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/25eb2e89-7f9f-4f93-8cd8-256922a84260"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/26f5cde1-6a8d-48da-acb3-d4382a1cc701">
    <rdfs:label>rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/c94bcbe2-224d-4093-a588-dc0ca3c4a40f"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/60af17fc-b7df-465b-96b4-08338273bc0c">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003281</ddiem:url>
    <rdfs:label>High serum ferritin</rdfs:label>
    <rdfs:comment></rdfs:comment>
    <dc:identifier>HP:0003281</dc:identifier>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/c265deb9-d858-40d9-8bbb-a4d7c1937e29">
    <ddiem:url>https://www.drugbank.ca/drugs/DB00421</ddiem:url>
    <rdfs:label>Spironolactone</rdfs:label>
    <dc:identifier>DB00421</dc:identifier>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/636793ff-bf83-43f5-9317-0659c6cebf62"/>
  </ddiem:Drug>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/dc74ce41-028c-4e50-bea3-21e06ba1fac1">
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0001266</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>choreoathetosis</rdfs:label>
    <dc:identifier>HP:0001266</dc:identifier>
  </ddiem:Phenotype>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/DDIEM_0000002">
    <rdfs:subClassOf rdf:resource="http://purl.obolibrary.org/obo/DDIEM_0000005"/>
    <obo:IAO_0000115 xml:lang="en">A therapeutic procedure in which a treatment directly or indirectly compensates for the loss or gain of activity of a genetically defective protein within the network or pathway of which that protein is a member. [PNS]</obo:IAO_0000115>
    <rdfs:label xml:lang="en">complementation therapy</rdfs:label>
  </owl:Class>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/00f802ef-ef87-4117-9677-e144bf5b6bd9">
    <dc:identifier>HP:0003107</dc:identifier>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0003107</ddiem:url>
    <rdfs:comment></rdfs:comment>
    <rdfs:label>High plasma cholesterol level*</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/e92590f0-74f8-4e54-8d3c-18e2ad76c48a">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/3c5406c9-58e0-4b8e-b3ed-88156affa3ca"/>
    <rdfs:label>Beneprotein</rdfs:label>
  </ddiem:Drug>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5154719e-c58a-4b4a-83cd-2db13e7e4524">
    <rdfs:label>Recombinant human Aspartylglucosamidase</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/592e2f7b-1b5e-445b-946e-93c84b8caf45"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/576abc89-a2b5-44dc-9f98-40ec6a2fa171">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/f4a0306b-626a-4409-9751-ef7e8be5452f"/>
  </rdf:Alt>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/f0fc0552-3e2a-411d-b806-a58a2577d9fe">
    <rdfs:comment></rdfs:comment>
    <ddiem:url>http://purl.obolibrary.org/obo/HP_0002574</ddiem:url>
    <dc:identifier>HP:0002574</dc:identifier>
    <rdfs:label>Acute episodic abdominal pain</rdfs:label>
  </ddiem:Phenotype>
  <ddiem:Phenotype rdf:about="http://ddiem.phenomebrowser.net/41cc2333-0aec-4b95-acba-21644bc70aaa">
    <rdfs:label>Low activity of the immature 4-HPPD enzyme</rdfs:label>
    <rdfs:comment></rdfs:comment>
  </ddiem:Phenotype>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/5aaa7abe-82b3-4bd1-850d-44736a933ff7">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/9a62dcaf-2b88-40fc-873b-9c9db24abe47"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/11ece21c-c063-406c-ba4d-6c883789e529">
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/f92ae2b9-ce50-49b9-b1ad-d86d35acc5d4"/>
    <rdfs:label>r LCAT</rdfs:label>
  </ddiem:Drug>
  <owl:Class rdf:about="http://purl.obolibrary.org/obo/OGMS_0000112"/>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/4137c365-9e80-41dd-be7b-9a5369824a30">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/4168f0a2-fdfd-4c54-a814-1d09279aadf8"/>
  </rdf:Alt>
  <ddiem:Drug rdf:about="http://ddiem.phenomebrowser.net/5a9661bf-f0d4-44bd-ba9a-ba6107600f9e">
    <rdfs:label>leucine-restricted diet</rdfs:label>
    <obo:RO_0000056 rdf:resource="http://ddiem.phenomebrowser.net/4e0159cb-c8f3-40b7-930a-f83104cb7c52"/>
  </ddiem:Drug>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/82b7726f-9206-4b56-9ede-ef7906f6c87c">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/6574ff20-1e19-4273-beb3-3269d9e7dcd0"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/1bf9e72f-3409-4fc3-9904-f25b3afdb011">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/ef971b86-96e4-4624-9719-9a6c7b9964f3"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/64e0ddad-e026-4de0-88a4-79a5b7355264">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/c5602c0e-8ddd-40e4-ba1b-edd6c9721046"/>
  </rdf:Alt>
  <rdf:Alt rdf:about="http://ddiem.phenomebrowser.net/3dafc1b1-bf6e-4b62-8ff3-252553c0aaa5">
    <rdf:li rdf:resource="http://ddiem.phenomebrowser.net/093bbbc4-73a3-4d0c-8a29-a30c1e7e918f"/>
  </rdf:Alt>
</rdf:RDF>
